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Aaron David Goldberg, Ph.D.
The Rockefeller University 2010

The eukaryotic genome is composed of chromatin, a complex polymer
of genomic DNA, RNA, and closely associated proteins. Histone proteins form
the core of the nucleosome, the fundamental repeating unit of chromatin. Variant
histone proteins play critical roles in the epigenetic regulation of gene expression
and in the development of multicellular organisms.
In this thesis, I describe the first genome-wide profiles of histone H3
variants in pluripotent mammalian embryonic stem (ES) cells, and I establish the
dependence and independence of these patterns on the histone chaperone Hira.
To distinguish H3 variants, I use designed zinc finger nucleases (ZFNs) to rapidly
knock epitope tags into a single allele of the endogenous histone H3.3B gene in
mouse ES cells.
Genome-wide analysis reveals that H3.3 is enriched in specific patterns
at active and repressed genes with high CpG content promoters, including
developmentally repressed bivalent H3K4me3 / H3K27me3 genes in ES cells,
in addition to transcribed non-coding regions, telomeres, ribosomal DNA (rDNA),
and genic and intergenic transcription factor binding sites (TFBS). Transcriptional
termination sites of highly transcribed genes are marked by peaks of H3.3 and
phosphorylated RNA polymerase II. Differentiation of ES cells into neural precursor
cells (NPCs) leads to specific changes in H3.3 localization, demonstrating that the
localization of H3.3 is dependent on cellular state. Targeted gene editing of H3.3B

to H3.2 or H3.1 using ZFNs demonstrates that these patterns are dependent on
the amino acid sequence of endogenous H3.3.
Using wild-type and Hira -/- ES cells, I show that the H3.3 chaperone Hira
is required for H3.3 enrichment at active and repressed genes. Strikingly, Hira
is not essential for deposition of H3.3 at rDNA, telomeres, and specific TFBS.
Immunoaffinity purification and mass spectrometry reveal that the proteins Atrx
and Daxx associate with H3.3 in a Hira-independent manner. Using Atrxflox and
Atrxnull mouse ES cells, I find that Atrx is specifically required for Hira-independent
enrichment of H3.3 at telomeres and rDNA, and for repression of telomeric and
ribosomal RNA. Overall, the data in this thesis demonstrate that multiple and
distinct pathways are responsible for H3.3 deposition at specific genomic locations
in mammalian cells.
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Chapter 1
GENERAL Introduction
“The major problem, I think, is chromatin…you can inherit something beyond
the DNA sequence. That’s where the real excitement of genetics is now.”
				

---James Watson (Watson, 2003).

One (mostly) identical genome, many cell types
One of the singular wonders of biology is the capacity of a single cell to give rise to
a multicellular organism. Every human begins life as an individual cell, the product
of fusion of sperm and oocyte, formed with a unique combination of paternal and
maternal genetic material. Despite the fact that a fully grown human being contains
an estimated ten trillion different cells (Dobzhansky, 1970; Savage, 1977), organized
into multiple organs and over four hundred spatially and functionally distinct cell
types (Vickaryous and Hall, 2006), the vast majority of all of these cells contain
identical genetic information (Gurdon and Melton, 2008) (Figure 1.1).
During the 1940s, scientists led by Avery, MacLeod, and McCarty here
at the Rockefeller University demonstrated that genetic information is carried
by DNA (Avery et al., 1979). However, it was not immediately clear that nearly
every cell in a multicellular organism is genetically identical. One possibility was
that organismal development might permanently alter the genomes of different
cell types, thereby rendering them genetically distinct from other tissues of the
body (Gurdon and Byrne, 2003; Gurdon and Melton, 2008). Beginning in the
mid twentieth century, developmental biologists including Robert Briggs, Thomas
King, and John Gurdon conducted a series of pioneering experiments involving
the transplantation of differentiated frog cell nuclei from various embryonic and
1

Figure 1.1: Mammalian development generates diverse cell types with identical genomes.
Sperm and oocyte contain distinct haploid genomes. Following fertilization, the paternal and
maternal pronuclei fuse to form the new genome of the diploid zygote, the unicellular embryo.
From this point on, most new and old cells of the developing mammal carry an identical diploid
genome throughout the lifetime of the organism, despite a vast diversity of differentiated cellular
phenotypes. After repeated mitotic divisions of the zygote, the mammalian embryo becomes
a morula (not shown), a ball of cells which begins at the 12-16 cell stage. About 4 days after
fertilization in humans, a fluid filled cavity forms in the morula, and the embryo is now known
as a blastocyst. Cells differentiate into an outer extraembryonic layer known as the trophoblast
(blue cells), which attaches to the endometrial epithelium and later gives rise to the placenta, and
an inner layer known as the inner cell mass (ICM) (pink cells), which gives rise to the embryo
itself. If the blastocyst stage embryo is harvested prior to implantation, pluripotent embryonic
stem (ES) cells can be derived from the ICM. ES cells have the capacity to self-renew and
maintain the pluripotent state in culture for extended periods of time. In addition, ES cells can
differentiate into cells of all germ lineages (ectoderm, endoderm, mesoderm), including neural
cells, cardiac cells, and pancreatic b-cells depicted below. When injected back into blastocyst
mouse embryos, ES cells contribute to the embryo to form chimeras, and can even give rise to
the germline for passage to the next generation. See (Meissner et al., 2009; Moore et al., 2008).
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adult tissues (including lung, heart, liver, and intestine) into enucleated frog eggs
(Gurdon and Byrne, 2003). Remarkably, Gurdon and colleagues found that some
of the frog embryos generated from nuclei of fully differentiated somatic cells were
able to develop into tadpoles and even into adult frogs (Gurdon and Byrne, 2003;
Laskey and Gurdon, 1970). These experiments were later successfully conducted
in mammals with the infamous cloning of Dolly the sheep from the nucleus of a
cultured adult mammary gland cell by Wilmut and colleagues (Campbell et al., 1996;
Wilmut et al., 1997) (Figure 1.2). Although this process of somatic cell nuclear
Somatic cell nuclear transfer (SCNT)
Reprogrammed status
of transplanted nuclei

Single nucleus injected
to enucleated egg

Somatic
cell

Egg

Blastula

Embryonic
stem cell

Pluripotent

Fetus

Pluripotent

Fertile adult

Totipotent

Second meiotic prophase

Adapted from Gurdon and Melton, Science 2008.

Figure 1.2: Cell differentiation is reversible
Nuclear transfer experiments by John Gurdon, Ian Wilmut and colleagues demonstrate
that cell differentiation is reversible (Gurdon and Byrne, 2003; Rossant, 2009). The
nucleus of a differentiated somatic cell can be transferred to an unfertilized, enucleated
egg. Some of the new embryos that are generated from nuclear transfer experiments
can give rise to pluripotent embryonic stem cells, to a new fetus, or a fertile adult.

transfer is not very efficient, particularly with nuclei from adult cells, the fact that
even 1-2% of differentiated cell nuclei could develop into a fully formed vertebrate
demonstrated that cell differentiation is reversible, and does not necessarily alter
the genetic content of a cell (Gurdon and Byrne, 2003; Gurdon and Melton, 2008;
Laskey and Gurdon, 1970). Gurdon and colleagues therefore concluded that the
genetic blueprint for normal cellular development is preserved in all somatic cells
of an organism, even in terminally differentiated cells that would normally have no
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chance of passing on their genetic material.
There are of course a few exceptions to this general principle of the
conversation of genetic identity during cellular differentiation. Certain immune
cells contain genes that are specifically mutated to increase the body’s ability to
respond to the diverse array of pathogens present in our environment (Teng and
Papavasiliou, 2007). Some cells such as red blood cells are so specialized that
they no longer contain any stable genetic information at all, having ejected their
DNA during terminal differentiation so as to be optimized for carrying oxygen from
the lungs to various tissues of the body (Chasis and Mohandas, 2008). However,
other than a few important exceptions, the vast majority of the trillions of cells that
make up the human body are genetically identical – unique and subtly different
from the cells of another human being, but identical to one another. Yet despite
this genetic uniformity, the cells of our body are organized into tissues and cell
types that are enormously different from one another in form and function (Ross
et al., 2009; Vickaryous and Hall, 2006) (Figure 1.1). If their genetic content is
identical, what makes one cell different from another?

A brief history of gene regulation
Some clues to the dizzying yet highly organized array of cellular diversity lie in
biochemical studies. Despite generally identical DNA content, the RNA and protein
content of different tissues can differ greatly (Alaiya et al., 2005; Cloonan et al.,
2008; Wang et al., 2009a). While some proteins and RNA are common to many
cell types, even the levels of these so-called ‘housekeeping’ genes and proteins
can be highly variable (de Jonge et al., 2007). For example, two-dimensional
electrophoresis studies of different tissue types clearly demonstrate that many
proteins, even those common to multiple tissues, have dramatically different levels
in distinct cell types (Alberts, 2002; Minden et al., 2009). Moreover, patterns of
5

RNA and protein content are so characteristic of cell type that they can be used
to identify cells of uncertain tissue origin (Alaiya et al., 2005; Bloom et al., 2004;
Rosenfeld et al., 2008). If different cells of an individual organism contain identical
DNA, perhaps what makes one cell phenotypically different from one another
therefore lies largely in the RNA and protein content of the cell.
Classic studies from Jacob and Monod in bacteria provided a model for
basic genetic control mechanisms by which the biochemical composition (RNA
and protein content) of a cell was determined by regulated transcription of DNA
into RNA, offering a potential solution to the problem of how an identical cellular
genome can give rise to such phenotypic diversity (Monod and Jacob, 1961). The
expression of specific genes can be regulated in a temporal and spatial manner
that allows for cellular differentiation and organismal development. In 1961, Jacob
and Monod wrote:
It may be in the interpretation and analysis of differentiation that the new
concepts derived from the study of microorganisms will prove of the greatest
value. One point at least already seems to be quite clear: namely that
biochemical differentiation (reversible or not) of cells carrying an identical
genome, does not constitute a “paradox,” as it appeared to do so for many
years, to both embryologists and geneticists….The control mechanisms
discovered in microorganisms govern the expression of genetic potentialities
(Monod and Jacob, 1961).
Thus, the concept of regulated cellular gene expression in the development
of higher eukaryotes was born in the field of bacterial genetics. However, the
mechanisms underlying the regulation of eukaryotic gene expression remained
initially obscure.
In 1969, a key component of this puzzle for eukaryotes was solved with
the landmark discovery of RNA polymerases by Robert Roeder (Roeder and
Rutter, 1969). As a graduate student in William Rutter’s lab, Roeder purified three
DNA-dependent RNA polymerases, now known as RNA polymerase (RNAP) I,
II, and III, and demonstrated that RNAPI was localized to the nucleolus (the site
6

of ribosomal DNA transcription), while RNAPII and RNAPII were restricted to the
nucleoplasm (Roeder and Rutter, 1969, 1970). The discovery that three different
enzymes catalyzed the transcription of DNA into RNA was quite surprising,
particularly given that most contemporary scientists believed that animal cells
contained a single enzyme (Roeder, 2003). In the following years, Roeder and
colleagues demonstrated that each of the three RNAP enzymes was dedicated
to the transcription of specific classes of genes (Abmayr and Workman, 2003;
Roeder, 2003). Specifically, RNAPI catalyzed the synthesis of ribosomal RNA
(rRNA), RNAPII catalyzed the synthesis of pre-messenger RNA (pre-mRNA), and
RNAPIII catalyzed the synthesis of transfer RNA (tRNA) and 5S rRNA (Weinmann
et al., 1974; Weinmann and Roeder, 1974).
With further biochemical studies, it soon became clear to Roeder and
colleagues that the mechanisms underlying eukaryotic gene regulation must
involve many more factors beyond the three different types of RNA polymerase.
For example, each of the different types of polymerase was found to be composed
of multiple subunits, most of which are unique to the specific type of polymerase
(Sklar et al., 1975). In addition, transcription of mammalian gene sequences by the
different RNA polymerases required multiple additional enzyme-specific recognition
factors, and the gene regulation field spent many productive years defining the
identity of these general transcription initiation factors, and the ordered assembly
of functional transcription pre-initiation complexes (Matsui et al., 1980; Roeder,
2003; Segall et al., 1980; Sikorski and Buratowski, 2009). After the sequencing
of the human genome, it was estimated that 200-300 genes code for proteins
that make up the general transcriptional machinery (Lander et al., 2001; Venter et
al., 2001). However, these general transcription factors are promiscuous in their
capacity to transcribe numerous genes (Luse et al., 1981; Sikorski and Buratowski,
2009), and the identification of general transcriptional machinery therefore did not
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solve the mystery of gene-specific and cell-type specific transcription that occurs
during normal development and cellular differentiation.
To activate or repress the transcription of particular genes, cells utilize
factors that recognize specific sequences of DNA.

Sequence-specific DNA

binding proteins were initially identified in prokaryotes (Jacob and Monod, 1961).
In 1980, the identification and purification of TFIIIA provided the first example of
a sequence-specific DNA binding transcription factor in eukaryotes (Abmayr and
Workman, 2003; Engelke et al., 1980; Roeder, 2003). Numerous sequence-specific
DNA binding proteins have been subsequently identified, and ~1400 proteins are
estimated to serve as transcription factors that bind to sequence-specific elements
in humans (Farnham, 2009; Vaquerizas et al., 2009). More recently, multiple groups
have identified large subunit complexes that mediate physical and functional links
between sequence-specific transcription factors and the general transcriptional
machinery, with certain subunits capable of interacting with specific TFs (Biddick
and Young, 2005; Kornberg, 2005; Malik and Roeder, 2005; Meisterernst et al.,
1991). Many of the activities of these complexes converge on the post-translational
modification of histones in chromatin (Black et al., 2006; Venters and Pugh, 2009),
a subject that will be addressed in a following section (Figure 1.3).
Tissue and lineage-specific transcription factors can play critical roles in
regulating and even defining cellular identity (Hemberger et al., 2009; Niwa et
al., 2000). Recently, these lineage-defining properties of transcription factors have
been used to switch and reprogram cells from one somatic lineage into differentiated
cells of a different lineage and even to pluripotent cells (Gurdon and Melton, 2008;
Jaenisch and Young, 2008; Yamanaka, 2009). For example, the expression of
the muscle specific transcription factor myoD is sufficient to switch a variety of
nonmuscle cell types into muscle (Weintraub et al., 1989). Some developmentally
important transcription factors often act in combination with other transcription
8

Figure 1.3: Contemporary view of gene activation
General transcription factors and RNA polymerase II (RNAPII) (green ovals) bind to thousands of
core promoter regions through recognition of common elements such as TATA boxes and initiators
(INR), but this binding alone provides very low transcriptional activity. Transcription can be increased
by (1) binding of a site-specific DNA binding factor (red trapezoid) to cis elements in the proximal
promoter region and stabilizing the recruitment of the transcriptional machinery. Promoter activity
can be further stimulated (+) by site-specific factors (orange) binding to enhancers (2), but this
step is not sufficient for high levels of transcription. Cell-type specific enhancer factors (pink) can
cooperate with site-specific factors to stimulate transcription by recruiting a coactivator (3) such as
a histone modifying enzyme (for example, a histone acetyltransferase, HAT) that can create a more
favorable environment for transcription (++). The bottom illustration represents long-distance looping
of a distal enhancer element to promote transcription in the context of chromatin. Nucleosomes
are depicted, with the possible contribution of histone variants (light green) and specific histone
tail modifications (small blue and pink spheres) to be discussed later. The elongating RNAPII
is phosphorylated on its C-terminal domain, and the pink strand represents the growing RNA
transcript. This figure has been adapted from (Farnham, 2009).
TF = transcription factor. TFBS = transcription factor binding site. TSS = transcription start site.
TES = transcription end site.
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factors (Chen et al., 2008b; Farnham, 2009), a realization that was utilized in the
landmark development of cellular reprogramming (Takahashi and Yamanaka, 2006).
In 2006, Yamanaka and colleagues demonstrated that the retroviral introduction of
genes encoding 4 transcription factors enriched in ES cells (Oct4, Sox2, Klf4, and
c-Myc) enabled differentiated fibroblasts to take on a cellular phenotype similar to
pluripotent ES cells, subsequently known as induced pluripotent stem (iPS) cells
(Takahashi and Yamanaka, 2006; Yamanaka, 2009) (Figure 1.4). Along with the
previous experiments of Gurdon and colleagues described above, such cellular
Reprogramming
Developmental potental
of reprogrammed cells

+ reprogramming factors
Pluripotent

Somatic
cell

Induced pluripotent
stem (iPS) cell

Regenerative
medicine

Patient
Neural cells

Cardiac cells

Adapted from Yamanaka, Cell 2009.

Hepatocytes

Pancreatic
β-cells

Figure 1.4: Cellular reprogramming generates induced pluripotent stem cells from
differentiated cells
Cellular reprogramming further demonstrates the reversibility of cell differentiation. As originally
developed by Yamanaka and colleagues in 2006, reprogramming factors (such as transcription
factors Oct4, Sox2, Klf4, and c-myc) can be introduced in a variety of ways into a differentiated
somatic cell. After a period of time, a number of these somatic cells will take on the morphology and
cellular phenotype of pluripotent ES cells, and such reprogrammed cells are subsequently known as
induced pluripotent stem (iPS) cells. Like ES cells, iPS cells have the capacity to differentiate into
cells of all germ lineages. Patient-derived iPS cells can be used to produce various differentiated
somatic cells with the same genotype as the patient, and these cells therefore have great potential
for use in cell transplantation therapy. This figure and legend has been adapted from (Yamanaka,
2009).
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reprogramming conclusively demonstrates that under specific conditions, cellular
differentiation is reversible. Moreover, cellular reprogramming also paves the way
for the development of patient specific iPS cells that could be used for therapeutic
purposes in regenerative medicine (Rossant, 2009; Yamanaka, 2009).
Although the advent of reprogramming has revolutionized the concept of
cellular identity, reprogramming remains a very inefficient process (Gurdon and
Melton, 2008). In addition, cellular reprogramming is most efficient with embryonic
cells, and becomes progressively less efficient as cells become more differentiated
(Gurdon and Melton, 2008; Yang et al., 2007). As cells differentiate, they not only
establish coordinated changes in patterns of cellular gene expression, but maintain
these patterns long after they are established (Hemberger et al., 2009). Despite
recent progress, the mechanisms underlying the establishment, maintenance, and
propagation of these epigenetic states remain major challenges in biology. What
accounts for this stability of cellular phenotype?
Nearly fifty years ago, Jacob and Monod already recognized that this relative
stability of gene expression in higher eukaryotes marked a clear difference with the
gene regulatory systems that they were uncovering in prokaryotes.
Most of the actual systems [involved in gene regulation in microorganisms]…
are entirely reversible, in the sense that the effects of inhibitors, inducers,
or repressors do not survive for any length of time after elimination of the
active agent, and the cells soon return to their initial state. Differentiation,
on the other hand, is stable, and persists once it has been induced. (Monod
and Jacob, 1961)
Some of this phenotypic stability in the differentiation of metazoan cells can be
attributed to autoregulatory loops of specific master regulatory transcription factors
that reinforce cellular gene expression programs (Jaenisch and Young, 2008;
Odom et al., 2006). However, transcription factors are not the only determinants
of cellular identity. Even after somatic cell nuclei have undergone two rounds of
transfer to the completely different cellular environment of the egg, these nuclei
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will sometimes inappropriately ‘remember’ their original tissue of origin, expressing
genes characteristic of their previous differentiated state (Ng and Gurdon, 2005,
2008). How do cell nuclei remember their tissue identity, even in the face of a
completely different cellular environment, with a distinct repertoire of transcriptional
regulatory proteins? What is the material actually being transferred during somatic
cell nuclear transfer? Recently, genetic and biochemical evidence has converged
to connect many of the mechanisms underlying cellular memory at the level of
chromatin, the complex of DNA and intimately associated proteins at the center of
a eukaryotic nucleus (Goldberg et al., 2007).

Epigenetics
As described above, the differentiation of cells in a multicellular organism involves
changes in gene expression, but largely not in DNA content (Hemberger et al.,
2009). Such a stable and heritable alteration in cellular phenotype in the absence
of DNA changes can be referred to as an ‘epigenetic’ phenomenon (Goldberg et
al., 2007).
Epigenetics has recently evolved from a collection of diverse phenomena
into a defined and far-reaching field of study (Allis et al., 2007). Historically, the
word ‘epigenetics’ was used to describe events that could not be explained by
genetic principles. Conrad Waddington (1905-1975), who is given credit for coining
the term, defined epigenetics as “the branch of biology which studies the causal
interactions between genes and their products, which bring the phenotype into
being” (Waddington, 1942). Over the years, numerous biological phenomena,
some considered bizarre and inexplicable, have been lumped into the category of
epigenetics. These include seemingly unrelated processes, such as paramutation
in maize (an interaction between two alleles in which one allele causes heritable
changes in the other allele) (Cuzin et al., 2008); position effect variegation (PEV)
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in the fruit fly Drosophila (in which the local chromatin environment of a gene
determines its expression) (Girton and Johansen, 2008); and imprinting of specific
paternal or maternal loci in mammals (Kacem and Feil, 2009; Weaver et al.,
2009). Although mysteries abound, the field is now beginning to uncover common
molecular mechanisms underlying epigenetic phenomena.
Epigenetics, in a broad sense, is a bridge between genotype and phenotype—a
phenomenon that changes the final outcome of a locus or chromosome without
changing the underlying DNA sequence. As described above, even though the
vast majority of cells in a multicellular organism share an identical genotype,
organismal development generates a diversity of cell types with disparate, yet
stable profiles of gene expression and distinct cellular functions. Thus, cellular
differentiation may be considered an epigenetic phenomenon, largely governed
by changes in what Waddington described as the “epigenetic landscape” rather
than alterations in genetic inheritance (Waddington, 1957); Figure 1.5). More
specifically, epigenetics may be defined as the study of any potentially stable,
and ideally, heritable change in gene expression or cellular phenotype that occurs
without changes in Watson-Crick base-pairing of DNA (Allis et al., 2007; Goldberg
et al., 2007). Despite the field’s recent progress, significant and fundamental
questions remain to be answered, many of which center on the propagation of
epigenetic information through cellular division and differentiation.

Chromatin biology and epigenetic mechanisms
Current epigenetic research has recently converged on the study of covalent and
non-covalent modifications of DNA and histone proteins, and the mechanisms by
which such modifications influence overall chromatin structure. Various overlapping
mechanisms have been implicated in the epigenetic regulation of gene expression,
including transcription factors (TFs), non-coding RNAs, covalent and non-covalent
14
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Figure 1.5: Early and contemporary views of epigenetics
In 1957, Conrad Waddington proposed the concept of an epigenetic landscape to represent the
process of cellular decision-making during development. At various points in this dynamic visual
metaphor, the cell (represented by a ball) can take specific permitted trajectories, leading to different
outcomes or cell fates. Today, developmental biology would represent the ball at its highest point as
an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell. Further differentiation can give
rise to precursor cells of a committed lineage, such as neural precursor cells or hematopoietic stem
cells, each of which can also give rise to further precursors or terminally differentiated cells within
that lineage. Figure reprinted and modified from Waddington, 1957.

modifications to histone proteins, and DNA methylation (Guttman et al., 2009;
Henikoff, 2008; Klose and Bird, 2006; Rando and Chang, 2009; Takahashi and
Yamanaka, 2006). Chromatin, the complex of protein and nucleic acids within
the nucleus of eukaryotic cells, provides an attractive candidate for shaping the
features of a cell’s epigenetic landscape (Bernstein et al., 2007; Goldberg et al.,
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2007).

Chromatin – the physiological form of the eukaryotic genome
The term ‘chromatin’ was originally coined by Walther Flemming around 1880 to
refer to “that substance in the nucleus which is readily stained” (Flemming, 1882;
Olins and Olins, 2003), and now generally refers to the complex of nuclear DNA,
RNA, and closely associated proteins (Allis et al., 2007). Chromatin packages
the eukaryotic genome into a periodic nucleoprotein structure, and serves as the
physiological substrate of all DNA-dependent processes, including gene regulation
(Wolffe, 1992). In each cell of higher eukaryotes, chromatin packs two meters worth
of genomic DNA more than 10,000 fold in order to fit into a nuclear compartment
only a few microns in diameter (Allis et al., 2007; Felsenfeld and Groudine, 2003;
Jiang and Pugh, 2009) (Figure 1.6A). Highly basic histone proteins form the core
of chromatin’s repeating nucleosome core particle (Kornberg, 1974; Kornberg and
Thomas, 1974; Olins and Olins, 1974; Oudet et al., 1975). In a single nucleosome,
two superhelical turns of approximately 146 base pairs of DNA wrap around an
octamer of histone proteins H2A, H2B, H3, and H4 (Luger et al., 1997) (Figure
1.6B). Critically, these repeating octamers of histone proteins and DNA do not
form a homogenous, uniform chromatin structure inside the cell’s nucleus. Rather,
the eukaryotic nucleus is compartmentalized, and the location of a gene within the
nucleus can significantly affect its expression (Lieberman-Aiden et al., 2009; Zhao
et al., 2009). In general, the interphase eukaryotic nucleus can be divided into
areas of highly condensed chromatin, known as heterochromatin, and regions with
less compacted chromatin, known as euchromatin (Allis et al., 2007) (Figure 1.6C).
Actively transcribed genes are generally found in euchromatin, which replicates
early in S-phase, while the more densely packed heterochromatin is gene poor,
enriched in repetitive DNA, and replicates late in S-phase (Carmo-Fonseca, 2002;
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Figure 1.6: Chromatin structure and organization
A. Chromatin is the physiological form of the eukaryotic genome. The fundamental unit of chromatin
organization is the nucleosome, in which 146 bp of DNA are wound around an octamer of histone
proteins. Nucleosomes are connected to one another by short stretches of linker DNA. At the
next level of organization, the string of nucleosomes is folded into a 30nm fiber, and these fibers
are further folded into higher order structures. Figure and legend adapted from (Felsenfeld and
Groudine, 2003).
B. The crystal structure of the nucleosome core particle was solved by Luger and colleagues
(Luger et al., 1997). Note the DNA double helix wrapped around an octamer of histone proteins H3,
H4, H2A, and H2B. One protruding histone H3 N-terminal tail is indicated in red, and such histone
tails are sites of dense covalent modifications (Allis et al., 2007; Kouzarides, 2007).
C. Electron micrograph of a plasma cell from bone marrow. The nucleus is divided into electrondense dark regions of heterochromatin (H) and lighter regions of euchromatin (E).

Martens et al., 2005).
Eukaryotic cells have evolved multiple overlapping mechanisms for
introducing biologically-relevant variation into chromatin. Nucleosome positioning
in eukaryotic genomes is non-random, with some aspects of nucleosome
organization encoded by intrinsic nucleotide sequence (Segal et al., 2006; Segal
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and Widom, 2009). In addition, the localization and stability of nucleosomes at
specific genomic locations appears to be regulated by a combination of factors,
including ATP-dependent chromatin remodeling enzymes, covalent modifications
to histone proteins and DNA, the binding of chromatin-associated effector proteins,
the localization and molecular interactions of specific non-coding RNAs, and
the incorporation of primary sequence histone variants (Henikoff, 2008; Jiang
and Pugh, 2009; Klose and Bird, 2006; Loyola and Almouzni, 2007; Rando and
Chang, 2009; Schones et al., 2008; Wilusz et al., 2009). (Figure 1.7) It is likely
that the macromolecular processes described below all significantly contribute
to the physiologically relevant organization of most eukaryotic genomes. These
entities, and possibly others yet unknown, should be considered collectively when
exploring epigenetic mechanisms. Each of these mechanisms will be discussed
briefly below, with a larger focus on histone variants.

Non-coding RNA
Recently, it has become evident that RNAs, particularly non-coding RNAs, play
critical roles in multiple epigenetic phenomena (Bernstein and Allis, 2005; Rinn et
al., 2007). Clear examples of RNA involvement range from dosage compensation
mechanisms in Drosophila and mammals mediated by the rox and XIST RNAs,
respectively, to the silencing of both genes and repetitive sequences by posttranscriptional (PTGS) and transcriptional (TGS) RNA interference (RNAi)-related
pathways, respectively, in almost all eukaryotes (Bernstein and Allis, 2005). These
RNAs often act in concert with various components of the cell’s chromatin modifying
and DNA methylation machinery to maintain active or inactive states of gene
expression (Wilusz et al., 2009). Although we might not consider PTGS–inducing
RNAs (e.g. microRNAs, siRNAs etc.) to be epigenetic in nature, TGS-evoking
RNAs (e.g. repeat associated siRNAs, Xist RNA, and small RNAs in S. pombe) are
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Figure 1.7: Mechanisms for introducing variation into chromatin
Eukaryotic cells utilize three primary mechanisms for intruding variation into the chromatin fiber.
Nucleosomes can be physically mobilized and remodeled by ATP-dependent chromatin remodeling
enzymes (top) (Clapier and Cairns, 2009). In addition, histones and DNA can be marked by
various types of covalent modifications (red and blue spheres, middle). These modifications can
result in distinct biological outcomes through direct physical effects, or through the binding of
modification-specific effectors (Kouzarides, 2007). Finally, variant histone proteins with distinct
amino acid compositions can be substituted into chromatin (bottom). These histone variants can
bring with them a unique repertoire of covalent modifications, or they can serve to replace existing
modifications (Loyola and Almouzni, 2007). In addition, histone variants can also have direct effects
on nucleosome stability and mobility (Henikoff, 2008; Jin and Felsenfeld, 2007).

more clearly epigenetic, as they can induce long term silencing effects that can be
inherited through cell division (Bernstein and Allis, 2005). In the last year, more
than ~1600 large intervening non-coding RNA (lincRNA) transcripts were identified
in mammalian cells, many of which were tissue-specific (Guttman et al., 2009). A
number of these lincRNAs have been shown to associate with chromatin-related
silencing proteins and affect gene expression (Khalil et al., 2009), and it seems
likely that our appreciation for the role of RNA in epigenetic phenomena will grow
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significantly in the near future.

DNA methylation
DNA methylation is perhaps the best-characterized and most clearly heritable
chemical modification of chromatin. In mammals, nearly all DNA methylation
occurs on cytosine residues of CpG dinucleotides (Ng and Bird, 1999). Regions of
the genome that have a high density of CpGs are referred to as CpG islands, and
DNA methylation of these islands correlates with transcriptional repression (Goll
and Bestor, 2005). Genomic patterns of cytosine methylation in mammals, whether
donated by de novo or maintenance DNA methyltransferases (DNMTs), play a
critical role in gene regulation and chromatin organization during embryogenesis
and gametogenesis (Goll and Bestor, 2005). Maintenance methyltransferases
add methyl groups to hemi-methylated DNA during DNA replication, whereas de
novo DNMTs act after replication (Groth et al., 2007b). Moreover, the formation of
heterochromatin in many organisms is mediated in part by DNA methylation and its
binding proteins, in combination with RNA and histone modifications characteristic
of silent chromatin (Zaratiegui et al., 2007). Methylated DNA can be recognized
by binding proteins such as MeCP2 (Jones et al., 1998), and mutations in MeCP2
have been shown to cause the human neurodevelopmental disorder Rett syndrome
(Chahrour and Zoghbi, 2007). DNA methylation plays a role in many cellular
processes including silencing of repetitive and centromeric sequences from fungi
to mammals; X chromosome inactivation in female mammals; and mammalian
imprinting, all of which can be stably maintained through cellular division (Yang
and Kuroda, 2007). Taken together, DNA methylation provides a stable, heritable,
and critical component of epigenetic regulation.
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Covalent histone modifications and chromatin remodeling
For many years, chromatin was considered largely an inert scaffold and packing
mechanism for nuclear DNA (Felsenfeld and Groudine, 2003). If anything, histone
proteins were recognized as a simple impediment to gene transcription, as they
were found to inhibit RNA synthesis (Allfrey et al., 1963), but they were not widely
seen as playing any active or regulatory role. However, over the last four decades,
significant genetic and biochemical evidence has accumulated to connect histone
modifications with the regulation of gene expression.
Histone proteins were originally recognized to carry a high level of acetylation
over 45 years ago (Phillips, 1963). In 1964, Vincent Allfrey and colleagues here
at the Rockefeller University proposed a possible function of post-translational
histone acetylation in the positive regulation of gene expression (Allfrey et al.,
1964). Allfrey and colleagues noted that histones were acetylated even in the
presence of inhibitors of protein synthesis, indicating that histone acetylation could
take place following protein translation (Allfrey et al., 1964). Moreover, they found
that unlike unacetylated histones, acetylated histones were relatively permissive
for RNA synthesis in isolated nuclei (Allfrey et al., 1964). Intriguingly, the timing
of histone acetylation was also correlated with gene transcription, with histone
acetylation preceding the increase in RNA synthesis (Pogo et al., 1966). In a
prescient suggestion, Allfrey and colleagues wrote:
The findings introduce the possibility that histone effects on nuclear RNA
metabolism may involve more than a simple inhibition of RNA synthesis,
and that more subtle mechanisms may exist which permit both inhibition
and reactivation of RNA production at different loci along the chromosome
(Allfrey et al., 1964).
The relationship between histone acetylation and gene transcription was further
supported by later studies showing that hyperacetylated core histones preferentially
associate with active areas of the genome that are more easily accessible to
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nuclease digestion (Sealy and Chalkley, 1978; Vidali et al., 1978). In addition,
genetic studies by Michael Grunstein and colleagues demonstrated that histone
acetylation sites are required to alleviate nucleosomal gene repression in yeast
(Durrin et al., 1991; Kurdistani and Grunstein, 2003). Biochemical experiments
also suggested that histone tail acetylation could directly facilitate transcription
factor access to nucleosomal DNA (Lee et al., 1993). However, despite this wealth
of correlative evidence linking histone acetylation and transcriptional regulation,
the specific molecular mechanisms responsible for histone covalent modifications
remained obscure for many decades.
In the mid 1990s, two discoveries led to a major paradigm shift in the field
of eukaryotic gene regulation, and forever upended the view that histones act
solely as passive “scaffolding” for packaging genomic DNA. Using a novel in-gel
activity assay, James Brownell, David Allis, and colleagues identified and purified
the first histone acetyltransferase (HAT) enzyme from the transcriptionally active
macronucleus of the ciliated protozoan Tetrahymena thermophila (Brownell and
Allis, 1995; Brownell et al., 1996). Critically, this first HAT was highly homologous
to the yeast protein Gcn5p, a transcriptional adaptor protein that had already
been implicated in transcriptional activation (Brownell et al., 1996). This finding
was soon followed by the identification of the first histone deacetylase (HDAC)
enzyme by Stuart Schreiber and colleagues, and this first HDAC was found to
be homologous to a yeast protein (Rpd3p) previously implicated in transcriptional
repression (Taunton et al., 1996). Together, these landmark discoveries immediately
suggested molecular mechanisms to employ “both inhibition and reactivation of
RNA production at different loci along the chromosome,” as originally suggested
by Allfrey, providing a critical and previously missing mechanistic link between
chromatin structure and transcriptional output (Allfrey et al., 1964; Struhl, 1998).
It is now clear that histones can be marked with a wide variety of chemical
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and peptide modifications in addition to acetylation, including methylation,
phosphorylation, ADP-ribosylation, ubiquitination, and sumoylation (Kouzarides,
2007). These covalent modifications can also be dynamically removed by a variety
of enzymes and mechanisms, including histone deacetylases, phosphatases,
dequbiquitinases, arginine demethyliminases, lysine demethylases, and direct
histone proteolysis (Duncan et al., 2008; Keogh et al., 2006; Litt et al., 2009;
Minucci and Pelicci, 2006; Nottke et al., 2009; Weake and Workman, 2008).
Genetic and biochemical evidence has recently converged to clearly connect
covalent histone modifications with longstanding epigenetic phenomena. Genetic
screens for suppressors of PEV (Su(var)) in Drosophila, for example, revealed
over 100 genes that encode vital constituents of heterochromatin. Many of these
genes are conserved from flies to humans, including heterochromatin protein 1
(HP1) and the histone H3K9 methyltransferase Su(var)3-9 (Schotta et al., 2003).
Drosophila genetics also provides another link between epigenetics and histone
modifications, in the form of two evolutionarily conserved families of proteins that
regulate homeotic genes antagonistically during development: the Polycomb
Group (PcG) and the Trithorax Group (TrxG). Further molecular characterization
of PcG genes reveals that they contribute to two distinct protein complexes that
are responsible for ‘writing’ (Polycomb Repressive Complex 2) and ‘reading’
(PRC1) methylation of H3K27 and facilitating chromatin condensation (Whitcomb
et al., 2007). Meanwhile, TrxG proteins mediate methylation of H3K4 and promote
transcriptionally active chromatin (Ringrose and Paro, 2004; Ruthenburg et al.,
2007a).
How might covalent histone modifications modify chromatin structure to
influence patterns of gene expression (Jenuwein and Allis, 2001)? A longstanding
literature suggests that charge-altering modifications such as acetylation and
phosphorylation can directly alter the physical properties of the chromatin fiber,
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leading to changes in higher-order structures (Hong et al., 1993; Struhl, 1998).
More recently, effector-mediated functions have been well documented, whereby
histone modifications recruit or stabilize the localization of specific binding partners
to chromatin. In the first example of an emerging epigenetic paradigm, the catalytic
enzyme Su(var)3-9 serves as a ‘writer’ of histone H3K9 methylation (Rea et al., 2000),
whereas HP1 serves as a ‘reader’ or ‘effector’ recognizing H3K9 methylation and
directing biological processes (such as heterochromatin stabilization) to particular
areas of the chromatin fiber (Lachner et al., 2001). In addition, effector-repulsive
functions have been demonstrated in which histone modifications abrogate the
binding of particular effectors (Fischle et al., 2005; Ooi et al., 2007).
Several investigators have noted that the combinatorial complexity of
various covalent modifications could provide the physical structure of the genome
with a powerful epigenetic marking system for conveying information outside of
DNA sequence itself (Jenuwein and Allis, 2001; Strahl and Allis, 2000; Turner,
2000). This “histone code” of post-translational modifications could be read
both by direct physical effects and by the binding of effector proteins, and could
potentially contribute to the heritability of transcriptional states through cell division
(Jenuwein and Allis, 2001; Strahl and Allis, 2000). Recent evidence suggests that
multiple histone modifications may provide a multivalent platform for combinatorial
interactions with several linked effector modules (Moriniere et al., 2009; Ruthenburg
et al., 2007b). However, it remains to be seen whether histone modifications are
truly ‘epigenetic,’ and much research is currently focused on determining if and
how patterns of histone modifications are inherited through DNA replication (Groth
et al., 2007b).
Non-covalent mechanisms such as chromatin remodeling provide the cell
with additional tools for introducing variation into the chromatin template (Figure
1.7). ATP-dependent chromatin remodeling complexes are thought to modify
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chromatin accessibility by altering histone-DNA interactions, perhaps by sliding
or ejecting nucleosomes (Smith and Peterson, 2005).

Specifically targeted

remodeling complexes may open or close chromatin in a localized area of the
genome, or globally remodel chromatin structure throughout the nucleus (Lusser
and Kadonaga, 2003; Smith and Peterson, 2005).
Chromatin remodelers are critical for a variety of nuclear processes,
including the proper spacing of nucleosomes following replication, access to DNA
during DNA repair processes, regulating the exposure of regulatory elements, and
the replacement and proper positioning of nucleosomes following transcription
(Clapier and Cairns, 2009). For precise control of gene expression, such modulation
of nucleosome location and stability may be particularly important in regulating
access of transcription factors to regulatory elements, as well regulating access of
the transcriptional machinery to promoters (Henikoff, 2008). Mutations in specific
chromatin remodelers have been linked to several human developmental disorders,
including alpha thalassemia and X-linked mental retardation (Gibbons et al., 2008),
a subject that will be discussed in more detail in Chapters Three and Four.
Mechanistic links between covalent and non-covalent mechanisms
have also been uncovered, as modification ‘effectors’ can include subunits of
nucleosome remodeling complexes (Wysocka et al., 2006). It is becoming clear
that significant ‘crosstalk’ exists between different epigenetic pathways. In S.
pombe, for example, biochemical purification of the RNAi machinery revealed
an interaction between small RNAs and chromatin regulators such as the
H3K9me-reading chromodomain-containing protein Chp1 (Grewal and Jia, 2007).
Silencing of the inactive X chromosome is another prime example, where Xist
RNA, DNA methylation, histone modifications, their ‘writers’ and ‘readers,’ all
play a role (Heard, 2005). Moreover, DNMTs act in part by interacting directly
or indirectly with chromatin modifying enzymes such as histone deacetylases
25

(Dobosy and Selker, 2001). Recent studies reveal that DNMT3L, an essential
accessory protein to the de novo DNMTs in the germline, interprets patterns of
histone modifications, adding weight to an emerging theme that DNA methylation
and histone modifications functionally interact (Freitag and Selker, 2005; Ooi et
al., 2007). Covalent modification, nucleosome remodeling, and histone variants
(discussed in detail below) work together to introduce meaningful variation into the
chromatin fiber, and their collective contribution to epigenetics is only now being
rigorously explored.

Chromatin immunprecipitation, high-throughput sequencing, and genomewide approaches to chromatin state
The development of chromatin immunoprecipitation (ChIP) has provided a powerful
tool to assess the precise localization of specific proteins or covalent modifications
in the genome (Kuo and Allis, 1999; O’Neill and Turner, 2003). For many years,
histone acetylation was indirectly associated with transcriptionally active areas of
the genome. For example, acetylated histones and active genes were both found
enriched in more open, accessible regions of the genome that were preferentially
released following nuclease digestion (Sealy and Chalkley, 1978; Vidali et al.,
1978; Weintraub and Groudine, 1976). However, one possibility was that the
use of nucleases released multiple populations of chromatin, one of which was
enriched in acetylated histones, and one of which was enriched in active genes
(Hebbes et al., 1988). How could one determine if the population of chromatin
with acetylated histones actually carried the sequences of active genes? The
direct association between histone modifications and active or repressed genes
therefore required the development of a new technique. In 1988, Crane-Robinson
and colleagues published the first example of ChIP, demonstrating that acetylated
histones were directly associated with active genes, and establishing a robust
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method that separates chromatin on the basis of the histone modification itself
(Hebbes et al., 1988).
ChIP allows one to determine whether a specific histone modification or
protein of interest is directly associated with a specific region of the genome. ChIP
is generally performed with either formaldehyde-mediated crosslinking of proteins
and nucleic acids within living cells followed by sonication (crosslinking, x-link
ChIP), or by micrococcal nuclease (MNase) digestion of harvested cell nuclei and
isolation of solubilized mono or short oligonucleosomes (native ChIP) (Figure 1.8).
Crosslinking ChIP ‘freezes’ protein and nucleic acid interactions and enables the
analysis of nucleosomal as well as non-nucleosomal proteins such as TFs and RNA
polymerase, while native ChIP is more suitable for the analysis of core chromatin
and nucleosomal components such as histones and histone modifications (Kuo
and Allis, 1999; O’Neill and Turner, 2003). After sonication or nuclease digestion
to separate chromatin into oligonucleosomal fragments, an antibody to a specific
protein or modification of interest is used to immunoprecipitate nucleosomes
or oligonucleosomal fragments that contain the specific protein or modification.
Unbound areas of the genome that do not contain the specific protein or modification
are washed away. Bound DNA can then be isolated and a variety of techniques
can be used to probe for the presence of specific sequences, including blotting
with radioactively labeled DNA probes, PCR, or semi-quantitative real-time PCR
(Figure 1.8).
Recently, the development of microarrays and high-throughput sequencing
has allowed ChIP to provide global, genome-wide views of chromatin state in various
cell types (Barski et al., 2007; Mendenhall and Bernstein, 2008; Mikkelsen et al.,
2007). The hybridization of ChIP DNA to microarrays that tile across a portion of the
genome (ChIP-chip) was one early iteration of genome-scale location analysis, and
this technology yielded important insights, particularly in model organisms such as
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Figure 1.8: Chromatin immunoprecipitation and methods of analysis
For crosslinking chromatin immmunoprecipitation (x-link ChIP), proteins and nucleic acids in living
cells are first crosslinked with a crosslinker (x-linker) such as paraformaldehyde. For native ChIP,
no crosslinker is used. Cells are lysed, and nuclei are sonicated (x-link ChIP) or digested with a
nuclease (native ChIP) to break up chromatin into smaller oligonucleosome or mononucleosome
fragments. Highly selective antibodies are used to immunoprecipitate specific proteins or
modifications of interest. In this case, the antibodies are depicted as previously bound or conjugated
to a magnetic bead (left), and the antibodies bind to a specific histone tail modification (small green
spheres on histone tails). Chromatin that is not bound by the antibody (right) is washed away.
Chromatin fragments containing the protein or modification of interest are kept, and DNA from this
chromatin is isolated. This immunoprecipitated DNA can be analyzed in a variety of ways, including
dot blots with radiolabeled probes for specific genomic regions (left), PCR with specific primers
for genomic DNA (lower left), real-time PCR for relative quantitation (lower center), and massively
parallel sequencing (ChIP-seq, right). ChIP-seq DNA reads can then be aligned and mapped to a
reference genome of interest, enabling nucleosome level resolution (lower right). Each blue or red
dot indicates a read that has been specifically aligned to the + or – strand.
For review of crosslinking and native ChIP, see (Kuo and Allis, 1999; O’Neill and Turner, 2003).
For review of ChIP-seq, see (Barski and Zhao, 2009; Mendenhall and Bernstein, 2008).
Please see Appendix for detailed discussion of ChIP and ChIP-seq, and for specific ChIP-seq
protocols.
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yeast where small genome size allowed for interrogation of the entire genome (Lee
et al., 2002b; Pokholok et al., 2005; Ren et al., 2000; Yuan et al., 2005). However,
for genome-wide analysis of larger, more complex eukaryotic genomes, ChIP-chip
has largely been rendered obsolete by the advent of relatively low cost, ultra highthroughput sequencing. Following ChIP and DNA isolation, bound DNA can be
directly sequenced using massively parallel sequencing technologies such as those
developed by Illumina/Solexa, and this technique is known as ChIP-seq (Barski
et al., 2007; Barski and Zhao, 2009; Mikkelsen et al., 2007). Cluster generation
and single-molecule-based sequencing produces millions of short (usually 36 bp)
sequence tags in a single experiment, and these short sequences can be aligned
to a reference genome to generate a genome-wide map (Figure 1.8) (Barski and
Zhao, 2009). There are multiple advantages of ChIP-seq, including a relatively
unbiased approach to genomic location, higher resolution, the analysis of repetitive
areas of the genome, and the potential use of sequence polymorphisms to analyze
allele-specific incorporation (Barski et al., 2007; Barski and Zhao, 2009; Mikkelsen
et al., 2007).
As with any technique, there are limitations to ChIP-seq, particularly in
the inherent bias of both crosslinking and native ChIP for the representation of
specific, more accessible regions of the genome. This bias makes it advisable
to compare the genome-wide pattern of a specific modification or protein to the
genome-wide pattern of input chromatin prior to IP, or to the genome-wide pattern
of an IgG control (Barski and Zhao, 2009). In addition, crosslinking ChIP can
preserve multimeric complexes across large looped regions of DNA, and ChIPseq data from crosslinking ChIP therefore has the caveat that enrichment might
be due to an artifact of looping and protein-protein interactions rather than direct
DNA binding (Barski and Zhao, 2009). Finally, like any ChIP experiment from
multiple cells, genome-wide patterns from ChIP-seq represent an aggregate of the
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chromatin state of all cell types in the examined population. Cell type heterogeneity
can therefore produce conflated results from multiple chromatin states, and
even the population of a single cell type can represent cells with specific genes
at various stages of transcription. For example, populations of undifferentiated
mouse embryonic stem cells display heterogenous expression of multiple genes
such as Dppa3, Nanog, Rex1, Pecam1, Brachyury, and Twist 2 (Tanaka, 2009).
However, despite these limitations, ChIP-seq has emerged as a powerful highresolution technique for examining genome-wide localization (Barski and Zhao,
2009; Mendenhall and Bernstein, 2008).

Genome-wide localization of nucleosomes
The majority of histone modifications are found in the context of nucleosomal
histones that are incorporated into chromatin (Loyola et al., 2006). Various studies
have examined the localization of nucleosomes in multiple organisms (Jiang and
Pugh, 2009; Schones et al., 2008; Yuan et al., 2005). Most nucleosome positioning
studies use MNase digestion followed by DNA hybridization to tiling microarrays or
sequencing in order to profile nucleosome locations, or perform ChIP-chip or ChIPseq with an antibody to a core histone (Schones et al., 2008; Yuan et al., 2005).
Nucleosome positioning is non-random, and many aspects of nucleosome position
are dictated by the underyling DNA sequence, while nucleosome positioning at
specific loci can also be modulated by chromatin modifications, histone variants,
and a variety of chromatin remodeling machinery (Field et al., 2009; Henikoff,
2008; Segal et al., 2006; Segal and Widom, 2009). Each nucleosome wraps
approximately 146 bp of DNA, and positioned nucleosomes have a characteristic
length of short linker DNA between them, which averages ~38bp in humans (Jiang
and Pugh, 2009; Luger et al., 1997; Schones et al., 2008).
At most loci, nucleosome position can be represented by a continuous
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distribution, while at other loci, highly phased nucleosomes are more precisely
positioned (Jiang and Pugh, 2009). The first nucleosome (+1) after the transcription
start site (TSS) of both active and inactive genes is well-positioned, although
the exact location differs slightly between active and inactive genes (Schones
et al., 2008). At active genes in human cells, the 5’ end of the +1 nucleosome
peaks at +40bp, while the +1 nucleosome peaks at +10bp in inactive genes, a
phenomenon that can perhaps be attributed to positional constraints placed by
binding of the transcriptional machinery at the TSS of active genes (Schones et
al., 2008). Multiple studies have also established that a nucleosome free, or at
least nucleosome-depleted region, exists at the TSS of both active and inactive
genes, a phenomenon that causes a dip in general histone profiles at the TSS
(Jiang and Pugh, 2009; Jin et al., 2009; Schones et al., 2008) (Figure 1.9). The
level of nucleosome depletion at the TSS is dependent on gene expression,
with increased depletion at the TSS of active genes (Schones et al., 2008).
Nucleosome depletion at the TSS has recently been attributed to the instability
of nucleosome core particles at this region, as well as the presence of specific
nucleosome destabilizing DNA sequences at high CpG content promoters (Jin et
al., 2009; Ramirez-Carrozzi et al., 2009). Unlike inactive genes, where only the
+1 nucleosome is precisely positioned, multiple nucleosomes surrounding the
TSS of actively transcribed genes are highly phased, with specific positioning and
regular spacing of at least three nucleosomes upstream and five nucleosomes
downstream of the TSS (Schones et al., 2008) (Figure 1.9). Recent studies have
established that nucleosomes are also highly phased at TFBS with bound TFs,
suggesting that TF binding may promote regulated nucleosome positioning by
chromatin remodeling complexes, potentially modulating TF access to regulatory
elements (Henikoff, 2008; Zheng et al., 2009).
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Figure 1.9: Nucleosomes are phased around active transcription start sites
A. Top profile represents the average pattern of general H3 around the TSS of transcriptionally active
genes. Note the slight dip of H3 at the TSS itself, corresponding to a localized region of nucleosome
depletion. The bottom data represent nucleosome profiles taken from genome-wide sequencing
of micrococcal nuclease digested chromatin. Data in this bottom profile and its description are
adapted from (Schones et al., 2008). Nucleosomes near the TSS of expressed genes are phased
with respect to the TSS. The y axis shows the normalized number of sequence tags from the sense
strand (red) and antisense strand (green) of DNA at each position. The inferred nucleosomes are
shown by filled ovals that are numbered. The -1 nucleosome (light gray) is lower than the -2 or +1
nucleosome level in both active and inactive genes. This nucleosome depletion has been quantified
by (Schones et al., 2008), though a recent study has suggested that this apparent depletion may
stem from the fragility of H3.3/H2A.Z nucleosomes near the TSS (Jin et al., 2009).
B. Top profile represents the average pattern of general H3 around the TSS of unexpressed genes.
Bottom data represents nucleosome profiles around unexpressed genes, with data represented in
similar manner to A. The bottom data and legend is also adapted from (Schones et al., 2008). Only
one well-positioned nucleosome exists near the TSS of unexpressed genes.

Genome-wide patterns and functions of histone modifications at genes and
regulatory elements
The genome-wide localization of histone modifications is intimately related to
their function. Using ChIP-chip and ChIP-seq, landmark studies have recently
established genome-wide maps of covalent histone modifications in multiple cell
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types, including pluripotent ES cells, differentiated NPCs, CD4+ T cells, and various
immortalized cancer cell lines (Barski et al., 2007; Heintzman et al., 2009; Meissner
et al., 2008; Mikkelsen et al., 2007; Wang et al., 2008). Focusing predominantly on
covalent modifications of histone H3 and H4 to which highly selective antibodies
are available, these genome-wide studies demonstrate that specific histone
modifications are highly correlated with gene expression (Barski et al., 2007;
Mikkelsen et al., 2007). Transcriptionally active and repressed genes maintain
distinct modification-specific patterns across their transcription start site (TSS),
gene body, and transcription end site (TES) (Figure 1.10, 1.11). Although ChIPchip and ChIP-seq data typically depict the patterns for individual proteins or histone
modifications, it is important to recall that that individual histones, nucleosomes,
and chromatin domains are highly modified in vivo, and the combinatorial nature of
multiple weak multivalent interactions are likely to be critical to chromatin biology
(Ruthenburg et al., 2007b; Wang et al., 2008). As described, histones are highly
covalently modified (Kouzarides, 2007), but only a subset of these modifications
have been rigorously studied at the genome-wide level. Therefore, the following
section will focus only on the specific genome-wide patterns of histone methyl and
acetyl marks that have been well characterized in mammalian cells.

H3K4 methylation
Histone H3 lysine 4 trimethylation (H3K4me3) is strongly associated with transcription
initiation, and represents one of the best studied histone modifications to date
(Guenther et al., 2007; Ruthenburg et al., 2007a). H3K4me3 is thought to serve
as a genomic landmark for the transcription start site (TSS) in various biological
processes (Guenther et al., 2007). In yeast, H3K4me3 is found at the 5’ end of
active but not inactive genes (Santos-Rosa et al., 2002). However, the correlation
of H3K4me3 with gene expression in higher eukaryotes is more complex. High CpG
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Figure 1.10: Patterns of specific histone H3 methylation marks at active genes
Representative patterns of histone methylation marks and general histone H3 are shown at active
genes and regulatory elements. Note that H3K4me1 is uniquely enriched at enhancer elements as
well as across active genes. H3K4me3 is more restricted to a few nucleosomes surrounding the
TSS, and is relatively unenriched at enhancer elements. In contrast, H3K36me3 marks a broad
domain across an actively transcribed gene, which in mammalian cells can span many kilobases.
Nucleosomes containing histone H3 are widespread throughout the genome, with specific patterns
around TSS, and nucleosome depletion at the TSS itself.

content promoter (HCP) genes in both ES cells and differentiated cells are marked
by a peak of histone H3K4me3 and the presence of RNAPII, regardless of
whether the gene is active or repressed (Barski et al., 2007; Guenther et al., 2007;
Mikkelsen et al., 2007). Notably, the magnitude of the H3K4me3 signal at active
and repressed HCP genes still correlates with transcriptional activity, with greater
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Figure 1.11: Patterns of specific histone H3 methylation marks at repressed genes
Representative patterns of histone methylation marks and general histone H3 are shown at
repressed genes. The TSS of repressed genes can be marked with lower levels of H3K4me1 and
H3K4me3, and maintenance of H3K4me3 at the TSS may help to poise repressed genes for future
activation (Guenther et al., 2007; Wang et al., 2009). Some repressed genes have no detectable
H3K4 or H3K27 methylation (not shown) (Mikkelsen et al., 2007), and these genes may be less
amenable to future activation. Repressed genes in mammalian cells are also frequently marked
with H3K27me3, and this modification is deposited and read by polycomb group proteins (Whitcomb
et al., 2007). Note also that repressed genes do not show any enrichment of H3K36me3 depicted
in the previous figure. Nucleosomes containing histone H3 are widely distributed throughout
repressed genes, with a slight depletion at the TSS.

H3K3me3 signal at active TSS, and lower, but still distinctive peaks of H3K4me3
at repressed HCP gene TSS (Barski et al., 2007; Mikkelsen et al., 2007) (Figure
1.11). Although the pattern of H3K4me3 is generally represented by a tight peak at
a few nucleosomes following a gene TSS (with specific nucleosome peaks at +50,
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+210, and +360 bp), certain regions of the genome such as the Hox loci can show
a broader pattern of H3K4me3 in specific developmental contexts, a pattern that
may be related to large-scale transcription of intergenic non-coding RNA (Barski
et al., 2007; Bernstein et al., 2005; Guenther et al., 2005; Guenther et al., 2007;
Guttman et al., 2009; Rinn et al., 2007; Shilatifard, 2008).
H3K4me3 can be recognized by various specific effector proteins to
mediate multiple different biological outputs (Guenther et al., 2007; Ruthenburg
et al., 2007a; Shilatifard, 2008). For example, in the facilitation of transcription
initiation, H3K4me3 can be recognized by PHD finger domains of a component
of the NURF chromatin remodeling complex, as well as a PHD domain of the
well studied protein TFIID, a component of the basal transcription machinery
(Shilatifard, 2008; Vermeulen et al., 2007; Wysocka et al., 2006). In contrast,
recognition of H3K4me3 by ING proteins is also important for the repression of
proliferation genes following DNA damage, while recognition of H3K4me3 by
RAG2 is required for efficient V(D)J recombination (Matthews et al., 2007; Shi et
al., 2006). Intriguingly, the H3K4 methyltransferase Set1 is required for ribosomal
DNA silencing and telomere length maintenance in yeast, as well as for normal
rates of cell growth, but not for yeast viability (Briggs et al., 2001; Dehe and Geli,
2006). In higher eukaryotes, proteins responsible for ‘writing’ and ‘reading’ H3K4
methylation are encoded by trithorax group proteins, and H3K4 methylation may
play a more important role in fine-tuning and maintaining the positive regulation
of gene expression in metazoans (Schuettengruber et al., 2007). Recognition of
H3K4me3 by NURF has been functionally linked to the maintenance of Hox gene
expression during vertebrate development (Wysocka et al., 2006). In addition, a
recent genetic study demonstrated that deletion of the enzymatic SET domain of
the H3K4 methyltransferase mixed lineage leukemia (MLL) protein recapitulates
the homeotic phenotype in mice, further suggesting a role for H3K4 methylation in
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the regulation of epigenetic memory in mammals, though other non-histone targets
of MLL could also be functionally important (Terranova et al., 2006).
Different methylation states on the same histone amino acid can show
distinct genome-wide patterns of localization and distinct functions. For example,
in contrast to H3K4me3, H3K4me1 shows a distinct pattern, with enrichment
surrounding the TSS of active genes, a dip at the peak of H3K4me3 nucleosomes,
and a broader distribution across the gene body of active genes (Figure 1.10)
(Barski et al., 2007; Meissner et al., 2008).

Unlike H3K4me3, H3K4me1has

recently been shown to have a strong genome-wide co-localization with TFBS,
enhancers, and regulatory elements (Heintzman et al., 2007; Robertson et al.,
2008; Wang et al., 2008) (Figure 1.10). H3K4me2 also shows a pattern that is
similar to H3K4me1, with enrichment surrounding the TSS, depletion at the peak
of H3K4me3, and broader enrichment into the gene body of active genes, as well
as enrichment at regulatory elements (Barski et al., 2007). Specific functions
for H3K4me1 and H3K4me2 at regulatory elements have not been determined,
although H3K4me2 was recently shown to play a role in the recruitment of HDACs
and the suppression of nucleosome acetylation at the 5’ end of transcribed genes
in yeast, just downstream of the high levels of nucleosome acetylation at H3K4me3
near the TSS (Kim and Buratowski, 2009).

H3K36 methylation
H3K36me3 is a robust marker of actively transcribed gene bodies (Barski et al.,
2007; Mikkelsen et al., 2007). In contrast to the tight peaks of a few nucleosomes
marked by H3K4me3, H3K36me3 is often found over wide transcribed domains,
particularly in larger eukaryotic genomes where smaller exons can be separated
by long introns of many kilobases (Barski et al., 2007; Mikkelsen et al., 2007)
(Figure 1.10). H3K36me3 is a highly conserved histone modification, and it has
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been associated with transcriptional elongation in a variety of eukaryotes, from
yeast to mice and humans (Bannister et al., 2005; Barski et al., 2007; Mikkelsen
et al., 2007). Intriguingly, despite its association with actively transcribed genes,
H3K36me3 has been functionally linked to transcriptional repression, and has
specifically been shown to function in the repression of spurious intragenic
transcripts (Carrozza et al., 2005; Keogh et al., 2005). Set2-mediated H3K36me3
is required for the recruitment of the HDAC Rpd3S complex to gene bodies in
yeast, leading to the model that H3K36me3 prevents aberrant transcriptional
initiation at sites other than the appropriate TSS, particularly at long or infrequently
transcribed genes (Carrozza et al., 2005; Li et al., 2007a; Li et al., 2007c). The
presence of unannotated H3K4me3 peaks followed by regions of H3K36me3 have
been recently used to identify novel transcripts and alternative TSS, as well as
thousands of large intergenic regions that give rise to non-coding RNA transcripts
(Guttman et al., 2009; Mikkelsen et al., 2007).

Histone lysine acetylation
For decades, histone acetylation has been associated with gene activation,
while histone deacetylation has been associated with gene repression (Struhl,
1998). Histone acetylation can have both direct and indirect effects on chromatin
(Shahbazian and Grunstein, 2007). Histone acetylation can be recognized by
bromodomains within specific effector proteins and chromatin regulatory complexes,
but can also directly regulate the degree of chromatin compaction, and is thought
to help overcome the inhibitory effects of nucleosomes on transcription (Dhalluin et
al., 1999; Shahbazian and Grunstein, 2007). Like histone methyl marks, different
histone acetyl marks are localized to distinct regions of active genes (Wang et
al., 2008). Histone acetyl marks such asH3K9ac and H3K18ac are enriched in
regions surrounding the TSS of active genes, while acetyl marks such as H4K12ac
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and H4K16ac are enriched in promoter and transcribed regions of active genes
(Wang et al., 2009b; Wang et al., 2008). Certain histone acetyl marks, such as
H3K18ac but not H3K14ac, are also enriched in a significant fraction of enhancers
(Wang et al., 2008). Genome-wide maps of histone acetylation, HATs, and HDACs
have recently been established, and these data reveal an unexpected association
of both HATs and HDACs with active genes (Wang et al., 2009b). Surprisingly, the
majority of HDACs are associated with active and poised genes, although some
HDACs are also associated with intergenic enhancers, and no HDACs were found
enriched at silent genes (Wang et al., 2009b). Current models suggest that most
HDACs function to remove acetylation from active genes, ‘resetting chromatin’ from
acetyl marks laid down by HATs associated with elongating polymerase in order
to maintain a level and localization of acetylation ideal for accurate transcription
(Wang et al., 2002; Wang et al., 2009b).

Histone H3K27 methylation marks repressed genes
In contrast to active genes, repressed genes are often marked by H3K27me3
(Schuettengruber et al., 2007).

Genome-scale studies have established that

H3K27me3 can be found at repressed genes either in broad domains, such as
at key developmental loci including the Hox genes, or in a more narrow domain
surrounding repressed TSS (Mikkelsen et al., 2007) (Figure 1.12). As mentioned
above, the ‘writing’ and ‘reading’ of H3K27 methylation is mediated by components
of the evolutionarily conserved polycomb group (PcG) proteins that are associated
with Hox gene repression (Whitcomb et al., 2007). Mammalian homologs of the
polycomb protein that recognizes H3K27 methylation in Drosophila are encoded
by the Cbx proteins, and these proteins have been found to play diverse roles in
the regulation of cell cycle, homeotic, and developmental genes (Bernstein et al.,
2006b; Whitcomb et al., 2007). H3K27me3 and polycomb proteins are enriched
40

60 kb

100 kb

H3K27me3

TSS

HoxA locus
ES

Gata6
ES
Figure 1.12: Different genomic patterns of H3K27me3

Two general patterns of H3K27me3 are found at repressed genes in mammalian cells. H3K27me3
can be found in relatively tight regions surrounding the TSS, as in the case of the repressed gene
Gata6 in ES cells (left). In contrast, larger regions such as the repressed Hox loci in ES cells can
be marked by broader domains of H3K27me3 (right).

at key developmental genes in ES cells, and polycomb proteins play critical roles
in gene repression and the maintenance of cellular state (Boyer et al., 2006; Lee
et al., 2006a). The PcG protein and H3K27 methyltransferase Ezh2 is required for
mammalian development, and Ezh2 and its homolog Ezh1 play complementary
roles in mediating H3K27me3 and transcriptional repression at key developmental
genes (Ho and Crabtree, 2008; O’Carroll et al., 2001; Shen et al., 2008). The
PcG protein Eed is required for global H3K27me2 and H3K27me3, and loss of
Eed leads to depression of multiple differentiation-specific PcG target genes in
undifferentiated ES cells (Boyer et al., 2006; Montgomery et al., 2005). More
recently, Ezh2 has been shown to play an important role in tissue-specific stem
cells, repressing specific proliferative and structural genes to fine-tune epidermal
differentiation (Ezhkova et al., 2009).

Cell type specific differences in chromatin state
Chromatin state has been shown to vary with cellular differentiation state. As
described previously (Figure 1.1), pluripotent embryonic stem (ES) cells have the
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Electron micrographs adapted from Niwa et al. 2007.
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Embryonic stem cells and differentiated cells display distinct chromatin

A. Electron micrographs of undifferentiated ES cells (left) and differentiated ES cells (right). Note
the large proportion of open euchromatin in the ES nucleus. Following differentiation into primitive
endoderm, the nucleus shrinks, and the distribution of electron-dense heterochromatin changes
dramatically.
B. Characteristic features of ES and differentiated cell chromatin. A variety of evidence suggests
that undifferentiated ES and iPS cells maintain a uniquely open and plastic epigenome (Bernstein
et al., 2007; Efroni et al., 2008; Gaspar-Maia et al., 2009; Meshorer et al., 2006; Niwa, 2007).

capacity to give rise to all differentiated cell types of the vertebrate embryo, and
they manifest a unique genome-wide chromatin state (Bernstein et al., 2007; Niwa,
2007). In particular, pluripotent ES cells have large and open nuclei with smaller
regions of heterochromatin, display hyperdynamic binding of structural chromatin
proteins, and exhibit global transcriptional hyperactivity (Efroni et al., 2008; GasparMaia et al., 2009; Meshorer et al., 2006) (Figure 1.13). ES cells also utilize unique
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chromatin remodeling complexes to maintain the pluripotent state. For example, the
esBAF chromatin remodeling complex is required for self-renewal and pluripotency
of mouse ES cells, but not for proliferation of differentiated fibroblasts (Ho et al.,
2009a; Ho et al., 2009b). In addition, the chromatin remodeling factor Chd1 is
required to maintain open, hyperdynamic chromatin and ES cell pluripotency
(Gaspar-Maia et al., 2009).

H3K4me3 and H3K27me3 bivalent domains mark specific repressed genes
As they have not yet committed to a particular lineage, ES cells must repress key
developmental lineage-specific genes in order to maintain the pluripotent state
(Chi and Bernstein, 2009; Jaenisch and Young, 2008). Some of the repression of
key developmental genes and upregulation of pluripotency genes can attributed to
reinforcing gene expression programs driven by specific TFs such as Oct4, Sox2,
and Nanog, as well as the expression of particular microRNA genes (Chen et al.,
2008b; Jaenisch and Young, 2008; Marson et al., 2008; Niwa, 2007). In addition,
recent studies have established that ES cells maintain unique global patterns of
specific covalent histone modifications at key lineage-specific genes (Barski et
al., 2007; Bernstein et al., 2006a; Meissner et al., 2008; Mikkelsen et al., 2007).
More than one-fifth of HCP genes in ES cells carry both H3K4me3 and H3K27me3
in their promoters (Bernstein et al., 2006a; Mikkelsen et al., 2007) (Figure 1.14).
These ‘bivalent’ genes are transcriptionally repressed in ES cells, and are enriched
in genes encoding key developmental TFs and cell surface proteins, leading to the
model that they represent repressed genes that are poised for activation following
cell differentiation (Bernstein et al., 2006a; Mikkelsen et al., 2007).
Upon cell differentiation, most H3K4me3 / H3K27me3 bivalent genes resolve
either to H3K4me3, H3K27me3, or neither mark, though a minority of these genes
remain bivalent (Figure 1.14) (Bernstein et al., 2006a; Mikkelsen et al., 2007).
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resolve to various chromatin states
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More than 20% of genes in ES cells
are marked with both H3K4me3 and
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downstream of the TSS, and H3K36me3
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Although most bivalent domains are located in punctuate regions around specific
TSS, certain regions of the genome such as the Hox loci are enriched in large-scale
bivalent domains (Figure 1.15) (Mikkelsen et al., 2007). As bivalent gene promoters
are transcriptionally repressed, but enriched in both H3K4me3 and H3K27me3,
these data suggest that repressive PcG activity is dominant over activating TrxG
activity (Bernstein et al., 2006a; Mikkelsen et al., 2007). Bivalent domains can
be divided into two classes based on their occupancy by PcG proteins (Ku et al.,
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Figure 1.15: Large-scale resolution of bivalent domains at the HoxA locus
In undifferentiated ES cells (left), the HoxA locus is bivalent and marked by widespread H3K4me3
and H3K27me3. Following differentiation into NPCs (right), the large bivalent domains at the
HoxA locus resolve into a region of active HoxA genes marked by H3K4me3 (left), and a region of
repressed HoxA genes marked by H3K27me3 (right). H3K4me3 and H3K27me3 ChIP-seq profiles
in ES cells were generated by Bernstein and colleagues (Mikkelsen et al., 2007), and are publicly
available from http://www.ncbi.nlm.nih.gov/geo/.

2008). Bivalent domains occupied by the polycomb repressive complex 1 (PRC1)
protein Ring1b are particularly enriched in developmental regulator proteins, and
these PRC1 positive bivalent domains are more likely to maintain H3K27me3 upon
differentiation (Ku et al., 2008). Although bivalent domains are not exclusive to
pluripotent cells and have been observed at lower frequency in differentiated cells,
ES cells are significantly enriched in bivalent domains relative to all other cell types
examined (Barski et al., 2007; Mikkelsen et al., 2007). Moreover, generation of
iPS cells also re-establishes bivalent domains at key developmental genes, further
suggesting that bivalent domains can reflect developmental potential (Mikkelsen
et al., 2008).
Although differentiated cells have a small number of repressed genes
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marked by both H3K4me3 and H3K27me3, a subset of genes in differentiated cells
marked only by H3K4me3 also remain surprisingly repressed (Guenther et al., 2007;
Wang et al., 2009b). These poised genes or ‘primed’ genes are transcriptionally
repressed, but still marked by the presence of H3K4me3, H2A.Z, and low levels
of histone acetylation near their TSS (Wang et al., 2009b). Poised genes rapidly
gain histone acetylation and increased RNAPII binding following treatment of cells
with HDAC inhibitors, suggesting that transient binding and cycling of HAT and
HDAC activity helps to keep these genes repressed but primed for future activation
(Wang et al., 2009b). The emerging picture of gene expression in mammalian cells
is therefore one in which there is a characteristic pattern of histone modifications
at active genes, and various patterns at poised, bivalent, or silent genes (Figure
1.14). Evidence suggests that multiple genes in undifferentiated and differentiated
cells are repressed, but poised for expression (Guenther et al., 2007; Mikkelsen
et al., 2007; Wang et al., 2009b). In ES cells, bivalent domains may enable large
numbers of genes to be poised with trithorax H3K4me3 activity and H2A.Z, but
the use of polycomb and H3K27me3 ensures an additional level of transcriptional
repression prior to differentiation.
Patterns of histone modifications at regulatory elements can also be
highly predictive of cellular state, and often vary more significantly than histone
modifications at promoters. A recent study has established that although histone
modifications at many promoters are largely invariant across cell types with different
patterns of gene expression, patterns of histone modifications at enhancers are
highly cell-type specific, and correlate strongly with global cell-type specific gene
expression programs (Heintzman et al., 2009). Taken together, recent genomewide studies demonstrate that different cell types use TFs, chromatin remodeling
machinery, DNA methylation, and histone modifications to reinforce cellular
gene expression programs, patterns of specific histone modifications are highly
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correlated with gene expression at promoters and enhancers, and genome-wide
maps of histone modifications and DNA methylation reflect lineage commitment
and cell state (Barski et al., 2007; Bernstein et al., 2006a; Boyer et al., 2006;
Heintzman et al., 2009; Meissner et al., 2008; Mikkelsen et al., 2007). However,
chromatin modifications and remodeling processes are not the only methods used
by cells to establish variation in the chromatin fiber.

Histone variants
In addition to chromatin modifications and nucleosome remodeling, eukaryotic
cells also generate variation in chromatin by the introduction of variant histone
proteins (Figure 1.7). Primary sequence variants of histones have been known for
some time (Allis et al., 1980; Allis et al., 1982; Bustin and Cole, 1968; Franklin and
Zweidler, 1977; Kinkade and Cole, 1966). Excluding histone H4, all core histone
proteins in mammals (H1, H2A, H2B, and H3) have several primary sequence
variants (Hake and Allis, 2006; Pusarla and Bhargava, 2005). These variants
can be classified into three general subtypes: replication-dependent, replicationindependent, and tissue-specific, based on their expression during the cell cycle,
tissue-specific expression, and their genomic organization (Albig and Doenecke,
1997; Frank et al., 2003; Hake and Allis, 2006).
During S-phase of the cell cycle, a eukaryotic cell must rapidly synthesize
histones in stoichiometric amounts (~108 molecules of each histone protein in a
mammalian cell) for the formation of chromatin with newly replicated DNA (Albig
and Doenecke, 1997; Marzluff et al., 2002). These cell-cycle regulated histones are
known as replication-dependent (RD) histones, and they account for the bulk of
histone synthesis in dividing cells (Albig and Doenecke, 1997). RD histone genes
are found in large, multigene, intronless clusters in the genomes of all metazoans,
and their transcripts lack a poly-A tail, ending instead in a highly conserved stem47

loop sequence (Heintz et al., 1981; Marzluff et al., 2002).
In contrast, replication-independent (RI) or so-called replacement histones
are synthesized throughout the cell cycle, independently from the replication of
DNA, and they are also synthesized in terminally differentiated or quiescent cells
(Frank et al., 2003). RI histone genes are solitary, typically intron-containing genes
located outside of the major histone gene clusters (Albig and Doenecke, 1997;
Carozzi et al., 1984; Heintz et al., 1981; Marzluff et al., 2002). RI histone gene
transcripts generally have long 5’ and 3’ UTRs, and are frequently polyadenylated
(Frank et al., 2003). In addition to RD and RI histones, metazoans also express a
number of tissue-specific (TS) histones. Some of the most highly studied examples
of TS histones are expressed during specific stages of gametogenesis, such as
the oocyte specific H1 variant H1oo (Tanaka et al., 2001), and the testis specific
H1 variants H1t and HILS1 (Drabent et al., 1996; Iguchi et al., 2003; Yan et al.,
2003).
Specific histone variants have been associated with particular biological
processes. For example, histone H2A.Z was first found specifically enriched in
transcriptionally active chromatin in Tetrahymena (Allis et al., 1986). More recently,
H2A.Z has been observed to be enriched at the transcriptional start sites of both
active and repressed genes and regulatory regions in specific organismal and
developmental contexts, and has been shown to play a variety of diverse roles
including the silencing of developmental genes in mouse ES cells, the suppression
of antisense RNA transcripts in S. pombe, and the protection of euchromatin
from the ectopic spread of heterochromatin in S. cerevisiae (Creyghton et al.,
2008; Jin et al., 2009; Meneghini et al., 2003; Raisner et al., 2005; Zofall et al.,
2009). Histone macroH2A has recently been shown to co-localize with Polycomb
complex members, and to facilitate the fine-tuning of Hox gene expression during
embryonic development (Buschbeck et al., 2009). In contrast, histone H2A.X is
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specifically phosphorylated in response to DNA damage, and this “guardian of the
genome” helps to facilitate the assembly of DNA repair complexes and maintain
genomic integrity (Celeste et al., 2002; Fernandez-Capetillo et al., 2004; Rogakou
et al., 1998). Variants of histone H1 are required for DNA methylation at specific
imprinted genes, and for the maintenance of global chromatin structure (Fan et al.,
2003; Fan et al., 2005; Happel and Doenecke, 2009).

H3.3 and the Histone H3 Variant Family
Recently, attention has focused on variants of histone H3, a highly evolutionarily
conserved family of histones whose members appear to be intimately associated
with a variety of critical biological processes, ranging from gene regulation and
centromeric function, to gametogenesis and early development (Govin et al., 2004;
Hake and Allis, 2006; Hodl and Basler, 2009; Howman et al., 2000; Loppin et al.,
2005).

Evolution of H3 variants
Mammals express at least five different types of H3 variants: a centromerespecific H3 variant CENP-A, replication-dependent H3.1 and H3.2, replicationindependent H3.3, and a testis-specific variant H3.1t (Hake and Allis, 2006). The
evolutionary conservation of non-centromeric H3 variants, and particularly of H3.3,
is remarkable (Malik and Henikoff, 2003). Outside of a centromeric H3 variant, the
budding yeast S. cerevisiae possesses only one H3 protein, and this H3 variant
is most closely related (>91% identity) to H3.3 in mammals (Malik and Henikoff,
2003). In yeast, the so-called H3.3 variant therefore serves all functions of histone
H3. Indeed, there is no known eukaryote which expresses H3.2 or H3.1 without
also expressing H3.3 (Malik and Henikoff, 2003). Over evolutionary time, various
branches of the eukaryotic tree have independently evolved distinct replication49

independent H3.3 and replication-dependent H3 variants on multiple occasions,
with replication-dependent H3 variants likely expanding in number to package larger
eukaryotic genomes, and H3.3 perhaps serving a more specialized function (Malik
and Henikoff, 2003; Thatcher et al., 1994; Waterborg and Robertson, 1996).

H3.3 differs from H3.2 and H3.1 at a small number of amino acids
Histone H3.3 differs from H3.2 and H3.1 at only 4 or 5 amino acids (Figure 1.16A).
Intriguingly, the location of these differences suggests that only one of these amino
acids (H3.3 serine 31) is accessible in the context of nucleosomal H3.3 (Davey
et al., 2002; Henikoff and Ahmad, 2005; Luger et al., 1997) (Figure 1.16B). The
H3 variant used in published structures of the nucleosome core particle was H3.2
(Davey et al., 2002; Luger et al., 1997). Examination of the nucleosome structure
indicates that the remainder of the differences between H3 variants (at positions
87, 89, 90, and 96) are buried within the H3 α-helix 2 beneath the DNA double
helices, and therefore inaccessible in an intact nucleosome (Henikoff and Ahmad,
2005). However, prior to nucleosome formation, pre-deposition machinery would
still be able to access and distinguish these amino acids in free H3.3 (Henikoff and
Ahmad, 2005).

H3.3 nucleosomes are less stable than H3.1 nucleosomes
Recent studies by Jin and Felsenfeld indicate that H3.3 nucleosomes may be
intrisinically less stable than nucleosomes containing H3.2 (Jin and Felsenfeld,
2007) (Figure 1.17). Nucleosomes containing H3.3 are unusually sensitive to
salt concentration (Jin and Felsenfeld, 2007). Following exposure to moderate
salt concentrations of 80mM, H3.3 nucleosomes isolated from chicken cells
preferentially lost H2A/H2B and H2A.Z/H2B, and H2A.Z in particular was not even
detectable. However, following nucleosome isolation under conditions of lower salt
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Figure 1.16: Sequence of H3 variants: most distinguishing H3 variant amino acids are not
accessible in the context of the nucleosome
A. Sequence alignment of mammalian H3.3, H3.2, and H3.1 histone variants. Histone H3 structural
elements such as the H3 tail and alpha helices are indicated above the sequences (Luger et al.,
1997). H3.3 differs from the replication-dependent (RD) variant H3.1 at two locations: position 31
in the H3 tail (red arrow), and at positions 87, 89, 90, and 96, a region towards the beginning of the
second alpha helix (red bracket). The RD variants H3.2 and H3.1 are identical, with the exception
of position 96.
B. Location of H3 variant amino acid differences in the context of the nucleosome. The nucleosome
core particle as crystallized by Luger and colleagues is shown here (Davey et al., 2002; Luger et al.,
1997). Core histone helices are shaded green. Histone protein backbones, including histone tails,
are shaded light blue. The nucleotide backbone of the surrounding DNA double helix is shaded
gray. The two views on the left represent the complete nucleosome core particle. Accessible
histone H3 tails are indicated by black brackets (left). In the two views on the right, all other
histones except H3 have been removed for purposes of visualization. The location of positions
31 (red arrows), as well as positions 87, 89, 90, and 96 (red brackets) are indicated. Note that
only position 31 in the H3 tail is accessible in the context of the nucleosome. The remainder of the
distinguishing H3 variant amino acids are buried and inaccessible in an intact nucleosome, though
they may impact nucleosome stability (Jin and Felsenfeld, 2007).
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(10mM), some H2A.Z was detectable with H3.3 nucleosomes, and H2A was not
preferentially depleted relative to H3.1 nucleosomes (Jin and Felsenfeld, 2007).
Relative quantitation of these stabilities revealed that H3.3/H2A.Z nucleosomes
were even more unstable than H3.3/H2A nucleosomes (Jin and Felsenfeld, 2007)
(Figure 1.17). This instability of H3.3 does not appear to depend on histone
RELATIVE STABILITY OF NUCLEOSOMES

H3.3 H2A.Z

H3.3

H2A

H3.1

H2A

H3.1 H2A.Z

?
Least stable

Most stable
Adapted from Jin and Felsenfeld, 2007.

Figure 1.17: Relative stability of H3 variant nucleosomes
Schematic representation of relative stability of nucleosomes containing different histone variants,
as assessed by Felsenfeld and colleagues (Jin and Felsenfeld, 2007).

acetylation, as identical results were observed in the presence and absence of
the HDAC inhibitor sodium butyrate (Jin and Felsenfeld, 2007). Intriguingly, H3.3/
H2A.Z nucleosomes exist in vivo, and are enriched in differentiated vertebrate
cells in specific areas of active chromatin, including active promoters and enhancer
elements (Jin and Felsenfeld, 2006, 2007; Jin et al., 2009). The relative instability
of H3.3 nucleosomes, and particularly of H3.3/H2A.Z nucleosomes, has been
suggested to reduce the energy required for nucleosome mobilization at dynamic
regions of the genome (Jin and Felsenfeld, 2007). Notably, this hypothesis has
yet to be rigorously demonstrated biochemically, as studies of nucleosome stability
have not yet been carried out with recombinant histone variants and remodeling
machinery. Overall, however, the results of Jin and Felsenfeld suggest that H3.3
may not simply function as an identical replacement variant, but may play a unique
role in active chromatin.
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Histone H3 genetics in mammals
In mice, the histone H3 variants H3.2 and H3.1 are encoded by 12 intron-less
genes located in two clusters (Marzluff et al., 2002). These multiple H3.2 and
H3.1 genes are expressed in all cycling cells, and their transcripts end in the highly
conserved stem-loop sequence characteristic of replication-dependent histone
genes (Marzluff et al., 2002; Plumb et al., 1983) (Figure 1.18). In contrast, H3.3
is encoded by two different genes (H3.3A and H3.3B) that code for the same
2 genes code for H3.3

1 kb

H3f3a

H3.3A

:chr1
0.5kb

H3f3b

H3.3B

:chr11

12 genes in 2 clusters code for H3.2 and H3.1
Hist1h3h

Hist1h3i

Hist1h3g

Hist1h3f

Hist1h3e
:chr13

Hist1h3d

Hist1h3c

Hist1h3b

Hist2h3c2

Hist2h3c1

Hist2h3b

Hist1h3a

0.5kb

0.5kb

:chr3

Figure 1.18: Genomic organization of mouse H3 variant genes
Genomic organization of mouse replication-independent H3.3 genes (top) and replicationdependent (RD) H3 genes (bottom) is depicted. Gene names are indicated in blue above the
gene, and chromosomal locations are shown on the right. Coding exons are depicted by thick blue
rectangles, non-coding exon sequence by thin blue rectangles. Note the presence of introns (thin
hashed lines) in H3.3A and H3.3B. The RD histone genes do not contain introns. RD histone H3
genes are found in two clusters on mouse chromosomes 13 and 3, along with other RD histone
H2B, H2A, and H4 genes (not shown). For more information on histone genomic organization in
mammals, see (Marzluff et al., 2002)
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amino acid sequence, but differ in their 5’ and 3’ UTRs, and also in their patterns
of developmental expression (Figure 1.18) (Albig et al., 1995; Bramlage et al.,
1997; Lopez-Fernandez et al., 1997; Wells et al., 1987). Unlike H3.2 and H3.1,
the expression of H3.3 genes is replication-independent, and H3.3 has long been
established as the only H3 variant synthesized in at high levels in quiescent, G1,
and G2 cells (Wu et al., 1982).

Genomic localization of H3.3 at genes and regulatory elements
Despite the very small number of amino acid differences between non-centromeric
H3 variants, groundbreaking work demonstrates that at least three of these amino
acids (A87, I89, G90 in H3.3) are critically important for regulating the genomic
localization of H3 variants in non-mammalian systems (Ahmad and Henikoff,
2002; Mito et al., 2005, 2007; Schwartz and Ahmad, 2005). Multiple lines of
experimental evidence suggest that H3.3 plays a role in transcriptionally active
chromatin in multicellular organisms. Using GFP-tagged histones H3.2 and H3.3
in Drosophila, Kami Ahmad and Steve Henikoff demonstrated in 2002 that a pulse
of H3.3 and not H3.2 is deposited at transcriptionally active ribosomal DNA arrays
in a replication-independent manner. In addition, they showed that three of the
four amino acid changes that distinguish H3.3 from H3.2 (A87, I89, G90 in H3.3,
see Figure 1.16A) allow H3.3-GFP to engage in replication-independent as well
as replication-dependent assembly into chromatin (Ahmad and Henikoff, 2002).
GFP-tagged H3.3 was also shown by David Spector’s group to be deposited
upon transcriptional induction of a transgene array in real-time analysis of single
mammalian cells (Janicki et al., 2004). In complementary studies, Schwartz and
Ahmad demonstrated that H3.3 deposition is temporally coupled to transcription
on Drosophila heat-shock genes (Schwartz and Ahmad, 2005). Strikingly, they
found H3.3 to be deposited and rapidly turned over at continually active genes,
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while incorporated H3.3 became stable at genes after transcription has ceased,
leaving behind an enduring marker of past transcriptional activity (Schwartz and
Ahmad, 2005, 2006). Mass spectrometry studies from our laboratory and others
have also revealed that specific post-translational histone modifications on histone
H3 associated with gene activation (H3K4 methylation, H3K36 methylation) are
significantly enriched on H3.3 in both Drosophila and mammalian cells (Hake et
al., 2006; Loyola et al., 2006; McKittrick et al., 2004).
Genome-scale profiling of tagged H3.3 provides strong evidence of H3.3
enrichment at transcriptionally active genes and cis-regulatory elements in
Drosophila S2 cells (Mito et al., 2005, 2007). Using chromatin immunoprecipitation
(ChIP) and tiling microarrays, Henikoff and colleagues found that H3.3 replacement
was significantly co-localized with sites of RNAPII and H3K4me2. They observed
that H3.3 was particularly prominent in the gene bodies of highly active genes,
which they suggest represent sites of ongoing transcription-coupled nucleosome
replacement (Mito et al., 2005). In 2007, Henikoff and colleagues found that H3.3
was also enriched in Drosophila at cis-regulatory domain boundaries and sites of
nuclease hypersensitivity, even outside of active or repressed genes (Mito et al.,
2007). This enrichment of H3.3 at Drosophila regulatory elements represented
an important demonstration that that specifically targeted H3.3 deposition was not
limited to sites of transcriptional activation, and showed that regulatory elements
are also sites of dynamic histone replacement (Mito et al., 2007).
Although genome-scale data regarding H3.3 localization in Drosophila has
been consistent, more limited experiments suggested alternative and sometimes
conflicting possibilities in vertebrates (Chow et al., 2005; Daury et al., 2006; Jin
and Felsenfeld, 2006; Sutcliffe et al., 2009; Tamura et al., 2009; van der Heijden
et al., 2007; Wirbelauer et al., 2005). One study found that H3.3 incorporation was
confined primarily to active promoters, while another reported that H3.3 is enriched
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throughout transcribed regions (Chow et al., 2005; Wirbelauer et al., 2005).
Felsenfeld and colleagues found no clear correlation between H3.3 incorporation
and levels of active transcription or histone modifications in chicken erythroid cells,
with enrichment of H3.3 found in upstream regulatory regions, coding regions, or
neither (Jin and Felsenfeld, 2006). H3.3 was shown to be constitutively unenriched
around the transcription start sites (TSSs) of two inducible genes in T-cells, but
enriched in the coding region upon gene induction (Sutcliffe et al., 2009). A recent
genome-wide study of H3.3 in HeLa cells found that H3.3 was enriched at the
TSSs of active genes, and also within the body of active genes in proportion
to transcriptional activity, but significant levels of H3.3 were not detected at the
TSSs of inactive genes in this differentiated human cancer cell line (Jin et al.,
2009). However, H3.3 was also recently shown to be constitutively enriched in the
promoter region of repressed interferon-inducible genes in fibroblasts, with levels
of enrichment increasing in the coding regions upon gene induction (Tamura et al.,
2009), and the precise pattern of H3.3 at active and inactive genes in vertebrates
therefore has yet to be clearly established.

Roles for H3.3 in large-scale nucleosome replacement
H3.3 has not been exclusively linked with transcriptional regulation at specific loci, but
has also been implicated in a variety of developmental processes and larger-scale
chromatin remodeling events that are likely to involve nucleosome replacement.
H3.3 appears to play particularly important roles in multiple phenomena related
to reproduction, including meiotic sex chromosome inactivation, sperm chromatin
remodeling, and paternal pronuclear decondensation (Orsi et al., 2009; Santenard
and Torres-Padilla, 2009).
H3.3

has

been

associated

with

chromosome-wide

formation

of

heterochromatin at the X and Y chromosomes during mouse male meiosis (van
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der Heijden et al., 2007).

During male meiotic prophase I, mammalian sex

chromosomes form a separate repressive chromatin domain known as the XY
body (Handel, 2004). The XY body is transcriptionally silenced, associated with a
variety of heterochromatic proteins and histone modifications, and restricted from
homologous recombination (Handel, 2004). Some of the heterochromatic proteins
and modifications enriched in the XY body include the histone variants macroH2A
and gammaH2A.X, H3K9 methylation, CBX1 (HP1beta), CBX3 (HP1gamma), as
well as the small ubiquitin modifier protein SUMO and the SUMO substrates PML
and Daxx (Handel, 2004; Metzler-Guillemain et al., 2003; Rogers et al., 2004).
Patterns of H3.3 gene expression coincide with the reported incorporation of
H3.3 protein at the XY body during meiotic sex chromosome inactivation (Bramlage
et al., 1997; van der Heijden et al., 2007). During mammalian spermatogenesis,
H3.3A mRNA can be detected throughout pre- and post-meiotic cells, while
expression of H3.3B appears to be more restricted but highly expressed during
meiotic prophase (Bramlage et al., 1997). Using an antibody specific to H3.1/H3.2,
van der Heijden and colleagues demonstrated that H3.1 and H3.2 are gradually
removed from the XY body during male meiotic prophase I (van der Heijden et al.,
2007). Moreover, using transgenic mice with tagged H3.3, they demonstrated that
H3.3 is simultaneously incorporated throughout the transcriptionally silenced X
and Y chromosomes during pachytene stages of spermatogenesis, coincident with
loss of most histone post-translational modifications and meiotic sex chromosome
inactivation (van der Heijden et al., 2007). This report marks the first demonstration
that H3.3 can also be associated with the large scale formation of repressive
heterochromatin.
H3.3 also plays a role in paternal pronuclear decondensation in a variety
of species (Orsi et al., 2009). The early stages of post-fertilization mammalian
development provide a remarkable example of genome-wide epigenetic
58

reprogramming, as gametic epigenetic marks are erased and replaced with
embryonic marks important for early embryonic development and toti/pluripotency
(Feil, 2009; Morgan et al., 2005). Soon after fertilization in mammals, paternal
genomic DNA is actively demethylated, the sperm pronucleus is decondensed,
and its protamines replaced by histones (Morgan et al., 2005). In Drosophila,
nucleosomes containing H3.3 and not H3.2 were shown to be specifically assembled
in the sperm pronucleus following fertilization, and the H3.3 chaperone HIRA and
the chromatin remodeling protein CHD1 are also required for male pronuclear H3.3
deposition (Bonnefoy et al., 2007; Konev et al., 2007; Loppin et al., 2005). There
is some evidence that H3.3 plays a similar role in mammals. The male pronucleus
in the pre-S-phase mouse zygote has been shown to be virtually devoid of H3.1/
H3.2, while H3.1/H3.2 is enriched in the female pronucleus (van der Heijden et
al., 2005). In addition, an antibody ostensibly specific to histone H3.3 has also
been used to demonstrate that H3.3 is present in the mouse oocyte as a maternal
factor, and incorporated preferentially into the male pronucleus prior to genome
activation, although this antibody is no longer available (Torres-Padilla et al.,
2006). Intriguingly, although most DNA in human sperm is packaged in protamines,
approximately 15% remains associated with histones, and both H3.3 and H3.1
have been shown to be present in core histones isolated from human sperm
(Gatewood et al., 1990). Therefore, it is also possible that incorporation of H3.3
might play a role in the recently demonstrated epigenetic marking that packages
key developmental loci in human sperm (Hammoud et al., 2009). However, despite
the association between H3.3 and various developmental processes, the precise
role of endogenous H3.3 in mammalian reproduction remains difficult to study due
to the lack of available antibody or genetic tools.
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H3.3 serine 31 phosphorylation is a mitosis specific mark
As mentioned above, the only residue unique to H3.3 that is accessible in the
context of the nucleosome is H3.3 serine 31 (H3.3S31) (Figure 1.16). H3.3S31
was recently established as a target for phosphorylation (H3.3S31p), and the
genomic localization of this phosphorylation appears to be developmentally
regulated (Hake et al., 2005; Wong et al., 2009). In human cervical cancer cells
(HeLa) and immortalized human embryonic kidney cells (HEK293), H3.3S31p is
specific to mitosis, and a timecourse of immunofluorescence (IF) studies revealed
that H3.3S31p is restricted to late prometaphase and metaphase (Hake et al.,
2005).

Chromosome spreads in HeLa and HEK293 show that H3.3S31p is

localized to regions surrounding centromeres on metaphase chromosomes (Hake
et al., 2005). Unlike in HeLa and HEK293 cells, H3.3S31p is localized to telomeres
in mouse ES cells (Wong et al., 2009) (Figure 1.19).

Telomeres and telomeric chromatin
Telomeres are specialized nucleoprotein structures that protect the ends of eukaryotic
chromosomes from DNA degradation and inappropriate DNA repair (Palm and
de Lange, 2008). Telomeres consist of tandem arrays of short DNA repeats, and
these sequences are maintained by the reverse transcriptase enzyme telomerase
(Blackburn et al., 2006; Luke and Lingner, 2009; Meyne et al., 1989; Palm and de
Lange, 2008). Telomere length and telomerase expression play important roles
in cellular lifespan and replicative capacity, and telomerase protects cells from
the cellular senescence and genomic instability that would otherwise result from
telomere shortening after excessive cell division (Allsopp et al., 1992; Bodnar et
al., 1998; Harley et al., 1990; Levy et al., 1992; Luke and Lingner, 2009). The ends
of linear eukaryotic chromosomes have the potential to be recognized as sites of
DNA damage, and a multi-protein complex known as shelterin therefore protects
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Figure 1.19: Developmentally regulated localization of H3.3S31 phosphorylation
A. Organization of mitotic mouse chromosomes. Unlike metacentric human chromosomes, with
their centromeres in the center of the chromosome, mouse chromosomes are acrocentric, with
their centromeres located extremely near one end of the chromosome. The distribution of major
(pericentric) and minor (centromeric) satellite repeats and of the various interspersed repetitive
elements are indicated.
B. The chromosomal localization of H3.3S31p is developmentally regulated (Wong et al., 2009).
In undifferentiated ES cells, H3.3S31p is localized to telomeres. However, upon retinoic acid
differentiation, H3.3S31p is relocalized to pericentromeric regions.

telomeres from recognition and repair by the non-homologous end joining and
homology directed DNA repair pathways (Palm and de Lange, 2008). Telomeres
are bordered by subtelomeric regions that are enriched in repetitive DNA and
contain a low density of genes (Blasco, 2007).
Like the rest of the eukaryotic genome, vertebrate telomeres are not made up
simply of naked DNA, but are packaged into nucleosomes containing core histones
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(Lejnine et al., 1995; Makarov et al., 1993; Tommerup et al., 1994). However,
telomeric chromatin appears to have unique features, including a short nucleosomal
repeat length, hypersensitivity to MNase, and higher intrinsic nucleosome mobility
(Pisano et al., 2007; Tommerup et al., 1994). Moreover, telomeric chromatin has
features that are consistent with repressive heterochromatin, including H3K9me3,
H4K20me3, hypoacetylation of H3 and H4, and DNA methylation of subtelomeric

Adapted from Blasco Nat Rev Genet 2007.

Figure 1.20: Telomeric chromatin has characteristics of heterochromatin
Telomeric and subtelomeric chromatin is heavily enriched in H3K9me3, H4K20me3, and HP1.
Subtelomeric DNA is heavily methylated by the DNA methyltransferases DNMT1, DNMT3A, and
DNMT3B. DNA methylation has been shown to inhibit telomere recombination. H3K9me3 and DNA
methylation act independently as negative regulators of telomere length. For review, see: (Blasco,
2007).

regions (Blasco, 2007) (Figure 1.20). In other organisms such as yeast and
Drosophila, telomeric heterochromatin has been shown to silence neighboring
genes in a phenomenon known as telomeric position effect (TPE), though clear
evidence for TPE in mammalian cells is still lacking (Ottaviani et al., 2008).
Although telomeres were long thought to be transcriptionally silent, recent studies
demonstrate that telomeres are transcribed into telomeric repeat-containing RNA
(TERRA), a large non-coding RNA that forms an integral component of telomeric
heterochromatin (Azzalin et al., 2007; Luke and Lingner, 2009; Luke et al., 2008;
Schoeftner and Blasco, 2008, 2009). The function of TERRA remains unclear, but
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it has been implicated in telomerase regulation, and has been suggested to play a
role in the stabilization and maintenance of telomeric heterochromatin state (Luke
and Lingner, 2009; Schoeftner and Blasco, 2009). Recent studies also indicate
that telomere chromatin state is developmentally regulated (Marion et al., 2009;
Schoeftner and Blasco, 2008). ES and iPS cell telomeres have unique features,
including telomerase activation during reprogramming, increased transcription
of telomeric RNA, and reduced levels of heterochromatic histone modifications
(Marion et al., 2009; Schoeftner and Blasco, 2008).

Developmentally regulated telomeric and pericentromeric localization of
H3.3 and H3.3 serine 31 phosphorylation
A study published in the last year suggests that H3.3 and H3.3S31p may play
a role in ES cell telomeric chromatin (Wong et al., 2009). Although H3.3S31p
is localized to telomeres of metaphase chromosomes in ES cells, upon ES cell
differentiation with retinoic acid H3.3S31p is re-localized to pericentromeric DNA
of metaphase chromosomes, similar to its localization in differentiated human
cancer cells (Hake et al., 2005; Wong et al., 2009) (Figure 1.19). H3.3S31p was
also found at the telomeres of mouse embryonic germ cells, further suggesting
that telomeric localization of H3.3S31p may be related to pluripotency (Wong et
al., 2009). Transfection of myc-tagged H3.3 and H3.2 revealed that H3.3 itself
was also specifically associated with telomeres in both metaphase chromosomes
and interphase nuclei, as demonstrated by colocalization with the telomeric
protein TERF1 (Wong et al., 2009). The telomeric localization of H3.3 increases
during early to late S/G2, suggesting that H3.3 telomeric deposition is coupled to
telomeric DNA replication, although the timing of H3.3 telomeric deposition has
not been conclusively established (Wong et al., 2009). Knockdown of H3.3A
and H3.B in ES cells induced a slight increase in telomere dysfunctional foci
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(TIFs), as assessed by the presence of DNA damage factors on telomeres such
as phosphorylation of gamma H2A.X (Wong et al., 2009). The authors of this
study also found that the putative H3.3 chaperone HIRA partially co-localized to
telomeres, and based on this co-localization they suggest that HIRA may mediate
H3.3 telomeric deposition (Wong et al., 2009). Notably, the precise function of H3.3
at telomeres remains unclear. Moreover, despite the co-localization of HIRA with
telomeres, the evidence described above also suggests that H3.3 is deposited at
telomeres during S-phase, while HIRA-mediated nucleosome assembly has been
demonstrated to occur independent of replication (Ray-Gallet et al., 2002; Tagami
et al., 2004; Wong et al., 2009). The authors do not remove HIRA and assess
telomeric incorporation, and therefore it is not clear whether HIRA is required for
H3.3 telomeric deposition in ES cells (Wong et al., 2009).

Functional requirements for H3.3 in transcriptional regulation and
development
Levels of H3 variants have been shown be important for regulating gene
expression in somatic cells and for organismal fertility (Couldrey et al., 1999;
Hodl and Basler, 2009; Sakai et al., 2009; Tamura et al., 2009). The expression
of specific genes in chicken erythroid cells was altered by expression of ectopic
H3.2 and H3.3, suggesting an active role for H3 variants, and raising concerns
regarding other experiments that use overexpressed tagged proteins to track H3
variants (Jin and Felsenfeld, 2006). In a mouse fibroblast cell line, knockdown of
H3.3 was also shown to inhibit the expression of interferon induced genes, again
implicating H3.3 in gene activation (Tamura et al., 2009). H3.3 may also play a
role in epigenetic memory (Ng and Gurdon, 2008), although later experiments
demonstrate that H3.3 is not absolutely required for development (Hodl and Basler,
2009; Sakai et al., 2009). Following nuclear transfer experiments, a number of
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embryos sometimes ‘remember’ their tissue of origin by inappropriately expressing
genes characteristic of their pre-transplantation lineage (Ng and Gurdon, 2005).
Intriguingly, overexpression of H3.3 has been shown to enhance this expression
of pre-transplantation lineage-specific genes following nuclear transplantation (Ng
and Gurdon, 2008). Although the role of H3.2 in this process was not directly
compared with H3.3, these experiments suggest that H3.3 levels (or at least H3
variant levels) may play a role in modulating epigenetic memory (Ng and Gurdon,
2008).

H3.3 in neurobiology
Chromatin regulation plays important roles in neuronal physiology and development
(Borrelli et al., 2008). Histone modifications and chromatin remodeling have been
linked with synaptic plasticity as well as with behavioral memory (Borrelli et al.,
2008; Fagiolini et al., 2009; Levenson and Sweatt, 2005). Moreover, multiple
neurological disorders involve mutations in genes that encode chromatin-binding
or chromatin-modifying enzymes.

Intriguing examples include mutations in a

chromatin remodeling protein that causes alpha-thalassaemia and X-linked
mental retardation (ATRX) syndrome, in a histone H3K4me3 demethylase that
causes epilepsy and X-linked mental retardation, in a DNA methylation binding
protein that causes Rett syndrome, and in a HAT that causes Rubinstein-Taybi
syndrome (Chahrour and Zoghbi, 2007; Gibbons et al., 2008; Murata et al., 2001;
Tahiliani et al., 2007). A common theme of these disorders is that mutations in
epigenetic regulators can alter chromatin structure and induce a broad spectrum
of neurodevelopmental defects.
Multiple lines of evidence suggest that H3.3 is likely to play an important
role in neuronal biology. Most neurons in the mammalian central nervous system
are post-mitotic, and H3.3 is the only H3 variant expressed at significant levels
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outside of S phase (Wu et al., 1982). H3.3 RNA and protein levels were observed
to increase during models of cell differentiation in non-neuronal systems (Krimer
et al., 1993; Lord et al., 1990; Wunsch and Lough, 1987). High levels of H3.3
protein have been found in differentiating rat neurons, and H3.3 has been shown
to become the dominant histone H3 variant protein in rat brain cortical neurons
(Pina and Suau, 1987; Scaturro et al., 1995). H3.3A and H3.3B mRNA are highly
expressed in distinctive, yet partially overlapping patterns of expression in the
mouse brain (Lein et al., 2007). Indeed, RNA in situ hybridization studies indicate
that H3.3A expression is relatively ubiquitous throughout the mouse brain, while
H3.3B is mostly expressed in the cerebellum and the hippocampus, particularly
in the dentate gyrus (Lein et al., 2007) (Figure 1.21).

Gene trap mice with

reduced expression of H3.3A also showed neuromuscular defects, with impaired
performance on tasks involving grip strength and muscle tone, further suggesting
a function for H3.3 in neuronal biology (Couldrey et al., 1999). However, due to the
hypomorphic nature of available studies and the lack of an available H3.3 antibody,
the specific role of H3.3 in mammalian neuronal biology has yet to be elucidated.

Requirements for H3.3 in sexual reproduction
H3.3 plays a critical role in sexual reproduction in multiple organisms. Given the
association of H3.3 with specific processes in the reproduction of a variety of
species, as described above (Cui et al., 2006; Loppin et al., 2005; Ooi et al., 2006;
Torres-Padilla et al., 2006), it is not surprising that recent studies have shown
that H3.3 is required for fertility in flies, ciliates, and mammals. Although the
functional requirements for H3.3 in transcriptional regulation are not absolute, the
requirements for H3.3 in fertility are clear (Couldrey et al., 1999; Hodl and Basler,
2009; Sakai et al., 2009).
In 1999, Couldrey and colleagues reported a retroviral gene trap insertion
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Figure 1.21: Patterns of H3.3A and H3.3B expression in the adult mouse brain
A. In situ hybridization of H3.3A and H3.3B RNA in the adult mouse brain reveals distinct, but
partially overlapping patterns of expression. Three-dimensional oblique views of the mouse brain
are shown, with structures depicted on the sagittal and coronal planes. H3.3A RNA expression
is shown in yellow (top), and H3.3B RNA expression is shown in orange (bottom). While H3.3A
expression is relatively ubiquitous, H3.3B expression is limited to the cerebellum (CB), hippocampus
(HIP), and olfactory bulb (OLF). Data was downloaded from the Allen Brain Atlas and represented
within the Allen Brain Atlas Brain Explorer.
B. Relative quantification of H3.3A and H3.3B expression level and expression density in specific
brain structures, as reported by the Allen Brain Atlas (Lein et al., 2007).
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into the first intron of murine H3.3A that created a hypomorphic mutation, resulting
in partial neonatal lethality, stunted growth, neuromuscular deficits, and male subfertility (Couldrey et al., 1999). H3.3A gene trap hypmorphic mice had significantly
fewer matings, and of these matings, only 6% of matings (1/16) of H3.3A
hypomorphic mice resulted in pregnancy, while 74% (48/65) of matings in wild-type
mice resulted in pregnancy (Couldrey et al., 1999). However, hypomorphic H3.3A
homozygotes still retained expression of H3.3A detectable by RT-PCR (Couldrey et
al., 1999), and the phenotype is also likely to have been rescued by the presence
of H3.3B, which codes for an identical protein. Therefore, the precise function of
H3.3 in mammalian development and physiology has yet to be established. More
recently, full knockouts of both copies of H3.3 have been reported in Drosophila
and Tetrahymena, and they show an absolute requirement of H3.3 for sexual
reproduction (Cui et al., 2006; Hodl and Basler, 2009; Sakai et al., 2009).
In both Drosophila and Tetrahymena, replication-independent H3.3 or H3.3like genes are not essential for growth, but are required for sexual reproduction
(Cui et al., 2006; Hodl and Basler, 2009; Sakai et al., 2009). In Tetrahymena, cells
can grow with expression of either replication-coupled or replication-independent
H3 variants, but they show an absolute requirement for the minor H3 variants (H3.3
and H3.4) in the production of viable sexual conjugation progeny (Cui et al., 2006).
Two groups recently reported that H3.3 was also absolutely required for fertility, but
only partially required for developmental viability of Drosophila (Hodl and Basler,
2009; Sakai et al., 2009). In Drosophila, loss of both copies of H3.3 leads to partial
but incomplete lethality (~42% viability), complete sterility, and transcriptional
defects, particularly at highly expressed genes (Sakai et al., 2009). However, the
survival of even less than half of H3.3 double null flies indicates that H3.3 is not
absolutely required for transcription (Hodl and Basler, 2009; Sakai et al., 2009).
Loss of both copies of H3.3 appears to be partially compensated by an increase
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in the expression of the normally replication-dependent histone genes, and these
upregulated histone gene transcripts were found to be polyadenylated (Sakai et
al., 2009). In double null H3.3 flies, expression of the H3.3 rescue transgene (but
not the H3.2 rescue transgene) suppresses overexpression of the endogenous H3
genes, suggesting that Drosophila cells can distinguish H3.3 expression from bulk
H3 (Sakai et al., 2009). These experiments also showed that maintaining wild-type
levels of H3K4 methylation is likely still important for transcriptional regulation, but
is still partially dispensable for normal fly development (Hodl and Basler, 2009), as
~20% of H3.3K4R mutant flies remain viable (Sakai et al., 2009).
The absolute requirement of H3.3 for fertility appears to be due to its role
in chromosome segregation during spermiogenesis, and remodeling of germline
chromatin (Sakai et al., 2009). H3.3 double null flies fail to properly condense and
segregate chromosomes during male meiosis, and they also show an abnormal
arrangement of chromatin in posmeiotic nuclei, indicating that H3.3 is critical for
remodeling of germline chromatin (Sakai et al., 2009). Intriguingly, in H3.3 double
null flies, H3.3S31A, H3.3K4R, and H3.3K9R rescue fly fertility, while expression of
H3.2 does not. Therefore, although known H3.3 modification sites are not required
for fertility, the H3.3 specific residues at 87, 89, and 90 (Figure 1.16) are absolutely
required, suggesting that these amino acids play an essential role in the remodeling
and packaging of germline chromatin (Sakai et al., 2009).

Histone H3 deposition machinery
Progress has also been made on the molecular machinery that deposit different
histones into chromatin (De Koning et al., 2007; Loyola and Almouzni, 2007).
Nucleosome deposition or nucleosome replacement occurs in a variety of
contexts, including DNA replication, DNA repair, and transcription, and elucidating
the mechanisms responsible for recruitment of histone deposition factors to these
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distinct genomic regions remains an intense area of research (De Koning et al.,
2007; Groth et al., 2007b; Polo and Almouzni, 2006).
Histone H3.3 has been shown to be deposited into Drosophila chromatin
in both a replication-coupled (RC) and replication-independent (RI) manner, while
H3.2 deposition is coupled to replication (Ahmad and Henikoff, 2002). Biochemical
purification of tagged-H3.1 and H3.3 from human HeLa cells by Nakatani, Almouzni
and colleagues yielded complexes with distinct histone chaperones (Tagami et
al., 2004). The chromatin assembly factor complex 1 (CAF-1) was associated
with H3.1, while histone regulatory protein A (HIRA) was associated with H3.3
(Tagami et al., 2004).

Intriguingly, CAF-1 has been shown to mediate DNA

synthesis-dependent nucleosome assembly, while HIRA mediates DNA synthesisindependent nucleosome assembly (Ray-Gallet et al., 2002; Tagami et al., 2004).
The H3.1 associated CAF-1 is composed of three subunits, p150, p60, and
p48, and this complex has been shown to promote chromatin assembly in the
context of DNA replication or DNA repair (Polo et al., 2006; Smith and Stillman,
1989; Verreault et al., 1996). Biochemical studies have established that CAF1 is required for DNA synthesis-dependent nucleosome assembly in Xenopus
egg extracts, as well as for H3.1 deposition at sites of DNA damage (Polo and
Almouzni, 2006; Polo et al., 2006; Tagami et al., 2004). CAF-1 colocalizes with
the proliferating cell nuclear antigen (PCNA) on newly replicating DNA, and is
also required for heterochromatin organization in pluripotent ES cells and for early
embryonic development (Shibahara and Stillman, 1999; Verreault et al., 1996).
In addition to CAF-1 and HIRA, which appear to be specific in their preferences
for H3.1 or H3.3, Nakatani, Almouzni, and colleagues identified a variety of proteins
were associated with both H3.1 and H3.3 (Tagami et al., 2004). Such common
partners included the histone H3-H4 chaperones anti-silencing function 1 (ASF1) A
and B, the H1 binding protein NASP, the histone acetyltransferase HAT1, and the
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common CAF-1 subunit p48, also known as retinoblastoma binding protein p48
(Tagami et al., 2004).

Deposition of H3-H4 as a heterodimer
H3 and H4 form a (H3-H4)2 tetramer in the context of the nucleosome, and
this tetramer is stable even in the absence of DNA, leading to the longstanding
suggestion that H3 and H4 are deposited into chromatin as a tetramer (Baxevanis
et al., 1991; De Koning et al., 2007; Luger et al., 1997). However, H3-H4 bound to
HIRA or CAF-1 was recently shown to exist as a H3-H4 heterodimer rather than a
tetramer (Tagami et al., 2004). Moreover, recent biochemical and crystallographic
studies have demonstrated that both yeast and human ASF1 bind to and stabilize
H3-H4 heterodimers, physically blocking assembly of (H3-H4)2 tetramers (Bao and
Shen, 2006; English et al., 2006; Natsume et al., 2007) (Figure 1.22). Soluble
H3-H4 heterodimers have also been shown to be heavily acetylated at H4K5
and H4K12 (Groth et al., 2007b; Loyola et al., 2006). In vertebrate cells, H4K5ac/
H4K12ac is largely mediated by the two subunit enzyme HAT1-RbAp46, and these
acetyl marks have been implicated in histone deposition in a variety of organisms
(Barman et al., 2006; Sobel et al., 1994; Sobel et al., 1995; Verreault et al.,
1996, 1998). HAT1 is surprisingly dispensable for replication-coupled chromatin
assembly in vertebrate cells, though HAT1-/- cells are sensitive to DNA damage,
and the precise function of H4K5/K12 diacetylation remains unclear (Barman et
al., 2006; Groth et al., 2007b).
Current models suggest that ASF1 serves as a donor for deposition of
H3.1-H4 or H3.3-H4 heterodimers by CAF-1 or HIRA (De Koning et al., 2007)
(Figure 1.22). CAF-1 and HIRA both bind to ASF1A, and ASF1A and ASF1B have
recently both been shown to play a role in both RI and RC nucleosome assembly
in human cells (Galvani et al., 2008; Tang et al., 2006). Interestingly, although
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Figure 1.22: Current view of H3 variant deposition pathways
The current view of histone H3 variants in chromatin assembly pathways is depicted here. Histone
H3 and H4 can exist in vitro as tetramers or dimers, and it remains unclear (question mark)
whether the H3-H4 dimer utilized in histone deposition comes from a split tetramer (upper left)
or a dimeric source (upper right). Asf1 (red) interacts with and stabilizes the H3-H4 dimer. In
replication-coupled chromatin assembly (right), Asf1a and Asf1a act as histone donors for CAF-1.
In replication-independent chromatin assembly (left), Asf1a and Hira act together to deposit H3.3
during transcription or specific developmental contexts. Chd1 may also cooperate with Hira to
deposit H3.3 into chromatin (Konev et al., 2007). Notably, in current models, Hira is required for
H3.3-specific deposition into chromatin (De Koning et al., 2007).
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HIRA is reported to physically interact with ASF1A but not ASF1B, depletion of
both ASF1A and ASF1B were required to inhibit G1-phase deposition of H3.3 into
chromatin, indicating that H3.3 deposition during G1 could still occur in the absence
of a HIRA-ASF1A interaction (Galvani et al., 2008; Zhang et al., 2005).
ASF1 can participate in both nucleosome assembly and disassembly (Groth
et al., 2007b). In human cells, ASF1 interacts with the putative replicative helicase
(MCM1-7) through a H3-H4 bridge, and ASF1A is required for vertebrate cellular
viability and chromatin assembly during replication (Groth et al., 2007a; Sanematsu
et al., 2006). In yeast and mammals, ASF1 is required for H3K56ac, a modification
that has been associated with sites of newly deposited histones in replicationcoupled, replication-independent, and DNA damage deposition pathways (Chen
et al., 2008a; Fillingham and Greenblatt, 2008; Li et al., 2008; Recht et al., 2006;
Yuan et al., 2009). Because of its common role in multiple H3 deposition pathways,
H3K56ac has been suggested as a universal signature of newly assembled yeast
chromatin (Fillingham and Greenblatt, 2008). Interestingly, despite its association
with chromatin assembly, H3K56ac has also been shown to be required for normal
promoter activation and chromatin disassembly in yeast (Williams et al., 2008).
Genome-scale profiles of H3K56ac have recently been established in human
ES cells, and this modification localizes to both active and inactive promoters,
significantly overlapping with binding sites for key regulators of pluripotency (Xie et
al., 2009). H3K56ac has been shown to increase the affinity of H3 for CAF-1 as well
as the histone chaperone Rtt106 in yeast, although it remains unclear if H3K56ac
can play a similar role in increasing affinity of H3.3 for HIRA in mammalian cells
(Chen et al., 2008a; Fillingham and Greenblatt, 2008; Li et al., 2008).
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HIRA – histone regulatory protein A
The H3.3-associated protein HIRA is required for replication-independent
nucleosome assembly in vitro, and for Drosophila male pronuclear decondensation
in vivo (Bonnefoy et al., 2007; Loppin et al., 2005; Ray-Gallet et al., 2002; Tagami et
al., 2004). Although humans have a single HIRA protein, both budding and fission
yeast have two homologs of HIRA that function together (Blackwell et al., 2004;
Kanoh and Russell, 2000; Lamour et al., 1995; Spector et al., 1997). The yeast
homologs of HIRA (Hir1 and Hir2 in S. cerevisiae) were initially identified as factors
that repress the transcription of histone genes outside of S phase, and subsequent
work has shown that these proteins are also required to maintain pericentromeric
heterochromatin in the fission yeast S. pombe (Blackwell et al., 2004; Lamour et al.,
1995; Spector et al., 1997). Consistent with its role in the promotion of repressive
yeast chromatin, nucleosomes bound by the yeast HIR complex are resistant
to chromatin remodeling by SWI/SNF (Prochasson et al., 2005). Intriguingly, a
recent study demonstrated that the S. pombe HIRA complex functions as a global
transcriptional repressor, and is particularly important for promoter silencing and
the suppression of cryptic antisense transcripts (Anderson et al., 2009). HIRA has
also been show to play a role in human heterochromatin, as HIRA and ASF1A drive
chromosome condensation during the formation of specialized heterochromatin
domains known as senescence associated heterochromatin foci (SAHF) (Adams,
2007; Ye et al., 2007; Zhang et al., 2007; Zhang et al., 2005). However, despite this
conserved functional association with heterochromatin and gene repression, the
human homolog of HIRA was specifically isolated with H3.3 from HeLa cells, and
as we have seen, H3.3 is largely associated with active chromatin (Ahmad and
Henikoff, 2002; Tagami et al., 2004).
Biochemical experiments clearly link HIRA to replication-independent
nucleosome assembly (Ray-Gallet et al., 2002; Tagami et al., 2004). HIRA is a
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large WD repeat containing protein with seven WD repeats conserved between
yeast and human HIR proteins, and both the mammalian and Xenopus homologs
of HIRA interact with core histones (Lorain et al., 1996; Lorain et al., 1998;
Magnaghi et al., 1998). Following this observation, the role of HIRA in nucleosome
assembly has largely been studied in Xenopus egg extracts, which provides a
powerful system for studying chromatin assembly (Ray-Gallet et al., 2002; Tagami
et al., 2004). Proteins contained within egg extracts will assemble chromatin on
plasmid DNA (Almouzni and Mechali, 1988; Gaillard et al., 1996; Gaillard et al.,
1999).

If the plasmid has been previously irradiated with UV, the Xenopus egg

extract will perform chromatin assembly in the presence of DNA synthesis during
the process of nucleotide excision repair (Gaillard et al., 1999). In Xenopus egg
extracts, immunodepletion of HIRA did not effect nucleosome assembly of UVirradiated plasmids coupled to nucleotide excision repair, but loss of HIRA severely
impaired DNA synthesis independent nucleosome assembly (Ray-Gallet et al.,
2002; Tagami et al., 2004). This defect in replication-independent nucleosome
assembly could be rescued by addition of recombinant HIRA protein and (H3-H4)2
tetramers, or HIRA enriched protein fractions from egg extract (Ray-Gallet et al.,
2002). More interestingly, RI nucleosome assembly could also be rescued by
purified H3.3 complexes from HeLa cells that contained HIRA, but not by purified
H3.1 complexes that contained CAF-1, or by recombinant HIRA or CAF-1 (RayGallet et al., 2002; Tagami et al., 2004). Conversely, CAF-1 was required for DNA
synthesis-dependent nucleosome assembly, and this defect could be rescued by
purified H3.1 complexes containing CAF-1, but not by H3.3 complexes (Tagami
et al., 2004). In summary, these experiments demonstrated that H3.3 and H3.1
associate with distinct complexes containing HIRA and CAF-1, and these complexes
are critical for replication-independent (HIRA) or replication-dependent (CAF-1)
chromatin assembly (Ray-Gallet et al., 2002; Tagami et al., 2004).
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Functional roles for HIRA and CHD1 in histone deposition, cellular
differentiation, and development
In vivo studies in Drosophila show that Hira is required for chromatin assembly
and H3.3 deposition in the male pronucleus (Loppin et al., 2005). Maternal HIRA
and FLAG-tagged H3.3 accumulate in the male pronucleus following fertilization
(Loppin et al., 2005). A specific point mutation in Hira (known as ssm) impairs
H3.3 deposition to the male pronucleus and prevents male pronucleus formation,
providing the first direct link between H3.3 deposition and Hira in vivo (Loppin et al.,
2005). Without male pronuclear formation, embryos from eggs laid by ssm females
are haploid, develop only with maternal chromosomes, and die before hatching
(Loppin et al., 2005; Loppin et al., 2000). Interestingly, this same mutation in Hira
enhanced variegation of a reporter transgene located between heterochromatin
and a site for H3.3 replacement, suggesting that Hira-directed H3.3 replacement
can help to counteract heterochromatin spreading in somatic cells (Nakayama et al.,
2007). Surprisingly, however, later studies demonstrated that paternal chromatin
assembly after fertilization is the only developmental process in flies that absolutely
required HIRA, as HIRA null flies were viable, but females were sterile (Bonnefoy et
al., 2007). Strikingly, HIRA is not required for global H3.3 deposition in Drosophila
embryos or adult cells, providing intriguing hints that alternate pathways exist to
mediate H3.3 nucleosome assembly (Bonnefoy et al., 2007).
Loss of Hira in mammals leads to a far more severe phenotype than the loss
of Hira in flies (Bonnefoy et al., 2007; Roberts et al., 2002). Targeted mutagenesis
of Hira in mice results in gastrulation defects and patterning abnormalities of
mesendodermal derivatives prior to early embryonic lethality (Roberts et al.,
2002).

Hira -/- embryos displayed a range of defects, including a distorted

primitive streak, delayed and abnormally displaced expression of the primitive
streak marker Brachyury, severe axial and paraxial defects, abnormally patterned
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neuroepithelium, abnormal placentation, and cardiovascular defects (Roberts et
al., 2002). Inbred Hira -/- embryos died by E10, and even Hira -/- embryos from
mice crossed to an outbred background all died by E11 (Roberts et al., 2002).
Despite this severe early embryonic lethality of Hira -/- embryos, Hira -/- ES cells
are surprisingly viable (Meshorer et al., 2006).
Hira -/- ES cells proliferate normally and express the pluripotency marker
Oct4, but show elevated levels of unbound histones (Meshorer et al., 2006). Hira
-/- ES cells display significantly reduced incorporation of both H3.3-YFP and H3.2YFP as assessed by rapid fluorescence recovery after photobleaching (FRAP),
and salt extraction also revealed an increased fraction of soluble H3 (Meshorer
et al., 2006). Intriguingly, Hira -/- ES cells underwent accelerated differentiation
during the formation of embyoid bodies, despite normal regulation of differentiation
specific genes in Hira -/- ES cells (Meshorer et al., 2006). However, while they
gave rise to early NPCs, Hira -/- cells failed to progress further into differentiated
neurons (Meshorer et al., 2006).

Overall, these results indicate that Hira is

dispensable for the survival of proliferating ES cells, but is required to maintain
normal levels of histone incorporation, and is required for normal gene regulation
and survival during cellular differentiation and early development (Meshorer et al.,
2006; Roberts et al., 2002).
HIRA has also been implicated in genome-wide DNA demethylation and
chromatin remodeling during establishment of the mammalian germ line (Hajkova
et al., 2008). Primordial germ cells (PGCs) are specified during early mammalian
development (Hayashi and Surani, 2009; Kurimoto et al., 2008; Ohinata et al., 2005).
In mice, this germline specification takes place at E7.25, followed by migration
of PGCs into the developing gonad (Saga, 2008). Between E11.5 and E12.5,
PGCs show genome-wide DNA demethylation and erasure of genomic imprinting
(Hajkova et al., 2002; Lee et al., 2002a), along with a concomitant genome-wide
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transient or persistent loss of histone modifications such as H3K9me3, H3K9ac, 4/
H2AR3me2, H3K27me3, and histone variants such as H1 (Hajkova et al., 2008).
This specific timepoint also exactly coincides with the nuclear localization of Hira
and the nuclear exclusion and cytoplasmic localization of CAF-1 (Hajkova et al.,
2008). These results implicate Hira-mediated histone replacement and potentially
H3.3 as likely players in mammalian germline chromatin remodeling, though the
lack of H3.3 antibodies has made further study of this question difficult.
More recently, the chromatin remodeling factor CHD1 was also shown to be
important for H3.3 deposition in Drosophila (Konev et al., 2007). Like Hira, maternal
CHD1 is required for H3.3 deposition into the male Drosophila pronucleus, and for
the participation of the male pronucleus in zygotic mitoses (Konev et al., 2007).
Embryos from homozygous CHD1-null females develop with only maternally
derived genomes, and die before hatching (Konev et al., 2007). CHD1 physically
associates with Hira, and has been suggested to work together with Hira to mediate
H3.3 incorporation into chromatin, with Hira proposed to be essential for histone
delivery, and CHD1 thought to facilitate histone deposition (Konev et al., 2007).
Recent studies have established that CHD1 plays an important role in the
regulation of chromatin state in mammalian cells (Gaspar-Maia et al., 2009; Sims and
Reinberg, 2009). The chromodomain of human CHD1 recognizes H3K4me2 and
H3K4me3, and CHD1 localizes to euchromatic promoter regions in mouse ES cells
(Gaspar-Maia et al., 2009; Sims et al., 2005). CHD1 is critical for the maintenance
of open chromatin in ES cells, as downregulation of CHD1 impaired the normally
hyperdynamic chromatin state of ES cells and significantly increased the number
of H3K9me3 nuclear foci (Gaspar-Maia et al., 2009). Surprisingly, CHD1 RNAi ES
cells showed global maintenance of the ES cell transcriptome (Gaspar-Maia et al.,
2009). However, CHD1 RNAi ES cells also have a high propensity for neuronal
differentiation, and failed to give rise to primitive endoderm or beating cardiac
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mesoderm, indicating that CHD1 is required for normal pluripotency (GasparMaia et al., 2009). After the recent finding that CHD1 is required for H3.3 male
pronuclear deposition in Drosophila (Konev et al., 2007), it has been speculated
that CHD1 may be mediating its role in pluripotency and open chromatin through
the deposition of H3.3 (Gaspar-Maia et al., 2009).

Localization and function of H2A.Z in undifferentiated and differentiated
cells
As described above, the histone H2A variant H2A.Z co-occupies nucleosomes with
H3.3 at specific regions of the genome in differentiated cells, including promoters
and regulatory elements, and H3.3/H2A.Z nucleosomes have been shown to be
less stable in vitro (Jin and Felsenfeld, 2006, 2007; Jin et al., 2009).
Recent ChIP-chip studies of H2A.Z have revealed that the genome-wide localization
of this variant changes dramatically upon ES cell differentiation (Creyghton et al.,
2008). Previous studies in differentiated cells have shown that H2A.Z is enriched
at promoters in proportion to transcriptional activity, as well as at regulatory regions
(Barski et al., 2007; Jin et al., 2009; Schones et al., 2008). However, in pluripotent
ES cells, H2A.Z localizes to the promoters of transcriptionally repressed polycomb
target genes, but changes its localization to the promoters of actively transcribed
genes upon ES cell differentiation to neural precursor cells (NPCs) (Creyghton
et al., 2008). Knockdown studies demonstrated that H2A.Z is required for the
repression of polycomb target genes, and that the localization of H2A.Z and the
PcG protein Suz12 at target promoters is interdependent, with loss of appropriate
localization of one upon depletion of the other (Creyghton et al., 2008). Embryoid
body differentiation and tetraploid complementation studies revealed that H2A.Z
depleted ES cells were defective in differentiation and lineage commitment, failing
to repress pluripotency genes and failing to express differentiation specific genes
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in an appropriate spatiotemporal manner (Creyghton et al., 2008). Overall, these
studies indicate that H2A.Z plays an unexpected role in gene repression in ES
cells, and is required for ES cell differentiation.

Concluding remarks – setting the stage for the study of H3.3 in mammalian
embryonic stem cells
As we have seen, the H3.3 Drosophila deposition factor Chd1 and the H3.3
nucleosome destabilizing partner H2A.Z are both required for mouse ES cell
pluripotency (Creyghton et al., 2008; Gaspar-Maia et al., 2009). In addition, the
Drosophila H3.3 chaperone HIRA is also required for normal ES cell differentiation
(Meshorer et al., 2006; Roberts et al., 2002). Given these findings, as well as the
conserved association between H3.3 and active chromatin, H3.3 itself has therefore
been speculated to play an important role in in establishing and maintaining the
pluripotent chromatin state (Creyghton et al., 2008; Gaspar-Maia et al., 2009).
However, as of yet, no genome-wide studies in pluripotent cells distinguish between
H3 variants, nor do they examine the genome-wide role of Hira or other histone
chaperones in specifying H3.3 deposition at specific genomic regions. Although
studies in non-mammalian systems point to a role for H3.3 in transcriptional
regulation and an absolute requirement for H3.3 in sexual reproduction (Hodl and
Basler, 2009; Sakai et al., 2009), the genomic localization and precise function of
H3.3 in mammalian cells remains an open question.
With this foundation, I set out to generate tools to examine the genomewide localization of histone H3.3 in mammalian cells. In Chapter Two, I will
describe a zinc finger nuclease technology that enables rapid targeting and point
mutagenesis of the endogenous histone H3.3B gene in mouse ES cells. After
differentiating these targeted ES cells into neural precursor cells (NPCs), I have
generated the first genome-wide profiles of H3.3 localization in pluripotent and
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differentiated cells. In Chapter Three, I use wild-type and Hira -/- ES cells to
determine the genome-wide dependence of H3.3 localization on the known H3.3
chaperone Hira. Surprisingly, my data show that while Hira is required for H3.3
deposition at active and repressed genes, Hira is not essential for H3.3 deposition
at telomeres, ribosomal DNA (rDNA), and specific TFBS. This striking result
opened up an entirely new area of investigation for my thesis, and for the field. To
identify H3.3 interacting proteins that might mediate Hira-independent deposition
at these elements, I purified H3 variant associated proteins from wild-type and Hira
-/- ES cells, and my collaborator Dr. Ileana Cristea performed mass spectrometry. I
found that the chromatin remodeling protein Atrx and the death domain associated
protein Daxx specifically associate with H3.3 in the presence and absence of Hira.
Finally, I show that Atrx is required for deposition of H3.3 at telomeres and rDNA,
and for the repression of telomeric and ribosomal transcription. In Chapter Four,
I will describe some additional collaborative studies in progress, and discuss the
implications of my work for the field. Chapter Five provides the materials and
methods used in my studies. In addition, I have included an appendix with a more
detailed discussion of ChIP and ChIP-seq, as well as the ChIP-seq protocols that
I have used throughout my work.

82

Chapter 2
Genome-Wide Patterns of Histone H3.3
In Mammalian Cells Are Dependent On
ENDOGENOUS Amino acid Sequence and
Cellular State
Summary
As described in Chapter One, recent landmark studies have established genomewide maps of covalent histone H3 modifications in undifferentiated mammalian
embryonic stem (ES) cells and differentiated cells (Barski et al., 2007; Mikkelsen
et al., 2007). However, mammalian cells express multiple, distinct genetically
encoded variants of histone H3 proteins (Ahmad and Henikoff, 2002). When I
began this project, there were no genome-wide or genome-scale profiles of histone
H3 variants in any mammalian cell type. Moreover, existing H3 antibodies used
by prior studies did not distinguish between these variants. As we have seen in
Chapter One, histone H3 variants are extremely similar in sequence, and most
of the amino acids that differ between them are inaccessible in the context of the
nucleosome (see Figure 1.16).
To distinguish histone H3 variants, I began a collaboration with Sangamo
Biosciences with the goal of rapidly editing the genomic sequence of an endogenous
mammalian histone H3.3 gene. I used designed zinc finger nucleases (ZFN) and
short, drug selection-less targeting constructs to rapidly knock-in epitope tags
into the endogenous histone H3.3B gene of mouse embryonic stem (ES) cells.
To establish the dependence of H3 variant localization on amino acid sequence,
I created point mutations to mutate endogenous H3.3B towards H3.2 or H3.1.
Using chromosome spreads and chromatin immunoprecipitation assays coupled to
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high-throughput sequencing (ChIP-seq), I have established the first genome-wide
profiles of histone H3 variants in mammalian ES cells. To facilitate the analysis of
this genome-wide ChIP-seq data, I began a collaboration with Assistant Professor
Deyou Zheng at the Albert Einstein College of Medicine. My collaborators and I found
enrichment of H3.3 in specific genic and intergenic regions and in specific repeats,
including telomeres. Surprisingly, we determined that H3.3, like H3K4 methylation,
is enriched around transcription start sites of high CpG content promoters in ES
cells at both transcriptionally active and transcriptionally repressed genes, as well
as the transcription start sites of H3K4me3/H3K27me3 bivalent genes. We also
found H3.3 enriched within the bodies of actively transcribed protein coding genes
as well as large intervening non-coding RNAs (lincRNAs), correlated with H3K36
methylation. We observed that the transcription end sites of highly transcribed
genes are marked by peaks of H3.3 and phosphorylated RNA polymerase II, a
phenomenon that has not been previously described in mammalian cells. We also
found that H3.3, like H3K4me1, is enriched at all known classes of transcription
factor binding sites (TFBS) in mouse ES cells, including intergenic sites. We
established that all specific patterns of H3.3 enrichment in mammalian cells are
dependent on H3.3-specific amino acid sequence. Following differentiation of
ES cells into neuronal precursor cells, we showed that the localization of H3.3
changes with cellular differentiation at specific genic and intergenic sites. The
work described in this chapter provides a foundation for integrating histone H3
variants into our understanding of the epigenetic regulation of gene expression in
mammalian cells.
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Results
Designed zinc finger nucleases enable highly efficient gene targeting of
histone H3.3B
In mammals, histone H3.3 is encoded by two different genes (H3.3A and H3.3B)
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Figure 2.1: Expression of H3.3A
and H3.3B in embryonic stem (ES)
cells and neural precursor cells
(NPCs)
Real-time PCR indicates expression
of H3.3A and H3.3B mRNAs in mouse
ES cells and differentiated NPCs, as
a percentage of Gapdh expression.
The pluripotency gene Pou5f1 (Oct4)
and the neural precursor marker
Olig1 serve as controls for cellular
differentiation state.

ES cells and neural precursor cells, with H3.3B
slightly more highly expressed than H3.3A in ES
cells (Figure 2.1).
To establish a rapid system for editing the
endogenous H3.3B gene, I began a collaboration
with Sangamo Biosciences, which has recently
developed a technology for highly efficient
targeting of mammalian genes (Urnov et al., 2005).
Gene editing using conventional technology has

been very successful (Hogan, 2007), but is generally inefficient (<~0.0025% of
electroporated cells) due to the low frequency of homologous recombination,
(Carroll, 2008; Hasty et al., 1991; te Riele et al., 1992). Despite the low efficiency
of homologous recombination, the introduction of a selectable antibiotic resistance
marker (neomycin phosphotransferase) and the use of antibiotics (neomycin, G418)
has made conventional gene targeting a viable and successful technology (Hogan,
2007; te Riele et al., 1992). Zinc finger nuclease (ZFN) mediated gene targeting
is based on the principle that a targeted DNA double-strand break can significantly
enhance the efficiency of homologous recombination at a target site by engaging
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the cell’s endogenous system of homologous recombination and homologydirected repair (Carroll, 2008; Urnov et al., 2005). The C2H2 zinc finger is the most
common DNA binding motif in all metazoa (Tupler et al., 2001; Vaquerizas et al.,
2009), and recent work has enabled the engineered design of linked zinc fingers to
recognize particular DNA sequences with high specificity (Klug, 2005; Moore et al.,
2001). Linked and engineered zinc fingers can be coupled to the nonspecific DNA
restriction enzyme FokI to target a DNA double strand break to a desired location,
producing homologous recombination with specific targeting rates as high as 20%
for the introduction of simple point mutations, even in the absence of selection
(Urnov et al., 2005).
Taking advantage of the highly efficient technique of targeted gene editing
mediated by ZFNs (Carroll, 2008), my collaborators and I used an archive of
validated two-finger modules (Doyon et al., 2008; Urnov et al., 2005) to generate
designed ZFNs specific to the last coding exon of the H3.3B gene (Figure 2.2A).
I designed two general strategies to knock-in epitope tags fused to the C-terminus
of H3.3B. One strategy was designed to knock-in the open reading frame (ORF) of
the enhanced yellow fluorescent protein (EYFP) (Figure 2.2B). To address possible
concerns regarding the large size of the EYFP tag (~25 kDa), I also designed a
parallel strategy to knock-in a shorter C-terminal hemagglutinin (HA) tag (~1 kDa),
along with an internal ribosomal entry site (IRES) and separately translated EYFP
tag to provide a fluorescent reporter of H3.3B gene expression (Figure 2.2C).
Promoter-less and selection-less donor constructs were designed and cloned out
of mouse B6 genomic DNA to include approximately 0.6kb of genomic sequence
at the 5’ end of H3.3B, an EYFP sequence with a short linker or a HA-IRES-EYFP
sequence fused to the final H3.3B coding exon, and approximately 1.3kb of the
H3.3B 3’UTR (Figure 2.2B-C). Because of the high efficiency of ZFN mediated
gene targeting (Carroll, 2008; Urnov et al., 2005), our donor constructs are far
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Figure 2.2: Zinc finger nuclease targeting scheme
A. Schematic of zinc finger nucleases (ZFNs) recognizing endogenous H3.3B (h3f3b) sequence
near the end of the last coding H3.3B exon on chromosome 11.
B-C. Designed zinc finger nucleases (ZFN) target the endogenous sequence of the final coding
exon of the mouse histone H3.3B gene on chromosome 11. Exon coding sequences are thick
rectangles, while non-coding untranslated sequences are thin rectangles. ZFN targets doublestrand break (DSB) formation at H3.3B, with H3.3B-EYFP or H3.3B-HA-IRES-EYFP donors
generating a new H3.3B allele with a C-terminal EYFP tag (B), or a C-terminal HA tag (red) and an
internal ribosomal entry site (IRES, blue) followed by an EYFP reporter (C). Location is indicated for
genomic forward primer outside donor sequence and reverse primer within EYFP sequence used
for PCR amplification and sequencing (2.6) of modified H3.3B alleles.
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shorter than traditional mouse targeting constructs (Deng and Capecchi, 1992;
Hasty et al., 1991).
I found ZFN-mediated targeting to be highly efficient at driving homologydirected addition of EYFP or HA epitope tags, as well as targeted editing of the
endogenous H3.3B gene. To evaluate the efficiency of ZFN-mediated targeting,
the donor construct was transfected in the presence and absence of ZFN. 5 days
post-transfection with H3.3-EYFP donor construct in the absence of ZFN, less

A

EYFP Donor Only

EYFP Donor + ZFNs

1.4%

Forward Scatter

Forward Scatter

0.0%

B

Yellow Fluorescence

Yellow Fluorescence

Figure 2.3: Zinc finger nucleases increase the efficiency of H3.3B gene targeting in mouse
embryonic stem cells by over 1000 fold.
A-B. Mouse ES cells were transfected with H3.3-EYFP donor alone (A) or H3.3-EYFP donor + zinc
finger nucleases (ZFN) (B) and analyzed by flow cytometry 3 days post-transfection. Percentage
EYFP positive are indicated.

than 1/100,000 cells were EYFP+ (Figure 2.3A), while in the presence of ZFN,
between 1-2% of cells were EYFP+ (Figure 2.3B), an over 1000 fold increase in
the frequency of EYFP+ cells.
To evaluate the dependence of H3.3 localization on amino acid sequence,
we also modified our donor constructs to knock-in point mutations at H3.3 codons
31, 87, 89, 90, and 96 and simultaneously mutate endogenous H3.3B towards H3.2
or H3.1 via marker co-conversion (Figure 2.4). While greater than 1% of ES cells
were correctly targeted with H3.3-EYFP or H3.3-HA-IRES-EYFP at one H3.3B
allele, we found that the introduction of point mutations decreased the efficiency
of gene targeting (Figure 2.5). Less than 0.5% of cells became EYFP+ following
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Figure 2.4: Gene conversion of endogenous H3.3B to epitope-tagged H3.2 or H3.1
A-B. Schematic of ZFN-mediated targeting of H3.3B EYFP tag and simultaneous co-conversion of
H3.3B sequence to H3.2 (A) or H3.1 (B). A similar ZFN-mediated co-conversion strategy was used
with H3.2-HA-IRES-EYFP and H3.1-HA-IRES-EYFP donor constructs. Point mutations in H3.3
sequence are indicated in green. F and R primers used for PCR (2.6) are indicated as in 2.2B-C.

transfection of H3.2-HA-IRES-EYFP or H3.1-HA-IRES-EYFP donor constructs,
and less than 1/5 of these EYFP+ clones were fully corrected to H3.2 or H3.1
codons at the modified allele (Figure 2.5, and data not shown). Notably, these
percentages are still far higher than traditional gene targeting in the absence of
ZFNs (te Riele et al., 1992).
Fluorescent cells were manually picked or sorted using flow cytometry
(Figure 2.3, 2.5), and screened by PCR (Figure 2.6A), sequencing of both H3.3B
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Figure 2.5: Efficiency of H3.3B gene targeting is dependent on donor sequence homology.
Introduction of point mutations decreases efficiency of targeting for H3-EYFP donors (top row) and
H3-HA-IRES-EYFP donors (bottom row). Mouse ES cells were transfected with H3-EYFP donor +
ZFN or H3-HA-IRES-EYFP donor + ZFN and analyzed by flow cytometry 3 days post-transfection.
% EYFP positive cells are indicated.

alleles (Figure 2.6B), and Southern blotting (Figure 2.6C). Nearly all (>90%) of the
EYFP+ ES lines targeted with H3.3B-EYFP were correctly targeted at the H3.3B
allele, as confirmed by genomic PCR and sequencing.

Multiple heterozygous

lines of ES cells were isolated with one targeted allele expressing H3.3-EYFP,
H3.2-EYFP, H3.1-EYFP, H3.3-HA-IRES-EYFP, H3.2-HA-IRES-EYFP, or H3.1S31HA-IRES-EYFP (Figure 2.6B-C). Initial screening was unable to isolate a line fully
converted to H3.1-HA; hence, lines denoted H3.1S31-HA retain the H3.3 serine
at position 31. All heterozygously tagged ES cells retain three “wild-type” copies
of H3.3 genes, including one copy of unmodified H3.3B (Figure 2.6C), and two
copies of H3.3A. Western blots demonstrate comparable protein expression in the
wild-type and mutated epitope-tagged H3.3B ES lines (Figure 2.6D).
Although ZFN-mediated gene targeting represents a far more efficient
method of mutageneis than conventional methods (Carroll, 2008; te Riele et al.,
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Figure 2.6: Generation and validation of H3.3B targeted ES lines
A. Genomic DNA from wild-type and targeted ES lines were subject to PCR amplification, using
primers indicated in 2.2 and 2.4.
B. Nucleotide sequence of wild-type and modified H3.3B alleles. PCR fragments shown in A were
sequenced and aligned to sequence from endogenous wild-type H3.3B allele. These nucleotide
sequences correspond to the amino acids shown in Figure 1.16. Note that in cell lines targeted
with H3.1-HA-IRES-EYFP, mutagenesis was incomplete, with H3.3B mutated to H3.1 sequences
at positions 87, 89, 90, and 96, but retaining a serine at position 31. These cell lines are hereafter
referred to as H3.1S31.
C. Genomic DNA from wild-type and targeted ES cells was digested with BsrBI and analyzed by
Southern blot, using a 638bp AvaII fragment of the H3.3B donor as probe.
D. Whole cell extracts from wild-type ES and targeted ES cell lines were immunoblotted with GFP,
HA, and C-terminal (untagged) H3 antibodies as indicated.
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1992; Urnov et al., 2005), it is still necessary to carefully screen targeted cells
to ensure desired genomic editing. For example, upon Southern blotting, my
collaborators and I found some clones (<20%) where the donor sequence had
misintegrated elsewhere in the genome (Figure 2.7A, right). In addition, I also
found that both the ‘modified’ and ‘unmodified’ allele had occasional (~10% of
sequenced clones) mutations and small deletions at the ZFN target site (Figure
2.7B), a phenomenon likely to reflect incomplete DNA repair by non-homologous
end joining (Carroll, 2008). It is important to note that the only ‘selection’ in this case
is EYFP fluorescence. Although the frequency of undesired mutations (~10-20%)
following ZFN-mediated gene targeting point to the necessity of careful screening,
the frequency of desired clones remains far higher than conventional targeting,
where several hundred clones are often screened even following antibiotic selection
(te Riele et al., 1992).

Specific enrichment of H3.3 in gene-rich euchromatic chromosome arms and
telomeres is dependent on amino acid sequence
To assess the incorporation and chromosomal distribution of H3 variants in mouse
ES cells, I initially examined chromosome spreads from metaphase-arrested ES
cells. Mouse chromosomes are acrocentric, with visible regions of DAPI-dense
heterochromatin around their centromeres (Martens et al., 2005) (see Figure
1.19). Analysis of H3.3-EYFP and H3.3-HA ES lines demonstrates that H3.3 is
specifically localized to euchromatic chromosome arms in mouse ES cells, and
is markedly depleted in DAPI-dense pericentric heterochromatin (Figure 2.8A-B,
2.9). In addition, telomeric foci of H3.3 are visible on the Y-chromosome in mouse
ES cells (Figure 2.8A-B, 2.9B-C, K-L, inset). This result is in agreement with
recent studies that found H3.3 serine 31 phosphorylation (H3.3Ser31p) enriched
at telomeres in mouse ES cells (Wong et al., 2009). However, it is notable that
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Figure 2.7: Misintegrations and mutations in some ZFN targeted lines
A. Uncropped Southern blots as in 2.6C. Some clones (for example, right) show additional genomic
integrations of donor construct.
B. Alignment of modified H3.3B alleles. Note examples of point mutation and deletion at the ZFN
target site. A slightly higher frequency (~10%) of similar deletions and point mutations were also
observed upon sequencing the ‘unmodified’ H3.3B allele (not shown).
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Figure 2.8: Genomic localization of histone H3.3 is dependent on amino acid sequence
A-D. H3.3-EYFP and H3.2-EYFP ES cells were treated with 0.2 μg/mL colchicine for 2 hrs at 37˚C.
Samples were prepared by cytospin, fixed, stained with DAPI, and visualized using DeltaVision
deconvolution microscopy. EYFP and DAPI overlays of maximum-intensity projections from multiple
Z-stacks are shown. Bar: 10μm. Panels A and C show EYFP fluorescence. Panels B and D show
EYFP and DAPI overlays. Inset shows a higher magnification image of the Y-chromosome, which
wwas. identified by its size and uniform DAPI density . For complete chromosome sprads including
DAPI alone, as well as H3.1-EYFP and H3.3-HA, please see the following Figure 2.9.
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Figure 2.9: Complete chromosome spreads of H3.3-EYFP, H3.2-EYFP, H3.1-EYFP, and H3.3HA ES cells
A-F. Full representative metaphase chromosome spreads as described in 2.8, including DAPI
fluorescence (A,D).
G-I. H3.1-EYFP localization is widespread throughout metaphase chromosomes, similar to H3.2EYFP.
J-L. H3.3-HA localization is similar to H3.3-EYFP localization. Chromosome spreads were
performed using anti-HA (HA.11) for immunofluorescence of H3.3-HA (green). The Y-chromosome
in all spreads was identified by its size and DAPI pattern, and is shown in the inset of A-L.
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Figure 2.10: Foci of H3.3 serine 31 phosphorylation represent a small subset of overall H3.3
on metaphase chromosomes
A-F. Metaphase chromosome spreads of H3.3-EYFP ES cells were performed as in previous
figures, and stained with DAPI (blue), anti-GFP (green), and H3.3Ser31p (red). Inset shows the
Y-chromosome. Note partial co-localization of H3.3 and H3.3Ser31p on Y-chromosome telomeric
foci.
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Figure 2.11: H3.3 significantly colocalizes with H3K4me3, and does not colocalize with
H3K9me3 pericentric heterochromatin on metaphase chromosomes
A-F. Metaphase chromosome spreads were stained with DAPI (blue), anti-GFP (green), and antiH3K4me3 (red). Note overlap of H3.3 and H3K4me3 (E).
G-L. Metaphase chromosome spreads were stained with DAPI (bleu), anti-GFP (green), and antiH3K9me3 (red). Note lack of overlap of H3.3 and H3K9me3 (K).
M-N. Scatterplots depicting colocalization of H3.3-EYFP and H3K4me3 (M) and H3.3-EYFP and
H3K9me3 (N), as anayzed with DeltaVision software through multiple Z-stacks. Each dot represents
a pixel, with red or green signal intensity plotted on the Y or X axes. The relative intensities of H3.3EYFP and H3K4me3 are significantly correlated (Pearson Coefficient of Correlation 0.9146), while
H3.3-EYFP and H3K9me3 are poorly correlated.
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most H3.3 is found incorporated on chromosome arms, while telomeric foci of
H3.3Ser31p represent only a small subset of overall H3.3 incorporation, and most
clearly co-localize with H3.3 at the Y-chromosome (Figure 2.10).
To determine if H3.3 colocalizes with euchromatic or heterochromatic histone
modifications, I co-stained H3.3-EYFP ES cell metaphase chromosomes with an
antibody to H3K4me3 or H3K9me3. H3K4me3 is associated with transcription
start sites of active and inactive genes (Guenther et al., 2007; Ruthenburg et al.,
2007a), while H3K9me3 is associated with repetitive pericentric heterochromatin in
areas such as major and minor satellite repeats (Martens et al., 2005) (see Chapter
One). Colocalization analysis revealed that H3.3 is significantly colocalized with
H3K4me3 on a chromosome-wide level (Figure 2.11, A-F, M, note yellow color
in E). In addition, H3.3 does not colocalize with H3K9me3, further indicating
that H3.3 is largely excluded from H3K9me3-rich pericentric heterochromatin
(Figure 2.11, G-L, N). These data provide further evidence that H3.3 is enriched
in euchromatic chromosome arms, and is largely excluded from H3K9me3-rich
pericentric heterochromatin.
To establish whether the specific patterns I observed for H3.3 are dependent
on amino acid sequence, I also performed chromosome spreads from ES cells
in which one allele of H3.3B was mutated to H3.2-EYFP or H3.1-EYFP (Figure
2.8A-D, 2.9). Metaphase chromosome spreads demonstrate that while each of
our EYFP-tagged H3 variants are incorporated into chromatin in ES cells, their
chromosomal localization is dependent on amino acid sequence (Figure 2.8AD). Despite expression of H3.2 or H3.1 from the endogenous H3.3B promoter,
with identical C-terminal epitope tags, specific patterns of H3.3 enrichment were
abolished upon mutation of H3.3 to H3.2 or H3.1, and exclusion from pericentric
heterochromatin is lost (Figure 2.8C-D, 2.9). In contrast to the telomeric localization
of H3.3 on the Y-chromosome, H3.2 and H3.1 are incorporated throughout the
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largely heterochromatic Y-chromosome (Figure 2.8C-D, inset, 2.9). Notably, I did
not observe significant differences in localization between H3.2 and H3.1, both
of which are broadly distributed throughout metaphase chromosomes (Figure
2.9). These results demonstrate that the sequence of an endogenous H3.3 gene
determines its genomic localization in mammalian cells.

ChIP-seq provides genome-wide maps of histone H3 variants
To extend my analysis at higher resolution, I next used ChIP-seq to analyze the
genome-wide localization of histone H3 variants in mouse ES cells. As described
in Chapter One, ChIP-seq provides an enormously powerful, relatively unbiased
technique for determining genome-wide localization and profiling chromatin state
(Barski and Zhao, 2009; Mendenhall and Bernstein, 2008). ChIP-seq provides
digital, quantitative data regarding genome-wide patterns of enrichment, allows
for the interrogation of repetitive sequences, and enables mononucleosome level
resolution (Barski and Zhao, 2009; Mendenhall and Bernstein, 2008).
As ChIP-seq is a relatively new technique, I performed multiple controls to
validate these findings, including comparison of native versus crosslinking ChIPseq, comparison of HA and EYFP tagged variants, sequencing of input ChIP DNA,
sequencing of anti-HA ChIP samples from untagged wild-type ES cells, ChIP-seq
of control histone modifications, and real-time PCR validation of independent ChIP
samples (see Chapter Five and Appendix for details). I also found remarkably
similar genome-wide patterns for H3.3 in mouse ES cell lines (C57BL/6J ES and F1
hybrid ES) of significantly distinct genetic backgrounds (Mikkelsen et al., 2007).
Following alignment of our sequenced ChIP DNA to the reference mouse
genome, I observed that gene-rich regions of the genome show greater enrichment
of H3.3 than H3.2 or H3.1S31 (Figure 2.12, 2.13). I also profiled the genome-wide
localization of H3K4me1, H3K4me3, H3K27me3, and H3K36me3, and compared
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Figure 2.12: Chromosome-scale map of ChIP-seq data reveals genic enrichment of H3.3
ChIP-seq profiles across a large representative genomic region (120 MB of chromosome 1) in
mouse ES cells, using antibodies as indicated. Y-axis represents the number of reads spanning
a genomic position, with scale indicated on the right (baseline, maximum). CpG islands (green)
and genes (positive strand (+) and negative strand (-)) along with chromosome coordinates are
shown below plots. Note the enrichment of H3.3 with genes, CpG islands, and markers of active
chromatin, including RNAPII Ser5p, H3K4me3, H3K36me3, and H3K4me1. Upon mutation of
H3.3-HA to H3.2-HA, enrichment in gneic regions is significantly reduced. See later figures for
higher resolution analyses. Data for general anti-H3 in ES cells is from (Mikkelsen et al., 2007).
Data for H3.1S31-HA is nearly identical to H3.2-HA, and is not shown.

these results to established profiles for these modifications in ES cells and NPCs
(Meissner et al., 2008; Mikkelsen et al., 2007). In all cases, histone modification
profiles from tagged ES cells were nearly identical to previously established
datasets (Figure 2.14, Figure 2.15).

The remarkable similarity between my

multiple controls and previous datasets from other laboratories underscores the
reliability and reproducibility of ChIP-seq, and gives me greater confidence in my
findings. Moreover, this result suggests that heterozygous mutation of H3.3B to
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Figure 2.13: Genomic locations of H3 variant enriched regions
Enriched regions were identified for H3 variants as described in Chapter Five, and
their relationship with annotation is plotted. Y-axis represents the number of enriched
regions, while the X-axis represents different categories of gene annotation and
transcription factor binding sites (TFBS). Known ES TFBS are from (Chen et al., 2008).
“Hybrid ES” experiments were performed in a genetically divergent F1 hybrid (castaneus/129) ES
line, the same ES line described in previous published ChIP-seq studies (Mikkelsen et al. 2007). I
have found that genome-wide patterns of H3.3 enrichment are extremely simliar in all analyzed ES
lines, regardless of genetic background. See Chapter Five for further details.

H3.2 or H3.1S31 does not significantly alter genome-wide patterns of histone
modifications.
My collaborators and I found 10,099 total genic and intergenic regions highly
enriched for H3.3 in crosslinking ChIP-seq of ES cells, in contrast to 1,442 regions
enriched for H3.2, and we found that gene-rich regions of the genome show greater
enrichment of H3.3 than H3.2 or H3.1S31 (Figure 2.12., 2.13). On a chromosomal
scale map, H3.3 enrichment correlated with markers of transcription, including
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Figure 2.14: Genome-wide patterns of histone modifications are not affected by heterozygous
conversion of H3.3B to H3.3-HA or H3.2-HA
Data is shown for a representative region of chromosome 12 containing Esrrb. H3 variant patterns
for this gene are shown in 2.26A. Y-axis represents the number of reads spanning a genomic
position, with scale indicated on the right. Genes (+ and - strand) along with chromosome 12
coordinates are shown below plots. Data for previously established datasets in mouse ES cells
and NPC are indicated (Meissner et al., 2008; Mikkelsen et al., 2007), and were downloaded from
http://www.ncbi.nlm.nih.gov/geo/ . For patterns of histone modifications in H3.3-HA vs H3.2-HA ES
cells, see also 2.24.

RNAPII, H3K4me3, H3K36me3, and H3K4me1 (Figure 2.12). Unbiased clustering
analyses confirmed the genome-wide correlation of H3.3 with active histone
modifications, particularly H3K4me1 (Figure 2.15). Despite different epitope tags,
we found extremely similar profiles of H3.3-HA and H3.3-EYFP (Figure 2.12). In
addition to genes, genome-wide analysis revealed specific enrichment of H3.3
at previously identified genic and intergenic ES TFBS (Chen et al., 2008b), as
well as peaks of H3.3 in specific unannotated intergenic regions (Figure 2.13).
These chromosome-wide patterns of H3.3 were largely eliminated upon mutation
of H3.3B towards H3.2 or H3.1 (Figure 2.12). Our data demonstrate that the amino
acid sequence of an endogenous H3.3 gene determines its genomic localization in
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Figure 2.15: Genome-wide correlation of ChIP-seq datasets
Mouse chromosomes were divided into non-overlapping 2-kb regions and then the number
of ChIP-Seq reads in each region was counted to generate a vector representing the genomewide distribution of each ChIP-Seq experiment. Pearson’s correlation coefficients were computed
between every pair of ChIP-Seq data and the resulting correlation matrix was clustered and shown
as a heat map.
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mammalian cells.

Genome-wide patterns of H3 variants at repetitive elements
Unlike ChIP-chip technologies, which are limited by probe design, ChIP-seq
enables the localization of proteins to repetitive regions of the genome (Mikkelsen
et al., 2007). To analyze H3 variant enrichment in different classes of repeats, we
determined the relative enrichment of specific repeat sequences from our ChIP-seq
experiments and compared it to that from control input DNA (see Chapter Five).
H3.3 was reproducibly depleted in satellite repeat sequences and in Y-chromosomal
repeat DNA, while enriched in rDNA repeats (Figure 2.16). Our ChIP-seq results
are consistent with the visible exclusion of H3.3 from DAPI-dense pericentric
heterochromatin (Figure 2.8A-B, 2.9, 2.11), as pericentric heterochromatin is
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Figure 2.16: Enrichment of H3 variants in different classes of repeats
Analysis of H3 variants in repetitive elements. Reads from HA-tagged H3 variants were aligned
directly to a library of mouse consensus repetitive sequences (http://www.girinst.org). Note
particular enrichment of H3.3 in the canonical (TTAGGG)n vertebrate telomeric repeat sequence
(Meyne et al., 1989). Data are represented as fold enrichment over input.
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enriched in satellite repeats (Martens et al., 2005), and the relative depletion of
H3.3 from the Y-chromosome. Notably, we found the most significant (5-fold)
enrichment of H3.3 in the (TTAGGG)n repeat that is the conserved telomeric DNA
sequence among vertebrates (Meyne et al., 1989) (Figure 2.16). This telomeric
enrichment of H3.3 is consistent with the telomeric foci of incorporation visible on
the largely heterochromatic Y-chromosome (Figure 2.8A-B, 2.9B-C, K-L, 2.10,
inset). Mutation of H3.3B to H3.2 or H3.1S31 demonstrates that repeat-specific
patterns of H3.3 enrichment or depletion are dependent on amino acid sequence
(Figure 2.16).

H3.3 is enriched around transcription start sites of both active and repressed
genes, but is enriched in the bodies of only active protein-coding and noncoding RNA genes
As there has been some disagreement regarding the patterns of H3.3 at active
versus repressed genes in vertebrates (Chow et al., 2005; Daury et al., 2006;
Jin and Felsenfeld, 2006; Sutcliffe et al., 2009; Tamura et al., 2009; Wirbelauer
et al., 2005), we used ChIP-seq to address the genome-wide patterns of H3
variant enrichment around gene transcription start sites (TSS) in mouse ES cells.
Surprisingly, we find that H3.3 is not exclusively a marker of transcriptionally active
genes.
Mammalian genes can be divided into classes based on the CpG
dinucleotide content of their promoters. High CpG content promoters (HCP) are
over-represented in nuclear, metabolic, and transcriptional regulatory genes, and
HCP genes are likely to be either ubiquitously expressed housekeeping genes or
to have complex, developmentally regulated patterns of expression (Mikkelsen
et al., 2007; Saxonov et al., 2006). In contrast, genes with low CpG content
promoters (LCP) are frequently involved in specific physiological processes and
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are often highly tissue-specific, such as olfactory receptor genes and keratin genes
(Saxonov et al., 2006). Previous studies have found that the majority of high CpG
content promoters in both ES cells and differentiated cells are marked by histone
H3K4me3 and the presence of RNAPII, regardless of whether the gene is active
or repressed (Barski et al., 2007; Guenther et al., 2007; Mikkelsen et al., 2007).
When we divide HCP genes into low, medium, and high expression in ES cells (see
Materials and Methods), we find that H3.3, like H3K4me3 and RNAPII, is enriched
around the TSS of both active, highly expressing genes, as well as repressed, low
expressing genes (Figure 2.17A, D). In both native and crosslinking ChIP-seq, we
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Figure 2.17: H3.3 is enriched around transcription start sites of both active and inactive
genes with high CpG content promoters, and into the body of active genes
A-I. Profiles of H3 variants, H3, H3 modifications, or RNAPII as indicated above each panel across
the TSS for highly active (red), medium expressing (black), or low expressing (green) CpG rich
genes. Y-axis represents the average number of tags per gene per 200 bp per 1 million mapped
reads. Data for H3 in ES cells is from (Mikkelsen et al., 2007).
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Figure 2.18: Mononucleosome resolution profiles of H3 variants and H3K4me3 at TSS
Y-axis represents the average number of tags per gene per 10 bp per million mapped reads.
Red represents sequence tags from the sense strand, and green represents sequence tags from
the antisense strand. The color bars above profiles mark the estimated nucleosomes around
TSSs. The data for H3.3 in panel G (dark blue = sense H3.3, light blue = antisense H3.3, red =
sense H3K4me3, green = antisense H3K4me3) are scaled by a factor of 50 to match the profile of
H3K4me3.
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the -1 nucleosome at the TSS of active and inactive genes has been extensively
described (Schones et al., 2008), and has been recently attributed both to the
instability of nucleosome core particles containing H3.3 and H2A.Z, and to the
presence of specific sequences at CpG promoters that directly reduce nucleosome
stability (Jin et al., 2009; Ramirez-Carrozzi et al., 2009).
While H3.3 is incorporated around the TSS of both active and repressed
genes, we find that H3.3 is enriched in the body of active genes, but not that of
repressed genes (Figure 2.17A, D). Mononucleosome resolution analysis indicates
that H3.3 is incorporated into the +1 nucleosomes in both activated and repressed
genes, but up to +3 nucleosomes and further into the coding regions in activated
genes (Figure 2.18). The level of H3.3 deposition in gene bodies is correlated
with gene expression, particularly at highly expressed genes (Spearman’s rank
correlation coefficient ρ = 0.54, p < 2.2e-16; see Figure 2.17A, D, 2.19). Highly
active genes (Figure 2.17A, D, red) have higher levels of H3.3 in their gene bodies,
while medium (black) and lower expressed genes (green) have lower levels of
H3.3. Strikingly, upon mutation of H3.3 to H3.2 or H3.1S31, H3.3 specific patterns
of enrichment around the TSS and gene body are lost, generating patterns similar
to general H3 (Figure 2.17B, C, E, F).
Genome-wide studies recently demonstrated that more than 20% of HCP
genes in ES cells carry both H3K4me3 and H3K27me3 in their promoters (Bernstein
et al., 2006a; Mikkelsen et al., 2007). These ‘bivalent’ genes are transcriptionally
repressed in ES cells, and many encode key developmental TFs and cell surface
proteins, leading to the model that they represent repressed genes that are poised
for activation following cell differentiation (Bernstein et al., 2006a; Mikkelsen et
al., 2007). While bivalent genes are defined by their pattern of H3 modifications,
the relative distribution and identity of the H3 variants that carry these marks has
not been established. When we analyzed the pattern of H3 variants at bivalent
112

Figure 2.19: Correlation of H3.3 with gene expression
The left Y-axis represents read density that was computed as average number of ChIP-Seq reads
per 2-kb genomic sequence per million mapped reads.
A-D. Densities of H3.3 and H3K36me3 reads in coding gene bodies are correlated with gene
expression, particularly for highly expressed genes, in both ES (A-B) and NPC (C-D). Gene
expression data are from (Mikkelsen et al., 2007). For the X-axis, gene expression values were
uniformly divided into 20 groups to yield genes with low to high levels of expression. Mean gene
expression values for each group shown on the right Y-axis in B and D. H3.3 deposition in gene
bodies is correlated with gene expression, particularly at highly expressed genes (Spearman’s
rank correlation coefficient ρ = 0.54, p < 2.2e-16). By comparison, H3K36me3 shows a greater
correlation (ρ = 0.76), but H3.1S31 (ρ = 0.31) and H3.2 (ρ = 0.25) show significantly smaller
correlations.
E-H. Densities of H3.3 and H3K36me3 in lincRNAs are correlated with gene expression at highly
expressed lincRNAs. lincRNAs were divided into 5 groups on the basis of lincRNA expression
data (Guttman et al., 2009) , downloaded from http://www.ncbi.nlm.nih.gov/geo/ , (GSE13765).
lincRNA expression values are shown on the right Y-axis in F and H.
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Figure 2.19
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TSS by ChIP-seq, we found that H3.3 is enriched around the TSS of H3K4me3/
H3K27me3 bivalent genes in ES cells, while mutation of H3.3 towards H3.2 or
H3.1 abolishes this enrichment (Figure 2.20A, 2.21E-F). In contrast to repressed
bivalent H3K4me3/H3K27me3 genes, H3.3 is significantly enriched around the
TSS as well as into the coding region of active monovalent H3K4me3 genes
(Figure 2.20B).
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Figure 2.20: Specific examples of H3.3 incorporation at the transcription start sites of active
and repressed coding genes, and actively transcribed non-coding RNA
A. H3.3 is enriched around the TSS, but not into the gene body of the H3K4me3/H3K27me3 bivalent
and transcriptionally repressed Zfpm2 gene in ES cells.
B. H3.3 is enriched around the TSS and also in the gene body of the highly expressing ribosomal
protein S19 gene Rps19.
C. H3.3 is enriched around the TSS and into the body of the non-coding RNA gene Gas5, but less
enriched in the gene body of the neighboring low expressing Zbtb37 gene in ES cells. The Y-axes in
J-L are identical (indicated in the right side of panel J), and represent the number of reads spanning
a genomic position. Gene is shown to scale below plot, with start and direction or transcription
indicated by arrow. Green rectangles above the gene represent CpG islands.
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Figure 2.21: Genome-wide profiles of H3.3 at transcription start sites change with cellular
differentiation and resolution of bivalent domains
A-L. Profiles of H3 variants or H3 modifications as indicated above each panel around the TSS of
H3K4me3/H3K27me3 bivalent genes in ES cells. ES bivalent genes are classified by resolution in
NPCs to H3K4me3 only (red), H3K27me3 only (green), or no mark (black). H3K4me3/H3K27me3
data and bivalent gene definitions are from (Mikkelsen et al., 2007). Y-axes are as in 2.17.

Recent studies have also shown that mammalian cells produce over 1600
large intergenic non-coding RNA (lincRNA) transcripts (Guttman et al., 2009). When
we examined the genomic loci of lincRNA transcripts, we found that lincRNAs
known to be expressed in ES cells show enrichment of H3.3 around their TSS, as
well as into their non-coding RNA gene bodies, similar to the pattern of H3.3 found
at active genes. Again, these patterns of H3.3 at lincRNAs are dependent on H3.3
amino acid sequence (Figure 2.19, 2.20C).
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Transcription end sites of highly expressed genes are marked by peaks of
H3.3 and phosphorylated RNA polymerase II
When we examined the patterns of H3.3 incorporation at transcriptionally active
HCP genes, we noticed that enrichment of H3.3 often extended beyond the gene
body and past the transcriptional end site (TES), particularly at highly active genes
(Figure 2.20B-C). To determine whether this is a genome-wide phenomenon, we
used the same division of HCP genes into high, medium, and low expression, and
analyzed the ChIP-seq patterns of H3 variants and histone modifications around
TES. In accordance with previous studies in Drosophila and human cells (Henikoff
et al., 2009; Jin et al., 2009; Mito et al., 2005), we find that the enrichment of H3.3
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Figure 2.22: H3.3 and RNA polymerase Ser5p are enriched after the transcriptional end site
of highly expressed genes
A-L. Profiles of H3 variants, H3, H3 modifications, or RNAPII as indicated above each panel across
the TES for highly active (red), medium expressing (black), or low expressing (green) CpG rich
genes, with data represented as in Figure 3. All data except for D and H are for mouse ES cells.
Panel D shows data from differentiated NPCs. The data in panel H are for human CD4+ T cells
(Barski et al., 2007). The data in C and L are from a previous study (Mikkelsen et al., 2007).
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(Figure 2.22A, E) and in differentiated NPCs (Figure 2.22D).
At highly expressed genes such as beta-actin, H3.3 enrichment increases
immediately after the TES, and peaks at approximately +700 bp ± 200 bp after
the TES (Figure 2.22A, E, 2.23). This post-TES enrichment of H3.3 was also
dependent on amino acid sequence, as we did not observe significant enrichment
of H3.3 mutated to H3.2 or H3.1S31, or of general H3 (Figure 2.22B, C, F, G, 2.23).
Control ChIP-seq experiments revealed the expected patterns of incorporation
and lack of post-TES enrichment for H3K4me3, H3K4me1, and H3K36me3, in
TSS
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Figure 2.23: Profiles of H3 variants, H3 modifications, and RNA polymerase around the
highly expressed housekeeping gene beta-actin
H3.3 and RNAPII Ser5p are enriched in the gene body and after the TES of the highly expressed
gene Actb (beta-actin) in ES cells. Data for the RNAPII unphos 8WG16 track are from (Mikkelsen et
al., 2007). Y-axis is indicated on the right as in Figure 2 and 3. RNA-seq data are from (Cloonan et
al., 2008). The neighboring Fbx1118 gene is not highly expressed in ES cells, and does not show
gene body enrichment of H3.3.
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Figure 2.24: TSS and TES enrichment of H3 variants, histone modifications, and RNAPII
Profiles of H3 variants, H3 modifications, or controls as indicated above each panel across the TSS
and TES for highly active, medium expressing, or low expressing CpG rich genes as shown. Y-axis
represents the average number of tags per gene per 200 bp per 1 million mapped reads.
A,C,E,G. H3.3 profiles are similar across the TSS and TES for both HA and EYFP-tagged H3.3.
D,F,H. Mutation of H3.3B towards H3.2 or H3.1 abolishes H3.3 patterns of enrichment.
I. H3K4me1 patterns are similar to H3.3 around the TSS, though levels of H3K4me1 decline into
the gene body of highly expressed genes, while H3.3 levels increase and peak beyond the TES.
J. Background of anti-HA antibody. Sequencing of anti-HA ChIP from untagged wild-type ES
cells shows enrichment at the TSS, likely representing the enrichment of nucleosome-poor DNA
following cross-linking and sonication.
K-N. Profiles of H3K4me3 and H3K36me3 in H3.3-HA and H3.2-HA ES cells. Heterozygous
mutation of H3.3 to H3.2 does not alter genome-wide profiles of H3K4me3 or H3K36me3 around
TSS and TES.
O. Profiles of RNAPII Ser5p in H3.3-HA ES cells at TSS and TES. P) Profiles of unphosphorylated
RNAPII at TSS and TES in ES cells. Data for P are from (Mikkelsen et al., 2007).
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Figure 2.24
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both H3.3-HA and H3.2-HA ES cells (Figure 2.22J, K, 2.23, 2.24). H3K36me3 has
been associated with transcriptional elongation in a variety of eukaryotes, from
yeast to mammals (Bannister et al., 2005; Barski et al., 2007; Mikkelsen et al.,
2007). H3.3 and H3K36me3 are both enriched in the gene body of active genes,
with levels of both positively correlated with gene expression (Figure 2.17A, D,
I, Figure 2.19, Figure 2.22A, E, K). Unlike H3.3, however, levels of H3K36me3
at active genes begin to decline prior to the TES, and decline more significantly
following the TES (Figure 2.22K, 2.23). While H3.3 is correlated with H3K36me3
in active gene bodies, H3.3 and H3K36me3 maintain distinctive patterns near the
TES of active genes.
As a control, we performed ChIP-seq with a mouse monoclonal antibody
(CTD4H8) to the Ser-5 phosphorylated C-terminal domain (CTD) of RNAPII. To
our surprise, we observed significant peaks of enrichment of phosphorylated
RNAPII not only at the TSS of high and low expressing genes (Figure 2.17G), but
also after the TES of high expressing genes (Figure 2.22I, 2.23). Interestingly, the
distributions of these post-TES peaks of phosphorylated RNAPII at active genes
are closely co-localized with the peaks of H3.3, with the phosphorylated RNAPII
peak slightly downstream (~200 bp) from the H3.3 peak.
Previous studies have shown that the unphosphorylated CTD form of RNAPII
is enriched in the promoter of both active and inactive genes, while differentially
phosphorylated CTD forms of RNAPII are associated with elongating polymerase
in the gene body of actively transcribed protein coding genes and small nuclear
RNA genes (Guenther et al., 2007; Koch et al., 2008). When we analyzed the
patterns of unphosphorylated RNAPII CTD (Mikkelsen et al., 2007) in mouse ES
cells, we observed a peak of unphosphorylated RNAPII CTD at the TSS of high
and low expressing HCP genes (Figure 2.23, 2.24). However, we did not find any
significant peak of unphosphorylated RNAPII CTD around the TES of high or low
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expressing HCP genes (Figure 2.21L, 2.22), providing further evidence that this
post-TES enrichment of RNAPII is specific to the phosphorylated form of RNAPII.
To determine if the enrichment of H3.3 and the phosphorylated CTD of
RNAPII is specific to ES cells, we also analyzed their distributions in other cell
types. Our results indicate that post-TES enrichment of H3.3 and phosphorylated
RNAPII CTD is not specific to ES cells. When we generated profiles of H3.3 at high,
medium, and low-expressing genes in differentiated NPCs, we observe that H3.3
enrichment at highly active genes continues after the TES (Figure 2.22D). While
it has not previously been used in ChIP-seq studies of ES cells, the monoclonal
CTD4H8 antibody has also been used in genome-wide studies in human CD4+T
cells (Barski et al., 2007). When we analyze these datasets, we observe a similar
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Figure 2.25: Analysis of H3.3 post-TES at HCP genes without repeats in their TES
HCP genes without repeats (as annotated by the RepeatMasker in the UCSC table browser data)
in their TES regions (-500 bp to +2kb) were separated into three groups based on their expression
values, and then the distribution of ChIP-Seq reads around TSSs for these three groups of genes
were generated as described above in 2.23.
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differentiated human CD4+ T cells (Figure 2.22H).
To ensure that the extension of phosphorylated RNAPII and H3.3 did not
represent a previously unrecognized extension of transcription beyond the TES of
high-expressing genes, we analyzed a published RNA-seq dataset from mouse
ES cells (Cloonan et al., 2008). We observed peaks of transcribed RNA in exons,
as expected, and did not find significant extension of transcription beyond the TES
of active genes such beta-actin (Figure 2.23). We were also concerned that the
H3.3 peak downstream of TESs could be due to the presence of Alu or other active
repetitive elements in some highly expressed genes. However, this post-TES peak
remained prominent when we focused our analysis on genes without repeats
in their TES regions (-500 bp to + 2kb) (Figure 2.25). From these analyses, we
conclude that both H3.3 and phosphorylated RNAPII are significantly enriched
beyond the TES of highly expressed genes in undifferentiated and differentiated
mammalian cell types.

The profile of H3.3 at cell-type specific genes changes with cell
differentiation
To determine how the genome-wide patterns of H3.3 change with cell differentiation,
we used an established protocol to differentiate both H3.3-HA and H3.2-HA ES
cells to NPCs (Conti et al., 2005). To confirm that both H3.3-HA and H3.2-HA NPCs
were similar in their genome-wide profiles of histone modifications to previously
analyzed NPCs (Meissner et al., 2008; Mikkelsen et al., 2007), we performed
control H3K36me3 ChIP-seq experiments from both H3.3-HA and H3.2-HA NPCs
and found profiles that were extremely similar to established datasets (Figure
2.14, Figure 2.15).
Our results demonstrate that the profile of H3 variants changes in
undifferentiated ES cells and differentiated NPCs at cell-type specific genes. In ES
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cells, H3.3 was enriched in the gene body of expressed pluripotency genes such as
Esrrb, Nanog, and Oct4, correlated with H3K36me3 (Figure 2.26A, 2.27). As with
other high expressing genes, enrichment of H3.3 in the gene body of pluripotency
genes is dependent on amino acid sequence, as mutation to H3.2 or H3.1S31
abolishes this enrichment (Figure 2.26A, 2.27). Upon differentiation of ES cells
to NPCs, the expression of most pluripotency genes is lost (Conti et al., 2005).
Accordingly, the enrichment of H3.3 and H3K36me3 in the bodies of pluripotency
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Figure 2.26: H3.3 localization changes at cell-type specific genes with cell differentiation
and resolution of bivalent domains
A. H3.3, H3K4me1, and H3K36me3 are enriched in the gene body of the highly expressed
pluripotency gene Esrrb in ES cells, and this enrichment is largely lost upon differentiation to
NPCs.
B. The epidermal growth factor receptor gene Egfr is H3K4me3/H3K27me3 bivalent and
transcriptionally repressed in ES cells (Mikkelsen et al. 2007). Upon differentiation to NPCs, H3.3,
H3K4me1, and H3K36me3 are enriched in the Egfr gene body.
C. H3.3, H3K4me1, and H3K36me3 are enriched in the gene body of the highly expressed
housekeeping gene lactate dehydrogenase A Ldha in both ES cells and NPCs, and are not enriched
in the low expressed neighboring Ldhc gene. The Y-axes in panels A-C are identical (indicated in
the right side of panel C).
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genes largely disappeared upon cell differentiation (Figure 2.26A, 2.27).
We next sought to examine how the pattern of H3 variants changes
at H3K4me3/H3K27me3 bivalent genes (Bernstein et al., 2006a) that are
transcriptionally repressed in ES cells, but poised for expression in later
developmental lineages (see Figure 1.14). Analysis of 2,525 HCP genes defined
as bivalent in mouse ES cells (Mikkelsen et al., 2007) demonstrated that H3.3 is
enriched around the TSS, but not within the gene body of bivalent differentiationspecific genes in ES cells (Figure 2.20A, 2.21E). Again, this enrichment of H3.3
around the TSS of bivalent ES genes is dependent on amino acid sequence, as
mutation of H3.3 to H3.2 eliminated TSS enrichment at ES bivalent genes (Figure
2.21F).
Following differentiation of ES cells to NPCs, the profile of H3.3 changes at
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Figure 2.27: Cell-type specific enrichment of H3.3 at pluripotency genes and transcription
factor binding sites
A. H3.3 and H3K4me1 are enriched around intergenic and genic TFBS near the Nanog gene in ES
cells. In all cases, H3.3-specific enrichment is lost upon mutation of H3.3B to H3.2 or H3.1S31.
B. H3.3 and H3K4me1 are enriched around intergenic and genic TFBS near the Oct4 (Pou5f1)
gene in ES cells.
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Figure 2.28: H3.3 is enriched at genes involved in cellular and metabolic processes in both
ES cells and NPC cells
Genes with H3.3 peaks in their promoter regions were analyzed for enrichment of individual GO
terms using the program DAVID (Huang da et al., 2009). The top 25 GO categories are shown here
with p-values indicated, and the x-axis representing the fraction of H3.3 genes in a GO category.
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poised TSS with the resolution of bivalent domains. 92% of H3K4me3/H3K27me3
bivalent genes in ES cells have been shown to resolve to either H3K4me3 only
(Figure 2.21, red), H3K27me3 only (green), or lose both modifications (black) upon
differentiation to NPCs (Mikkelsen et al., 2007). In bivalent ES genes that resolve
to H3K4me3 and become transcriptionally active in NPCs, H3.3 was maintained
around the TSS and also incorporated into the gene body, in correlation with
H3K36me3 and H3K4me1 (red, Figure 2.21G, I-K). For example, the epidermal
growth factor receptor gene Egfr is bivalent and transcriptionally repressed in ES
cells, yet resolves to H3K4me3 and is expressed in NPCs. Upon differentiation to
NPCs, H3.3 extended into the gene body of Egfr, correlating with H3K36me3 and
ES

H3K4me1 (Figure 2.26B). In contrast, for bivalent

NPC
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H3.3 enrichment was reduced at the TSS upon
cell differentiation to NPCs (Figure 2.21K). As
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TSS following differentiation to NPCs (Figure
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Figure 2.29: Expression of
pluripotency and differentiationspecific genes in H3.3-HA and
H3.2-HA ES cells and NPCs
Whole cell extracts of H3.3-HA and
H3.2-HA ES cells and NPCs were
immunoblotted with antibodies as
indicated.

While the pattern of H3.3 changes at celltype-specific genes, housekeeping genes that
remain highly expressed in both ES cells and
NPCs retain similar enriched patterns of H3.3
incorporation. In both ES cells and NPCs, H3.3
is most highly enriched in genes associated with
cellular and metabolic processes (Figure 2.28).

For example, the housekeeping gene lactate dehydrogenase A Ldha is expressed
in both ES and NPCs (Figure 2.29). In contrast to the cell-type specific genes
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Essrb and Egfr, H3.3 remains enriched around the TSS and within the gene body
of Ldha in both ES cells and NPCs (Figure 2.26C). Our data show that the overall
relationship between H3.3 incorporation and gene expression is retained in ES and
NPCs, with H3.3 and H3K4 methylation marking the TSS of active and poised HCP
genes, and H3.3 enriched in the body and TES of active HCP genes. However, at
cell-type specific genes, H3.3 localization changes with cellular state.

Genome-wide enrichment of H3.3 at transcription factor binding sites is
dependent on amino acid sequence and cellular differentiation state
To determine enriched regions of H3 variants genome-wide, we used a modified
segmentation algorithm (see Chapter Five). Unexpectedly, we found that 36%
(3,627) of the enriched regions of H3.3 in mouse ES cells were located outside
of known annotated genes (Figure 2.13, 2.27, 2.30). Genome-scale studies
have previously demonstrated that in addition to genes (Mito et al., 2005), H3.3
replacement marks the boundaries of cis-regulatory elements in Drosophila (Mito
et al., 2007). Therefore, we considered the possibility that H3.3 might mark genic
and intergenic TF binding sites in mammalian cells genome-wide.
Significant progress has been made regarding the core transcriptional
regulatory networks that regulate pluripotency in mammalian cells. We therefore
compared our genome-wide distributions for histone H3 variants in ES cells and
NPCs with established genome-wide maps for 13 distinct sequence-specific TFs
in ES cells (Chen et al., 2008b). Remarkably, 3,878 (38%) of the overall regions
enriched for H3.3 in ES cells (Figure 2.13) correspond to previously identified
genic or intergenic TF binding sites (TFBS) (Chen et al., 2008b). As with specific
patterns of H3.3 at genes, peaks of H3.3 at TFBS are dependent on H3.3 amino
acid sequence, as mutation of H3.3B to H3.2 or H3.1S31 eliminated these peaks
of enrichment (Figure 2.27, 2.30, 2.31).
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Figure 2.30: Cell-type specific enrichment of H3.3
at transcription factor binding sites
A. H3.3 and H3K4me1 are enriched at an intergenic
region bound by multiple transcription factors (multiple
transcription factor binding locus, MTL) (Chen et al.,
2008) specifically in ES cells.
B. H3.3 and H3K4me1 are enriched at an intergenic
region specifically in NPCs, which may represent an
uncharacterized TFBS.
C. H3.3 is enriched at an intergenic MTL specifically
in ES cells. In this case, H3K4me1 does not appear
enriched at this location. The Y-axes in panels A-C
are identical and indicated in the right side of panel C.
TFBS identified in mouse ES cells by previous ChIPseq studies (Chen et al., 2008) are indicated above
the plots. NPC H3K4me3 data is from (Mikkelsen et
al., 2007).

(1, 20)

Mmp17 chr5

chr11

Zfp11

129

(F1 hybrid)

H3.3 H3K4me1 H3.2

H3.1

S31
(F1 hybrid)

H3

Neural precursors
H3.3 H3K4me1 H3.2

0.2

promoter
gene body
intergenic

promoter
gene body
intergenic

Esrrb

H3.3

0.3

0.4

B

Embryonic stem cells

0.4
0.2

0.3

Nanog

H3.1S31_antiHA

0.4
0.2

0.3

Oct4

H3.1S31_antiHA

0.4
0.2

0.3

Sox2

H3.1S31_antiHA

0.2

0.3

Klf4

H3.1S31_antiHA

0.0

0.1

Klf4

0.4

0.5 0.0

0.1

Sox2

0.5 0.0

0.1

Oct4

0.5 0.0

0.1

Nanog

0.5 0.0

0.1

Esrrb

0.5

A

−3000

0

3000 −3000

0

3000 −3000

0

3000 −3000

0

3000 −3000

0

3000 −3000

0

3000

−3000

0

3000 −3000

0

3000 −3000

0

3000

Data in A-B produced in collaboration with Deyou Zheng.

Figure 2.31: Genome-wide patterns of H3.3 at transcription factor binding sites are dependent
on H3 amino acid sequence and cellular state
A-B. H3.3 and H3K4me1 are enriched genome-wide around ES cell TFBS. Genome-wide profiles
of H3 variants (crosslinking ChIP-seq, HA tagged variants) and H3K4me1 as indicated around
ES binding sites for Esrrb, Nanog, Oct4, Sox2, and Klf4. TFBS in mouse ES cells were identified
by a previous study using ChIP-seq (Chen et al., 2008), and classified as promoter (black), gene
body (dark blue), or intergenic (light blue). Panel A represents data from ES cells, while panel B
represents data from NPCs at identical regions. Y-axis represents number of tags per binding site
per 200 bp per 1 million mapped reads. Data for H3 in ES cells is from (Mikkelsen et al., 2007).
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Many of the specific peaks of H3.3 at TFBS are cell-type specific, especially
those located in intergenic regions. 976 intergenic peaks of H3.3 that co-localize
with known binding sites for pluripotency-regulating TFs in ES cells are lost
upon differentiation to NPCs (Figure 2.30A, C). For example, the locus for the
pluripotency gene Nanog is highly regulated and is a target for multiple transcription
factors in ES cells (Chen et al., 2008b). Patterns of H3.3 enrichment at the Nanog
locus correspond with known TFBS in ES cells (Chen et al., 2008b), as well as
previously identified DNAseI hypersensitive sites (Levasseur et al., 2008) (Figure
2.27A). These peaks of H3.3 incorporation around Nanog are significantly reduced
following ES cell differentiation to NPCs (Figure 2.27A). In addition to ES cell
specific peaks of H3.3 (Figure 2.27, 2.30A, C), we also found peaks of H3.3 that
are specific to differentiated NPCs (Figure 2.30B). Intriguingly, 2478 (~90%) of
the intergenic and NPC-specific H3.3 peaks do not overlap with known ES TFBS
(Chen et al., 2008b) (Figure 2.30B).
Our data suggest that overlapping peaks of H3.3 and H3K4me1 may
identify known and novel TFBS. H3K4me1has recently been shown to have a
strong genome-wide co-localization with TFBS, enhancers, and other regulatory
elements (Heintzman et al., 2007; Robertson et al., 2008; Wang et al., 2008).
Our analysis found that 30% of the intergenic peaks enriched with both H3.3 and
H3K4me1 overlap with known TFBS (Figure 2.30A, B, D, 2.31), compared with
23.7% for all intergenic H3.3 peaks and 26.5% for all intergenic H3K4me1 peaks.
Genome-wide patterns of H3.3 and H3K4me1 are similar (Figure 2.15). Indeed,
we note that 26% of H3K4me1 peaks overlap with H3.3 peaks, and peaks of H3.3
are 5 times more likely to be associated with peaks of H3K4me1 than H3K4me3 (p
<< 0.00001). Notably, we found 724 intergenic peaks of both H3.3 and H3K4me1
in NPCs that do not correspond to any known TFBS (Figure 2.30B, 2.32), and
it is possible that these represent uncharacterized, cell-type specific regulatory
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Figure 2.32: Genome-wide changes in intergenic peaks of H3.3 and H3K4me1
H3.3 and H3K4me1 intergenic peaks were identified as described in Data Analysis. Data is for
crosslinking ChIP-seq with H3.3-HA. Those intergenic peaks were then defined as ‘known ES
TFBS’ if they overlap with an intergenic TFBS identified in ES cells (Chen et al., 2008), or ‘unknown’
if they do not overlap with known TFBS. A plots the total number of peaks in each category while B
plots the relative fraction of peaks in each category. Note the relative increase in enriched unknown
intergenic regions in NPCs for H3.3, H3K4me1, and H3.3 and H3K4me1.

133

regions. However, there are exceptions to the co-occupancy of TFBS by H3.3 and
H3K4me1, such as TFBS marked only by peaks of H3.3 but not H3K4me1 (Figure
2.30C).
To examine the relationship between H3.3 incorporation and TFBS genomewide, we took the TFBS identified by ChIP-seq in mouse ES cells for Nanog, Oct4,
STAT3, Smad1, Sox2, Zfx, c-Myc, n-Myc, Klf4, Esrrb, Tcfcp2l1, E2f1, and CTCF
(Chen et al., 2008b), and classified those binding sites as gene promoter, gene
body, or intergenic. Remarkably, we find that H3.3 and H3K4me1 are enriched
genome-wide at TFBS for all 13 characterized TFs in ES cells, whether these
binding sites are in the gene promoter, gene body, or intergenic (Figure 2.31A).
Upon mutation of H3.3B to H3.2 or H3.1S31, the enrichment of H3.3 at all 13 TFBS
is lost, demonstrating the genome-wide dependence of H3.3 TFBS localization on
amino acid sequence in mammalian cells (Figure 2.30A).
When we examine specific peaks of H3.3 at TFBS in ES cells, we find that
many of them are co-localized with regions bound by multiple TFs (Figure 2.27,
2.30A, C). Genomic locations bound by more than four TFs have been described
as multiple transcription factor-binding loci (MTL), and a subset of MTL bound by
Oct4-Sox2-Nanog have been shown to serve as ES cell-specific enhanceosomes
(Chen et al., 2008b). Our genome-wide analysis shows that the density of H3.3 in
ES cell MTL increases significantly with the number of bound TFs (Figure 2.33A).
Again, this relationship between transcription factor binding and H3.3 incorporation
is dependent on amino acid sequence, as mutation of H3.3 to H3.2 eliminates
this correlation (Figure 2.33A). Surprisingly, we do not find a correlation between
TF binding in MTL and levels of H3K4me1 (Figure 2.33A), despite the strong
concurrence between H3K4me1 and individual TFBS (Figure 2.31A). These data
suggest that the level of H3K4me1 at MTL may saturate with lower numbers of
TFBS, while levels of H3.3 continue to increase with increasing TF binding.
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Figure 2.33: Cell-type specific enrichment of H3.3 at multiple transcription factor binding
loci
A-B. In ES cells (A) and NPCs (D), levels of H3.3 at ES MTL are dependent on H3 amino acid
sequence and cellular state. Box-and-whisker plots showing the ChIP-Seq read densities at MTL
separated by # of TFBS at a locus (x-axis). Y-axis represents # of normalized ChIP-Seq tags at a
group of MTL with the same # of TFBS, where the central bar is median, box shows 25th and 75th
percentiles, and whiskers mark the 1.5x interquartile range.

Following differentiation to NPCs, the genome-wide relationships between
H3.3, H3K4me1, and TFBS are reduced, but not entirely eliminated (Figure 2.31B,
2.33B). At some specific TFBS (Figure 2.30A, C), H3.3 and H3K4me1 enrichment
is lost upon differentiation to NPCs. However, at other TFBS, such as those 5’ and
3’ of Nanog, H3.3 and H3K4me1 enrichment is reduced, but partially maintained
(Figure 2.27A). At the genome-wide level, we observe that the overall enrichment
of H3.3 at TFBS is significantly reduced, but not eliminated, upon differentiation
from ES to NPCs (Figure 2.31B). At ES MTL, the relationship between multiple
transcription factor binding and H3.3 enrichment is clearly dependent on cellular
differentiation state (Figure 2.33A-B). Following differentiation to NPCs, MTL for
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known ES cell TFs do not show increased levels of H3.3 (Figure 2.33B).

Specific patterns of H3.3 at genes, regulatory elements, and repeats
The data that we have seen in this chapter provide the first genome-wide maps of
histone H3 variants in mammalian pluripotent cells and NPCs. I have established
the normal patterns of histone H3.3 at active and repressed genes, TFBS, and
specific repeats such as telomeres, and have demonstrated that these genomewide patterns are critically dependent on endogenous H3.3 amino acid sequence.
At cell-type specific genes and regulatory regions, the localization of H3.3 changes
with cell differentiation. Therefore, genome-wide patterns of H3.3 enrichment are
also dependent on cellular state. These findings raise many questions. Although
H3.3 is clearly enriched at a variety of regions, what is the function of H3.3 at these
elements? Does H3.3 play a similar role in TSS and gene bodies as it does after
TES, at TFBS, and at telomeres? The work that I will describe in Chapter Three
touches upon a potentially repressive function for H3.3 at telomeres and rDNA. In
Chapter Four, I will also discuss ongoing experiments that attempt to address the
function of H3.3 in mammalian development and cellular differentiation.
In addition to the function of H3.3, another critical question emerges from the
data presented in this chapter. What are the factors that are responsible for H3.3
deposition at these various elements? The histone chaperone HIRA associates with
H3.3 in HeLa cells, and it has been described to play a critical role in H3.3 deposition
during Drosophila male pronuclear decondensation (Loppin et al., 2005; Tagami et
al., 2004). Is HIRA required for H3.3 deposition at all classes of sites, or are there
site-specific mechanisms that deposit H3.3 at transcribed sequences, TFBS, and
telomeres? After establishing the ‘wild-type’ patterns of H3.3 in mammalian cells,
I next sought to determine how these genome-wide patterns of H3.3 are altered in
the absence of Hira. As we shall see, the results in Chapter Three indicate that the
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deposition of H3.3 at different genomic regions is significantly more complicated
than existing models proposed in the literature.
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Chapter 3
Hira and Atrx are required for H3.3 deposition
at distinct genomic regions
Summary
In Chapter Two, I described the first genome-wide profiles of histone H3
variant localization in mammalian embryonic stem (ES) cells and differentiated
neuronal precursor cells (NPCs). In this chapter, I establish the dependence and
independence of these patterns on previously identified as well as novel factors
involved in H3.3 deposition. To determine the dependence of genome-wide H3.3
patterns on the putative H3.3 chaperone Hira, I compared the genome-wide
localization of H3.3 in wild-type and Hira -/- ES cells. These studies are the first to
demonstrate that Hira is required for genome-wide H3.3 enrichment at active and
repressed genes. Surprisingly, I found that H3.3 enrichment at specific transcription
factor binding sites (TFBS), ribosomal DNA, and telomeres is Hira-independent.
To identify factors that might mediate Hira-independent deposition of H3.3, I used
a combined immunoprecipitation and mass spectrometry approach. My work
identifies the chromatin remodeling protein Atrx (alpha thalassemia and X-linked
mental retardation) and Daxx (death-domain associated protein) as proteins that
specifically associate with H3.3 in both pluripotent and non-pluripotent cells, both in
the presence and in the absence of Hira. After generating genome-wide profiles of
H3.3 in Atrxflox and Atrxnull mouse ES cells, I demonstrate that Atrx is not required for
H3.3 deposition at genes or TFBS. Finally, I show that Atrx is specifically required
for enrichment of H3.3 at telomeres and rDNA in ES cells, and for the repression
of telomeric and ribosomal RNA.
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Results
Hira is required for enrichment of H3.3 at active and repressed genes
After establishing the genome-wide patterns of H3.3 in undifferentiated ES cells
and differentiated NPCs, I sought to determine whether all of these patterns were
dependent on the putative H3.3 chaperone Hira. Hira has been shown to associate
with H3.3 in human cells, and to be required for assembly of H3.3 nucleosomes
on paternal chromatin during male pronucleus formation in Drosophila (Loppin
et al., 2005; Tagami et al., 2004).

Moreover, as described in Chapter One,

Hira is believed to be required for H3.3-specific deposition, perhaps working
in combination with CHD1 to engage in replication-independent (RI) chromatin
assembly (De Koning et al., 2007; Konev et al., 2007) (see Figure 1.22). Hira -/mice die during early embryogenesis following gastrulation defects and significant
patterning abnormalities (Roberts et al., 2002). Although Hira -/- cells are incapable
of terminal differentiation into functional neurons, Hira -/- ES cells are surprisingly
viable, proliferate normally in culture, and display normal ES colony morphology
(Meshorer et al., 2006). Hira -/- mice and ES cells were generated in the laboratory
of Dr. Peter Scambler (Meshorer et al., 2006; Roberts et al., 2002).
For the next portion of my thesis work, I therefore began a collaboration with
Dr. Scambler’s laboratory, who generously provided me with wild-type W9.5 and
Hira -/- ES cells. Using the techniques described in the previous chapter, I used
zinc finger nucleases (ZFNs) and my H3.3B-EYFP knock-in donor constructs to
tag one allele of the endogenous H3.3B gene in Hira -/- ES cells with a C-terminal
EYFP tag. Hira -/- ES cells express H3.3B at slightly lower, but comparable levels
to wild-type ES cells (Figure 3.1).
To determine the distribution of H3.3 in wild-type and Hira -/- ES cells, I initially
examined chromosome spreads from metaphase arrested cells. In agreement with
previous studies in Drosophila embryos and adult cells (Bonnefoy et al., 2007), I
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Figure 3.1: Expression of H3.3 and pluripotency genes in wild-type and Hira -/- ES cells
A. Immunoblots from whole-cell extracts showing expression of H3.3-EYFP in wild-type and Hira
-/- ES cells, with antibodies as indicated.
B. Hira -/- ES cells maintain expression of Oct4, Nanog, H3.3A, and H3.3B. Real-time PCR was
performed following RNA extraction and cDNA synthesis. Data were normalized to Gapdh, and
plotted as expression in Hira -/- relative to W9.5 ES cells.

find that H3.3 is still globally incorporated into chromatin in the absence of Hira
(Figure 3.2). In Hira -/- ES cells, H3.3 has a somewhat weaker signal, and is
concentrated in foci near the end of chromosomes (Figure 3.2).
I also sought to determine if H3.3 post-translational modifications were
altered in the absence of Hira. For example, H3.3 serine 31 phosphorylation
(H3.3S31P) is a post-translational modification that is enriched in mitosis and is
specific to H3.3 (Hake et al., 2005). H3.3S31P co-localizes with telomeres in ES
cells, but becomes more localized to pericentromeric heterochromatin following
cell differentiation (Hake et al., 2005; Wong et al., 2009) (see Figure 1.19). I
found that H3.3S31P is also Hira-independent, as mitotic enrichment of H3.3S31P
enrichment is fully maintained in Hira -/- ES cells (Figure 3.3).
To compare the genome-wide distribution of H3.3 in wild-type and Hira -/ES cells at higher resolution, I again performed native ChIP-seq. Although Hira has
been suggested to play a critical role in deposition of mammalian H3.3 (Meshorer et
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Figure 3.2: Chromosomal localization of H3.3 in wild-type and Hira -/- ES cells
A-F. Metaphase chromosome spreads from WT H3.3-EYFP and Hira -/- H3.3-EYFP ES cells, using
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Figure 3.3: H3.3 serine 31 phosphorylation is Hira-independent
Immunoblots of whole cell extracts from WT and Hira -/- ES cells grown asynchronously (left two
lanes) or blocked in metaphase with nocodazole (right two lanes).
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al., 2006; Tagami et al., 2004), this hypothesis has never been rigorously examined
through ChIP, likely due to the difficulty of raising an antibody to distinguish H3.3
from the other H3 variants. As might be expected, my data show that Hira is
specifically required for genome-wide H3.3 enrichment at active and repressed high
CpG content promoter (HCP) genes (Figure 3.4A-D). In the absence of Hira, the
pattern of H3.3 around active and repressed genes (Figure 3.4D) resembles H3.2
(Figure 3.4C), and general H3 (Figure 2.17C), with no enrichment surrounding
the TSS, and depletion of H3.3 at the TSS itself. For example, in Hira -/- ES cells,
the enrichment of H3.3 around the TSS of repressed bivalent genes such as Pparg
is abolished (Figure 3.4E). At highly expressed housekeeping genes such as the
ribosomal protein-coding gene Rps19, the enrichment of H3.3 in the gene body
and after the TES is mostly eliminated in the absence of Hira (Figure 3.4F). These
data demonstrate that the vast majority of H3.3 enrichment at both active and
repressed genes in ES cells is Hira-dependent, as expected from the existing
literature.
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Figure 3.4: Enrichment of H3.3 at active and repressed genes is Hira-dependent
A-D. Native ChIP-seq profiles of H3 variants, in wild-type ES cells (B-D) and Hira -/- ES cells (E)
across the TSS and TES for highly active (red), medium expressing (black), or low expressing
(green) CpG rich genes, with data represented as in Figure 2.
E. H3.3 enrichment at the TSS of repressed bivalent gene Pparg is Hira-dependent.
F. H3.3 enrichment at the active, ribosomal-protein coding gene Rps19 is Hira-dependent.
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Hira -/- ES cells maintain global patterns of ES cell gene expression
Given the lack of genic H3.3 enrichment in the absence of Hira, one possible
explanation for the alteration in genome-wide patterns of H3.3 at active and
repressed genes is a significant alteration in patterns of gene expression.
Therefore, my collaborators and I sought to determine if Hira -/- ES cells show
genome-wide alterations in gene expression. Remarkably, microarray analysis
reveals that global patterns of ES cell gene expression are maintained in Hira -/ES cells (Figure 3.5A-C). Moreover, genome-wide patterns of H3K36me3 are also
extremely similar in wild-type and Hira -/- ES cells (Figure 3.6). What accounts for
the strikingly ‘normal’ phenotype of Hira -/- ES cell growth and gene expression,
but for the significant defects seen upon Hira -/- ES cell differentiation?
Intriguingly, the phenotype of Hira -/- ES cells is similar to that of CHD1 shRNA
ES cells (Gaspar-Maia et al., 2009). Like Hira -/- ES cells, CHD1 shRNA ES cells
maintain global patterns of ES cell gene expression, but display significant defects
upon differentiation (Gaspar-Maia et al., 2009). CHD1 was recently shown to play
a role in H3.3 deposition during Drosophila pronuclear decondensation, and was
suggested to work together with Hira (Konev et al., 2007). It is therefore possible
that the defects upon differentiation of Hira -/- and CHD1 shRNA ES cells could
result from impaired replication-independent (RI) H3.3 deposition in more slowly
dividing or post-mitotic cells. Rapidly dividing Hira -/- and CHD1 shRNA ES cells
could be partially ‘rescued’ by replication-dependent (RD) histone deposition,
enabling global maintenance of the ES cell transcriptome, and I will discuss this
hypothesis in greater detail in the following chapter.
Notably, I cannot at this time rule out more subtle defects in transcription
that were not detectable by genome-wide microarray studies of Hira -/- ES cells.
For example, Hira -/- ES cells could still manifest low levels of spurious transcripts,
as the S. pombe HIRA protein homologs were recently shown to be required for
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Figure 3.5: Microarray analysis of gene expression in wild-type and Hira -/- ES cells
A-C. Triplicate GeneChip® Mouse Gene 1.0 ST Arrays were hybridized with cDNA from three
independent biological replicates of HIRA-/- ES (cl34) and WT ES (W9.5) cell lines. The data
was analyzed using the LIMMA package of Bioconductor v2.0 and R v.2.9.2, applying GC-RMA
normalization and correction for multiple testing (Benjamini-Hochberg) with a significance threshold
of p<0.05.
A. Significant differentially expressed genes were binned according to their fold-change.
B. The number of differentially expressed genes was determined for each low, medium, high
expression gene sets derived from WT ES cells. High, medium, and low expression genes were
determined from a previous microarray of WT ES cells (Mikkelsen et al., 2007) as detailed in
Materials and Methods. Overall, only a small number of genes in these gene sets were affected in
Hira -/- ES cells.
C. Differential expression of ES cell related genes in wild-type (W9.5) vs Hira -/- ES cells.
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Figure 3.6: H3K4me1 and H3K36me3 are maintained at genes in the presence and absence
of Hira
A-D. Profiles of H3K4me1 (A-B) and H3K36me3 (C-D) in wild-type (A,C) and Hira -/- (B,D) H3.3EYFP ES cells across TSS and TES for highly active, medium, or low expressed CpG rich genes.
Y-axis represents the average number of tags per gene per 200 bp per 1 million mapped reads.
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promoter silencing and global repression of cryptic antisense transcripts (Anderson
et al., 2009). Overall, my data show that genome-wide enrichment of H3.3 at active
and repressed genes in ES cells is Hira-dependent. However, Hira-dependent
genic deposition of H3.3 is not required for maintenance of the undifferentiated ES
cell transcriptome.

Hira-independent enrichment of H3.3 at transcription factor binding sites
Due to the significant enrichment of H3.3 at genic and intergenic TFBS, (Figure
2.28, 2.29), I also examined whether these patterns were dependent on
Hira. As the ES cell transcriptome is globally maintained in Hira -/- ES cells, I
reasoned that the overall profile of TFBS would be similar in wild-type and Hira -/ES cells, enabling us to use the same existing dataset of 13 different ES cell TFBS
(Chen et al., 2008b). Surprisingly, despite the observation that Hira is required for
genome-wide H3.3 enrichment at active and repressed genes, my collaborators
and I find that Hira is not essential for genome-wide H3.3 enrichment at TFBS.
Global profiles of H3.3 are largely maintained at ES cell TFBS in Hira -/- ES
cells (Figure 3.7, 3.8), demonstrating that H3.3 enrichment at most regulatory
elements is Hira-independent. For example, H3.3 enrichment at an intergenic
MTL approximately 30 KB from the Mmp17 gene is maintained in Hira -/- ES cells
(Figure 3.7B), as is H3.3 enrichment at an intergenic MTL near the repressed
Foxi3 gene (Figure 3.7C). Indeed, levels of H3.3 are increased at some TFBS
in Hira -/- ES cells (Figure 3.9). However, we note that levels of H3.3 are also
reduced at other TFBS in Hira -/- ES cells (Table 3.1, Figure 3.8). Of all previously
identified ES TFBS (Chen et al., 2008b), 34% show greater than 2-fold more
H3.3 tags in Hira +/+ than in Hira -/-, while 12% show greater than 2-fold more
H3.3 tags in Hira -/-, indicating that targeting of H3.3 to the majority (54%) of
known ES TFBS is Hira-independent (Table 3.1, Figure 3.8). Global profiles of
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H3K4me1 are very similar in wild-type and Hira -/- ES cells (Figure 3.6A-B, 3.8C),
indicating that Hira is also not required to maintain the localization of H3K4me1.
Overall, these data demonstrate that mammalian ES cells utilize Hira-independent
mechanisms to deposit and enrich H3.3 at many non-genic elements.

Hira-independent association of Atrx and Daxx with histone H3.3
To identify candidates that might mediate Hira-independent deposition of H3.3, I
began a collaboration with Assistant Professor Ileana Cristea of Princeton University,
formerly a postdoctoral fellow with Dr. Brian Chait here at Rockefeller University. Dr.
Cristea and I used an immunoaffinity purification and mass spectrometry approach
optimized to help maintain protein complexes in their original state (Cristea et al.,
2005). Using an anti-GFP antibody, proteins interacting with EYFP-tagged H3
variants in wild-type and Hira -/- ES cells were immunoprecipitated, resolved using
gel electrophoresis and identified using mass spectrometry (Figure 3.10A, 3.11).
We also performed immunoblots of immunoprecipitated proteins to confirm specific
candidates (Figure 3.10B).
We found many interacting proteins common to all H3 variants in wild-type
and Hira -/- ES cells, including core histones and previously described members
common to both RC and RI chromatin assembly complexes, such as Nasp, Asf1a,
Asf1b, and Rbap48 (a full list of identified proteins is presented in Table 3.2).
Notably, the previously described H3.3 chaperone Hira (Tagami et al., 2004) was
identified specifically in proteins isolated with H3.3.
However, in addition to Hira, we also identified Atrx and Daxx as proteins
that specifically associate with H3.3 (Figure 3.10, 3.11, 3.12). Atrx is a member of
the SNF2 family of chromatin remodeling factors (Picketts et al., 1996). Mutations
of human ATRX give rise to the ATR-X syndrome, a disorder characterized by
a form of X-linked mental retardation that is frequently associated with multiple
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Figure 3.8 H3.3 enrichment at ES TFBS is partially perturbed in Hira -/- ES cells, but is not
significantly affected in Atrxnull ES cells
A-C. H3.3 and H3K4me1 read densities at ES TFBS (Chen et al., 2008) were analyzed and plotted
from anti-GFP and anti-H3K4me1 native ChIP-seq experiments. TFBS were first separated into
different groups based on their H3.3 (or H3K4me1) ChIP-seq read densities in wild-type ES cells
(X-axis). Corresponding ChIP-seq read densities from Hira -/- or Atrx null samples are shown on
the Y-axis as boxplots. Upper schematics depict possible results. H3.3 levels at ES TFBS in
wild-type and Hira -/- ES cells remain generally correlated, indicating that H3.3 enrichment is not
completely abolished at ES TFBS in Hira -/- ES cells (A). However, H3.3 levels at ES TFBS are
reduced at many ES TFBS in Hira -/- ES cells, and increased at other ES TFBS, particularly at ES
TFBS with a high density of reads, suggesting that Hira affects H3.3 deposition in some but not all
TFBS. H3.3 enrichment at ES TFBS remains highly correlated betwen wild-type and Atrxnull ES
cells (B), and H3K4me1 enrichment at ES TFBS remains highly correlated between wild-type and
Hira -/- ES cells (C).
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Figure 3.8
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Figure 3.9: Real-time PCR confirmation of ChIP-seq results
Real-time PCR of ChIP DNA confirms ChIP-seq results. Note similar profiles of H3.3 at genes and
TFBS in Atrxflox (green) and Atrxnull (blue) ES cells. At genes, particularly active gene bodies and
TES, H3.3 enrichment is decreased in Hira -/- ES cells (orange), while at TFBS, H3.3 enrichment
is Hira-independent. Primer sequences are listed in Appendix. Data are plotted as fold enrichment
over intergenic (%input at location / %input at intergenic).
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Table 3.1: Global fraction of ES TFBS with differential H3.3 deposition between wild-type
and Hira -/- ES cells
Significant difference is defined here as 2-fold greater H3.3 tag densities from either wild-type or
Hira -/- ChIP-Seq analyses.
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Figure 3.10: Atrx and Daxx association with H3.3 is Hira-independent
A. H3.3-EYFP, H3.2-EYFP, H3.1-EYFP, and Hira -/- H3.3-EYFP associated proteins were
immunopurified from heterozygous H3.3B ES cells via the EYFP tag, resolved by SDS-PAGE, and
visualized by Coomassie Blue. Proteins were identified by mass spectrometry, and those listed in
red are specific to H3.3. The arrow indicating Hira points to a polypeptide in the H3.3 lane running
immediately above the polypeptide Nasp (*), which is common to all purified H3 variants. A full list
of identified proteins is presented in Table 3.2.
B. Immunoblots of immunopurified H3 variant associated proteins from ES cells with antibodies
as indicated.
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MS/MS data analysis performed by Ileana Cristea, and used with permission.

Figure 3.11: Probing the specificity of Atrx association with H3.3 using hypothesis-driven
MS/MS analysis
Hypothesis-driven multistage mass spectrometry (Kalkum et al., 2003) was utilized to obtain a highly
sensitive detection of specific peptides from proteins of interest, even if these peptide species could
not be discerned in the primary matrix-assisted laser desorption/ionization MALDI MS analysis
because of insufficient signal-to-noise. Even if Atrx peptides were not observed in the H3.2 and
H3.1 samples at the MS level, their corresponding m/z values ([M+H]+) were selected, subjected to
collision induced dissociation (CID) fragmentation, and analyzed using MALDI IT MS/MS analyses.
The expected fragmentation pattern for the Atrx peptides was confirmed only in the sample isolated
with H3.3 (A-B) as assessed by b and y ion fragments and the preferential cleavages C-terminus
of Glu and N-terminus of Pro residues. See also top row of Table 3.2.
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Table 3.2: List of H3 variant associated proteins identified by mass spectrometry
The presence of the interacting partners in the isolations of the different H3 variants (H3.3, H3.2,
H3.1, Hira -/- H3.3 and Hira -/- H3.2) is indicated with + (detected) and - (not detected). Only the
proteins identified as main hits by database searching and confirmed by manual data interpretation
are illustrated. The specificity of Hira, Atrx, and Daxx association with H3.3 were confirmed by
western blots and further experiments (see main text for details). The specific association of other
proteins with particular H3 variants will require further investigation. The number of peptides, protein
sequence coverage and XProteo d’ (discriminability) score obtained following the analysis of the
MS data are indicated for each protein isolated with the H3 variants. The XProteo score is based on
an improved version of the ProFound Bayesian algorithm (Zhang and Chait, 2000) and measured
as d’—the normalized distance between the score distribution (of the candidate protein) and the
distribution of randomly matched proteins (in units of standard deviation). A d’=4 correspond to a
true positive rate of 0.99 and a false positive rate of 0.05. Candidate proteins were confirmed by
CID MS/MS analyses of the indicated peptides that were acquired and interpreted manually.
*See Figure 3.11 for an example of MS/MS analysis of ATRX peptides.
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Table 3.2
Protein name

Atrx*

Protein ID

gi|6678609|ref|NP_033556.1

H3.3

+

H3.2

-

H3.1

-

Hira

Hira

-/-

-/-

H3.3

H3.2

+

-

peptides selected for MS/MS

FGQTKPVYVYR*
FLPPKHEYVLAVR*
WAEEFNDETNVR
EEISDHENNVTILLEDSDLRR
TTSTSNPSSPAPDWYKDFVTDTDAEV-

LEHSGK

Daxx

gi|24636788|sp|O35613|

+

-

-

+

-

LEQLLALYVAEIR
TETSDHPEVVPFLHK
ENRTLAMNR
NSEPAEGLR
ELDLSELDDPDSSYLQEAR

hnRNP G-T

gi|94381180|ref|XP_914797.2

-

-

-

+

-

RDPYLGPR
VAQATKPVFESGR

Macf1

gi|94373701|ref|XP_996894.1

-

-

-

+

-

Hira

gi|52426778|ref|NP_034565.2

+

-

-

-

-

LQAALASTQQFQQMFDELR
SLNQPTPPPMPILSQSEAKNPR
FPEILATLR
YLVNEGFEYR

Dnmt3a

gi|13938621|gb|AAH07466.1

+

-

-

-

-

Ssrp1

gi|110283006|sp|Q08943|

+

-

-

-

-

RGS9

gi|2739458|gb|AAC99481.1

+

-

-

-

-

LFFEFYR
AIYEVLQVASSR
FDEISFVNFAR
NEVTLEFHQNDDAEVSLMEVR
SPPGMNNVLDYGLDR
EAANTVDITQVMSK

FACTp140

gi|110287968|sp|Q920B9|

+

-

-

-

-

NEGNIFPNPEATFVK
APGEQTVPALNLQNAFR
VEALTKEELEFEVPFR

mHEL-5

gi|71153505|sp|O70133|

+

+

+

+

+

DFVNYLVR
LAHFEPSQR
EGERVEPYK
DINTDFLLVVLR
TTQVPQYILDDFIQNDR

SNF2H

gi|14028669|gb|AAK52454.1|

+

+

+

+

+

YLVIDEAHR
QPNVQDFQFFPPR
TPEEVIEYSAVFWER

NASP

gi|13384598|ref|NP_058057.2

+

+

+

+

+

5730410I19Rik

gi|51261128|gb|AAH79531.1

+

+

+

+

+

EIEELKELLPEIR
SLQENEEEEIGNLELAWDMLDLAK
REDIQQFFEEFQSK
DAATYWPLNWR

RBBP-4

gi|90101524|sp|Q60972|

+

+

+

+

+

TVALWDLR
TPSSDVLVFDYTK
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Dnajc9

gi|23956266|ref|NP_598842.1

+

+

+

+

+

Parp1

gi|74144748|dbj|BAE27352.1

+

+

+

+

+

EIPAYSAFVK
ISLEDIQAFEK
TLGDFLAEYAK
QPDVEVDGFSELR
DELGFRPEYSASQLK

Ubiquitin

gi|51701919|sp|P63049|

+

+

+

+

+

ESTLHLVLR
EGIPPDQQR

ASF1A

gi|13384964|ref|NP_079817.1

+

+

+

+

+

ASF1B

gi|12859888|dbj|BAB31809.1

+

+

+

+

+

ENPPVKPDFSK
VGYYVNNEYTETELR
VGYYVNNEYPDPELR
ENPPPKPDFSQLQR

Atp5b

gi|23272966|gb|AAH37127.1

+

+

+

+

+

H2A

gi|28316756|ref|NP_783589.1

+

+

+

+

+

H2B

gi|30061385|ref|NP_835507.1

+

+

+

+

+

VALTGLTVAEYFR
AIAELGIYPAVDPLDSTSR
AGLQFPVGR
VTIAQGGVLPNIQAVLLPK
LLLPGELAK
AMGIMNSFVNDIFER

H2A.Z

gi|7949045|ref|NP_058030.1

+

+

+

+

+

GDEELDSLIK
AGLQFPVGR
ATIAGGGVIPHIHK
VGATAAVYSAAILEYLTAEVLELAGNASK

YFP

gi|3891568|pdb|1YFP|

+

+

+

+

+

H3

gi|53734121|gb|AAH83353.1

+

+

+

+

+

FEGDTLVNR
SAMPEGYVQER
YRPGTVALR
VTIMPKDTQLAGR
EIAQDFK
STELLIR

H4

gi|85057093|gb|AAI11814.1

+

+

+

+

+

VFLENVIR
ISGLIYEETR

MCM2

gi|37359742|dbj|BAC97849.1

+

+

+

+

+

MCM6

gi|6678832|ref|NP_032593.1

+

+

+

+

+

ISHLPLVEELR
IFASIAPSIYGHEDIKR
DFYVAFQDLPTR
EIPFAKDFYVAFQDLPTR

MCM7

gi|74210112|dbj|BAE21331.1

+

+

+

+

+

Hsp1

gi|40556608|ref|NP_032328.2

+

+

+

+

+

HAT1

gi|28076885|ref|NP_080391.2

+

+

+

+

+

LMMEQRSR
GFTPAQFQAALDEYEELNVWQVNTSR
HLEINPDHPIVETLR
HNDDEQYAWESSAGGSFTVR
FQELVEDYRR
FPEDLENDIR
LLVTDMSDAEQYR
YYISFPTVLDITAEDPSR

HSP70

gi|74211667|

+

+

+

+

+

ARFEELNADLFR
TVTNAVVTVPAYFNDSQR

Mass spectrometry analysis performed in collaboration with Ileana Cristea, and used with permission.
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congenital abnormalities and alpha thalassemia (Gibbons et al., 2008). ATRX
has been described to co-exist in a chromatin-remodeling complex with the death
domain-associated protein Daxx, and these proteins have been localized to
heterochromatin and promyelocytic leukemia (PML) nuclear bodies in human and
mouse cells (Ishov et al., 2004; Tang et al., 2004; Xue et al., 2003). As Atrx and
Daxx specifically associate with H3.3 both in wild-type and Hira -/- ES cells, we
conclude that this association is Hira-independent (Figure 3.10A-B).
To determine if the association between H3.3, Atrx, and Daxx was also
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conserved in differentiated human cells, I collaborated with Dr. Peter Lewis, a
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Figure 3.12: H3.3 specific association with Atrx and Daxx is conserved in differentiated
human cells
A. Immunoblots of Atrx, Daxx and FLAG-HA-H3 from HeLa cells stably expressing H3.3-FLAG-HA
(FHA) or H3.1-FHA (Tagami et al., 2004).
B. Oligonucleosomes purified from H3.3-FHA and H3.1-FHA HeLa cells. Micrococcal nuclease
digested chromatin was incubated with M2 agarose beads in order to purify H3.3-FHA and H3.1FHA oligonucleosomes and associated proteins. Two adjacent FLAG elution fractions (FE1 and
FE2) from each H3.3-FHA and H3.1-FHA purification are shown in B-C. Oligonucleosomal DNA
was purified and run on a 1% agarose gel, with fragment size indicated.
C. Immunoblots of eluate from two adjacent FLAG elution fractions (FE1 and FE2) following FLAG
affinity purification from H3.3-FHA and H3.1-FHA oligonucleosomes (B).
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postdoctoral fellow in the Allis lab. We isolated oligonucleosomes and chromatinassociated proteins from human cervical cancer (HeLa) cells carrying stably
expressed FLAG-HA tagged H3.3 or H3.1 (Tagami et al., 2004) (Figure 3.12).
Following FLAG affinity purification and FLAG peptide elution, immunoblots
of H3.3 and H3.1 associated proteins reveal that both Daxx and Atrx are also
specifically associated with H3.3 but not H3.1 oligonucleosomes in human cells
(Figure 3.12C).
H3.3B / H3.3-EYFP
Atrx Atrx Atrx Hira
flox null null -/1 2

Atrx is required to maintain H3.3 deposition at
telomeric DNA and for repression of telomeric
(TERRA) in ES cells

Atrx

To determine if Atrx is required for H3.3 enrichment

Hira

in genes, regulatory regions, or telomeres, I
GFP

again used ZFNs to knock-in an epitope tag

Oct4

into the endogenous allele of H3.3B, generating

Data produced in collaboration with
Kyung-Min Noh.
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Figure 3.13: Expression of H3.3EYFP in Atrxflox, Atrxnull, and
Hira -/- ES cells

background of Atrxflox and Atrxnull mouse ES cells

Immunoblots showing expression of
H3.3-EYFP in Atrxflox, Atrxnull, and
Hira -/- ES cells, with antibodies as
indicated.

generous gift from the laboratory of Dr. Douglas

(Figure 3.13). Atrxflox and Atrxnull ES cells were a

Higgs and Dr. Richard Gibbons (Garrick et al.,
2006). Although Atrxnull mice die by E9.5 due to

a defect in trophoblast development, Cre-mediated deletion of Atrx from Atrxflox
ES cells results in viable Atrxnull ES cells (Garrick et al., 2006). Immunoblots
demonstrate comparable expression of H3.3B-EYFP in Atrxflox and Atrxnull ES cells
(Figure 3.13).
I used native ChIP-seq to generate genome-wide profiles of H3.3 in
the presence and absence of Atrx. My collaborators and I find that Atrx is not
160
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Zheng (A), Kyung-Min Noh (B), and
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Figure 3.15: Atrx is required for Hira-independent enrichment of H3.3 at telomeres
A. Analysis of H3.3 enrichment at repetitive elements in Atrxflox, Atrxnull, and Hira -/- ES cells.
Fold enrichment of repetitive elements in ChIP-seq data are plotted over input.
B. Dot blot with Sty11 telomeric probe (left) or control Bam repeat probe (right) of ChIP-seq DNA
from Atrxflox H3.3-EYFP or Atrxnull H3.3-EYFP IPed with indicated antibody (GFP, H3K4me3, or
H3K9me3) or Input DNA.

required for H3.3 incorporation at active or repressed genes (Figure 3.14A-B),
or at regulatory elements (Figure 3.8, 3.14C), as genome-wide profiles of H3.3
are similar at genes and TFBS in Atrxflox and Atrxnull ES cells. Strikingly, analysis
of repeats demonstrates that Atrx, but not Hira, is specifically required for H3.3
enrichment at telomeres (Figure 3.15).
To determine whether there were any functional consequences of Atrx
deletion and the loss of Atrx-dependent telomeric enrichment of H3.3, we examined
the chromatin state and transcriptional output of ES cell telomeres. The chromatin of
ES and induced pluripotent cell telomeres has previously been shown to have lower
levels of the heterochromatin marker H3K9me3, increased telomere length, and
increased transcription of telomeric repeat-containing RNA (TERRA) in comparison
to differentiated cells (Marion et al., 2009) (see Figure 1.20). In particular, TERRA
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Figure 3.16: Atrx is required for repression of
telomeric RNA
A. Immunoblots of Atrx in Atrxflox, Atrxnull, and Atrxflox
ES cells 4 days after treatment with retroviral Cre.

Gapdh

B. Representative northern blot for TERRA (upper
panel) and Gapdh (lower panel) in Atrxflox and Atrxnull
ES cells in the presence and absence of Cre. To ensure
that signal is from RNA, samples on the right were
treated with RNase for 30 minutes as indicated.
C. Quantification of TERRA normalized to Gapdh.
Error bars represent the standard deviation of three
independent experiments.

has recently been identified as a component of telomeric heterochromatin and an
inhibitor of telomerase, and levels of TERRA have been shown to be regulated
by chromatin modifying enzymes (Azzalin and Lingner, 2008; Azzalin et al., 2007;
Luke and Lingner, 2009; Schoeftner and Blasco, 2008; Yehezkel et al., 2008).
Human ATR-X patients have also previously been shown to have altered DNA
methylation in subtelomeric repeats (Gibbons et al., 2000). ChIP of H3K4me3 and
H3K9me3 does not show a significant difference in telomeric enrichment between
Atrxflox and Atrxnull ES cells (Figure 3.15B). However, northern blots from Atrxflox,
Atrxnull, and Atrxflox ES cells 4 days after treatment with Cre reveal reproducible
(~1.7 fold) upregulation of TERRA in the absence of Atrx (Figure 3.16A-C).
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Atrx is required to maintain H3.3 deposition at ribosomal DNA and for
repression of ribosomal RNA in ES cells
In addition to subtelomeric repeats, ATRX patients also show alterations in
DNA methylation at rDNA arrays (Gibbons et al., 2000). Genome-wide and
immunofluorescence studies in differentiated human cells have previously
demonstrated that ATRX is localized to rDNA as well as heterochromatin (Law,
2006; McDowell et al., 1999). To determine whether enrichment of H3.3 at rDNA
90F/
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Data in B produced by Martin
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Figure 3.17: Atrx is required for Hira-independent enrichment of H3.3 at ribosomal DNA, and
for repression of ribosomal RNA
A. (Top) Scale diagram showing positions of real-time PCR amplicons (blue boxes) across mouse
rDNA. Numbering is kilobases from the start of transcription. Coding regions are shown in red.
Yellow bar indicates transcribed region. Location of the real-time PCR amplicon used for rDNA
primary transcript analysis in H (90F/146R) is indicated. (Bottom) Analysis of H3.3 enrichment
at mouse rDNA sequences using real-time PCR of H3.3-EYFP ChIP DNA from Atrxflox (green),
Atrxnull (blue) and Hira -/- (orange) ES cells, plotted as fold enrichment over intergenic region.
B. Total RNA extracted from wild-type and Atrxnull ES cells was reverse transcribed and real-time
PCR was used to determine levels of ribosomal RNA primary transcript relative to Gapdh mRNA.
Error bars represent standard deviation from four ES cell subclones.
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might also be dependent on Hira or Atrx, I analyzed ChIP samples from H3.3-EYFP
Atrxflox, Atrxnull, and Hira -/- ES cells using real-time PCR primers specific for mouse
rDNA. Intriguingly, H3.3 enrichment at the transcribed region of rDNA is also Hiraindependent and Atrx-dependent (Figure 3.17A). While H3.3 enrichment at rDNA
transcribed regions is reduced in Atrxnull ES cells, levels of rDNA transcripts are
also increased in Atrxnull ES cells (Figure 3.17B). Therefore, in both telomeres and
rDNA, Atrx is required for H3.3 enrichment in these transcribed repetitive elements,
and the transcription of telomeres and rDNA is increased in the absence of Atrx.

ATRX ADD domain interacts with the histone H3 tail
ATRX associates specifically with H3.3 in the presence and absence of Hira (Figure
3.10-3.12). In addition, I have shown that ATRX is required for H3.3 deposition
at telomeres and rDNA, and for the repression of TERRA and rRNA (Figure 3.153.17). However, the mechanism by which ATRX directs H3.3 deposition remains
unknown. ATRX is a very large protein of approximately 280 kDa, with two highly
conserved domains (Gibbons et al., 2008). At its N-terminus, ATRX contains
an ATRX-DNMT3-DNMT3L (ADD) domain, a PHD finger-like domain, and at
its C-terminus, ATRX contains an ATPase domain with seven highly conserved
helicase motifs (Gibbons et al., 2008) (see Chapter Four for further discussion of
ATRX functional domains). The ADD domain of DNMT3L was recently shown to
bind preferentially to the unmodified histone H3 tail (Ooi et al., 2007).
To determine if the ADD domain of ATRX might mediate a direct association
between ATRX and histone H3.3, I performed peptide pull-down studies with the
recombinant ATRX ADD domain (residues 159–296) (Argentaro et al., 2007) and
biotintylated histone peptides (Figure 3.18). As controls, I used recombinant
DNMT3L (Ooi et al., 2007), as well as WDR5, which has been shown to preferentially
bind to H3K4me2 (Ruthenburg et al., 2006; Wysocka et al., 2005). I found that the
165

ATRX ADD domain interacts specifically with the histone H3 tail, amino acids 1-20,
similar to the described interaction of H3 1-20 with DNMT3L (Ooi et al., 2007),
(Figure 3.18A). As DNMT3L shows a strong preference for H3 1-20 unmethylated
at H3K4, I used histone H3 tail peptides methylated at K4 and K9 to determine if
the ATRX ADD domain displays a similar preference. I found that the ATRX ADD
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Figure 3.18: ATRX ADD domain interacts with H3 1-20, and does not show a preference for
H3.3 specific sequences
A-C. Peptide interaction assays with modified or unmodified biotinylated histone H3 peptides as
indicated, incubated with the human ATRX ADD domain, or full-length DMNT3L and WDR5 as
controls.
A. The ATRX ADD domain prefers the N-terminal 1-20 amino acids of H3.
B. The ATRX ADD domain interacts with the N-terminus of H3, is relatively unaffected by H3K4
methylation, and displays a slight preference for H3K9 methylation.
C. The ATRX ADD domain does not prefer H3.3-specific peptides, but interacts with the N-terminal
1-20 amino acids of H3.
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higher H3K9 methylation states (Figure 3.18B). DNMT3L binding was completely
abolished by H3K4 methylation, as previously reported (Ooi et al., 2007), while
a fraction of the ATRX ADD domain still bound to H3 1-20 peptides methylated
at H3K4 (Figure 3.18B).

Recent unpublished studies from other laboratories

confirm that the ATRX ADD domain binds to unmodified H3 tails, and this binding
is enhanced by di and tri-methlyation of H3K9 (D. Neuhaus, D. Rhodes, Y. Shi,
personal communication). However, as described previously, the histone H3 tail
residues 1-20 are identical in all non-centromeric H3 variants (Figure 1.16), and
this interaction therefore does not demonstrate why I have seen such a selective
association of ATRX with H3.3.
The amino acids that distinguish H3.3 from H3.1/H3.2 are located in the
N-terminal tail at position 31, as well as in a core region at 87, 90, 90, and 96
(Figure 1.16). Therefore, I also used peptide sequences spanning these regions to
determine if the ATRX ADD domain might show any H3 variant-specific preference.
Disappointingly, the ATRX ADD domain did not interact significantly with H3 19-38
or 22-41 from H3.3 or H3.2/H3.1, or with 86-97 from H3.3 or H3.2 (Figure 3.18B).
Therefore, the mechanism by which ATRX associates with and specifically deposits
H3.3 remains to be established.

A new perspective on H3.3 deposition pathways
The studies described in this chapter make clear that H3.3 deposition in mammalian
cells is significantly more complicated than current models suggested by the field
(De Koning et al., 2007; Loyola and Almouzni, 2007) (Figure 1.22). Although Hira
plays an essential role for H3.3 deposition at genes and multiple TFBS, it is only
responsible for a subset of genome-wide H3.3 deposition patterns in mammalian
cells. Deposition of H3.3 at specific TFBS, telomeres, and rDNA is Hira-independent.
In addition, my work has identified two novel players in H3.3 deposition: ATRX
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and Daxx. We have seen that ATRX is required for H3.3 deposition at telomeres
and rDNA, and for repression of TERRA and rRNA transcription. Although many
questions remain, the data in this chapter provide a new perspective on the
complexity of genomic region-specific H3.3 deposition in mammalian cells. In
the following chapter, I will discuss the implications of my work, describe ongoing
projects and future studies, and discuss the potential functions of H3.3 deposition
in mammalian development and cellular differentiation.
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Chapter 4
GENERAL Discussion, work in progress, and
future directions
The data presented in the previous chapters represent the first comprehensive
evaluation of non-centromeric H3 variant localization in undifferentiated mammalian
embryonic stem (ES) cells and differentiated neuronal precursor cells (NPCs).
Chromatin immunoprecipitation (ChIP) grade antibodies that distinguish
H3.3 from the other H3 variants are not available. Therefore, in Chapter Two,
I introduced a system for the rapid knock-in of epitope tag sequences into the
endogenous histone H3.3B gene in mouse ES cells. Using these genetically
engineered ES cells in combination with point mutagenesis of H3.3B, I have found
compelling evidence that genome-wide patterns of H3.3 are dependent on H3.3specific amino acid sequence. H3.3 displays specific patterns of incorporation in
the mammalian genome, while H3.2 and H3.1 are much more widely distributed.
Following the differentiation of ES cells into NPCs, I demonstrated that patterns of
H3.3 enrichment at cell-type specific genes and transcription factor binding sites
(TFBS) are dependent on cellular state. Overall, the data in this thesis identify
three general categories of H3.3 enrichment in mammalian cells: 1) genes and
other transcribed non-repetitive sequences, 2) TFBS, and 3) ribosomal DNA (rDNA)
and telomeres. Remarkably, as shown in Chapter Three, each of these general
categories of H3.3 enrichment in ES cells are mediated by distinct mechanisms of
deposition.
In Chapter Three, I examined genome-wide patterns of H3.3 deposition
in the presence and absence of the histone chaperone Hira. As expected, the
H3.3 chaperone Hira is required for enrichment of H3.3 at active and repressed
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genes. Unexpectedly, deposition of H3.3 at specific TFBS, rDNA, and telomeres
is Hira-independent. Immunoaffinity purification of H3.3 associated proteins in the
presence and absence of Hira revealed a specific, Hira-independent association of
H3.3 with the chromatin remodeling protein Atrx (alpha thalassemia and X-linked
mental retardation) and the death domain associated protein Daxx. Using Atrxflox
and Atrxnull ES cells, my collaborators and I found that Atrx is specifically required
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Figure 4.1: Hira and Atrx are required for deposition of H3.3 at distinct genomic regions
The patterns and levels of H3.3 enrichment at specific elements are represented by green profiles.
At highly repetitive elements with short repeat length such as telomeres, the precise pattern of
H3.3 across the element cannot be determined, and the relative enrichment is indicated by a green
hashed box.
H3.3 is enriched in specific patterns at active and repressed genes with high CpG content promoters
(HCP), genic and intergenic transcription factor binding sites (TFBS), ribosomal DNA (rDNA), and
telomeres. TSS = transcription start site, TES = transcription end site. The H3.3 chaperone HIRA
is required for H3.3 enrichment at active genes, repressed genes, and specific TFBS. Based on
the described localization of CHD1 to transcription start sites in embryonic stem cells (GasparMaia et al., 2009), and the cooperative role of Hira and CHD1 in H3.3 nucleosome assembly in
Drosophila (Konev et al., 2007), it is possible that CHD1 may also play a role in H3.3 deposition
at these locations, but this possibility has not been examined. Surprisingly, H3.3 enrichment at
specific TFBS, rDNA, and telomeres is Hira-independent. The boxed question mark denotes as yet
unidentified factors that are required for Hira-independent and Atrx-independent H3.3 deposition
at specific TFBS. ATRX is required for H3.3 enrichment at rDNA and telomeres. Although Daxx
specifically associates with both H3.3 and Atrx, the role of Daxx in H3.3 deposition has not yet been
established. Note that the profiles shown in this chapter are generalized summary depictions. For
actual ChIP-seq data, see Chapters Two and Three.
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for H3.3 deposition at telomeres and rDNA.
Overall, these data demonstrate that mammalian cells utilize distinct
mechanisms to deposit histone H3.3 at different genomic locations (Figure 4.1). As
presented in Chapter One, the chromatin field generally accepts a model in which
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Figure 4.2: Genome-wide localization of H3.3 requires H3.3-specfic amino acid sequence
Mutation of endogenous H3.3B to H3.2 or towards H3.1 abolishes H3.3 enrichment at TFBS,
active and repressed genes, rDNA, and telomeres. Data is summarized in a manner similar to the
previous figure.
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Hira is the sole H3.3-specific chaperone required for H3.3 deposition. Therefore,
the results presented in this thesis provide a significant conceptual advance to
this overly simplistic paradigm. The observation that Atrx is required for H3.3
deposition at telomeres and rDNA opens up a new area of investigation regarding
the mechanisms, recruitment, and function of genomic region-specific histone
deposition machinery.

More speculatively, these results may suggest potential

connections between H3.3 deposition and human genetic disease. Below, I will
discuss some of the implications of our findings, describe some current work in
progress, and suggest some possibilities for future studies.

Genomic localization of H3.3 is specific and requires H3.3 amino acid
sequence
The data presented in Chapter Two demonstrate that H3.3 is enriched in specific
patterns at active and repressed coding and non-coding genes, including lincRNA
(Guttman et al., 2009), as well as TFBS, ribosomal DNA , and telomeres (Figure
4.1).

Using point mutagenesis of the endogenous H3.3B gene, I provided

strong evidence that this localization pattern requires H3.3-specific amino acid
sequence. Expression of a non-H3.3 variant from the H3.3 promoter is insufficient
for proper targeting and localization of H3.3, as genome-wide H3.3 patterns are
abolished upon the mutation of H3.3B to H3.2 or H3.1 (Figure 4.2). Notably, I
have not performed the reciprocal experiment that places H3.3 under a replicationdependent H3.1 or H3.2 promoter. Therefore, it remains possible that the timing of
H3 variant expression may still play an important role in H3 variant localization if
the H3 variant is only expressed during the defined window of S-phase. However,
the results presented in this thesis clearly show that the sequence of the H3 variant
dictates genome-wide localization when expressed from the endogenous H3.3B
promoter (Figure 4.2).
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Constitutive incorporation of H3.3 at active and repressed genes with CpG
rich promoters
In Drosophila, H3.3 is constitutively enriched around poised HSP70 promoters,
even in the absence of heat shock (Mito et al., 2007). However, in previous studies
of vertebrates, the profile of H3.3 at repressed genes differed depending on the
system being studied (see Chapter One) (Jin and Felsenfeld, 2006; Jin et al.,
2009; Sutcliffe et al., 2009).
Our data show that genome-wide patterns of H3.3 around TSS in mammalian
ES cells and NPCs vary significantly based on the CpG content of gene promoters.
H3.3 is constitutively enriched around the TSS of both active and repressed high
CpG content promoter (HCP) genes in ES cells and NPCs, including the TSS
of bivalent genes in ES cells (Figure 4.2). In contrast to HCP genes, we do not
observe any significant pattern of H3 variant enrichment at low CpG content
promoter (LCP) genes in ES cells and NPCs (data not shown).
LCP and HCP genes have been described to display distinct modes of
regulation (Mikkelsen et al., 2007; Ramirez-Carrozzi et al., 2009; Saxonov et al.,
2006). Most HCP genes in both undifferentiated and differentiated cells show
evidence of transcriptional initiation, assemble unstable nucleosomes, and do not
require SWI/SNF nucleosome remodeling complexes for gene induction, while
LCP genes assemble stable nucleosomes and require SWI/SNF (Guenther et
al., 2007; Ramirez-Carrozzi et al., 2009). Indeed, nearly all (99%) of HCP genes
are marked by H3K4me3 in mouse ES cells, whether they are transcriptionally
active or repressed, while only 6.5% of LCP genes in ES cells carry H3K4me3
(Mikkelsen et al., 2007). Our results are therefore consistent with a model in which
H3K4 methylation and H3.3 deposition at HCP TSS are coupled to transcriptional
initiation.
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Gene body deposition and transcription end site peaks of H3.3 in mammalian
cells are proportional to transcriptional activity
In addition to constitutive TSS deposition of H3.3 at HCP genes, we find enrichment
of H3.3 in the gene body and after the transcription end site (TES) in proportion
to transcriptional activity (Figure 4.2). These gene body and TES patterns of
H3.3 are distinct from other histone modifications. While H3.3 and H3K36me3
are strongly correlated in gene bodies, H3K36me3 begins to decline prior to the
TES at highly expressed genes (see Figure 1.10), while levels of H3.3 and Ser5 phosphorylated RNA polymerase II (RNAPII) increase and are enriched in a
specific peak beyond the TES of highly expressed genes (Figure 4.2).
Significant peaks of H3.3 were not initially observed after the 3’ ends of
genes in Drosophila (Mito et al., 2005, 2007). However, a more recent report found
a peak of H3.3 at genic 3’ ends of both active and inactive Drosophila genes,
particularly from chromatin fractions extracted in low-salt (Henikoff et al., 2009).
Interestingly, a dramatic enrichment of trypanosome-specific histone variants H3V
and H4V was recently observed at the probable RNAPII transcriptional termination
sites of polycistronic transcription units (Siegel et al., 2009), leading to the proposal
that “chromatin-based transcriptional punctuation” in trypanosomes may represent
an evolutionary adaptation to regulate transcription in eukaryotes that lack
sophisticated regulatory sequences (Talbert and Henikoff, 2009). In addition, TES
peaks of H3.3 were also observed in a recent genome-wide study of HeLa cells
(Jin et al., 2009). Here, I have shown that “transcriptional punctuation” by histone
variant H3.3 and phosphorylated RNA polymerase also marks the boundaries of
highly expressed genes in both undifferentiated and differentiated mammalian
cells, calling attention to a potentially more universal mechanism for histone variant
utilization as a genomic “boundary marker.”
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Figure 4.3: H3.3 localization at cell-type specific genes changes with cell differentiation
Representative ES and NPC profiles for H3.3 are depicted for housekeeping genes, pluripotency
genes, neural precursor genes, and non-neural genes with HCP promoters.
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What is the function of H3.3 deposition after transcriptional end sites? Does
genic and post-TES deposition of H3.3 simply demarcate active genes, or does H3.3
play a more active role? Previous studies suggest that H3.3 deposition in actively
transcribed gene bodies may be coupled to transcription, potentially mediated by
factors associated with elongating polymerase (Daury et al., 2006; Janicki et al.,
2004; Schwartz and Ahmad, 2005; Tagami et al., 2004; Wirbelauer et al., 2005).
Recent studies in human cells documented accumulation of RNAPII beyond the
site of RNA transcript cleavage and downstream of H3K36me3, suggesting that
paused RNAPII may accumulate prior to release at the end of genes (Brodsky
et al., 2005; Lian et al., 2008). One can speculate that the colocalized post-TES
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Figure 4.4: H3.3 localization at cell-type regulatory elements changes with cell
differentiation
H3.3 enrichment at ES cell specific enhancers is decreased in NPCs (top). In addition, numerous
unannotated cell-type specific peaks were found, and these represent candidates for possible celltype specific regulatory elements.
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peaks of phosphorylated RNAPII and H3.3 at highly active genes in mammalian
cells represent a site of significant chromatin disruption, as transcription-coupled
deposition of H3.3 “builds up” with paused RNAPII prior to polymerase release.
It is also possible that peaks of significant H3.3 replacement may play an active
role in slowing the extension of RNAPII to facilitate transcriptional termination, as
nucleosomes have been shown to serve as a barrier to transcriptional elongation
(Armstrong, 2007).

H3.3 localization changes at specific loci following embryonic stem cell
differentiation
I chose ES cells as a model system because they would enable me to study how
patterns of H3 variants change during mammalian cellular differentiation. I have
found that the overall pattern of H3.3 enrichment remains consistent in ES cells
and NPCs, with H3.3 enriched at the TSS of active and inactive genes, within active
gene bodies and after active TES, as well as TFBS, rDNA, and telomeres (Figure
4.3). Notably, my collaborators and I found remarkable genome-wide changes
of H3.3 localization at cell-type specific genes and TFBS, including pluripotency
genes, differentiation-specific genes, and known regulatory regions (Figure
4.3, 4.4). In addition, we also found multiple cell-type specific sites of H3.3 and
H3K4me1 enrichment that do not correspond to annotated genes or TFBS (Figure
4.4). When combined with future datasets, it is possible that our data will yield
additional insights, perhaps as a means of identifying novel ES or NPC regulatory
and transcribed regions. A similar approach recently used genome-wide patterns
of H3K4me3 and H3K36me3 to identify novel mammalian lincRNAs (Guttman et
al., 2009; Mikkelsen et al., 2007), and genome-wide patterns of p300 to identify
tissue-specific enhancers (Visel et al., 2009).
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Comparison of H3.3 and H2A.Z localization in embryonic stem cells and
neural precursor cells
As described in Chapter One, the histone variants H3.3 and H2A.Z have been
found to co-occupy nucleosomes at specific regions of the genome, and such
H3.3/H2A.Z nucleosomes were found to be relatively unstable in vitro (Jin and
Felsenfeld, 2006, 2007; Jin et al., 2009). H3.3 was previously found to be coenriched with H2A.Z at active promoters and enhancers of differentiated chicken
and human cells (Jin and Felsenfeld, 2007; Jin et al., 2009).
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Figure 4.5: Predicted genic locations of H3.3 / H2A.Z nucleosomes in ES cells and NPCs
based on current study and reported literature
Genome-scale patterns of H2A.Z in ES cells and NPCs have been previously reported (Creyghton
et al., 2008). Based on this published data and on the data presented in this thesis, H3.3 / H2A.Z
nucleosomes can be predicted to co-exist at the TSS of repressed genes in ES cells, but active
genes in NPCs.
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localization of H3.3/H2A.Z nucleosomes has not been previously reported in ES
cells. Interestingly, the data I have presented in Chapter Two shows that genomewide patterns of H3.3 in ES cells differ significantly from the described patterns of
H2A.Z (Creyghton et al., 2008).
In ES cells, H2A.Z is enriched in the promoters of repressed polycomb
target genes, but upon differentiation to NPCs, H2A.Z becomes enriched at the
promoters of highly expressed genes (Creyghton et al., 2008). I have shown that
H3.3 is enriched more widely than the reported patterns of H2A.Z in both ES cells
and NPCs, as H3.3 is enriched around the TSS of both active and repressed
genes, in addition to expressed gene bodies, TFBS, and telomeres. Moreover,
while H3.3 enrichment changes at specific locations upon cell differentiation, the
overall relationship between H3.3 enrichment and gene expression remains similar
in undifferentiated and differentiated cells. In both ES cells and NPCs, the greatest
enrichment of H3.3 is found at highly expressed metabolic and housekeeping
genes (Figure 2.27). If we integrate the previous results of Boyer, Creyghton,
and colleagues with the data presented here, one potential implication is that
destabilizing H3.3/H2A.Z nucleosomes in ES cells would be present specifically
at the TSS of repressed, poised genes, rather than at active housekeeping genes
(Figure 4.5). It is possible that such cell-type specific localization of destabilizing
nucleosomes may be important to prepare developmental genes in ES cells for
future expression. However, no one has yet demonstrated the genome-wide
localization of H3.3/H2A.Z nucleosomes in any mammalian cell type other than
HeLa cells (Jin et al., 2009).

Therefore, the first step would be to confirm the

existence and localization of H3.3/H2A.Z nucleosomes in ES cells and NPCs, an
experiment which would now be possible by performing a double anti-HA and antiH2A.Z ChIP-seq from the H3.3B / H3.3B-HA ES cells described in this thesis.
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Hira-dependent enrichment of H3.3 at active and repressed genes
The data described in Chapter Three represent the first genome-wide study
to compare chromatin in the presence and absence of a mammalian histone
chaperone. Previous biochemical experiments showed that Hira specifically
associates with H3.3 in mammalian cells, and in vivo experiments determined that
Hira is required for H3.3 deposition and chromatin assembly in the Drosophila
male pronucleus (Bonnefoy et al., 2007; Loppin et al., 2005; Tagami et al., 2004).
In addition, biochemical and fluorescence recovery after photobleaching (FRAP)
studies in wild-type and Hira -/- ES cells showed global increases in unbound H3 in
the absence of Hira (Meshorer et al., 2006). From these studies, one would expect
that Hira would play an important role in H3.3 deposition. However, although
these experiments were suggestive, the data in this thesis are the first to directly
show by ChIP that Hira is required for genome-wide H3.3 enrichment at active and
W9.5
wild-type

cl34
Hira -/Figure 4.6: Hira -/- ES cells are defective in
teratoma formation
Teratomas from Hira -/- ES cells are significantly
smaller than teratomas from wild-type ES
cells. 5*10^6 W9.5 or Hira -/- ES cells were
injected into NOD-SCID mice, and teratomas
were harvested at day 21. Representative
teratomas are shown. Experiments were
performed in collaboration with Jiyeon Kim, Dr.
Marco Seandel, and Dr. Shahin Rafii.

repressed genes. How is Hira targeted to these specific genomic regions?
Previous studies hypothesize that H3.3 deposition in actively transcribed
gene bodies may be coupled to transcription, potentially mediated by factors
associated with elongating polymerase (Daury et al., 2006; Janicki et al., 2004;
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Schwartz and Ahmad, 2005; Tagami et al., 2004; Wirbelauer et al., 2005). Our
data are consistent with Hira-dependent transcription-coupled deposition of H3.3
at transcribed non-repetitive sequences. However, Hira has not been found in
purifications of the general transcriptional machinery, and the likely association
between Hira and RNAPII would therefore be mediated through factors that have
yet to be determined. Much further work is needed on the recruitment of Hira to
active and inactive genes.

Hira-mediated deposition of H3.3 and embryonic stem cell differentiation
Remarkably, although Hira is required for early embryonic development (Roberts
et al., 2002), my collaborators and I do not observe a significant phenotype in
Hira -/- ES cells, despite a global lack of H3.3 enrichment at active and repressed
genes. However, published experiments (Meshorer et al., 2006; Roberts et al.,
2002) as well as recent collaborative data indicates that despite their maintenance
of the ES cell phenotype in culture, Hira -/- ES cells are significantly defective in
cell differentiation.
One

test

of

pluripotency

involves

the

injection

of

cells

into

immunocompromised mice. Following injection into non-obese diabetic severe
combined immunodeficiency (NOD-SCID) mice, pluripotent cells such as ES and
induced pluripotent stem (iPS) cells will differentiate into multi-lineage tumors known
as teratomas (Takahashi and Yamanaka, 2006). In collaborative experiments with
Jiyeon Kim, Dr. Marco Seandel, and Dr. Shahin Rafii, wild-type and Hira -/- ES
cells were injected into NOD-SCID mice. Examination of the resulting teratomas
revealed that Hira -/- teratomas were remarkably smaller than wild-type teratomas
(Figure 4.6). It is possible that this defect in teratoma formation could simply be
due to slower growth of Hira -/- cells. However, at least in culture, Hira -/- ES cells
divide as rapidly as wild-type ES cells, and show a similar preponderance of cells
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in S phase (Ariane Chapgier and Peter J. Scambler, unpublished data).
Intriguingly, preliminary histological analysis indicated that unlike wild-type
teratomas, Hira -/- teratomas failed to form fully differentiated tissue such as cartilage
(data not shown). This data is also consistent with the reported inability of Hira
-/- ES cells to fully differentiate into post-mitotic neurons (Meshorer et al., 2006).
However, it must be noted that these experiments are preliminary, and much work
will be required to explore the function of Hira in mammalian cell differentiation.
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Figure 4.7: Defects in Hira -/- ES cells upon cell differentiation may be due to impaired
replication-independent histone deposition
Rapidly cycling cells such as ES cells and NPCs are competent for both replication-dependent (RD)
and replication-independent (RI) histone deposition. However, post-mitotic neurons are dependent
upon RI histone deposition. In Hira -/- cells (bottom), rapidly cycling ES cells and NPCs may be
rescued by RD histone deposition during frequent S-phases. However, Hira -/- ES cells do not
differentiate into post-mitotic neurons (Meshorer et al., 2006), and it is possible that such postmitotic cells may be unable to compensate for the loss of Hira-mediated RI histone deposition.
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What might account for the differentiation-specific phenotype of Hira -/- cells?
As both Hira -/- ES cells and Hira -/- embryos display significant patterning
abnormalities following differentiation (Meshorer et al., 2006; Roberts et al.,
2002), I speculate that rapidly dividing Hira -/- ES cells may be rescued by the
replication-coupled deposition of histones during the frequent S-phases of ES
cells (Figure 4.7). ES cells cycle very rapidly, have a short G1 phase, and lack a
G1/S checkpoint (Burdon et al., 2002). It is possible that in the absence of Hiradependent incorporation of genic H3.3, differentiating cells with slower cell cycles
may be deficient in replacing histones at active or initiating gene loci. Without H3.3
or sufficient localized replication-dependent H3.1 or H3.2 as substrates for specific
post-translational modifications (K4 and K27 methylation) to mark particular loci,
more slowly-dividing or terminally differentiated cells may become progressively
incapable of epigenetic memory.
This hypothesis regarding the developmental importance of RI dependent
H3.3 deposition by Hira fits with the patterning abnormalities and early lethality
of Hira -/- embryos, the inability of Hira -/- ES cells to undergo terminal neuronal
differentiation (Meshorer et al., 2006), the neuromuscular defects seen in H3.3A
hypomorphs (Couldrey et al., 1999), and with earlier descriptions of H3.3 in the
literature, in which H3.3 RNA and protein levels were observed to increase during
models of cell differentiation (Krimer et al., 1993; Lord et al., 1990; Wunsch and
Lough, 1987). High levels of H3.3 protein have been found in differentiating rat
neurons, and as noted in Chapter One, H3.3 has been shown to become the dominant
histone H3 variant in rat brain cortical neurons (Pina and Suau, 1987; Scaturro et
al., 1995). In further support of this hypothesis, recent studies in Drosophila have
determined that surviving H3.3 null flies are ‘rescued’ by upregulation of replicationdependent histones (see Chapter One) (Sakai et al., 2009).
Future experiments by my colleagues in the Allis laboratory and in Dr. Peter
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Scambler’s laboratory will further explore the functional role of Hira-mediated
deposition of H3.3 in ES cell differentiation. In particular, my colleagues Simon
Elsaesser and Dr. Ariane Chapgier will use the wild-type and Hira -/- H3.3B-HA
ES cells I have generated to examine the specific requirements of Hira for H3.3
deposition in differentiated cells, as my experiments in Hira -/- cells have only
examined H3.3 incorporation in ES cells. Although the precise function of Hira
in cellular differentiation remains to be established, Hira is clearly required for
early embryonic development (Roberts et al., 2002), and the data presented in
this thesis are the first to demonstrate that Hira is required for genome-wide genic
incorporation of H3.3.

CHD1 in mammalian H3.3 deposition
CHD1 is important for H3.3 deposition in the Drosophila male pronucleus, and ChIPchip studies show that CHD1 localizes to gene TSS in ES cells (Gaspar-Maia et al.,
2009; Konev et al., 2007). However, the role of CHD1 in H3.3 incorporation has
not yet been explored in mammalian cells. While both CHD1 and Hira are likely to
play important roles beyond H3.3 incorporation, it is notable that the phenotype of
CHD1 shRNA and Hira -/- ES cells is similar, with global maintenance of the ES cell
transcriptome and specific defects upon cellular differentiation (Gaspar-Maia et al.,
2009; Meshorer et al., 2006; Roberts et al., 2002). For example, CHD1 shRNA ES
cells appear to be unable to differentiate into post-mitotic cardiomyocytes (GasparMaia et al., 2009). Future collaborative studies could use the tagged H3.3B mouse
ES cells that I have developed in combination with CHD1 shRNA (Gaspar-Maia
et al., 2009) to examine the potential requirements for CHD1 in mammalian H3.3
deposition.
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Figure 4.8: Hira is required for deposition of H3.3 at active genes, repressed genes, and
specific transcription factor binding sites
In Hira -/- ES cells, H3.3 enrichment at active and repressed genes, as well as at specific TFBS, is
lost. Some TFBS show increased H3.3 in the absence of Hira, while other TFBS show decreased
H3.3, and at most TFBS, H3.3 deposition is unaffected. Therefore, H3.3 enrichment at many TFBS
is maintained by Hira-independent factors (boxed question mark). H3.3 deposition at rDNA and
telomeres is mediated by ATRX and possibly Daxx, and is Hira-independent.

Hira-independent H3.3 deposition at regulatory elements
Recent studies found specific peaks of H3.3 deposition at TFBS in Drosophila and
human cells (Jin et al., 2009; Mito et al., 2007). Deposition of H3.3 at TFBS has
been proposed to serve as a mechanism for maintaining regulatory elements in a
more accessible chromatin conformation (Henikoff, 2008). Thus, while I anticipated
an evolutionarily conserved role for H3.3 deposition at regulatory elements, the
extent of H3.3-specific deposition at mammalian ES TFBS was unexpected.
Close comparison of our data to a recent dataset of 13 different TFs in mouse ES
cells (Chen et al., 2008b) shows H3.3 enriched in ES cells at all known types of
TFBS genome-wide, whether in gene bodies, promoters, or intergenic regions.
My collaborators and I also found a strong positive correlation between previously
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identified loci bound my multiple transcription factors (MTL) and H3.3 deposition,
indicating particular enrichment of H3.3 at enhancer elements. In all cases, patterns
of H3.3 enrichment at TFBS were abolished upon mutation of H3.3 to H3.2 or
H3.1S31.
Our data demonstrate that Hira is involved in H3.3 deposition at some genic
and intergenic TFBS. However, we also find that genome-wide H3.3 enrichment at
many regulatory elements is Hira-independent and Atrx-independent. Collectively,
these data therefore suggest that H3.3 deposition at TFBS may be mediated by
multiple and distinct factors, including Hira, with different factors mediating H3.3
deposition at specific regulatory elements (Figure 4.8). Notably, genome-wide
patterns of H3.3 correspond closely with H3K4me1, and this correlation between
H3.3 and H3K4me1 is more apparent at regulatory elements than at genes or
other genomic regions. Perhaps H3K4me1, potentially in combination with other
enhancer-enriched histone modifications (Wang et al., 2008), may serve to recruit
or stabilize as yet unidentified H3.3 deposition machinery at specific regulatory
elements.

ATRX and Daxx: new histone variant deposition machinery?
Using ChIP-seq in both undifferentiated ES cells and NPCs, the data presented
in Chapter Two demonstrate that H3.3 is specifically enriched in the canonical
(TTAGGG)n repeat that is the hallmark of telomeres in vertebrates (Meyne et al.,
1989). Cell imaging studies also show that H3.3 is present in telomeric foci on the
largely heterochromatic Y-chromosome in ES cells, and H3.3S31 phosphorylation
is also present on the telomeres of ES cell chromosomes. These results agree
with a recent report that described the enrichment of H3.3S31 phosphorylation and
overexpressed MYC-tagged H3.3 on telomeres in ES cells (Wong et al., 2009).
Surprisingly, the data presented in Chapter Three demonstrate that telomeric
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Figure 4.9: Atrx is required for H3.3 deposition at ribosomal DNA and telomeres, and for the
repression of ribosomal RNA and telomeric repeat-contaning RNA
In Atrxnull ES cells, H3.3 enrichment at active genes, repressed genes, and TFBS is unaffected.
However, H3.3 enrichment at rDNA and telomeres is lost in in Atrxnull ES cells. In addition, rRNA
and telomeric repeat-containing RNA (TERRA) transcripts are increased in the absence of Atrx.

H3.3 deposition, rDNA H3.3 deposition, specific TFBS H3.3 deposition, and mitotic
H3.3 serine 31 phosphorylation are all Hira-independent. These observations led
to a search for factors that might be responsible for Hira-independent deposition of
H3.3. In collaboration with Drs. Ileana Cristea and Peter Lewis, I have identfied Atrx
and Daxx as proteins that associate with H3.3 oligonucleosomes in the presence
and absence of Hira. Using ChIP-seq, my colleagues and I have demonstrated
that Atrx is required for H3.3 enrichment at telomeres and rDNA.
Our results suggest that Atrx is required for the maintenance of telomere
and rDNA chromatin state in ES cells. Recent studies have shown that the
Drosophila homolog of Atrx, XNP, co-localizes with H3.3 at sites of nucleosome
replacement on polytene chromosomes, but is not required for H3.3 localization at
these sites (Schneiderman et al., 2009). The data presented in this thesis show
that Atrx is required for enrichment of H3.3 at mammalian ES cell telomeres and
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the transcribed regions of rDNA, potentially defining a new category of specifically
targeted histone variant deposition machinery. Moreover, in the absence of Atrx,
ES cells show a similar upregulation of both telomeric repeat-containing RNA
(TERRA) and ribosomal RNA (rRNA) (Figure 4.9). This result is similar to a recent
finding in human patients with ICF (immunodeficiency, centromeric region instability,
facial anomalies) syndrome, where mutations in DNMT3B and hypomethylation of
subtelomeric DNA are also associated with increased levels of TERRA (Yehezkel
et al., 2008).

rDNA and telomeres:

specialized, transcribed repetitive regions of

heterochromatin
Could ATRX and Daxx serve as specific H3.3 variant deposition machinery for
specialized heterochromatin and repetitive regions such as telomeres and rDNA?
What might telomeres and rDNA have in common? Transcription of both of these
repetitive elements is subject to epigenetic regulation by DNA methyltransferases
and histone modifying enzymes (Luke and Lingner, 2009; McStay and Grummt,
2008). Although ribosomal RNA synthesis represents the majority of transcriptional
activity in dividing cells, even in highly proliferative cells, a significant portion of rDNA
is silenced (McStay and Grummt, 2008). The ratio of active and silent rDNA clusters
is regulated by chromatin modifying complexes, and these complexes promote
distinct patterns of DNA methylation, histone modifications, and nucleosome
positions at active and silent rDNA repeats (McStay and Grummt, 2008). Similarly,
subtelomeric regions and transcribed telomeric repeats share characteristics of
heterochromatin, including DNA methylation of subtelomeric regions, H3K9me3
and H4K20me3, and histone deacetylase activity (Blasco, 2007; Luke and Lingner,
2009; Marion et al., 2009; Schoeftner and Blasco, 2009).
As originally established by Roeder and colleagues and described in Chapter
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Figure 4.10: Hypothetical model for Atrx/Daxx-mediated deposition of H3.3 at telomeres and
ribosomal DNA
A. In wild-type ES cells, Atrx and Daxx mediate H3.3-contaning nucleosome replacement at
telomeres and ribosomal DNA (rDNA). Telomeric chromatin is depicted here, though a similar
model would apply for rDNA. The ATRX-DMNT3L-DNMT3A (ADD) domain of ATRX interacts
with an unmodified or H3K9me3 histone tail to stabilize ATRX on chromatin. Daxx interacts
specifically with H3.3 as well as ATRX, and Daxx presents H3.3-H4 dimers to ATRX for deposition
and nucleosome assembly. rDNA and possibly telomeres are transcribed by RNA polymerase
I (RNAPI). The growing pink strand with UUAGG represents telomeric repeat-containing RNA
(TERRA). Transcription evicts nucleosomes, which are replaced by H3.3-containing nucleosomes
deposited by the actions of Atrx and Daxx. It is possible that Atrx/Daxx-mediated deposition of
H3.3 at telomeres and rDNA may be coupled to RNAPI transcription, though this hypothesis has
not been tested.
B. In Atrxnull ES cells, nucleosomes are depleted at rDNA and telomeres by transcription. In the
absence of Atrx-Daxx-mediated nucleosome replacement, nucleosome density at telomeres and
rDNA decreases, and aberrant spurious TERRA and rRNA transcription takes place.
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One, rDNA is transcribed by RNAPI (Grummt, 2003; McStay and Grummt, 2008;
Roeder, 2003; Roeder and Rutter, 1969, 1970). While RNAPII is believed to play
a major role in TERRA transcription, various data also suggest that that another
RNA polymerase (RNAPI or RNAPIII) could function in mammalian telomeric
transcription (Luke and Lingner, 2009). As RNAPI is responsible for transcription
of rDNA, it is therefore possible that Atrx-dependent H3.3 deposition at telomeres
and rDNA may both be coupled to RNAPI-mediated transcription. Like the RNA
polymerases discovered by Roeder, distinct histone deposition complexes may
be specialized to perform the same activity (H3.3 deposition) at distinct genomic
regions. How might ATRX-mediated deposition of H3.3 serve to repress telomeric
and ribosomal RNA transcription?
In the absence of Atrx-mediated deposition of H3.3, transcribed telomeric
and rDNA chromatin might acquire an inappropriately low nucleosome density,
enabling aberrant upregulation of TERRA and rRNA (Figure 4.10). Just as
H3K36me3 recruitment of histone deacetylases (HDACs) prevents spurious
intragenic transcription from initiating within gene bodies (Carrozza et al., 2005;
Joshi and Struhl, 2005; Keogh et al., 2005; Li et al., 2007b; Li et al., 2007c), Atrxmediated replacement of H3.3 containing nucleosomes may be required to prevent
aberrant upregulated transcription of TERRA and rRNA. Indeed, recent experiments
show a reduction in total histone H3 occupancy at the human rDNA promoter and
transcribed region in alpha thalassemia and X-linked mental retardation (ATR-X)
syndrome patient lymphoblastoid cells (Martin Law, Richard Gibbons, Douglas R.
Higgs, personal communication).

Daxx as a potential H3.3 binding partner
While this thesis does not explore the role of Daxx, recent data from my laboratory
colleagues Dr. Peter Lewis and Simon Elsaesser suggest that Daxx is likely to
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play an important role in H3.3 deposition. Like Atrx and Hira, Daxx is required
for embryonic development, and loss of Daxx results in embryonic lethality by
E9.5 (Michaelson et al., 1999; Salomoni and Khelifi, 2006). Daxx is a ubiquitously
expressed ~120 kDa protein with two predicted paired amphipathic helices, an
acid-rich domain and a Ser/Pro/Thr (SPT)-rich domain (Hollenbach et al., 2002).
Daxx is known to interact with many proteins in mammalian cells, including various
transcription factors, and has been shown to function as a transcriptional repressor
at specific TFBS (Chang et al., 2005; Croxton et al., 2006; Hollenbach et al.,
2002; Huang and Shih, 2009; Mizuta and Kuroda, 2004; Muromoto et al., 2006;
Puto and Reed, 2008; Wethkamp and Klempnauer, 2009). As we have seen in
Chapter Three, the association between Daxx/ATRX and H3.3 is conserved in
both undifferentiated ES cells and human cervical cancer (HeLa) cells.
The localization of Daxx has been shown to be developmentally regulated.
Daxx is localized to promyelocytic leukemia (PML) bodies in differentiated human
cells, but in undifferentiated human ES cells, Daxx localizes to specific foci that
do not overlap with PML bodies (Butler et al., 2009). Intriguingly, Daxx has been
specifically localized to the transcriptionally silenced XY body in mid to late stage
pachytene spermatocytes (Rogers et al., 2004), as has H3.3 (van der Heijden et
al., 2007). Notably, the timing of Daxx co-localization with the XY body actually
coincides better with H3.3 (peaking in mid to late pachytene) than the timing of
Hira localization with the XY body (early pachytene) (Rogers et al., 2004; van der
Heijden et al., 2007). Therefore, I speculate that Daxx may be required to mediate
H3.3 deposition in the XY body.
My colleagues in the Allis laboratory are currently engaged in further studies
of Daxx and H3.3. Like Atrxnull ES cells, Daxx -/- ES cell are viable (Michaelson et
al., 1999). Therefore, Dr. Kyung-Min Noh and I have recently used the zinc finger
nuclease method that I described in Chapter Two to generate Daxx -/- H3.3B / H3.3192

A

B
ATRX mutations

5’utr

3’ untranslated region
ATMDS

ATRXt
ADD

C

% similarity

PQ

Helicase domains

100

Adapted from Gibbons
Orphanet J Rare Dis 2006.

Scale
200 amino acids

2,492 aa;

ATRX ~280 kDa

80
60

Adapted from Gibbons
et al. Hum Mut 2008.

40
20

Telomere

Centromere

Telomere

chr16

chr16:

130000

135000

C16orf35
C16orf35
C16orf35
C16orf35

2_

Mammal Cons

140000

145000

150000

HBZ

155000
HBM

160000

165000
HBA2
HBA1

UCSC Genes Based on RefSeq, UniProt, GenBank, CCDS and Comparative Genomics
CpG Islands (Islands < 300 Bases are Light Green)

HBA1

170000
HBQ1

HBA1

Vertebrate Multiz Alignment & Conservation (44 Species)
Placental Mammal Basewise Conservation by Phylo

-0.3 _

Figure 4.11: Clinical and molecular features of alpha-thalassemia and X-linked mental
retardation syndrome
A. Child of 8 yrs with the characteristic facial features of ATR-X syndrome. Note the upswept frontal
hair line, hypertelorism, epicanthic folds, flat nasal bridge, small triangular upturned nose, tented
upper lip, everted lower lip and hypotonic facies. In addition to characteristic facial dysmorphism,
ATR-X syndrome is generally associated with profound developmental delay and mental retardation,
genital abnormalities, and alpha thalassemia. Picture and legend adapted from (Gibbons, 2006).
B. ATRX mutations cluster in the highly conserved ADD domain and helicase domain. Top portion
represents a schematic diagram of the human ATRX gene: boxes represent the 35 exons; thin
horizontal lines represent introns (not to scale). The 3’ and 5’ untranslated regions (utr) are shown
flanking the open reading frame. The locations of mutations described in boys with ATR-X syndrome
are shown above the gene, and mutations described in ATMDS (myelodysplastic syndrome) are
shown below the gene. The two protein products ATRX and the alternative splice product ATRXt are
shown as rectangles. The principal domains, the zinc finger motif (ADD), and the highly conserved
helicase motif are indicated, as are the P box (P) and a glutamine-rich region (Q). The lower part
of B provides a graphical representation of the amino acid similarity between human and mouse
ATRX proteins. See (Gibbons et al., 2008) for more detail.
C. The alpha-globin genes downregulated in ATR-X syndrome are located extremely near the
telomere of human chromosome 16. The top of C. depicts a schematic of human chromosome
16, with the telomeres and centromere indicated. A very small portion (red) near the telomere
of chromosome 16 is enlarged below, with chromosomal coordinates, genes, CpG islands, and
mammalian conservation indicated. Data was downloaded from the UCSC genome browser.
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A. In the presence of ATRX, H3.3-containing nucleosomes are incorporated at the telomere,
subtelomeric DNA is methylated, TERRA transcription is regulated, and telomeres maintain localized
characteristics of heterochromatin such as H3K9me3, HP1 binding, and H4K20me3. Telomerase
extends the telomere in pluripotent ES cells.
B. In Atrxnull ES cells, and possibly in ATR-X patient cells, H3.3 containing nucleosomes are no
longer enriched at telomeres. Telomeric nucleosome density decreases, with aberrant increased
transcription of TERRA. As TERRA may inhibit telomerase (Luke and Lingner, 2009), it is also
possible that telomeres may be slightly shorter in Atrxnull cells. With increased TERRA, telomeric
heterochromatin spreads to silence susceptible genes such as the alpha-globin locus near
telomeres.
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HA-IRES-EYFP ES cells (data not shown). Future experiments will involve ChIPseq of these targeted Daxx -/- ES cells to examine the genome-wide localization
of H3.3 in the presence and absence of Daxx. Remarkably, recent biochemical
experiments suggest that Daxx may serve as a direct H3.3 binding protein (S.
Elsaesser and P. Lewis, unpublished data), and additional future studies will
explore the specific role of Daxx and Atrx in nucleosome assembly using defined
factors in vitro.

Potential implications for ATR-X syndrome pathogenesis
More speculatively, the results in this thesis raise the possibility that the pathogenesis
of human ATR-X syndrome might involve an early developmental alteration in
telomeric chromatin state.
ATRX has been previously localized to heterochromatin, and the ATRX/Daxx
complex has been shown to have chromatin remodeling activity (Tang et al., 2004;
Xue et al., 2003). However, despite significant advances in the characterization
of the ATRX protein and the specific mutations that occur in ATR-X syndrome,
the molecular mechanisms underlying the pathogenesis of this syndrome remain
a mystery (Gibbons, 2006; Gibbons et al., 2008; Higgs et al., 2005). Intriguingly,
patients with ATR-X syndrome show a downregulation in alpha-globin gene
expression, but not beta-globin gene expression, and human alpha globin genes
are located near the telomere of human chromosome 16 (Higgs et al., 2005)
(Figure 4.11). While it has been speculated that this chromosomal environment
might be important for the pathogenesis of ATR-X syndrome (Higgs et al., 2005),
this thesis is the first report to document that Atrx plays a role at telomeres.
One hypothesis is that Atrx-mediated telomeric deposition of H3.3 is required
to prevent the spreading of heterochromatin and silencing of susceptible genes
adjacent to telomeres in later development (Figure 4.12). Better described in lower
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Figure 4.13: Pluripotent embryonic stem cells give rise to chimeras and are competent for
tetraploid complementation
A. In conventional generation of mice from ES cells, diploid donor ES cells (green) are injected
into diploid blastocysts. The resulting mice are chimeras of the diploid donor ES cells and the
pluripotent cells from the recipient blastocyst inner cell mass (pink).
B. Tetraploid complementation provides a rapid method to generate fully ES-derived mice, but this
procedure is only effective with healthy, pluripotent cells. Two cell embryos are fused to generate
a tetraploid cell (4N), and the resulting tetraploid blastocyst is injected with diploid donor ES cells
(green). Tetraploid cells of the blastocysts will only give rise to extra-embryonic tissues such as
the placenta (blue), while injected diploid ES cells will give rise to the entire embryo (green). See
(Eggan et al., 2001; Meissner et al., 2009).

eukaryotes, this phenomenon of silencing of telomere proximal genes is known as
telomere position effect (Ottaviani et al., 2008) (Figure 4.12). In support of this
hypothesis, in addition to the telomere proximal alpha globin genes downregulated
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in ATR-X human patients, the top two genes downregulated in a microarray analysis
of Atrxnull mouse forebrain at E13.5 and P0.5 (Dhrsxy and Csf2ra) are located near
telomeres (Levy et al., 2008). In the absence of Atrx, TERRA is upregulated, and
TERRA has been associated with maintenance of the telomeric heterochromatin
state (Luke and Lingner, 2009). Other histone variants (H2A.Z) in yeast have been
shown to antagonize spreading of telomeric heterochromatin and the silencing of
telomere adjacent euchromatin (Meneghini et al., 2003). To test the hypothesis that
spreading of telomeric heterochromatin may be important for ATR-X pathogenesis,
future collaborative experiments will examine the chromatin state of telomeres and
proximal telomeric regions in wild-type and Atrxnull ES cells, as well as patients
with ATR-X syndrome.

Localization and function of H3.3B in mammalian development – recent
progress towards a H3.3B-HA-IRES-EYFP mouse line
Given the nature of the genetic modifications that I have made to ES cells in order
to track the localization of histone H3.3, it is important to determine whether or not
these cells remain pluripotent. Moreover, for future experiments, it is desirable
to examine the genomic localization of H3.3 in differentiated mammalian tissues,
as well as to establish the endogenous pattern of H3.3B expression. There are
a variety of tests to determine the developmental potential of ES cells, including
embryoid body formation, teratoma formation in immunocompromised mice, and
the generation of chimeras following injection of ES cells into diploid blastocyst
embryos (Meissner et al., 2009). The most rigorous test of pluripotency involves the
injection of diploid ES cells into tetraploid blastocysts (Eggan et al., 2001; Meissner
et al., 2009) (Figure 4.13). As tetraploid cells can maintain extraembryonic tissues
such as the placenta, but are largely incapable of giving rise to the embryo itself,
the injected diploid ES cells will generate the entire embryo (Eggan et al., 2001;
197

A

B

Blastocyst injections and in vivo experiments performed by Duancheng Wen and Shahin Rafii, and data used with permission.

Figure 4.14: Generation of H3.3B-HA-IRES-EYFP mice
H3.3B / H3.3-HA-IRES-EYFP ES cells injected into diploid B6 blastocysts contribute to mice with
high chimerism. Most ES cells described in this study are B6 but maintained on a tyrosinase -/background, and their coat color is therefore albino.
A. H3.3B / H3.3-HA-IRES-EYFP ES cells gave rise to a healthy mouse that is ~100% donor ESderived as judged by white coat color and genotyping. In this case, the chimera is surprisingly from
diploid blastocyst injection, but healthy H3.3B / H3.3-HA-IRES-EYFP mice were also obtained from
tetraploid complementation.
B. Other mice from the same litter show significant chimerism.

Meissner et al., 2009) (Figure 4.13).
In collaboration with Dr. Duancheng Wen and Dr. Shahin Rafii, heterozygous
H3.3B / H3.3-EYFP and H3.3B / H3.3-HA-IRES-EYFP ES cells were injected into
both diploid and tetraploid blastocysts. Despite many attempts with several clones,
H3.3B-EYFP ES cells generated pups with generally poor (<45%) chimerism (data
not shown). In addition, none of the of H3.3B / H3.3-EYFP chimeras was found to
be capable of H3.3-EYFP germline transmission.
It is possible that the poor chimerism and lack of germline transmission of
H3.3B-EYFP ES cells could be due to a hypomorphic effect of the EYFP tag. The
EYFP tag (238aa) is large relative to the H3.3 histone (135aa). Although the data
presented in Chapter Two indicate that genome-wide patterns of H3.3-EYFP are
extremely similar to H3.3-HA, the bulky fluorescent tag could have resulted in a
mild hypomorphic effect on nucleosome assembly or nucleosome interactions that
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is manifested during development. H2B-GFP fusions have been used in various
lines of fertile mice (Hadjantonakis; Hadjantonakis and Papaioannou, 2004; Tumbar
et al., 2004). However, there is precedent for hypomorphic effects of a H3 family
GFP fusion in vivo, following knock-in of a GFP tag fused to the H3 centromeric
variant CENP-A (Kalitsis et al., 2003). Although Cenpa-GFP heterozygous mice
were completely healthy and fertile, Cenpa-GFP homozygotes died at E10.5 of
embryonic development, with significant chromosome missegregation, aneuploidy
and apoptosis (Kalitsis et al., 2003).
Despite the lack of success with H3.3B-EYFP ES cells, recent injections of
H3.3B / H3.3-HA-IRES-EYFP ES cells into diploid blastocysts yielded viable pups
with extremely high chimerism from several different clones, with almost 100% ES
contribution in one particular chimera (Figure 4.14). In addition, several clones
of H3.3B / H3.3-HA-IRES-EYFP ES cells also gave rise to healthy pups following
complementation of tetraploid blastocysts, with 100% contribution from the tagged
ES cells (D. Wen, data not shown). These results are strong evidence for pluripotency
of H3.3B / H3.3-HA-IRES-EYFP ES cells. Beyond tetraploid complementation, the
only further test of pluripotency involves germline transmission. Once old enough
for breeding, these mice will be bred to establish a permanent H3.3B / H3.3-HAIRES-EYFP mouse line.
The establishment of H3.3B / H3.3-HA-IRES-EYFP mice opens up a wide
array of experimental possibilities. The localization of H3.3 during and following
X chromosome inactivation (Chow and Heard, 2009) can now be assessed using
female H3.3B-HA mouse embryos, female H3.3B-HA mouse ES cells, and somatic
cells from adult female H3.3B-HA mice. H3.3B / H3.3-HA-IRES-EYFP mice will also
enable analysis of the developmental expression of H3.3B in vivo, a subject that
has previously only been addressed through northern blots and in situ hybridization
of select tissues (Bramlage et al., 1997). Although I have profiled the genome-wide
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localization of H3.3 in ES cells and NPCs, the establishment of H3.3B-HA mice will
also allow us to profile the genome-wide localization of H3.3 in other embryonic
and adult mammalian cell types, including derived cell lines as well as organs such
as liver and brain (Meissner et al., 2008; Visel et al., 2009; Wederell et al., 2008).
Multiple H3.3B-HA cell lines can be derived for ChIP-seq and immunofluorescence
studies, including mouse embryonic fibroblasts, and spermatogonial stem cells
(SSCs) (Seandel et al., 2007).
Provided that H3.3B is expressed in primordial germ cells (PGCs), the
role of H3.3 in germ cell specification during embryonic development can also
be addressed, as previous studies of PGCs were hampered by the lack of a
H3.3 antibody (Hajkova et al., 2008). Moreover, the localization of endogenously
expressed H3.3B in spermatogenesis can also be determined.

Could H3.3

localization to the repressive XY body be dependent on Daxx, and not Hira (Rogers
et al., 2004; van der Heijden et al., 2007)? In addition, although most sperm
chromatin is packaged in protamines, specific histone H3 modifications have been
shown to mark particular developmental genes in sperm, and both H3.3 and H3.1
have been found at lower levels in human sperm chromatin (Gatewood et al.,
1990; Hammoud et al., 2009). Are these sperm H3 histone modifications carried
on H3.3? ChIP-seq from sperm isolated from H3.3B / H3.3-HA-IRES-EYFP mice
could be used to address these questions. Finally, the localization of endogenously
expressed H3.3B in paternal pronuclear decondensation can also be addressed in
mammals for the first time (Bonnefoy et al., 2007; Konev et al., 2007; Loppin et al.,
2005; Torres-Padilla et al., 2006).
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Figure 4.15: Strategy for homozygous targeting of H3.3B
Left. Zinc finger nucleases (ZFNs) in combination with H3.3B-HA-IRES-EYFP and H3.3B-HAIRES-mCherry donors enable homozygous targeting of H3.3B, via double-strand break (DSB)
potentiated homologous recombination. Exon coding sequences are thick rectangles, while noncoding untranslated sequences are thin rectangles. The resulting EYFP and mCherry doublepositive cells have both H3.3B alleles fused to a C-terminal HA epitope tag, with an IRES and
separately translated EYFP or mCherry reporter.
Center. A similar strategy can be used to enable homozygous addition of a destabilizing domain
(DD) sequence (brown) as well as an HA epitope tag fused to the C-terminus of H3.3B. In the
absence of shield ligand, DD-tagged H3.3B protein is degraded, but in the presence of shield
ligand, H3.3B-DD-HA protein expression is maintained. For more details regarding destabilizing
domains, see: (Banaszynski et al., 2006).
Right. A similar strategy can be used to generate a homozygous knockout of H3.3B, with full
replacement of coding exons by EYFP and mCherry.
All of these cells can used with and without the addition of lentiviral shRNA vectors for H3.3A
knockdown.
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Ongoing experiments to probe the function of H3.3 through H3.3B knockout,
regulated protein expression, and H3.3A shRNA
Although H3.3B-HA-IRES-EYFP mice unlock a wide range of experimental
possibilities, fundamentally these mice will only enable the tracking of epitopetagged H3.3B through development and differentiation. To determine the functional
significance of H3.3, it is necessary to generate cellular models that reduce,
eliminate, or regulate H3.3 protein expression. Recent collaborative experiments
with Dr. Laura Banaszynski in our laboratory provide significant progress towards
this goal.
Mammalian cells contain four alleles that code for H3.3, including two alleles
of H3.3B and two alleles of H3.3A (Bramlage et al., 1997; Marzluff et al., 2002). To
target both copies of H3.3B, Dr. Banaszynski and I devised a strategy to modify my

H3.3B +/+
H3.3A +/+
ES cells

Embryoid body formation
NPC differentiation
Neuronal differentiation
Teratoma formation
Chimera formation
Tetraploid complementation
Germline transmission

?

H3.3B -/H3.3A shRNA
ES cells

+/- shield
H3.3B DD / DD
H3.3A shRNA
ES cells

?

Figure 4.16: Experiments to assess the function of H3.3 in mammalian development and
cellular differentiation
Wild-type H3.3B +/+ H3.3A +/+ ES cells are pluripotent, and are competent in all of the assays
listed. The phenotypes of H3.3 ‘null’ (middle) or H3.3B-DD ‘rescue’ ES cells in these assays are
unknown, and these experiments are currently underway.
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donor construct to include the red fluorescent protein mCherry in place of EYFP.
Following transfection of cells with zinc finger nucleases and both EYFP and
mCherry H3.3B donor constructs, cells that become stably EYFP and mCherry
double positive are likely to be doubly targeted at both H3.3B alleles (Figure 4.15).
This strategy can be used for homozygous tagging of H3.3B with epitope tags
(Figure 4.15, left). In addition, Dr. Banaszynski modified my donor constructs to
fuse a destabilizing domain to the C-terminus of H3.3B (Banaszynski et al., 2006).
Such destabilizing domains (DD) were developed by Dr. Banaszynski during her
graduate work, and they enable rapid, reversible, and tunable regulation of protein
levels through the use of a small molecule (Banaszynski et al., 2006). Targeting
of both H3.3B alleles with H3.3B-DD-HA-EYFP and H3.3B-DD-HA-mCherry donor
constructs will allow total control over H3.3B protein expression (Figure 4.15,
center). To generate a full H3.3B knockout, I also modified my donor constructs
to fully replace the coding exons of H3.3B with the open reading frame of EYFP
and mCherry (Figure 4.15, right). To knock-down expression of H3.3A, we have
validated several lentiviral shRNA vectors that enable greater than 90% H3.3A
mRNA knock-down (data not shown).
H3.3 ‘null’ (H3.3B -/- + H3.3A shRNA, or H3.3B-DD-HA + H3.3A shRNA)
ES cells have recently been established, and they are being used for a variety of
experiments. Preliminary experiments suggest that H3.3 null ES cells are viable,
but display a mild growth defect in culture (data not shown). Most immediately, Dr.
Banaszynski is examining the expression of rRNA and TERRA in the absence of
H3.3. If the function of ATRX-mediated H3.3 nucleosome replacement at rDNA and
telomeres is to repress transcription of these heterochromatic repeats, then loss
of H3.3 may also lead to aberrant upregulation of rRNA and TERRA (Figure 4.10).
In addition, my colleagues will use whole transcriptome profiling (RNA-seq) (Wang
et al., 2009a) to examine whether loss of H3.3 leads to any global alterations in
203

transcriptional regulation.
To assess the function of H3.3 in mammalian development and cellular
differentiation, wild-type and H3.3 null ES cells will be used in several experiments
(Figure 4.16). In vitro cell differentiation assays will include embryoid body formation,
retinoic acid differentiation, NPC formation, and differentiation into post-mitotic
neurons (Conti et al., 2005). In collaboration with Dr. Shahin Rafii’s laboratory,
H3.3 null ES cells will also be injected into immunocompromised mice in teratoma
formation experiments, as well into diploid and tetraploid blastocysts to assess the
requirements for H3.3 in vivo (Figure 4.16). In addition, Dr. Duancheng Wen has
already generated chimeras from heterozygous H3.3B / H3.3B-KO-EYFP ES cells
into diploid blastocysts (data not shown), and these chimeras will be bred with
wild-type mice in an attempt to establish a heterozygous H3.3B +/EYFP line.

Perspective, predictions, future questions, and challenges
This thesis provides the first genome-wide profiles of histone H3 variants in
mammalian pluripotent cells. My collaborators and I have shown that Hira is
required for H3.3 deposition at genes, and we identify Atrx as required for Hiraindependent H3.3 deposition at telomeres and rDNA. Our data also suggest the
existence of Hira and Atrx-independent specific machinery responsible for H3.3
deposition at specific regulatory elements. Overall, the work presented in this
thesis raises the prospect that distinct, region-specific chaperone and remodeling
complexes mediate the targeting of a single histone variant (H3.3) to particular
genomic regions.
These findings raise multiple questions. What is the function of H3.3 at
these different genomic sites? Does H3.3 play a similar role at genes, TFBS,
rDNA and telomeres? I predict that H3.3 has largely evolved to function in
nucleosome replacement and ‘chromatin repair’ in a variety of genomic, cellular,
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A

H3.3 replacement nucleosomes mediate
‘chromatin repair’ and maintain chromatin
dynamics.
nucleosome
replacement

nucleosome
eviction

H3.3

H3.2 / H3.1

B
In the absence of H3.3, RD H3.2 and H3.1
nucleosome assembly partially rescues chromatin.

spurious transcripts?

nucleosome
eviction

Figure 4.17: Speculative model: the primary non-reproductive functions of H3.3 are
nucleosome replacement and chromatin repair at regions of chromatin disruption
A. In wild-type cells, nucleosome replacement with H3.3-containing nucleosomes enables
‘chromatin repair’ at regions of chromatin disruption, while the intrinsic instability of H3.3-containing
nucleosomes also promotes dynamic chromatin. At regions of chromatin disruption such as genes
and regulatory elements, H3.3 containing nucleosomes strike an ideal balance between overly
exposed naked DNA and overly stable H3.2 or H3.1 nucleosomes.
B. In the absence of H3.3, nucleosome replacement at regions of chromatin disruption is impaired.
Nucleosome replacement and chromatin ‘rescue’ can be partially mediated by H3.2 or H3.1
containing nucleosomes, most likely through replication-dependent (RD) nucleosome assembly
(Sakai et al., 2009). However, nucleosome replacement in mammalian cells may be inadequate in
the absence of H3.3. Loss of H3.3 could potentially result in progressive defects such as spurious
transcripts, particularly in post-mitotic cells that lack the capacity for RD nucleosome assembly.
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and developmental contexts, and that this nucleosome replacement function
is critically important in the large-scale chromatin remodeling that takes place
during specific developmental transitions in multicellular organisms (Orsi et al.,
2009). In addition, recent data shows that H3.3-containing nucleosomes are
more sensitive to salt-sensitive disruption than H3.1-containing nucleosomes,
suggesting intrinsic differences in stability that could reduce the energy required
for nucleosome mobilization (Jin and Felsenfeld, 2007). Therefore, it is likely that
H3.3 nucleosomes do not only serve a replacement function, but also contribute to
chromatin dynamics (Figure 4.17).
What is the function of H3.3 in mammalian development? Recent studies
have shown that H3.3 plays a role in Drosophila transcription regulation, and is
essential for fly fertility (Hodl and Basler, 2009; Ng and Gurdon, 2008; Sakai et al.,
2009). As lower levels of H3.3A already lead to partial neonatal lethality, fertility
defects, and neuromuscular deficits in mice (Couldrey et al., 1999), it is likely that
H3.3 many play an even more important role in mammals. Do cellular requirements
for H3.3 differ in dividing versus post-mitotic cells, where replication-independent
deposition might play a larger role?
Recent studies from yeast may be informative regarding the possible
phenotypes of H3.3 deletion. The yeast homologs of HIRA also play a role in
replication-independent histone deposition, and localize to transcribed regions in S.
cerevisiae (Green et al., 2005; Nourani et al., 2006). Intriguingly, the S. pombe HIRA
homologs were recently shown to be required for genome-wide promoter silencing
and for the repression of cryptic antisense transcripts (Anderson et al., 2009). The
HIRA complex has therefore been proposed to restore chromatin structure in the
wake of RNAPII (Anderson et al., 2009). Intriguingly, H2A.Z has also recently been
observed to suppress spurious antisense transcripts in S. pombe (Zofall et al.,
2009). Therefore, I predict that H3.3 containing nucleosomes may also serve to
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replace nucleosomes disrupted by a variety of processes, including transcription
and transcription factor binding, and that this ‘chromatin repair’ function of H3.3
may be critical for the repression of spurious transcripts (Figure 4.17). It is likely
that such a ‘chromatin repair’ function of H3.3 would be particularly important for
post-mitotic cells that are incapable of RD histone deposition during S-phase.
The surprising finding that distinct factors are required to deposit H3.3 at
specific genomic regions also raises many questions. How are Hira and Atrx
targeted to specific genomic regions? Neither Hira nor Atrx have been shown
to interact directly with transcription machinery, and significant work remains
regarding the recruitment of these complexes to distinct regions. It is likely that
like many chromatin-mediated processes, the targeted recruitment of Hira and Atrx
may depend significantly on an interaction with site-specific DNA binding factors
(Farnham, 2009). As Daxx interacts with multiple transcription factors (Chang et
al., 2005; Croxton et al., 2006; Hollenbach et al., 2002; Huang and Shih, 2009;
Mizuta and Kuroda, 2004; Muromoto et al., 2006; Puto and Reed, 2008; Salomoni
and Khelifi, 2006; Wethkamp and Klempnauer, 2009), it is possible that Daxxmediated interaction with both H3.3 and cell-type specific TFs may be important
for targeting of H3.3 to specific regions.
Finally, what is the mechanism by which H3.3 is deposited? Despite the
biochemical requirement of Hira for replication-independent nucleosome assembly,
we have very little insight into how Hira, much less Atrx and Daxx, mediate H3.3
deposition into chromatin. Is Atrx-mediated deposition of H3.3 also replicationindependent, like Hira, or does it occur during replication? Why are there sitespecific mechanisms that deposit H3.3 at transcribed sequences, TFBS, rDNA and
telomeres? Many of these questions regarding the mechanism of H3.3 deposition
are the subject of active work by my laboratory colleagues, and I am confident that
we can look forward to significant advances in the near future.
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Overall, the data presented in this thesis make clear that the existing paradigm
of Hira-dependent deposition of H3.3 is too simplistic for mammalian cells. While
many questions remain, these findings lay the groundwork for a more nuanced
understanding of H3 variants in mammalian cells, and provide a foundation for
future studies of H3.3 in mammalian development.
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Chapter 5
MATERIALS AND METHODS
Mouse embryonic stem cells
The parental “C6” embryonic stem (ES) cell line was derived from tyrosinase
-/- (white, albino) homozygous mouse embryos of B6(Cg)-Tyrc-2J/J C57BL/6J
background. http://jaxmice.jax.org/strain/000058.html The parental “965” ES line
is an F1 hybrid 129SVJae x M. m. castaneus (Eggan et al., 2001; Mikkelsen et al.,
2007), and was a gift from Dr. Rudolf Jaenisch. Parental W9.5 and Hira -/- (cl34)
ES cells were a gift from Dr. Peter Scambler, and have been described previously
(Meshorer et al., 2006). Parental Atrxflox and Atrxnull ES cells were a gift from Drs.
David Garrick, Richard Gibbons, and Douglas Higgs, and have been described
previously(Garrick et al., 2006).

ES cell culture and neural precursor cell differentiation
Undifferentiated mouse ES cells were cultured under standard conditions in the
presence of leukemia inhibitory factor (LIF) (Meissner et al., 2009).

For early

passages, undifferentiated ES cells were maintained on a feeder layer of mitomycin
C treated or irradiated mouse embryonic fibroblasts (MEFs) in standard ES cell
media, KO-DMEM (Invitrogen 10829-018), 2mM L-glutamine (Sigma G7513)
and pen-strep, 15% ES grade fetal bovine serum (Gibco 10439-024), 10-4 mM
2-mercaptoethanol, and leukemia inhibitory factor (LIF) (Meissner et al., 2009). To
remove feeders for ES cell whole cell extracts, chromosome spreads, chromatin
immunoprecipitation, and NPC differentiation, ES cells were passaged at least
two passages off of feeders on to gelatin-coated plates. Neural precursor cell
(NPC) differentiation was performed as described (Conti et al., 2005). NPCs
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were cultured and expanded on gelatin-coated plates in NeuroCult® NSC Basal
Medium (Mouse, Stem Cell Technologies, cat#05700) supplemented with 2mM
final L-glutamine and pen-strep (Omega Scientific PG-30), modified N2 supplement
freshly prepared in house as described (Conti et al., 2005), and 10ng/ml of both
mouse EGF (Peprotech 315-09) and human FGF-2 (Peprotech 100-18B).

Zinc finger nuclease design, targeting, and verification
Zinc finger nucleases (ZFNs) directed against the mouse H3.3B (h3f3b) gene
were designed using an archive of validated two-finger modules (Doyon et al.,
2008; Urnov et al., 2005). Zinc finger nucleases (ZFNs) were designed against
a region immediately upstream of the H3.3 stop codon (see Figure 2.2), since
gene conversion tracts from DSBs induced by I-SceI (Elliott et al., 1998) and by
ZFNs in somatic mammalian cells are rather narrow. My goal was to both tag
the native H3.3B open-reading frame (ORF) at the C-terminus (Figure 1B) as
well as co-convert the H3.3B coding region to a H3.2 or H3.1 allelic form (Figure
S1D-E). ZFNs were designed using an archive of validated two-finger modules
(Doyon et al., 2008; Shukla et al., 2009; Urnov et al., 2005), assembled using a
PCR-based method, cloned into expression vectors and validated as described
(Urnov et al., 2005). The ZFNs used carried obligate heterodimer forms of the FokI
endonuclease (Miller et al., 2007). ZFN target sequences and the recognition
helices are provided below.
ZFN target site and designed zinc finger helices sequences
Locus

ZFN Binding Sequence (underlined)

h3f3b

GACATCCAGTTGGCTCGCCGGATACGGGG
CTGTAGGTCAACCGAGCGGCCTATGCCCC

ZFN
#25000
#25001
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Finger 1

Finger 2

Finger 3

Finger 4

RSDHLSE
DRSALSR

RNDTRKT
TSANLSR

QSSNLAR
RSDVLSE

RSDDRKT
QRNHRTT

H3.3B EYFP and HA-IRES-EYFP donor plasmid construction
Briefly, a PCR fragment of genomic DNA from mouse H3.3B was cloned out of a
genomic bacterial artificial chromosome (BAC) from C57BL/6J mouse chromosome
11 using Phusion polymerase (NEB F-530L) and into a pCR2.1 vector (pCR2.1H3.3B) using TA-TOPO cloning (Invitrogen K4500-02). To generate the H3.3BEYFP donor construct (pCR2.1-H3.3B-EYFP), a 6 amino acid (SRPVAT) linker
(Ahmad and Henikoff, 2002) followed by the open-reading frame of EYFP
(Clontech) was inserted in-frame into the last coding exon of H3.3B, using ligationindependent cloning (LIC) (Geiser et al., 2001) The H3.3B-EYFP donor included
no H3.3B promoter sequence, containing approximately 0.6kb of 5’ homologous
genomic sequence starting at the second H3.3B codon, including introns, until
the last H3.3B coding amino acid, followed by the linker and EYFP, a stop codon,
and approximately 1.3kb homologous to the H3.3B 3’UTR (see Figure 2.4). To
generate the H3.3B-HA-IRES-EYFP construct (pCR2.1-H3.3B-HA-IRES-EYFP), a
C-terminal HA-IRES sequence was cloned out of the vector pMSCV-F-del Casp9.
IRES.GFP (Straathof et al., 2005), Addgene Plasmid 15567, and inserted in-frame
using LIC into the pCR2.1-H3.3B-EYFP vector. To generate H3.2-EYFP, H3.1EYFP, H3.2-HA-IRES-EYFP, and H3.1-HA-IRES-EYFP donors, point mutations
were made in pCR2.1-H3.3B-EYFP and pCR2.1-H3.3B-HA-IRES-EYFP using the
Quick-Change Mutagenesis II kit (Stratagene).

ZFN targeting and verification
To deliver ZFNs and donor constructs, mouse ES cells were transfected by Amaxa
nucleofection. In brief, immediately prior to transfection, ES cells were feeder
depleted by harvesting the ES cells, plating on a feeder-free dish for 30min, and
then collecting the ES-enriched non-adherent cells for transfection. 2-5*10^6
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cells ES cells were resuspended in 90μl solution, mixed with two non-linearized
plasmids (1 μg of ZFN plasmid with both ZFNs separated by a 2A peptide sequence
+ 10μg of donor plasmid) in 10μl nucleofection solution, and transfected using
program A-013 as described in the Amaxa manufacturer’s protocol for mouse
ES cells. Following transfection, we used sterile plastic pipettes to transfer the
cells to warm ES media in tissue culture dishes that were already prepared with
feeders. After transfer, ES cells were cultured in standard conditions on treated
feeders for 3-5 days prior to fluorescent activated cell sorting (FACS) (Figure 2.3,
2.5) or fluorescent colony picking. Following colony picking, clonal isolation and
expansion, we prepared genomic DNA using the Qiagen DNeasy Blood & Tissue Kit
(Qiagen 69504). Individual clones were screened by PCR using a forward H3.3B
primer (TTGGTGGAGTATCTGCCCGTTCTG) outside of the donor construct and
reverse primer (GTTCTTCTGCTTGTCGGCCATGATA) within EYFP (see Figure
2.6). To verify that the wild-type H3.3B allele remained intact, we also amplified
both H3.3B alleles by using the same forward primer above, and a reverse primer
(TGAAGCCAACCTGCTGCTCTACAGT) outside the donor construct, performed
gel electrophoresis, and isolated the smaller band corresponding to the wild-type
H3.3B allele (data not shown). PCR products from both wild-type and modified
H3.3B alleles were sequenced using standard methods (Figure 2.6). To confirm
heterozygosity, we used the primers described above to sequence both H3.3B
alleles from all ES lines used in this study. For further confirmation of heterozygosity,
we performed Southern blotting on a subset of the ES lines. To perform Southern
blotting, we digested genomic DNA from wild-type and targeted ES cells with
BsrBI, and used a labeled 638bp AvaII fragment of the H3.3B donor as probe to
visualize wild-type H3.3B and integrated H3.3B donors. All targeted C6 ES lines
used for manuscript were found to be pure heterozygotes (Figure 2.6). The hybrid
H3.3-HA ES line and the Hira -/- H3.3-EYFP ES lines were heterozygous, with one
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H3.3B allele targeted, but also had additional donor integrations by Southern blot.
Western blot analysis indicates that the hybrid ES H3.3-HA is not overexpressed
relative to the pure heterozygote hybrid H3.1S31-HA ES line (data not shown), and
global patterns of H3.3 were extremely similar to patterns in the pure heterozygous
C6 H3.3-HA and H3.3-EYFP ES lines. H3.3-HA and H3.2-HA ES cells were also
fully karyotyped, and found to have normal male mouse karyotypes (data not
shown).

RT-PCR
Total RNA from ES cells and NPCs was isolated using TRIzol Reagent
(Invitrogen) or RNeasy (Qiagen). 1μg of RNA from each sample was used to
generate cDNA using the Superscript First-Strand Synthesis kit (Invitrogen).
Real-time PCR was performed with SYBR Green PCR master mix (Applied
Biosystems) according to the manufacturer’s instructions.

Pooled cDNA was

used to generate a standard curve from which the relative amount of cDNA
amplified in each sample was determined as indicated. Primer sequences for
RT-PCR are as follows.
Gapdh_R:
2005),
_R:

Gapdh_F: GGTTGTCTCCTGCGACTTCAACAGC,

CGAGTTGGGATAGGGCCTCTCTTGC
Pou5f1_F:

et

TTGGGCTAGAGAAGGATGTGGTT,

GGAAAAGGGACTGAGTAGAGTGTGG

Nanog_F:

(Chew

(Chew

CCTCTTCAAGGCAGCCCTGATTCT,

et

al.,
Pou5f1-

al.,

2005),
Nanog_R:

AGAGTTCTTGCATCTGCTGGAGGCT, Olig1_F: GCTCGCCCAGGTGTTTTGT,
Olig1_R:

GCATGGAACGTGGTTGGAAT (Boyer et al., 2006), h3f3a_F:

ACAAAAGCCGCTCGCAAGAG,
h3f3b_F:

h3f3a_R:

ATTTCTCGCACCAGACGCTG,

TGGCTCTGAGAGAGATCCGTCGTT,

GGATGTCTTTGGGCATGATGGTGAC,
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h3f3b_R:

Flow cytometry
FACS and analysis was performed on a BD FACSAriaII-2. In brief, ES cells were
trypsinized and gently separated to single cells for FACS, and resuspended in
PBS + 5% ES quality FBS (Gibco 10439-024). FACS collection tubes were precoated with ES quality FBS for at least 30 minutes prior to the sort. To prevent
clumping during the sort, cells were gently filtered into a single cell suspension
through a cell-strainer mesh (Polystyrene Round-Bottom Tube with Cell-Strainer
Cap, Falcon #352235). Following sort, cells were immediately plated on feeders
with ES media.

Isolation of protein complexes and mass spectrometric analysis
Immunoaffinity purications of GFP-tagged H3.3, H3.2, H3.1, H3.3 HIRA-/-, and
H3.2 HIRA -/- were performed as previously described (Cristea et al., 2005), and
MALDI MS and MS/MS analyses were performed as described (Luo et al., 2009).
Briefly, for each isolation, ~2.5g cryogenically ground cells were extracted in 9 ml
of 20 mM K-HEPES, pH 7.4, 110 mM K-acetate, 0.1% Tween 20, 0.5% Triton, 300
mM NaCl, and 1/100 (v/v/) protease inhibitor cocktail (Sigma-Aldrich). Resulting
cell homogenates were incubated with 12 mg M-270 epoxy magnetic beads (Dynal,
Oslo, Norway), conjugated with in-house developed rabbit polyclonal anti-GFP
antibodies (5µg antibodies/mg beads) for one hour at 4°C. Isolated proteins were
eluted in 700 µl 0.5N NH4OH, 0.5mM EDTA for 20 minutes at room temperature,
dried by vacuum centrifugation, suspended in protein electrophoresis sample buffer,
resolved by 1-D SDS-PAGE (4–12% NuPAGE Novex Bis-Tris gel, Invitrogen), and
stained with Coomassie Blue (GelCode Blue, Pierce). The entire gel lanes were cut
into sections (~30 sections per gel lane), and proteins were digested with 12.5ng/
μl sequencing grade modified trypsin (Promega, WI, USA). Resulting peptides
were extracted on reverse phase resin (Poros 20 R2, PerSeptive Biosystems),
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eluted in 2 mg/ml α-cyano-4-hydroxycinnamic acid, 70% (v/v) acetonitrile and 0.1%
(v/v) trifluoroacetic acid, and deposited onto an in-house made magnetic MALDI
target, as described (Blethrow et al., 2007). MALDI MS and MS/MS analyses
were performed using prOTOF (Perkin Elmer), vMALDI LTQ XL (Thermo Electron,
Bremen, Germany), and MALDI LTQ Orbitrap XL (Thermo) mass spectrometers,
as described (Blethrow et al., 2007; Luo et al., 2009). Protein candidates were
identified by database searching against the most recent version of the National
Center for Biotechnology Information nonredundant protein database using the
XProteo computer algorithm (http://www.xproteo.com). The MS/MS CID data was
acquired and interpreted manually to confirm the candidate peptides.

Antibodies
Antibodies used for western blotting, immunofluorescence, and ChIP-seq were
as follows. H3K4me1 (Abcam ab8895), H3K4me3 (Abcam ab8580), H3K27me3
(Upstate/Millipore #07-449), H3K36me3 (Abcam ab9050), C-terminal H3 (Abcam
ab1791), anti-HA (mouse monoclonal 12CA5, western and ChIP-seq), anti-HA
(mouse monoclonal HA.11, Covance MMS-101R, immunofluorescence), Oct-3/4
(BD Biosciences 611202), affinity-purified rabbit polyclonal anti-GFP (Cristea et
al., 2005), Ldha (Santa Cruz H-160, sc-33781), Atrx (mouse monoclonal 23c)
(McDowell et al., 1999). The mouse monoclonal antibody to the RNA polymerase
CTD phosphorylated on Ser5 CTD4H8 (Upstate/Millipore #05-623) was raised
against a chemically synthesized phospho-Ser 5 peptide sequence from the CTD
of the largest RPB1 subunit of RNAPII, and has been extensively characterized
previously (Stock et al., 2007). The anti-Nestin hybridoma (Rat-401) developed by
Susan Hockfield was obtained from the Developmental Studies Hybridoma bank
developed under the auspices of the NICHD and maintained by the University of
Iowa, Dept. of Biological Sciences, Iowa City, IA 52242. Mouse monoclonal anti215

HA (12CA5) antibody was a gift from Dr. Christina Hughes, and mouse monoclonal
anti-Hira (WC119) antibody was a gift from Dr. Peter Adams.

Cellular extract preparation and metaphase chromosome spreads
Whole cell extracts were prepared by resuspending cell pellets in SDS-Laemmli
sample buffer, followed by brief sonication and boiling. Chromosome spreads were
performed as described (Perez-Burgos et al., 2004).

Gene expression analysis of wild-type and Hira -/- ES cells
RNA expression data for W9.5 and Hira -/- ES cells was generated from polyA
RNA and random primers using the GeneChip Mouse Gene 1.0 ST Array kit
(Affymetrix).

TERRA analysis
RNA was isolated using RNeasy Mini Kit (Qiagen), and TERRA analysis was
performed as described (Azzalin et al., 2007; Sfeir et al., 2009).

Peptide pull-downs and protein expression
Histone peptide pull-downs were performed as described (Ooi et al., 2007).
Recombinant ATRX ADD domain was a gift from Dr. Daniela Rhodes (Argentaro et
al., 2007), DNMT3L was a gift from Dr. Emily Bernstein (Ooi et al., 2007). WDR5
plasmid was a gift from Dr. Alex Ruthenburg, and recombinant WDR5 protein was
expressed as previously described (Ruthenburg et al., 2006).

ChIP and ChIP-seq
Crosslinking and native ChIP were performed as described (Barski et al., 2007;
Lee et al., 2006), with minor modifications as described in Appendix A. Please
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see Appendix A for detailed native and crosslinking ChIP and ChIP-seq methods
and protocols. Purified ChIP DNA was used for cluster generation on Illumina/
Solexa flow cells, and sequencing analysis was performed on an Illumina/Solexa
Genome Analyzer 2 following manufacturer protocols. Primer sequences for ChIP
validation are listed in Table 5.1. Table 5.2 lists ChIP-seq assays performed and
total tag# for each experiment.
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Table 5.1: Real-time PCR primers and validation of ChIP-seq
Sequence of forward and reverse primers and mouse genomic position (mm9) is provided. Data
is presented as fold enrichment over chr8 intergenic (%input at location / % input at intergenic).
Primers with Hira-independent enrichment of H3.3 (TFBS and rDNA) are indicated in bold.
Genomic position

Description

H3.3
enrichment

Forward primer

Reverse primer

chr7:2566879525669006

Rps19-1

3.39

TGGGGGATCATGAGTTCAAAGCC

TGCCGGAGTCTGGTTGTTCA

chr7:2566920725669375

Rps19-2

2.18

GCCACATGTCATAGTGCCTTTTCCC

CGGGAACAAGGAGGCGGAAA

chr7:2566991625670076

Rps19-4

4.64

TGAGGGAGCGGGGTGTGGAG

CGTCGCCAGTCCACCCCAAA

chr7:2567109925671315

Rps19-5

9.68

ATGTCCACGGGATCCACTTTGTTTC

TGCACGCTTGCTTCCAAGAG

chr7:2567234325672506

Rps19-6

17.03

GCTGTCTTGCTGCTTACAGCCTCTAAATAG

TGCAATGGGGATTCTAGCCG

chr7:2567415325674369

Rps19-7

17.69

TCTGCAGAGTGAGTGCCAGGACTATACA

CCATCCCAAGCTGTGTAAACCTGG

chr7:2567498925675167

Rps19-8

18.19

TTGTCCTCAAGACACCAGTGGAGCT

ATCTGCTCAACCGCACTTGG

chr7:2567568625675847

Rps19-9

7.46

AATTCCAGCTCCTAGTTCGTTGGGA

AACCCCCTTCCATGAGCTTG

chr5:143667188143667378

Actin-3

6.15

TTGATAGTTCGCCATGGATGACGA

ATCGATCCCCAAGAAAACCCCA

chr5:143665065143665289

Actin-5

3.75

TTAAAAACTGGAACGGTGAAGGCG

ATGGACGCGACCATCCTCCTCTTA

chr5:143664523143664714

Actin-6

17.39

TGGGCTAGGCCTTGCTGATGGTAT

TGCAGATGGAGGCAAAGGGT

chr5:143664113143664319

Actin-7

17.57

AGCTCCAGCCTTTGTCAGTCGTGA

TTGTTTGGGTGGGTGAAGGG

chr5:143663236143663455

Actin-8

16.62

GTAACAGAGGCCCAGGTAACACAGACA

TGGCAAAGATGGAAGGCGCA

chr17:3564091935641088

Oct4-4

11.84

GGAACTGGGTGTGGGGAGGTTGTA

AGCAGATTAAGGAAGGGCTAGGACGAGAG

Chew et al.
2005

chr17:3564429135644494

Oct4-10

5.62

GGAGTCCCCTAGGAAGGCATTAATAGTTT

GGATTCTCTCGGCTTCAGACAGACTTT

Chew et al.
2005

chr17:3564675935646950

Oct4-12

13.88

CCCTTCCAGAGCCCCTTTCAGTAA

GCACCAGGGTCTCCGATTTGCATA

chr6:122660079122660280

Nanog-6

4.48

TCTGCTGCCTAAGCTCTTGTGCTGT

CTGCTCTTTCCAATCCCTTCTCCC

chr18:1105173911051976

Gata6

5.54

CCTTCCCATACACCACAACC

CCCCTCCTTCCAAATTAAGC

Boyer et al.
2006

chr15:4048751340487666

Zfpm2

6.47

GGATGAAGTTCTCAGAGCTGGT

GCGCGAACTTTTACACCTACTT

Bernstein et
al. 2006

chr3:8777349187773703

Nestin-4

1.64

TTTGCTATGTAGAGGCTGGCCTCAA

GCATGGTGCACCTGTACACACACA

chr3:8777498787775219

Nestin-6

3.75

TCAGCTCGCTGCTGGAATCCTCCG

TGCTCCTCCAGCGTCTTGACCC

chr3:8778115587781365

Nestin-10

1.50

ATGAGACCCAGGGTTCATTGAGGC

TCGTTCTCTAGCTTGCTCTCAGCCA

chr5:130137827130138046

TF5-2

10.78

ACTACCCCATTGTGGCAGTCGATG

GATGGCACACAAAAGGAAGCATGG

chr5:130139506-

TF5-4

12.51

TGTGATGGCAGAATGCT-

GAGCCAAATGAAC-

CAATCCTG

CTTTTCCTCCC

130139707
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Primer
sequence
previously
published

chr2:172342091172342310

TF2-4

10.13

TGGCGGCTAGAGCTTCTTTAATGCA

TCGAAATCTCCGCCTGCCAA

chr1:7227569372275847

TF_Oct4-43

10.34

GCAATGGTTAAGCGAGGTTACAGGAACACA

AACCCTAAGGCCAGGATGGTCAGTAG

Chen et al.
2008

chr1:182854966182855138

TF_Nanog-34

7.46

GGGGAAATACAGTAATTGACCAATCAGC

CCAAGACCACCAAAGTTCCACCTACCCTCA

Chen et al.
2008

repeat

rDNA_90F_146R

3.42

CTTTTTACTGGCTTGGGTCTGTCG

GGAAGCGTGGCTCGGGGAC

repeat

rDNA_743F_811R

2.17

CTCTTCTCGTTCTGCCAGCG

TGCCTTCCACACACCACCG

repeat

rDNA_2801F_2860R

1.90

CGAGGGCAAAGGGAAAGAGGC

CAACAGACCACCACACCGTCG

repeat

rDNA_5319F_5451R

4.41

GATTCCGTGGGTGGTGGTGC

AGAAGTTGGGGGACGCCGAC

repeat

rDNA_6007F_6060R

1.64

AAGGGGTGGGTGGGGTCG

AGGGGAAATCGGAGGCGG

repeat

rDNA_6814F_6878R

1.80

GGTCGTTGGGGGACTGTGCC

CGTATCGGTATTTCGGGTGTGAGC

repeat

rDNA_7147F_7200R

1.20

GGCGGTTGTCGGTGTGGC

GGCGGAGCGGGAAGAAGC

repeat

rDNA_9752F_9862R

2.99

CGGGCGTGGAATGCGAGTG

GGGGTCTGATGAGCGTCGGC

repeat

rDNA_13366F_13419R

1.40

GTGTGGAGGCGGAGAGGGTC

TTGGGGGGGAAAAAATGGAAG

chr1:136431721136431906

TF_Nanog-37

9.16

TTCAAAACCTTTTCTAATGTTAAGTATGGG

GCAGGCTAAAACAATTGGTGCTCTGACATC

Chen et al.
2008

chr4:135702804135702993

TF_Nanog-36 (lincRNA)

7.75

ACACCTACGAGGCATTATTAAGCTAATTCC

GCCCATAAATGATTACAACAGCAGACTAA

Chen et al.
2008

repeat

MajSat

1.17

GACGACTTGAAAAATGACGAAATC

CATATTCCAGGTCCTTCAGTGTGC

Martens et
al. 2005

repeat

MinSat

1.03

CATGGAAAATGATAAAAACC

CATCTAATATGTTCTACAGTGTGG

Martens et
al. 2005
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Table 5.2: Summary of ChIP-seq experiments
ChIP-seq method, cell type, antibody, and read numbers are indicated. Data correspond to files
deposited in GEO (late 2009, accession number GSE16893).
sample number

ChIP, method, cell-type
as listed in Figure S5

Antibody

GEO sample name

TagSize

totalRead

MappedRead

1

H3.3-HA, x-link, H3.3HA ES

anti-HA
(12CA5)

ES_H33_HA_antiHA_
xChIPSeq

36

9035477

5459510

1

H3.3-HA, x-link, H3.3HA ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

7879052

3746969

1

H3.3-HA, x-link, H3.3HA ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

35

6936913

4505457

2

H3K36me3, x-link, H3.3HA ES

H3K36me3
(Abcam
ab9050)

ES_H33_HA_
H3K36me3_xChIPSeq

36

6022772

3521419

3

H3K4me1, x-link, H3.3HA ES

H3K4me1
(Abcam
ab8895

ES_H33_HA_
H3K4me1_xChIPSeq

36

9101416

6203945

4

RNAPII CTD4H8, x-link,
H3.3-HA ES

RNAPII
CTD4H8
(Upstate/
Millipore
#05-623)

ES_H33_HA_RNAPII_
CTD4H8_xChIPSeq

36

10380059

5466893

5

H3.2-HA, x-link, H3.2HA ES

anti-HA
(12CA5)

ES_H32_HA_antiHA_
xChIPSeq

36

7175197

4189238

5

H3.2-HA, x-link, H3.2HA ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

35

7662575

4667154

5

H3.2-HA, x-link, H3.2HA ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

8022943

3754658

6

H3K36me3, x-link, H3.2HA ES

H3K36me3
(Abcam
ab9050)

ES_H32_HA_
H3K36me3_xChIPSeq

36

8258652

4128488

7

H3.3-HA, x-link, H3.3HA NPC

anti-HA
(12CA5)

NP_H33_HA_antiHA_
xChIPSeq

36

10468958

6374820

7

H3.3-HA, x-link, H3.3HA NPC

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

35

6507833

4593473

7

H3.3-HA, x-link, H3.3HA NPC

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

8474427

4224225

8

H3K36me3, x-link, H3.3HA NPC

H3K36me3
(Abcam
ab9050)

NP_H33_HA_
H3K36me3_xChIPSeq

36

6099447

4124703

9

H3K4me1, x-link, H3.3HA NPC

H3K4me1
(Abcam
ab8895)

NP_H33_HA_
H3K4me1_xChIPSeq

36

10408633

6652275

10

RNAPII CTD4H8, x-link,
H3.3-HA ES

RNAPII
CTD4H8
(Upstate/
Millipore
#05-623)

NP_H33_HA_RNAPII_
CTD4H8_xChIPSeq

36

10340552

4836974

11

H3.2-HA, x-link, H3.2HA NPC

anti-HA
(12CA5)

NP_H32_HA_antiHA_
xChIPSeq

36

8424873

3587825
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11

H3.2-HA, x-link, H3.2HA NPC

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

6438827

2946810

11

H3.2-HA, x-link, H3.2HA NPC

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

35

6935320

4006635

12

H3K36me3, x-link, H3.2HA, ES

H3K36me3
(Abcam
ab9050)

NP_H32_HA_
H3K36me3_xChIPSeq

36

6639414

4283010

13

Input, x-link, H3.3-HA
hybrid ES

x-link
ChIP input
control. No
antibody.

ESHyb_H33_HA_Input_xChIPSeq

36

9110275

5371094

14

H3.3-HA, x-link, H3.3HA hybrid ES

anti-HA
(12CA5)

ESHyb_H33_HA_antiHA_xChIPSeq

36

9676064

5894951

14

H3.3-HA, x-link, H3.3HA hybrid ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

9784425

5997655

14

H3.3-HA, x-link, H3.3HA hybrid ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

34

6268370

3836705

15

H3K36me3, x-link, H3.3HA hybrid ES

H3K36me3
(Abcam
ab9050)

ESHyb_H33_HA_
H3K36me3_xChIPSeq

34

6463354

3789693

16

Input, x-link, H3.1S31HA hybrid ES

x-link
ChIP input
control. No
antibody.

ESHyb_H31S31_HA_Input_xChIPSeq

36

9173252

5397974

17

H3.1S31-HA, x-link,
H3.1S31-HA hybrid ES

anti-HA
(12CA5)

ESHyb_H31S31_HA_
antiHA_xChIPSeq

36

5780596

3603934

17

H3.1S31-HA, x-link,
H3.1S31-HA hybrid ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

10048249

6076492

17

H3.1S31-HA, x-link,
H3.1S31-HA hybrid ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

8300087

4699124

18

H3K36me3, x-link,
H3.1S31-HA hybrid ES

H3K36me3
(Abcam
ab9050)

ESHyb_H31S31_HA_
H3K36me3_xChIPSeq

36

8371173

4773789

19

H3.3-HA, native, H3.3HA ES

anti-HA
(12CA5)

ES_H33_HA_antiHA_
nChIPSeq

36

11966966

6541403

19

H3.3-HA, native, H3.3HA ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

11704727

7346788

20

H3K4me3, native, H3.3HA ES

H3K4me3
(Abcam
ab8580)

ES_H33_HA_
H3K4me3_nChIPSeq

36

8200550

5167942

21

Input, native, H3.3-HA
ES

native
ChIP input
control. No
antibody.

ES_H33_HA_input_
nChIPSeq

36

11427929

6039408

22

H3.2-HA, native, H3.2HA ES

anti-HA
(12CA5)

ES_H32_HA_antiHA_
nChIPSeq

36

2133418

1361872

22

H3.2-HA, native, H3.2HA ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

36

13362561

7074823
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22

H3.2-HA, native, H3.2HA ES

anti-HA
(12CA5)

deeper sequencing
replicate within sample
directory above

32

9664647

5528131

23

H3K4me3, native, H3.2HA ES

H3K4me3
(Abcam
ab8580)

ES_H32_HA_
H3K4me3_nChIPSeq

32

6402480

4415020

24

H3K27me3, native,
H3.2-HA ES

H3K27me3
(Upstate/
Millipore
#07-449)

ES_H32_HA_
H3K27me3_nChIPSeq

32

8741662

5428037

25

Input, native, H3.2-HA
ES

native
ChIP input
control. No
antibody.

ES_H32_HA_input_
nChIPSeq

32

8715354

5479449

26

H3.3-EYFP, native,
H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

ES_H33_EYFP_antiGFP_nChIPSeq

36

5193695

3744380

26

H3.3-EYFP, native,
H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

deeper sequencing
replicate within sample
directory above

36

5595554

3395192

26

H3.3-EYFP, native,
H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

deeper sequencing
replicate within sample
directory above

36

6047143

3191111

27

Input, native, H3.3EYFP ES

native
ChIP input
control. No
antibody.

ES_H33_EYFP_Input_
nChIPSeq

36

5726370

3531774

28

H3K4me1, native, H3.3EYFP ES

H3K4me1
(Abcam
ab8895)

ES_H33_EYFP_antiH3K4me1_nChIPSeq

36

5780578

4385502

29

H3K36me3, native,
H3.3-EYFP ES

H3K36me3
(Abcam
ab9050)

ES_H33_EYFP_antiH3K36me3_nChIPSeq

36

8600269

5174908

30

H3.3-EYFP, native, Hira
-/- H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

Hiranull_ES_H33_
EYFP_antiGFP_
nChIPSeq

36

11564437

6590765

30

H3.3-EYFP, native, Hira
-/- H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

deeper sequencing
replicate within sample
directory above

36

12460001

5457471

31

H3K4me1, native, Hira
-/- H3.3-EYFP ES

H3K4me1
(Abcam
ab8895)

Hiranull_ES_H33_
EYFP_antiH3K4me1_
nChIPSeq

36

8915573

6420547

32

H3K36me3, native, Hira
-/- H3.3-EYFP ES

H3K36me3
(Abcam
ab9050)

Hiranull_ES_H33_
EYFP_antiH3K36me3_
nChIPSeq

36

7999631

4416253

33

Input, native, Hira -/H3.3-EYFP ES

native
ChIP input
control. No
antibody.

Hiranull_ES_H33_
EYFP_Input_nChIPSeq

36

8156833

5292703

34

H3.3-EYFP, native, Atrxflox H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

Atrxflox_ES_H33_
EYFP_antiGFP_
nChIPSeq

36

6476017

4304375

34

H3.3-EYFP, native, Atrxflox H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

deeper sequencing
replicate within sample
directory above

36

9088918

5313474

34

H3.3-EYFP, native, Atrxflox H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

deeper sequencing
replicate within sample
directory above

36

9236425

6207716
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35

Input, native, Atrxflox
H3.3-EYFP ES

native
ChIP input
control. No
antibody.

Atrxflox_ES_H33_
EYFP_Input_nChIPSeq

36

6060126

4117751

36

H3.3-EYFP, native, Atrxnull H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

Atrxnull_ES_H33_
EYFP_antiGFP_
nChIPSeq

36

7806156

4811353

36

H3.3-EYFP, native, Atrxnull H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

deeper sequencing
replicate within sample
directory above

36

9685286

6402420

36

H3.3-EYFP, native, Atrxnull H3.3-EYFP ES

anti-GFP
(Cristea et
al., 2005)

deeper sequencing
replicate within sample
directory above

36

8575771

5495831

37

Input, native, Atrxnull
H3.3-EYFP ES

native
ChIP input
control. No
antibody.

Atrxnull_ES_H33_
EYFP_Input_nChIPSeq

36

7102030

4758929

38

anti-HA, x-link, W9.5
wild-type ES

anti-HA
(12CA5)
control. No
HA epitope
in untagged
ES cells

ES_wild_type_antiHA_
control_xChIPSeq

36

7099906

3065689
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Data Analysis
All ChIP-seq data analysis was performed in collaboration with Dr. Deyou Zheng.
ChIP-seq or input reads were mapped to the mouse genome (build 37, or mm9)
using the ELAND alignment software within the Illumina Analysis Pipeline. Profiles
in specific genomic regions were displayed in the Affymetrix Integrated Genome
Browser. For analysis of repetitive elements, reads were aligned directly to a library
of mouse consensus repetitive sequences (http://www.girinst.org). For analysis
at TSS and TES, we segregated reference gene (refSeq) annotation into low,
medium and high expression based on a previous microarray analysis (Mikkelsen
et al., 2007). For analysis of TFBS, binding sites for 13 TFs in mouse ES cells
were obtained from a previous ChIP-seq analysis (Chen et al., 2008). To generate
density profiles ± 5kb around TSS, TES, bivalent genes, and TFBS, we used a
sliding window method which summed the number of ChIP-seq reads in each 200
bp window. The sums were then normalized by the number of genes or TFBS in
each group and the total mapped reads obtained in a ChIP-seq experiment.

Genome-wide density maps of H3 variants and determination of enriched regions.
All reads were mapped to the mouse genome (build 37, or mm9) using the ELAND
alignment software within the Illumina Analysis Pipeline in multi/extended mode.
Unique reads mapped to a single best-matching location with no more than two
mismatches were kept. During our data analysis, each read was extended 100 nt
in its 3’ direction to account for the estimated ChIP DNA fragment size of ~300 bp.
Using these extensions, we generated genome-wide distributions of H3 variants,
histone modifications, and RNAPII represented by the number of reads spanning
individual genomic locations. These profiles were displayed in the Affymetrix
Integrated Genome Browser (IGB) and also used for the determinations of genomic
regions enriched with ChIP-Seq signals. Like H3K36me3, the signals for H3.3 are
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very dispersed and often found in large extended regions (Figure 2.11, 2.19., 2.22,
2.26). As a result, my collaborators and I tried several existing peak identification
programs and found that they were not very effective in identification of H3.3
enriched regions. We therefore employed a simple segmentation algorithm. We
first applied a Poisson distribution to model the genome-wide ChIP-Seq profile, and
then selected positions with read coverage above a threshold that was determined
for each experiment specifically at the p-value of 0.1. Adjacent positions above
this threshold and less than 600 bp apart were then merged to form genomic
blocks, which were subsequently filtered by a minimal length of 300 bp to generate
candidates of enriched regions. The final enriched regions, furthermore, must also
have twice more reads in a ChIP assay than its control input run (after normalization
by read depths). As a comparison, 95% and 97% of the peaks identified by our
method for H3K4me1 and H3K4me3 ChIP-Seq experiments, respectively, were
also determined as peaks by a popular ChIP-Seq peak analysis program, MACS
(Zhang et al., 2008), suggesting that we only called peaks of high confidence.
Figure 2.12 and Figure 2.14 summarize the numbers of enriched regions for
selected ChIP-experiments and their spatial relationships to gene annotation and
transcription factor binding sites.

The relative depositions of H3 variants in repetitive elements. Reads were aligned
directly to a library of mouse consensus repetitive sequences (http://www.girinst.
org). The proportion of reads aligning to each class of repeats was computed for
H3.3, H3.2, and H3.1S31, on the condition that the alignment length and sequence
identity must be ≥ 25-bp and ≥ 90%, respectively. The resulting numbers were
compared to the corresponding proportions calculated for input controls to yield
relative fold-enrichments.
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Distributions of H3 variants in transcription start and end sites. The reference gene
(refSeq or known genes) annotation was downloaded from the UCSC browser
(http://genome.ucsc.edu), and genes were segregated into low, medium and high
expression based on expression data obtained from a previous microarray analysis
(Mikkelsen et al., 2007) . The expression values for these three categories were
defined as 5~20, 50~200, and >500, respectively. Based on the CpG contents
in their promoters, genes were further divided into three types: high (HCP),
intermediate (ICP) and low CpG (LCP) promoters (Mikkelsen et al., 2007). Data
shown here are mostly for low, medium and high expression HCP genes (~1800
genes in each group). The three groups of genes were comparatively analyzed
for density profiles of H3 variants or modifications around their transcription start
sites (TSSs) and transcription end sites (TESs). Briefly, after dividing the ± 5kb
regions across TSSs (or TESs) into 50 non-overlapping windows (200-bp in size),
we summed the number of ChIP-Seq reads ending in each window over all genes.
The sums were then normalized by the gene number in each group and the total
of mapped reads obtained in a ChIP-Seq experiment to generate final aggregated
ChIP-Seq profiles of H3 variants or modifications. This sliding window method was
also applied to analyze a set of genes with “bivalent” marks at their promoters in
mouse ES cells but not in mouse NPC (Mikkelsen et al., 2007).

The relative enrichment of H3 variants in TFBS. The lists of binding sites for 13
transcription factors in mouse ES cells were obtained from a previous ChIP-Seq
analysis (Chen et al., 2008). RefSeq gene annotation was used to segregate
TFBS into three groups: promoter (± 5 kb of TSS), intergenic (5 kb away from
genes), and otherwise gene body. After extending each of these TFBS from its 5’
and 3’ direction to span 10-kb sequence, we applied a sliding-window approach,
similar to the one for TSSs, to generate density profiles over TFBS for different
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H3 variants or histone modifications. (Chen et al., 2008) has also defined a set
of multiple transcription factor-binding loci (MTL) that were bound by more than
four different transcription factors. For these MTL, we computed the read density
(number of reads per 5-kb sequence) to characterize the correlation between
number of bound factors and the abundance of different H3 variants.
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Appendix
Chromatin immunoprecipitation (CHIP) and
Detailed protocols for Chip-seq
The crosslinking ChIP-seq protocol described below was adapted from a ChIPchip protocol originally published by the laboratory of Dr. Richard Young (Lee et
al., 2006b). In addition, a number of the steps in this protocol grew out of detailed
discussions with Dr. Tom Milne, Sarah Whitcomb, and Dr. Nicolai Siegel. For native
ChIP-seq, I adapted a native ChIP protocol from Dr. Keji Zhao’s laboratory (Barski
et al., 2007).

Crosslinking and native ChIP
ChIP is generally performed with either formaldehyde-mediated crosslinking of
proteins and nucleic acids within living cells followed by sonication (crosslinking,
x-ChIP) or by micrococcal nuclease digestion of harvested cell nuclei and isolation
of solubilized mono or short oligonucleosomes (native ChIP).

Crosslinking

ChIP ‘freezes’ protein and nucleic acid interactions and enables the analysis
of nucleosomal as well as non-nucleosomal proteins such as TFs and RNA
polymerase, while native ChIP is more suitable for the analysis of core chromatin
and nucleosomal components such as histones and histone modifications (Kuo and
Allis, 1999; O’Neill and Turner, 2003) (See Figure 1.8). I used a slightly modified
version of described protocols (Barski et al., 2007; Lee et al., 2006b) to perform
both native and crosslinking ChIP. Both protocols use Invitrogen Dynal magnetic
beads (Invitrogen Dynabeads anti-mouse M-280 #112-02, or Dynabeads antirabbit M-280 #112-04, or Dynabeads Protein A #100-02D). I have found that these
magnetic beads generate low background when washed as described (Barski et
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al., 2007; Lee et al., 2006b), and also are free of salmon sperm DNA which might
otherwise contaminate ChIP-seq results. The use of a protocol that omits salmon
sperm or other non-specific DNA blocking agents is absolutely critical for ChIPseq, as such non-specific nucleic acids overwhelm the actual sequence reads
from specifically immunprecipitated DNA (D Zheng, personal communication).
For x-ChIP, I harvested embryonic stem (ES) cells and neural precursor cells
(NPCs) immediately prior to fixation with 1% paraformaldehyde, as I found that
crosslinking on gelatin-coated plates also crosslinks gelatin. Approximately 1*10^7
cells were used for each ChIP. For sonication, I used a Bioruptor (Diagenode)
and optimized sonication conditions to generate DNA fragments of approximately
300-500bp. Following a published x-ChIP protocol (Lee et al., 2006b) through
overnight crosslink reversal at 65˚C, RNase digestion, and proteinase K digestion,
I then isolated ChIP DNA and ChIP input DNA using the Qiagen Qiaquick PCR
purification kit (28104), eluting in 50μl 10mM Tris pH8.5. For native ChIP, I used
the published protocol (Barski et al., 2007) as described, with slight modifications.
Following the final wash, I eluted off of magnetic beads using 50mM Tris-HCl pH
8.0, 10mM EDTA, and 1% SDS, as described in the x-link ChIP protocol (Lee
et al., 2006b). Following elution, I digested proteins with proteinase K (Roche,
recombinant, PCR grade, 03115828001), and isolated DNA with Qiagen PCR
purification kit as described for x-ChIP protocol. Following DNA isolation from
native ChIP, ChIP-seq library preparation is largely identical to the crosslinking
ChIP-seq protocol.

Validation of ChIP prior to ChIP-seq
To validate the ChIP, I used real-time PCR with SYBR Green PCR master mix
(Applied Biosystems) to amplify ChIP samples and ChIP inputs, determining %
input of ChIP samples at target locations and control intergenic locations. Real229

time PCR is critical for ChIP quality control prior to ChIP-seq. Primer sequences
and ES % inputs are listed in Table 5.1. To confirm telomere enrichment, ChIPseq DNA libraries were also probed with a TTAGGG repeat probe and BamHI
repeat probe as described (Sfeir et al., 2009).

ChIP-seq library preparation
For ChIP-seq of x-link or native ChIP DNA, I took 30 ul of remaining ChIP DNA
or ~180ng of input DNA, repaired DNA ends to generate blunt-ended DNA using
the Epicentre DNA ENDRepair kit (Epicentre Biotechnologies, cat# ER0720), and
purified repaired DNA using Qiagen PCR purification kit (28104). Following DNA
END Repair, I added A bases to the 3’ end of the DNA fragments using Klenow
Fragment (NEB M0212L), and purified DNA using Qiagen MinElute (28004). I ligated
Illlumina/Solexa adapters (#FC-102-1003) to DNA fragments overnight, using T4
DNA ligase (NEB M0202L). Following overnight ligation, I purified adapter-ligated
DNA fragments with Qiagen MinElute. To generate libraries for Solexa sequencing,
I performed 18 cycles of PCR with Illumina/Solexa primers 1.1 and 2.1, checked
the fragment size for 1/10 of the amplified library on an agarose gel, and purified
the remaining ChIP-seq library using Qiagen MinElute. I did not use gel purification
to isolate the ChIP-seq library, as standard methods of gel purification have been
shown to decrease the representation of A+T-rich sequences (Quail et al., 2008),
and I have also found decreased DNA yield following gel purification (data not
shown). Detailed protocols for all of these steps are provided below. For details of
Solexa sequencing and ChIP-seq data analysis, please see Chapter Five.
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Detailed protocols for crosslinking ChIP-seq
Prepare cells and paraformaldehyde
1.
For ChIP-seq, seed cells so as to reach ~1*10^7 cells / IP.
Prepare 10% paraformaldehyde stock as follows:
Microwave 18ml of PBS in a 50ml tube placed in a beaker with water until water
starts to boil (leave lid of tube slightly ajar). Do the subsequent steps in a hood. Add
2 grams of paraformaldehyde (wear a mask when weighing this out) and 140λ of
1M KOH. Vortex (be careful since this is a hot solution) and the paraformaldehyde
should dissolve. QS to 20 ml. Cool to 370 before use. Can be stored frozen
indefinitely.
Cross-link and fix cells
2.
Fix cells for 10 minutes with 1% freshly made or frozen paraformaldehyde in
media @ 370. Count another plate in parallel to have some idea of cell #.
* aside for BM (and other non-adherent) cells - fix in a small volume of Pf/media
(~5ml) and then dilute 10X with 45 ml RPMI.
Fix trypsinized ES or non-adherent cells in 10ml warm media +1ml 10% PF, rotating
in a 50ml conical tube at RT. (Fixing ES cells on a gelatinized plate crosslinks
the gelatin, and generates a goopy, disastrous mess. Hence, trypsinize ES cells
first.)
For adherent cells grown on tissue culture dishes without gelatin, add 1 ml
10% paraformaldehyde to 10 ml media for 10 min at 37.
3.
Quench unreacted paraformaldehyde with 2.5M glycine, 5 min @ RT,
rotating if the cells are already out of the tissue culture dish. (2.5M glycine is ~20X,
ie 500µl / 10ml media with 1% paraformaldehyde.)
4.
Dilute with 40ml cold media with FBS. This step may neutralize any residual
trypsin or formaldehyde, but is not required.
5.
Spin fixed cells down. Remove media/paraformaldehyde and rinse and
resuspend cells with 5ml PBS + protease inhibitors (PI). Add PI just before use.
Transfer to a new tube (15ml or 1.5 ml tube). Cold PBS + inhibitors rinse. (Make
sure to include protease inhibitors in last PBS rinse prior to flash freeze. I use 1
tablet of PI / 7ml of PBS. Roche, complete mini EDTA-free 11-836-170-001)
6.
Pellet cells @ 1200rpm, 5’. Flash-freeze pellet in liquid nitrogen and store
0
@-80 . Alternately, you can continue with protocol. If continuing, note that a single
freeze/thaw helps break up cells.
Bind antibody to Dynabeads/ block beads (afternoon prior to ChIP)
Block Solution (for 1 ChIP)
500ml
1x PBS
2.5g BSA		
--> 0.5% w/v
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1.
150uL Dynabeads (anti-mouse M-280, cat# 112-02, or anti-rabbit M-280
cat#112-04, to eppendorff (for 2 ChIPs)
2.
3x wash 1ml block solution: gently mix, collect beads, remove sup
3.
resuspend beads in 500uL block solution + ~15ug antibody (20ul H3K4me3
ab8580) (scale antibody and beads accordingly: 100ul beads, ~10ug antibody –
aim for more rather than less antibody – you will wash any remaining antibody
away after binding to the beads). Per IP, you will use > 50ul of antibody bound
beads, >5ug antibody, for ~ 1*10^7 cells.
4.
O/N rotating @ 4 deg
5.
3x wash in 1ml block solution
6.
resuspend beads in 150uL block solution
Lysis and Sonication
LB1 for 100mL
5mL		
1M Hepes-KOH, pH 7.5 -->
2.8mL 		
5M NaCl			
0.2mL		
0.5M EDTA			
-->
20mL		
50% glycerol			
-->
5mL		
10% NP-40			
-->
2.5mL		
10% Triton x-100		
-->
64.5mL
ddH2O

50mM
-->
140mM
1mM
10%
0.5%
0.25%

1.
pipette resuspend x-linked cell pellet in 1mL LB1 + protease inhibitors (PI)
(per1*10^7 cells! ie, for 9*10^7 cells, use 9ml) -- if using large cell #s, the next few
steps can be done in a conical -- just make sure to sufficiently resuspend pellet.
2.
10 min rotating @ 4deg
3.
spin 5 min @ 1,350g @ 4deg
LB2 for 100mL
1mL		
1M Tris-HCl, pH 8.0		
4mL		
5M NaCl			
0.2mL		
0.5M EDTA			
0.1mL		
0.5M EGTA			
94.7mL
ddH2O
1.
2.
3.

-->
-->
-->
-->

10mM
200mM
1mM
0.5mM

pipette resuspend pellet in 1mL LB2 + PI
10 min rock @ RT
spin 5 min @ 1,350g @ 4deg

LB3 for 100mL
1mL		
1M Tris-HCl, pH 8.0		
2mL		
5M NaCl			
0.2mL		
0.5M EDTA			
0.1mL		
0.5M EGTA			
1mL		
10% Na-Deoxycholate

-->
-->
-->
-->
-->
232

10mM
100mM
1mM
0.5mM
0.1%

2.5mL		
93.2mL

20% N-lauroylsarcosine
ddH2O

-->

0.5%

1.

resuspend pellet in 600µl LB3 + PI, for 1*10^7 cell# ChIP-seq)
Note: for multiple ChIPs from the same sample, resuspend in more LB3,
		
for ChIP-seq, ~600ul LB3 / 1*10^7 cells / IP, pool resuspended
cells.
pass through 27 gauge needle 2-3x to break up cell clumps
-split into aliquots for Bioruptor sonication, no more than 300ul per tube
2.
sonicate BioRuptor 7x 30”/30” in ice water, high power, replace ice, repeat
7x sonication.
3.
Pool sonicated chromatin from one sample in a 15ml conical. Add 1/10
volume of 10% Triton X-100 to sonicated lysate (DO NOT FORGET TO ADD
TRITON OR YOU WILL NOT SOLUBILIZE YOUR NUCLEAR MEMBRANE) (for
ex., 80ul for 800ul).
4.
Aliquot and spin 10min @ 20,000g @ 4deg to crack nuclei; save sup = IP
input
Aliquot 600µl sup for each IP.
save 30uL (5%) freeze for sonication check (agarose)
save 30uL (5%) freeze for ChIP INput (compare w/ChIP elute)
Freeze remaining sup in aliquots for future IPs.
IP Chromatin
1.
add 70uL antibody bound bead mix to sonication sup (600ul) – if you are
using fewer than 1*10^7 cells per IP, you can scale your antibody and beads down
accordingly
2.
rotate O/N @4deg

Wash
RIPA Wash Buffer (for 250mL)
12.5mL
1M Hepes-KOH, pH 7.6
125mL
1M LiCl			
0.5mL		
0.5M EDTA			
25mL		
10% NP-40			
17.5mL
10% Na-Deoxycholate
69.5mL
ddH2O

-->
-->
-->
-->
-->

50mM
500mM
1mM
1%
0.7%

@ 4 deg
0.
start water bath to 65deg for elution and rev X-link!
1.
3-7x (Suggestion: 8x !) wash 1mL RIPA wash buffer - on magnetic stand
2.
wash 1mL TE + 50mM NaCl
3.
spin (3 min @ 960g @ 4deg and carefully remove residual TE with a pipet
– (do NOT attempt to use magnet at this step or you will lose your sample)
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Elute
Elution Buffer (for 100mL)
5mL 1M Tris-HCL, pH 8.0
2mL 0.5M EDTA			
10mL 10% SDS			
83mL ddH2O			

-->
-->
-->

50mM
10mM
1%

1.
add 210uL elution buffer
2.
elute 30 min @ 65deg- resuspend beads every 2 min by briefly vortexing
– make sure caps on tubes are not loose – also, the 65 degree water bath can
bleed the marker – write in strong marker and keep track of tubes
3.
spin down 1 min @ 16,000g @ RT
4.
remove 200uL sup transfer to new eppendorff
Reverse Crosslinks
1.
bring ChIP IN samples (30uL) and sonication check samples (30uL) frozen
yesterday to 200uL with elution buffer
2.
ChIP elutions (IP), ChIP IN, sonication check samples O/N @ 65 deg
Digest RNA and protein
1.
add 2uL 500 ug/ml RNase (Roche, RNase, DNase free, Cat. No. 11 119 915
001), vortex briefly to mix
2.
1 hour @ 37deg (bring water bath to 55 deg)
3.
add 2uL 14-22 mg/mL Proteinase K (Roche, proteinase K, recombinant,
PCR grade, Cat. No. 03 115 828 001) proteinaseK --> 0.2ug/mL final, vortex
briefly.
4.
2 hours @ 55 deg
DNA purification
5.
Recover DNA by Qiagen PCR purification kit. Add 1ml of Binding reagent
PBI to each RNased, PK digested sample. Mix.
6.
Bind DNA through Qiagen spin columns as described in protocol, using
no more than 0.75ml of sample at one time / column. Ie, apply the first 0.7ml,
spin, discard flow-through, then apply then second ~0.5ml, spin, etc. Continue as
described in Qiagen PCR purification protocol. Elute with 50µl Qiagen elution
buffer EB. Take 5 ul of ChIPed, purified DNA for real-time PCR analysis.
Store remaining 45ul at -20, and use for ChIP-seq only pending real-time
PCR analysis.
Real-time PCR analysis
Make 1:100 dilution of each input and sample (5ul + 495ul H2O) for real-time
PCR. I use SYBR green (Applied Biosystems SYBR Green PCR Master Mix,
#4309155) for real-time quantification.
For each primer set, make the appropriate mix. Keep on ice until adding to plate.
Use 15λ of each mix / well of 96-well real-time PCR plate. Add 10λ of appropriate
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1:100 dilution to each well for 25λ total. Make sure to pipet up and down. Quick
spin 96 well plate for 30 sec. at 450rpm to make sure mix is even in all wells.
		
			
1:100 DNA		
10.0 λ
2X SYBR Mix:
12.5 λ		
			
Fwd primer		
0.5 λ
			
Rev primer		
0.5 λ
			
H20			
1.5 λ
			
Total			
25.0 λ
Preparing ChIP samples for ChIP-seq
Note on yield of ChIP DNA: ChIP DNA amounts are generally <10ng / ul, and not
accurately quantifiable by nanodrop. Therefore, I do not base my decision about
whether to use the sample for ChIP-seq on the relative DNA yield, but rather on
real-time PCR analysis, looking at % input at an enriched location vs % input at
an unenriched location. Antibody quality and the relative biological abundance of
their epitopes can be variable, but the real-time PCR analysis is critical to make
sure that you are sequencing high quality, specifically IPed material.
Note on yield of input DNA: Typical yields of purified input DNA (pre-IP) are ~50100+ ng / µl, with 50 µl EB representing 5% (2.5 to 5 µg) of the original input (~
50-100 µg.)
DNA end repair
1. Repair DNA ends to generate blunt-ended DNA using the Epicentre DNA
ENDRepair
kit (Epicentre Biotechnologies, cat# ER0720)
1-34 μl DNA (0.3 μg)
5 μl 10x End repair buffer (330 mM Tris-acetate, pH7.8, 660 mM
potassium acetate, 100 mM magnesium acetate, 5 mM DTT)
5 μl 2.5 mM each dNTPs
5 μl 10 mM ATP
x μl H2O to adjust the reaction volume to 49 μl
1 μl End-Repair Enzyme mix (T4 DNA Pol + T4 PNK)
For ex.:
30 μl ChIP DNA from remaining 45ul (~180ng of input DNA, add H20 to
reach 30µl)
Make mix qs to 19µl 5 μl 10x End repair buffer
				
5 μl 2.5 mM dNTP mix
				
5 μl 10 mM ATP
				
4 μl H2O to adjust the reaction volume to 49 μl
1 μl End-Repair Enzyme mix (T4 DNA Pol + T4 PNK)
Keep at room temperature for 45 min.
2. Use QIAquick PCR purification kit and elute in 34µl Qiagen EB
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Add ‘A’ bases to the 3’ end of the DNA fragments
3. Add “A” to 3′ ends
34 μl DNA from above
Make mix qs to 13µl
		
5 µl Klenow buffer NEB2 (10X)
		
1 µl dATP (10mM)
		
7 µl dH20
3µl Klenow enzyme (Klenow Fragment (3´→ 5´ exo- ), NEB M0212L 5000
un/ml)
Total volume: 50 μl
Incubate for 30 min at 37°C.
4. Purify DNA with Qiagen MinElute (cat. 28004) and elute in 11µl Qiagen EB.
Inputs

-----------H3.3 H3.1
HA
S31
HA

Size

-------

H3.3-HA ES

H3.1S31-HA ES

----------------------- ----------------------Inp
HA K36me3 nIgG
Inp
HA
K36me3 nIgG
1
2
3
4
5
6
7
8

2000
1850
1000
850
650
500
400
300
200

Preamplification

100

Post-amplification

Figure A1: Gel image of crosslinking ChIP-seq DNA pre and post-amplification for Solexa
sequencing
Sonicated ChIP inputs and ChIP samples were amplified and prepared for Solexa sequencing.
~180ng of ChIP input DNA and 35μl of each ChIP sample were used in end repair, A addition,
adapter ligation, and amplification (see detailed steps above). 300 ng of ChIP input DNA was loaded
for comparison (pre-amplification, left). Following 18 cycle PCR amplification with Solexa primers
1.1 and 2.1, 4μl of unpurified 50ul PCR reaction was loaded in each lane to assess fragment sizes
of the amplified ChIP-seq libraries (post-amplification, right). DNA ladder (center) indicates that the
ChIP-seq libraries are predominantly between 300-500bp. The remaining 46μl post-amplification
PCR reaction was then directly purified with Qiagen MinElute (without gel purification) and eluted
into 15μl EB for Solexa sequencing.
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Ligate adapters to DNA fragments
5. Linker ligation. The oligo mix should contain 10x molar excess of the DNA
templates.
10 μl DNA
Make mix qs to 17µl 		
		
3 µl 10x T4 DNA ligase buffer
		
13 μl H2O (nuclease free)
		
1 μl Solexa adapter oligo mix (try 1:10 dilution)
3 μl T4 DNA ligase (NEB M0202L, 400 units/μl)
Total volume: 30 μl
Incubate at room temperature for 15 min and then overnight in PCR program
below.
1) 4°C for 2 hrs. 2) 0.1° / s to 16°C. 3) 16°C for 20min. 4) 0.1° / s to 4°C.
5) Go to 1, 6 times. 6) 4°C forever.
6. Purify DNA with QIAGEN MinElute and elute in 11µl Qiagen EB.
Amplify adapter-modified DNA fragments by PCR to generate ChIP-seq
library
7. Amplify the DNA using Solexa primers and enzyme mix
10 μl of DNA
		
Make mix qs to 39.5µl
10 μl of 5X Phusion HF buffer
						
1.5 μl of dNTP mix (10mM dNTP)
						
0.75 µl Solexa primer 1.1
						
0.75 µl Solexa primer 2.1
						
1.5 µl DMSO
						
25 µl dH20 (nuclease free)
0.5 µl Phusion
Total volume: 50 μl
Denature at 98°C for 30 sec. 98°C, 10sec; 65°C, 30sec; 72°C, 30sec. (18
cycles) 72°C, 5 min. hold @ 4 degrees.
8. Try 18 cycles first, check 4 μl of product on 2% gel. If the band is not
clearly visible, do 3 more cycles. Check again.
9. Purify remaining 46µl DNA with Qiagen MinElute (cat. 28004) and elute in 15µl
Qiagen EB.
10. Nanodrop and store at -20 prior to Solexa sequencing. Typical nanodrop
yields post amplification and MinElute purification are 170-270 ng / µl, 15 µl total
volume in Qiagen EB.
237

REFERENCES
Abmayr, S.M., and Workman, J.L. (2003). Transcription factors prominently in
Lasker Award to Roeder. Cell 115, 243-246.
Adams, P.D. (2007). Remodeling of chromatin structure in senescent cells and its
potential impact on tumor suppression and aging. Gene 397, 84-93.
Ahmad, K., and Henikoff, S. (2002). The histone variant H3.3 marks active chromatin
by replication-independent nucleosome assembly. Mol Cell 9, 1191-1200.
Alaiya, A., Al-Mohanna, M., and Linder, S. (2005). Clinical cancer proteomics:
promises and pitfalls. J Proteome Res 4, 1213-1222.
Alberts, B. (2002). Molecular biology of the cell, 4th edn (New York, Garland
Science).
Albig, W., Bramlage, B., Gruber, K., Klobeck, H.G., Kunz, J., and Doenecke, D.
(1995). The human replacement histone H3.3B gene (H3F3B). Genomics 30, 264272.
Albig, W., and Doenecke, D. (1997). The human histone gene cluster at the D6S105
locus. Hum Genet 101, 284-294.
Allfrey, V.G., Faulkner, R., and Mirsky, A.E. (1964). Acetylation and Methylation of
Histones and Their Possible Role in the Regulation of Rna Synthesis. Proc Natl
Acad Sci U S A 51, 786-794.
Allfrey, V.G., Littau, V.C., and Mirsky, A.E. (1963). On the role of of histones in
regulation ribonucleic acid synthesis in the cell nucleus. Proc Natl Acad Sci U S A
49, 414-421.
Allis, C.D., Glover, C.V., Bowen, J.K., and Gorovsky, M.A. (1980). Histone variants
specific to the transcriptionally active, amitotically dividing macronucleus of the
unicellular eucaryote, Tetrahymena thermophila. Cell 20, 609-617.
Allis, C.D., Jenuwein, T., Reinberg, D., and Caparros, M.L., eds. (2007). Epigenetics
(Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press).
Allis, C.D., Richman, R., Gorovsky, M.A., Ziegler, Y.S., Touchstone, B., Bradley,
W.A., and Cook, R.G. (1986). hv1 is an evolutionarily conserved H2A variant that
is preferentially associated with active genes. J Biol Chem 261, 1941-1948.
Allis, C.D., Ziegler, Y.S., Gorovsky, M.A., and Olmsted, J.B. (1982). A conserved
histone variant enriched in nucleoli of mammalian cells. Cell 31, 131-136.

238

Allsopp, R.C., Vaziri, H., Patterson, C., Goldstein, S., Younglai, E.V., Futcher,
A.B., Greider, C.W., and Harley, C.B. (1992). Telomere length predicts replicative
capacity of human fibroblasts. Proc Natl Acad Sci U S A 89, 10114-10118.
Almouzni, G., and Mechali, M. (1988). Assembly of spaced chromatin promoted by
DNA synthesis in extracts from Xenopus eggs. Embo J 7, 665-672.
Anderson, H.E., Wardle, J., Korkut, S.V., Murton, H.E., Lopez-Maury, L., Bahler, J.,
and Whitehall, S.K. (2009). The fission yeast HIRA histone chaperone is required
for promoter silencing and the suppression of cryptic antisense transcripts. Mol
Cell Biol 29, 5158-5167.
Argentaro, A., Yang, J.C., Chapman, L., Kowalczyk, M.S., Gibbons, R.J., Higgs,
D.R., Neuhaus, D., and Rhodes, D. (2007). Structural consequences of diseasecausing mutations in the ATRX-DNMT3-DNMT3L (ADD) domain of the chromatinassociated protein ATRX. Proc Natl Acad Sci U S A 104, 11939-11944.
Armstrong, J.A. (2007). Negotiating the nucleosome: factors that allow RNA
polymerase II to elongate through chromatin. Biochem Cell Biol 85, 426-434.
Avery, O.T., MacLeod, C.M., and McCarty, M. (1979). Studies on the chemical
nature of the substance inducing transformation of pneumococcal types. Inductions
of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus
type III. J Exp Med 149, 297-326.
Azzalin, C.M., and Lingner, J. (2008). Telomeres: the silence is broken. Cell Cycle
7, 1161-1165.
Azzalin, C.M., Reichenbach, P., Khoriauli, L., Giulotto, E., and Lingner, J. (2007).
Telomeric repeat containing RNA and RNA surveillance factors at mammalian
chromosome ends. Science 318, 798-801.
Banaszynski, L.A., Chen, L.C., Maynard-Smith, L.A., Ooi, A.G., and Wandless, T.J.
(2006). A rapid, reversible, and tunable method to regulate protein function in living
cells using synthetic small molecules. Cell 126, 995-1004.
Bannister, A.J., Schneider, R., Myers, F.A., Thorne, A.W., Crane-Robinson, C., and
Kouzarides, T. (2005). Spatial distribution of di- and tri-methyl lysine 36 of histone
H3 at active genes. J Biol Chem 280, 17732-17736.
Bao, Y., and Shen, X. (2006). Asf1, a loveseat for a histone couple. Cell 127, 458460.
Barman, H.K., Takami, Y., Nishijima, H., Shibahara, K., Sanematsu, F., and
Nakayama, T. (2006). Histone acetyltransferase-1 regulates integrity of cytosolic
histone H3-H4 containing complex. Biochem Biophys Res Commun 373, 624239

630.
Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G.,
Chepelev, I., and Zhao, K. (2007). High-resolution profiling of histone methylations
in the human genome. Cell 129, 823-837.
Barski, A., and Zhao, K. (2009). Genomic location analysis by ChIP-Seq. J Cell
Biochem.
Baxevanis, A.D., Godfrey, J.E., and Moudrianakis, E.N. (1991). Associative behavior
of the histone (H3-H4)2 tetramer: dependence on ionic environment. Biochemistry
30, 8817-8823.
Bernstein, B.E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D.K., Huebert,
D.J., McMahon, S., Karlsson, E.K., Kulbokas, E.J., 3rd, Gingeras, T.R., et al. (2005).
Genomic maps and comparative analysis of histone modifications in human and
mouse. Cell 120, 169-181.
Bernstein, B.E., Meissner, A., and Lander, E.S. (2007). The mammalian epigenome.
Cell 128, 669-681.
Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B.,
Meissner, A., Wernig, M., Plath, K., et al. (2006a). A bivalent chromatin structure
marks key developmental genes in embryonic stem cells. Cell 125, 315-326.
Bernstein, E., and Allis, C.D. (2005). RNA meets chromatin. Genes Dev 19, 16351655.
Bernstein, E., Duncan, E.M., Masui, O., Gil, J., Heard, E., and Allis, C.D. (2006b).
Mouse polycomb proteins bind differentially to methylated histone H3 and RNA
and are enriched in facultative heterochromatin. Molecular and cellular biology 26,
2560-2569.
Biddick, R., and Young, E.T. (2005). Yeast mediator and its role in transcriptional
regulation. C R Biol 328, 773-782.
Black, J.C., Choi, J.E., Lombardo, S.R., and Carey, M. (2006). A mechanism for
coordinating chromatin modification and preinitiation complex assembly. Mol Cell
23, 809-818.
Blackburn, E.H., Greider, C.W., and Szostak, J.W. (2006). Telomeres and
telomerase: the path from maize, Tetrahymena and yeast to human cancer and
aging. Nat Med 12, 1133-1138.
Blackwell, C., Martin, K.A., Greenall, A., Pidoux, A., Allshire, R.C., and Whitehall,
S.K. (2004). The Schizosaccharomyces pombe HIRA-like protein Hip1 is required
240

for the periodic expression of histone genes and contributes to the function of
complex centromeres. Mol Cell Biol 24, 4309-4320.
Blasco, M.A. (2007). The epigenetic regulation of mammalian telomeres. Nat Rev
Genet 8, 299-309.
Blethrow, J.D., Tang, C., Deng, C., and Krutchinsky, A.N. (2007). Modular mass
spectrometric tool for analysis of composition and phosphorylation of protein
complexes. PLoS One 2, e358.
Bloom, G., Yang, I.V., Boulware, D., Kwong, K.Y., Coppola, D., Eschrich, S.,
Quackenbush, J., and Yeatman, T.J. (2004). Multi-platform, multi-site, microarraybased human tumor classification. Am J Pathol 164, 9-16.
Bodnar, A.G., Ouellette, M., Frolkis, M., Holt, S.E., Chiu, C.P., Morin, G.B., Harley,
C.B., Shay, J.W., Lichtsteiner, S., and Wright, W.E. (1998). Extension of life-span
by introduction of telomerase into normal human cells. Science 279, 349-352.
Bonnefoy, E., Orsi, G.A., Couble, P., and Loppin, B. (2007). The essential role of
Drosophila HIRA for de novo assembly of paternal chromatin at fertilization. PLoS
Genet 3, 1991-2006.
Borrelli, E., Nestler, E.J., Allis, C.D., and Sassone-Corsi, P. (2008). Decoding the
epigenetic language of neuronal plasticity. Neuron 60, 961-974.
Boyer, L.A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L.A., Lee, T.I., Levine,
S.S., Wernig, M., Tajonar, A., Ray, M.K., et al. (2006). Polycomb complexes repress
developmental regulators in murine embryonic stem cells. Nature 441, 349-353.
Bramlage, B., Kosciessa, U., and Doenecke, D. (1997). Differential expression of
the murine histone genes H3.3A and H3.3B. Differentiation 62, 13-20.
Briggs, S.D., Bryk, M., Strahl, B.D., Cheung, W.L., Davie, J.K., Dent, S.Y., Winston,
F., and Allis, C.D. (2001). Histone H3 lysine 4 methylation is mediated by Set1 and
required for cell growth and rDNA silencing in Saccharomyces cerevisiae. Genes
Dev 15, 3286-3295.
Brodsky, A.S., Meyer, C.A., Swinburne, I.A., Hall, G., Keenan, B.J., Liu, X.S., Fox,
E.A., and Silver, P.A. (2005). Genomic mapping of RNA polymerase II reveals sites
of co-transcriptional regulation in human cells. Genome Biol 6, R64.
Brownell, J.E., and Allis, C.D. (1995). An activity gel assay detects a single,
catalytically active histone acetyltransferase subunit in Tetrahymena macronuclei.
Proc Natl Acad Sci U S A 92, 6364-6368.
Brownell, J.E., Zhou, J., Ranalli, T., Kobayashi, R., Edmondson, D.G., Roth, S.Y.,
241

and Allis, C.D. (1996). Tetrahymena histone acetyltransferase A: a homolog to
yeast Gcn5p linking histone acetylation to gene activation. Cell 84, 843-851.
Burdon, T., Smith, A., and Savatier, P. (2002). Signalling, cell cycle and pluripotency
in embryonic stem cells. Trends Cell Biol 12, 432-438.
Buschbeck, M., Uribesalgo, I., Wibowo, I., Rue, P., Martin, D., Gutierrez, A., Morey,
L., Guigo, R., Lopez-Schier, H., and Di Croce, L. (2009). The histone variant
macroH2A is an epigenetic regulator of key developmental genes. Nat Struct Mol
Biol.
Bustin, M., and Cole, R.D. (1968). Species and organ specificity in very lysine-rich
histones. J Biol Chem 243, 4500-4505.
Butler, J.T., Hall, L.L., Smith, K.P., and Lawrence, J.B. (2009). Changing nuclear
landscape and unique PML structures during early epigenetic transitions of human
embryonic stem cells. J Cell Biochem 107, 609-621.
Campbell, K.H., McWhir, J., Ritchie, W.A., and Wilmut, I. (1996). Sheep cloned by
nuclear transfer from a cultured cell line. Nature 380, 64-66.
Carmo-Fonseca, M. (2002). The contribution of nuclear compartmentalization to
gene regulation. Cell 108, 513-521.
Carozzi, N., Marashi, F., Plumb, M., Zimmerman, S., Zimmerman, A., Coles, L.S.,
Wells, J.R., Stein, G., and Stein, J. (1984). Clustering of human H1 and core histone
genes. Science 224, 1115-1117.
Carroll, D. (2008). Progress and prospects: zinc-finger nucleases as gene therapy
agents. Gene Ther 15, 1463-1468.
Carrozza, M.J., Li, B., Florens, L., Suganuma, T., Swanson, S.K., Lee, K.K., Shia,
W.J., Anderson, S., Yates, J., Washburn, M.P., et al. (2005). Histone H3 methylation
by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious
intragenic transcription. Cell 123, 581-592.
Celeste, A., Petersen, S., Romanienko, P.J., Fernandez-Capetillo, O., Chen, H.T.,
Sedelnikova, O.A., Reina-San-Martin, B., Coppola, V., Meffre, E., Difilippantonio,
M.J., et al. (2002). Genomic instability in mice lacking histone H2AX. Science 296,
922-927.
Chahrour, M., and Zoghbi, H.Y. (2007). The story of Rett syndrome: from clinic to
neurobiology. Neuron 56, 422-437.
Chang, C.C., Lin, D.Y., Fang, H.I., Chen, R.H., and Shih, H.M. (2005). Daxx
mediates the small ubiquitin-like modifier-dependent transcriptional repression of
242

Smad4. J Biol Chem 280, 10164-10173.
Chasis, J.A., and Mohandas, N. (2008). Erythroblastic islands: niches for
erythropoiesis. Blood 112, 470-478.
Chen, C.C., Carson, J.J., Feser, J., Tamburini, B., Zabaronick, S., Linger, J., and
Tyler, J.K. (2008a). Acetylated lysine 56 on histone H3 drives chromatin assembly
after repair and signals for the completion of repair. Cell 134, 231-243.
Chen, X., Xu, H., Yuan, P., Fang, F., Huss, M., Vega, V.B., Wong, E., Orlov, Y.L.,
Zhang, W., Jiang, J., et al. (2008b). Integration of external signaling pathways with
the core transcriptional network in embryonic stem cells. Cell 133, 1106-1117.
Chew, J.L., Loh, Y.H., Zhang, W., Chen, X., Tam, W.L., Yeap, L.S., Li, P., Ang, Y.S.,
Lim, B., Robson, P., et al. (2005). Reciprocal transcriptional regulation of Pou5f1
and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 25,
6031-6046.
Chi, A.S., and Bernstein, B.E. (2009). Developmental biology. Pluripotent chromatin
state. Science 323, 220-221.
Chow, C.M., Georgiou, A., Szutorisz, H., Maia e Silva, A., Pombo, A., Barahona,
I., Dargelos, E., Canzonetta, C., and Dillon, N. (2005). Variant histone H3.3 marks
promoters of transcriptionally active genes during mammalian cell division. EMBO
Rep 6, 354-360.
Chow, J., and Heard, E. (2009). X inactivation and the complexities of silencing a
sex chromosome. Curr Opin Cell Biol 21, 359-366.
Clapier, C.R., and Cairns, B.R. (2009). The biology of chromatin remodeling
complexes. Annual review of biochemistry 78, 273-304.
Cloonan, N., Forrest, A.R., Kolle, G., Gardiner, B.B., Faulkner, G.J., Brown, M.K.,
Taylor, D.F., Steptoe, A.L., Wani, S., Bethel, G., et al. (2008). Stem cell transcriptome
profiling via massive-scale mRNA sequencing. Nat Methods 5, 613-619.
Conti, L., Pollard, S.M., Gorba, T., Reitano, E., Toselli, M., Biella, G., Sun, Y.,
Sanzone, S., Ying, Q.L., Cattaneo, E., et al. (2005). Niche-independent symmetrical
self-renewal of a mammalian tissue stem cell. PLoS Biol 3, e283.
Couldrey, C., Carlton, M.B., Nolan, P.M., Colledge, W.H., and Evans, M.J. (1999).
A retroviral gene trap insertion into the histone 3.3A gene causes partial neonatal
lethality, stunted growth, neuromuscular deficits and male sub-fertility in transgenic
mice. Hum Mol Genet 8, 2489-2495.
Creyghton, M.P., Markoulaki, S., Levine, S.S., Hanna, J., Lodato, M.A., Sha, K.,
243

Young, R.A., Jaenisch, R., and Boyer, L.A. (2008). H2AZ is enriched at polycomb
complex target genes in ES cells and is necessary for lineage commitment. Cell
135, 649-661.
Cristea, I.M., Williams, R., Chait, B.T., and Rout, M.P. (2005). Fluorescent proteins
as proteomic probes. Mol Cell Proteomics 4, 1933-1941.
Croxton, R., Puto, L.A., de Belle, I., Thomas, M., Torii, S., Hanaii, F., Cuddy, M.,
and Reed, J.C. (2006). Daxx represses expression of a subset of antiapoptotic
genes regulated by nuclear factor-kappaB. Cancer Res 66, 9026-9035.
Cui, B., Liu, Y., and Gorovsky, M.A. (2006). Deposition and function of histone H3
variants in Tetrahymena thermophila. Mol Cell Biol 26, 7719-7730.
Cuzin, F., Grandjean, V., and Rassoulzadegan, M. (2008). Inherited variation at the
epigenetic level: paramutation from the plant to the mouse. Curr Opin Genet Dev
18, 193-196.
Daury, L., Chailleux, C., Bonvallet, J., and Trouche, D. (2006). Histone H3.3
deposition at E2F-regulated genes is linked to transcription. EMBO Rep 7, 66-71.
Davey, C.A., Sargent, D.F., Luger, K., Maeder, A.W., and Richmond, T.J. (2002).
Solvent mediated interactions in the structure of the nucleosome core particle at
1.9 a resolution. J Mol Biol 319, 1097-1113.
de Jonge, H.J., Fehrmann, R.S., de Bont, E.S., Hofstra, R.M., Gerbens, F., Kamps,
W.A., de Vries, E.G., van der Zee, A.G., te Meerman, G.J., and ter Elst, A. (2007).
Evidence based selection of housekeeping genes. PLoS One 2, e898.
De Koning, L., Corpet, A., Haber, J.E., and Almouzni, G. (2007). Histone chaperones:
an escort network regulating histone traffic. Nat Struct Mol Biol 14, 997-1007.
Dehe, P.M., and Geli, V. (2006). The multiple faces of Set1. Biochem Cell Biol 84,
536-548.
Deng, C., and Capecchi, M.R. (1992). Reexamination of gene targeting frequency
as a function of the extent of homology between the targeting vector and the target
locus. Mol Cell Biol 12, 3365-3371.
Dhalluin, C., Carlson, J.E., Zeng, L., He, C., Aggarwal, A.K., and Zhou, M.M.
(1999). Structure and ligand of a histone acetyltransferase bromodomain. Nature
399, 491-496.
Dobosy, J.R., and Selker, E.U. (2001). Emerging connections between DNA
methylation and histone acetylation. Cell Mol Life Sci 58, 721-727.

244

Doyon, Y., McCammon, J.M., Miller, J.C., Faraji, F., Ngo, C., Katibah, G.E., Amora,
R., Hocking, T.D., Zhang, L., Rebar, E.J., et al. (2008). Heritable targeted gene
disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 26,
702-708.
Drabent, B., Bode, C., Bramlage, B., and Doenecke, D. (1996). Expression of the
mouse testicular histone gene H1t during spermatogenesis. Histochem Cell Biol
106, 247-251.
Duncan, E.M., Muratore-Schroeder, T.L., Cook, R.G., Garcia, B.A., Shabanowitz,
J., Hunt, D.F., and Allis, C.D. (2008). Cathepsin L proteolytically processes histone
H3 during mouse embryonic stem cell differentiation. Cell 135, 284-294.
Durrin, L.K., Mann, R.K., Kayne, P.S., and Grunstein, M. (1991). Yeast histone
H4 N-terminal sequence is required for promoter activation in vivo. Cell 65, 10231031.
Efroni, S., Duttagupta, R., Cheng, J., Dehghani, H., Hoeppner, D.J., Dash, C.,
Bazett-Jones, D.P., Le Grice, S., McKay, R.D., Buetow, K.H., et al. (2008). Global
transcription in pluripotent embryonic stem cells. Cell Stem Cell 2, 437-447.
Eggan, K., Akutsu, H., Loring, J., Jackson-Grusby, L., Klemm, M., Rideout, W.M.,
3rd, Yanagimachi, R., and Jaenisch, R. (2001). Hybrid vigor, fetal overgrowth, and
viability of mice derived by nuclear cloning and tetraploid embryo complementation.
Proc Natl Acad Sci U S A 98, 6209-6214.
Elliott, B., Richardson, C., Winderbaum, J., Nickoloff, J.A., and Jasin, M. (1998).
Gene conversion tracts from double-strand break repair in mammalian cells. Mol
Cell Biol 18, 93-101.
Engelke, D.R., Ng, S.Y., Shastry, B.S., and Roeder, R.G. (1980). Specific interaction
of a purified transcription factor with an internal control region of 5S RNA genes.
Cell 19, 717-728.
English, C.M., Adkins, M.W., Carson, J.J., Churchill, M.E., and Tyler, J.K. (2006).
Structural basis for the histone chaperone activity of Asf1. Cell 127, 495-508.
Ezhkova, E., Pasolli, H.A., Parker, J.S., Stokes, N., Su, I.H., Hannon, G.,
Tarakhovsky, A., and Fuchs, E. (2009). Ezh2 orchestrates gene expression for the
stepwise differentiation of tissue-specific stem cells. Cell 136, 1122-1135.
Fagiolini, M., Jensen, C.L., and Champagne, F.A. (2009). Epigenetic influences on
brain development and plasticity. Curr Opin Neurobiol 19, 207-212.
Fan, Y., Nikitina, T., Morin-Kensicki, E.M., Zhao, J., Magnuson, T.R., Woodcock,
C.L., and Skoultchi, A.I. (2003). H1 linker histones are essential for mouse
245

development and affect nucleosome spacing in vivo. Mol Cell Biol 23, 4559-4572.
Fan, Y., Nikitina, T., Zhao, J., Fleury, T.J., Bhattacharyya, R., Bouhassira, E.E.,
Stein, A., Woodcock, C.L., and Skoultchi, A.I. (2005). Histone H1 depletion in
mammals alters global chromatin structure but causes specific changes in gene
regulation. Cell 123, 1199-1212.
Farnham, P.J. (2009). Insights from genomic profiling of transcription factors. Nat
Rev Genet 10, 605-616.
Feil, R. (2009). Epigenetic asymmetry in the zygote and mammalian development.
Int J Dev Biol 53, 191-201.
Felsenfeld, G., and Groudine, M. (2003). Controlling the double helix. Nature 421,
448-453.
Fernandez-Capetillo, O., Lee, A., Nussenzweig, M., and Nussenzweig, A. (2004).
H2AX: the histone guardian of the genome. DNA Repair (Amst) 3, 959-967.
Field, Y., Fondufe-Mittendorf, Y., Moore, I.K., Mieczkowski, P., Kaplan, N., Lubling,
Y., Lieb, J.D., Widom, J., and Segal, E. (2009). Gene expression divergence in
yeast is coupled to evolution of DNA-encoded nucleosome organization. Nat Genet
41, 438-445.
Fillingham, J., and Greenblatt, J.F. (2008). A histone code for chromatin assembly.
Cell 134, 206-208.
Fischle, W., Tseng, B.S., Dormann, H.L., Ueberheide, B.M., Garcia, B.A.,
Shabanowitz, J., Hunt, D.F., Funabiki, H., and Allis, C.D. (2005). Regulation of
HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature
438, 1116-1122.
Flemming, W. (1882). Zellsubstanz, Kern und Zelltheilung ... Mit ... Tafeln (pp. viii.
424. Leipzig).
Frank, D., Doenecke, D., and Albig, W. (2003). Differential expression of human
replacement and cell cycle dependent H3 histone genes. Gene 312, 135-143.
Franklin, S.G., and Zweidler, A. (1977). Non-allelic variants of histones 2a, 2b and
3 in mammals. Nature 266, 273-275.
Freitag, M., and Selker, E.U. (2005). Controlling DNA methylation: many roads to
one modification. Current opinion in genetics & development 15, 191-199.
Gaillard, P.H., Martini, E.M., Kaufman, P.D., Stillman, B., Moustacchi, E., and
Almouzni, G. (1996). Chromatin assembly coupled to DNA repair: a new role for
246

chromatin assembly factor I. Cell 86, 887-896.
Gaillard, P.H., Roche, D., and Almouzni, G. (1999). Nucleotide excision repair
coupled to chromatin assembly. Methods Mol Biol 119, 231-243.
Galvani, A., Courbeyrette, R., Agez, M., Ochsenbein, F., Mann, C., and Thuret,
J.Y. (2008). In vivo study of the nucleosome assembly functions of ASF1 histone
chaperones in human cells. Mol Cell Biol 28, 3672-3685.
Garrick, D., Sharpe, J.A., Arkell, R., Dobbie, L., Smith, A.J., Wood, W.G., Higgs,
D.R., and Gibbons, R.J. (2006). Loss of Atrx affects trophoblast development and
the pattern of X-inactivation in extraembryonic tissues. PLoS Genet 2, e58.
Gaspar-Maia, A., Alajem, A., Polesso, F., Sridharan, R., Mason, M.J., Heidersbach,
A., Ramalho-Santos, J., McManus, M.T., Plath, K., Meshorer, E., et al. (2009).
Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature
460, 863-868.
Gatewood, J.M., Cook, G.R., Balhorn, R., Schmid, C.W., and Bradbury, E.M.
(1990). Isolation of four core histones from human sperm chromatin representing
a minor subset of somatic histones. J Biol Chem 265, 20662-20666.
Geiser, M., Cebe, R., Drewello, D., and Schmitz, R. (2001). Integration of PCR
fragments at any specific site within cloning vectors without the use of restriction
enzymes and DNA ligase. Biotechniques 31, 88-90, 92.
Gibbons, R. (2006). Alpha thalassaemia-mental retardation, X linked. Orphanet J
Rare Dis 1, 15.
Gibbons, R.J., McDowell, T.L., Raman, S., O’Rourke, D.M., Garrick, D., Ayyub,
H., and Higgs, D.R. (2000). Mutations in ATRX, encoding a SWI/SNF-like protein,
cause diverse changes in the pattern of DNA methylation. Nat Genet 24, 368371.
Gibbons, R.J., Wada, T., Fisher, C.A., Malik, N., Mitson, M.J., Steensma, D.P.,
Fryer, A., Goudie, D.R., Krantz, I.D., and Traeger-Synodinos, J. (2008). Mutations
in the chromatin-associated protein ATRX. Hum Mutat 29, 796-802.
Girton, J.R., and Johansen, K.M. (2008). Chromatin structure and the regulation of
gene expression: the lessons of PEV in Drosophila. Adv Genet 61, 1-43.
Goldberg, A.D., Allis, C.D., and Bernstein, E. (2007). Epigenetics: a landscape
takes shape. Cell 128, 635-638.
Goll, M.G., and Bestor, T.H. (2005). Eukaryotic cytosine methyltransferases. Annual
review of biochemistry 74, 481-514.
247

Govin, J., Caron, C., Lestrat, C., Rousseaux, S., and Khochbin, S. (2004). The
role of histones in chromatin remodelling during mammalian spermiogenesis. Eur
J Biochem 271, 3459-3469.
Green, E.M., Antczak, A.J., Bailey, A.O., Franco, A.A., Wu, K.J., Yates, J.R., 3rd,
and Kaufman, P.D. (2005). Replication-independent histone deposition by the HIR
complex and Asf1. Curr Biol 15, 2044-2049.
Grewal, S.I., and Jia, S. (2007). Heterochromatin revisited. Nature reviews 8, 3546.
Groth, A., Corpet, A., Cook, A.J., Roche, D., Bartek, J., Lukas, J., and Almouzni,
G. (2007a). Regulation of replication fork progression through histone supply and
demand. Science 318, 1928-1931.
Groth, A., Rocha, W., Verreault, A., and Almouzni, G. (2007b). Chromatin challenges
during DNA replication and repair. Cell 128, 721-733.
Grummt, I. (2003). Life on a planet of its own: regulation of RNA polymerase I
transcription in the nucleolus. Genes Dev 17, 1691-1702.
Guenther, M.G., Jenner, R.G., Chevalier, B., Nakamura, T., Croce, C.M.,
Canaani, E., and Young, R.A. (2005). Global and Hox-specific roles for the MLL1
methyltransferase. Proc Natl Acad Sci U S A 102, 8603-8608.
Guenther, M.G., Levine, S.S., Boyer, L.A., Jaenisch, R., and Young, R.A. (2007). A
chromatin landmark and transcription initiation at most promoters in human cells.
Cell 130, 77-88.
Gurdon, J.B., and Byrne, J.A. (2003). The first half-century of nuclear transplantation.
Proc Natl Acad Sci U S A 100, 8048-8052.
Gurdon, J.B., and Melton, D.A. (2008). Nuclear reprogramming in cells. Science
322, 1811-1815.
Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., Huarte, M.,
Zuk, O., Carey, B.W., Cassady, J.P., et al. (2009). Chromatin signature reveals
over a thousand highly conserved large non-coding RNAs in mammals. Nature
458, 223-227.
Hadjantonakis, A.K., and Papaioannou, V.E. (2004). Dynamic in vivo imaging and
cell tracking using a histone fluorescent protein fusion in mice. BMC Biotechnol 4,
33.
Hajkova, P., Ancelin, K., Waldmann, T., Lacoste, N., Lange, U.C., Cesari, F., Lee,
C., Almouzni, G., Schneider, R., and Surani, M.A. (2008). Chromatin dynamics
248

during epigenetic reprogramming in the mouse germ line. Nature 452, 877-881.
Hajkova, P., Erhardt, S., Lane, N., Haaf, T., El-Maarri, O., Reik, W., Walter, J., and
Surani, M.A. (2002). Epigenetic reprogramming in mouse primordial germ cells.
Mech Dev 117, 15-23.
Hake, S.B., and Allis, C.D. (2006). Histone H3 variants and their potential role in
indexing mammalian genomes: The “H3 barcode hypothesis”. Proc Natl Acad Sci
U S A.
Hake, S.B., Garcia, B.A., Duncan, E.M., Kauer, M., Dellaire, G., Shabanowitz, J.,
Bazett-Jones, D.P., Allis, C.D., and Hunt, D.F. (2006). Expression patterns and
post-translational modifications associated with mammalian histone H3 variants. J
Biol Chem 281, 559-568.
Hake, S.B., Garcia, B.A., Kauer, M., Baker, S.P., Shabanowitz, J., Hunt, D.F., and
Allis, C.D. (2005). Serine 31 phosphorylation of histone variant H3.3 is specific to
regions bordering centromeres in metaphase chromosomes. Proc Natl Acad Sci U
S A 102, 6344-6349.
Hammoud, S.S., Nix, D.A., Zhang, H., Purwar, J., Carrell, D.T., and Cairns,
B.R. (2009). Distinctive chromatin in human sperm packages genes for embryo
development. Nature 460, 473-478.
Handel, M.A. (2004). The XY body: a specialized meiotic chromatin domain. Exp
Cell Res 296, 57-63.
Happel, N., and Doenecke, D. (2009). Histone H1 and its isoforms: contribution to
chromatin structure and function. Gene 431, 1-12.
Harley, C.B., Futcher, A.B., and Greider, C.W. (1990). Telomeres shorten during
ageing of human fibroblasts. Nature 345, 458-460.
Hasty, P., Rivera-Perez, J., and Bradley, A. (1991). The length of homology required
for gene targeting in embryonic stem cells. Mol Cell Biol 11, 5586-5591.
Hayashi, K., and Surani, M.A. (2009). Resetting the epigenome beyond pluripotency
in the germline. Cell Stem Cell 4, 493-498.
Heard, E. (2005). Delving into the diversity of facultative heterochromatin:
the epigenetics of the inactive X chromosome. Current opinion in genetics &
development 15, 482-489.
Hebbes, T.R., Thorne, A.W., and Crane-Robinson, C. (1988). A direct link between
core histone acetylation and transcriptionally active chromatin. Embo J 7, 13951402.
249

Heintz, N., Zernik, M., and Roeder, R.G. (1981). The structure of the human histone
genes: clustered but not tandemly repeated. Cell 24, 661-668.
Heintzman, N.D., Hon, G.C., Hawkins, R.D., Kheradpour, P., Stark, A., Harp, L.F.,
Ye, Z., Lee, L.K., Stuart, R.K., Ching, C.W., et al. (2009). Histone modifications at
human enhancers reflect global cell-type-specific gene expression. Nature 459,
108-112.
Heintzman, N.D., Stuart, R.K., Hon, G., Fu, Y., Ching, C.W., Hawkins, R.D., Barrera,
L.O., Van Calcar, S., Qu, C., Ching, K.A., et al. (2007). Distinct and predictive
chromatin signatures of transcriptional promoters and enhancers in the human
genome. Nat Genet 39, 311-318.
Hemberger, M., Dean, W., and Reik, W. (2009). Epigenetic dynamics of stem cells
and cell lineage commitment: digging Waddington’s canal. Nat Rev Mol Cell Biol
10, 526-537.
Henikoff, S. (2008). Nucleosome destabilization in the epigenetic regulation of
gene expression. Nat Rev Genet 9, 15-26.
Henikoff, S., and Ahmad, K. (2005). Assembly of variant histones into chromatin.
Annu Rev Cell Dev Biol 21, 133-153.
Henikoff, S., Henikoff, J.G., Sakai, A., Loeb, G.B., and Ahmad, K. (2009). Genomewide profiling of salt fractions maps physical properties of chromatin. Genome Res
19, 460-469.
Higgs, D.R., Garrick, D., Anguita, E., De Gobbi, M., Hughes, J., Muers, M.,
Vernimmen, D., Lower, K., Law, M., Argentaro, A., et al. (2005). Understanding
alpha-globin gene regulation: Aiming to improve the management of thalassemia.
Ann N Y Acad Sci 1054, 92-102.
Ho, L., and Crabtree, G.R. (2008). An EZ mark to miss. Cell Stem Cell 3, 577578.
Ho, L., Jothi, R., Ronan, J.L., Cui, K., Zhao, K., and Crabtree, G.R. (2009a).
An embryonic stem cell chromatin remodeling complex, esBAF, is an essential
component of the core pluripotency transcriptional network. Proc Natl Acad Sci U
S A.
Ho, L., Ronan, J.L., Wu, J., Staahl, B.T., Chen, L., Kuo, A., Lessard, J., Nesvizhskii,
A.I., Ranish, J., and Crabtree, G.R. (2009b). An embryonic stem cell chromatin
remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and
pluripotency. Proc Natl Acad Sci U S A 106, 5181-5186.
Hodl, M., and Basler, K. (2009). Transcription in the Absence of Histone H3.3. Curr
250

Biol.
Hogan, B. (2007). A shared vision. Dev Cell 13, 769-771.
Hollenbach, A.D., McPherson, C.J., Mientjes, E.J., Iyengar, R., and Grosveld,
G. (2002). Daxx and histone deacetylase II associate with chromatin through an
interaction with core histones and the chromatin-associated protein Dek. J Cell Sci
115, 3319-3330.
Hong, L., Schroth, G.P., Matthews, H.R., Yau, P., and Bradbury, E.M. (1993). Studies
of the DNA binding properties of histone H4 amino terminus. Thermal denaturation
studies reveal that acetylation markedly reduces the binding constant of the H4
“tail” to DNA. J Biol Chem 268, 305-314.
Howman, E.V., Fowler, K.J., Newson, A.J., Redward, S., MacDonald, A.C., Kalitsis,
P., and Choo, K.H. (2000). Early disruption of centromeric chromatin organization
in centromere protein A (Cenpa) null mice. Proc Natl Acad Sci U S A 97, 11481153.
Huang, Y.S., and Shih, H.M. (2009). Daxx positively modulates beta-catenin/TCF4mediated transcriptional potential. Biochem Biophys Res Commun 386, 762-768.
Iguchi, N., Tanaka, H., Yomogida, K., and Nishimune, Y. (2003). Isolation and
characterization of a novel cDNA encoding a DNA-binding protein (Hils1) specifically
expressed in testicular haploid germ cells. Int J Androl 26, 354-365.
Ishov, A.M., Vladimirova, O.V., and Maul, G.G. (2004). Heterochromatin and ND10
are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of
the transcription repressor Daxx and SWI/SNF protein ATRX. J Cell Sci 117, 38073820.
Jacob, F., and Monod, J. (1961). Genetic regulatory mechanisms in the synthesis
of proteins. J Mol Biol 3, 318-356.
Jaenisch, R., and Young, R. (2008). Stem cells, the molecular circuitry of pluripotency
and nuclear reprogramming. Cell 132, 567-582.
Janicki, S.M., Tsukamoto, T., Salghetti, S.E., Tansey, W.P., Sachidanandam, R.,
Prasanth, K.V., Ried, T., Shav-Tal, Y., Bertrand, E., Singer, R.H., et al. (2004). From
silencing to gene expression: real-time analysis in single cells. Cell 116, 683-698.
Jenuwein, T., and Allis, C.D. (2001). Translating the histone code. Science 293,
1074-1080.
Jiang, C., and Pugh, B.F. (2009). Nucleosome positioning and gene regulation:
advances through genomics. Nat Rev Genet 10, 161-172.
251

Jin, C., and Felsenfeld, G. (2006). Distribution of histone H3.3 in hematopoietic cell
lineages. Proc Natl Acad Sci U S A 103, 574-579.
Jin, C., and Felsenfeld, G. (2007). Nucleosome stability mediated by histone
variants H3.3 and H2A.Z. Genes Dev 21, 1519-1529.
Jin, C., Zang, C., Wei, G., Cui, K., Peng, W., Zhao, K., and Felsenfeld, G. (2009).
H3.3/H2A.Z double variant-containing nucleosomes mark ‘nucleosome-free
regions’ of active promoters and other regulatory regions. Nat Genet.
Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger,
N., Strouboulis, J., and Wolffe, A.P. (1998). Methylated DNA and MeCP2 recruit
histone deacetylase to repress transcription. Nat Genet 19, 187-191.
Joshi, A.A., and Struhl, K. (2005). Eaf3 chromodomain interaction with methylated
H3-K36 links histone deacetylation to Pol II elongation. Mol Cell 20, 971-978.
Kacem, S., and Feil, R. (2009). Chromatin mechanisms in genomic imprinting.
Mamm Genome.
Kalitsis, P., Fowler, K.J., Earle, E., Griffiths, B., Howman, E., Newson, A.J., and
Choo, K.H. (2003). Partially functional Cenpa-GFP fusion protein causes increased
chromosome missegregation and apoptosis during mouse embryogenesis.
Chromosome Res 11, 345-357.
Kanoh, J., and Russell, P. (2000). Slm9, a novel nuclear protein involved in mitotic
control in fission yeast. Genetics 155, 623-631.
Keogh, M.C., Kim, J.A., Downey, M., Fillingham, J., Chowdhury, D., Harrison, J.C.,
Onishi, M., Datta, N., Galicia, S., Emili, A., et al. (2006). A phosphatase complex
that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery.
Nature 439, 497-501.
Keogh, M.C., Kurdistani, S.K., Morris, S.A., Ahn, S.H., Podolny, V., Collins, S.R.,
Schuldiner, M., Chin, K., Punna, T., Thompson, N.J., et al. (2005). Cotranscriptional
set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell
123, 593-605.
Khalil, A.M., Guttman, M., Huarte, M., Garber, M., Raj, A., Rivea Morales, D.,
Thomas, K., Presser, A., Bernstein, B.E., van Oudenaarden, A., et al. (2009). Many
human large intergenic noncoding RNAs associate with chromatin-modifying
complexes and affect gene expression. Proc Natl Acad Sci U S A 106, 1166711672.
Kim, T., and Buratowski, S. (2009). Dimethylation of H3K4 by Set1 recruits the
Set3 histone deacetylase complex to 5’ transcribed regions. Cell 137, 259-272.
252

Kinkade, J.M., Jr., and Cole, R.D. (1966). A structural comparison of different
lysine-rich histones of calf thymus. J Biol Chem 241, 5798-5805.
Klose, R.J., and Bird, A.P. (2006). Genomic DNA methylation: the mark and its
mediators. Trends Biochem Sci 31, 89-97.
Klug, A. (2005). Towards therapeutic applications of engineered zinc finger proteins.
FEBS Lett 579, 892-894.
Koch, F., Jourquin, F., Ferrier, P., and Andrau, J.C. (2008). Genome-wide RNA
polymerase II: not genes only! Trends Biochem Sci 33, 265-273.
Konev, A.Y., Tribus, M., Park, S.Y., Podhraski, V., Lim, C.Y., Emelyanov, A.V.,
Vershilova, E., Pirrotta, V., Kadonaga, J.T., Lusser, A., et al. (2007). CHD1 motor
protein is required for deposition of histone variant H3.3 into chromatin in vivo.
Science 317, 1087-1090.
Kornberg, R.D. (1974). Chromatin structure: a repeating unit of histones and DNA.
Science 184, 868-871.
Kornberg, R.D. (2005). Mediator and the mechanism of transcriptional activation.
Trends Biochem Sci 30, 235-239.
Kornberg, R.D., and Thomas, J.O. (1974). Chromatin structure; oligomers of the
histones. Science 184, 865-868.
Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693705.
Krimer, D.B., Cheng, G., and Skoultchi, A.I. (1993). Induction of H3.3 replacement
histone mRNAs during the precommitment period of murine erythroleukemia cell
differentiation. Nucleic Acids Res 21, 2873-2879.
Ku, M., Koche, R.P., Rheinbay, E., Mendenhall, E.M., Endoh, M., Mikkelsen, T.S.,
Presser, A., Nusbaum, C., Xie, X., Chi, A.S., et al. (2008). Genomewide analysis
of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS
Genet 4, e1000242.
Kuo, M.H., and Allis, C.D. (1999). In vivo cross-linking and immunoprecipitation for
studying dynamic Protein:DNA associations in a chromatin environment. Methods
19, 425-433.
Kurdistani, S.K., and Grunstein, M. (2003). Histone acetylation and deacetylation
in yeast. Nat Rev Mol Cell Biol 4, 276-284.
Kurimoto, K., Yabuta, Y., Ohinata, Y., Shigeta, M., Yamanaka, K., and Saitou, M.
253

(2008). Complex genome-wide transcription dynamics orchestrated by Blimp1 for
the specification of the germ cell lineage in mice. Genes Dev 22, 1617-1635.
Lachner, M., O’Carroll, D., Rea, S., Mechtler, K., and Jenuwein, T. (2001).
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature
410, 116-120.
Lamour, V., Lecluse, Y., Desmaze, C., Spector, M., Bodescot, M., Aurias, A., Osley,
M.A., and Lipinski, M. (1995). A human homolog of the S. cerevisiae HIR1 and HIR2
transcriptional repressors cloned from the DiGeorge syndrome critical region. Hum
Mol Genet 4, 791-799.
Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon,
K., Dewar, K., Doyle, M., FitzHugh, W., et al. (2001). Initial sequencing and analysis
of the human genome. Nature 409, 860-921.
Laskey, R.A., and Gurdon, J.B. (1970). Genetic content of adult somatic cells tested
by nuclear transplantation from cultured cells. Nature 228, 1332-1334.
Law, M. (2006). Targets and targeting of ATRX. In Medical Sciences Division
(University of Oxford), pp. 196.
Lee, D.Y., Hayes, J.J., Pruss, D., and Wolffe, A.P. (1993). A positive role for histone
acetylation in transcription factor access to nucleosomal DNA. Cell 72, 73-84.
Lee, J., Inoue, K., Ono, R., Ogonuki, N., Kohda, T., Kaneko-Ishino, T., Ogura,
A., and Ishino, F. (2002a). Erasing genomic imprinting memory in mouse clone
embryos produced from day 11.5 primordial germ cells. Development 129, 18071817.
Lee, T.I., Jenner, R.G., Boyer, L.A., Guenther, M.G., Levine, S.S., Kumar, R.M.,
Chevalier, B., Johnstone, S.E., Cole, M.F., Isono, K., et al. (2006a). Control of
developmental regulators by Polycomb in human embryonic stem cells. Cell 125,
301-313.
Lee, T.I., Johnstone, S.E., and Young, R.A. (2006b). Chromatin immunoprecipitation
and microarray-based analysis of protein location. Nat Protoc 1, 729-748.
Lee, T.I., Rinaldi, N.J., Robert, F., Odom, D.T., Bar-Joseph, Z., Gerber, G.K., Hannett,
N.M., Harbison, C.T., Thompson, C.M., Simon, I., et al. (2002b). Transcriptional
regulatory networks in Saccharomyces cerevisiae. Science 298, 799-804.
Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A.F.,
Boguski, M.S., Brockway, K.S., Byrnes, E.J., et al. (2007). Genome-wide atlas of
gene expression in the adult mouse brain. Nature 445, 168-176.

254

Lejnine, S., Makarov, V.L., and Langmore, J.P. (1995). Conserved nucleoprotein
structure at the ends of vertebrate and invertebrate chromosomes. Proc Natl Acad
Sci U S A 92, 2393-2397.
Levasseur, D.N., Wang, J., Dorschner, M.O., Stamatoyannopoulos, J.A., and Orkin,
S.H. (2008). Oct4 dependence of chromatin structure within the extended Nanog
locus in ES cells. Genes Dev 22, 575-580.
Levenson, J.M., and Sweatt, J.D. (2005). Epigenetic mechanisms in memory
formation. Nat Rev Neurosci 6, 108-118.
Levy, M.A., Fernandes, A.D., Tremblay, D.C., Seah, C., and Berube, N.G. (2008).
The SWI/SNF protein ATRX co-regulates pseudoautosomal genes that have
translocated to autosomes in the mouse genome. BMC Genomics 9, 468.
Levy, M.Z., Allsopp, R.C., Futcher, A.B., Greider, C.W., and Harley, C.B. (1992).
Telomere end-replication problem and cell aging. J Mol Biol 225, 951-960.
Li, B., Carey, M., and Workman, J.L. (2007a). The role of chromatin during
transcription. Cell 128, 707-719.
Li, B., Gogol, M., Carey, M., Lee, D., Seidel, C., and Workman, J.L. (2007b).
Combined action of PHD and chromo domains directs the Rpd3S HDAC to
transcribed chromatin. Science 316, 1050-1054.
Li, B., Gogol, M., Carey, M., Pattenden, S.G., Seidel, C., and Workman, J.L.
(2007c). Infrequently transcribed long genes depend on the Set2/Rpd3S pathway
for accurate transcription. Genes Dev 21, 1422-1430.
Li, Q., Zhou, H., Wurtele, H., Davies, B., Horazdovsky, B., Verreault, A., and
Zhang, Z. (2008). Acetylation of histone H3 lysine 56 regulates replication-coupled
nucleosome assembly. Cell 134, 244-255.
Lian, Z., Karpikov, A., Lian, J., Mahajan, M.C., Hartman, S., Gerstein, M., Snyder,
M., and Weissman, S.M. (2008). A genomic analysis of RNA polymerase II
modification and chromatin architecture related to 3’ end RNA polyadenylation.
Genome Res 18, 1224-1237.
Lieberman-Aiden, E., van Berkum, N.L., Williams, L., Imakaev, M., Ragoczy,
T., Telling, A., Amit, I., Lajoie, B.R., Sabo, P.J., Dorschner, M.O., et al. (2009).
Comprehensive mapping of long-range interactions reveals folding principles of
the human genome. Science 326, 289-293.
Litt, M., Qiu, Y., and Huang, S. (2009). Histone arginine methylations: their roles in
chromatin dynamics and transcriptional regulation. Biosci Rep 29, 131-141.

255

Lopez-Fernandez, L.A., Lopez-Alanon, D.M., Castaneda, V., Krimer, D.B., and del
Mazo, J. (1997). Developmental expression of H3.3A variant histone mRNA in
mouse. Int J Dev Biol 41, 699-703.
Loppin, B., Bonnefoy, E., Anselme, C., Laurencon, A., Karr, T.L., and Couble, P.
(2005). The histone H3.3 chaperone HIRA is essential for chromatin assembly in
the male pronucleus. Nature 437, 1386-1390.
Loppin, B., Docquier, M., Bonneton, F., and Couble, P. (2000). The maternal
effect mutation sesame affects the formation of the male pronucleus in Drosophila
melanogaster. Dev Biol 222, 392-404.
Lorain, S., Demczuk, S., Lamour, V., Toth, S., Aurias, A., Roe, B.A., and Lipinski,
M. (1996). Structural Organization of the WD repeat protein-encoding gene HIRA
in the DiGeorge syndrome critical region of human chromosome 22. Genome Res
6, 43-50.
Lorain, S., Quivy, J.P., Monier-Gavelle, F., Scamps, C., Lecluse, Y., Almouzni, G.,
and Lipinski, M. (1998). Core histones and HIRIP3, a novel histone-binding protein,
directly interact with WD repeat protein HIRA. Mol Cell Biol 18, 5546-5556.
Lord, K.A., Abdollahi, A., Hoffman-Liebermann, B., and Liebermann, D.A. (1990).
Dissection of the immediate early response of myeloid leukemia cells to terminal
differentiation and growth inhibitory stimuli. Cell Growth Differ 1, 637-645.
Loyola, A., and Almouzni, G. (2007). Marking histone H3 variants: how, when and
why? Trends Biochem Sci 32, 425-433.
Loyola, A., Bonaldi, T., Roche, D., Imhof, A., and Almouzni, G. (2006). PTMs on
H3 variants before chromatin assembly potentiate their final epigenetic state. Mol
Cell 24, 309-316.
Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F., and Richmond, T.J. (1997).
Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389,
251-260.
Luke, B., and Lingner, J. (2009). TERRA: telomeric repeat-containing RNA. EMBO
J.
Luke, B., Panza, A., Redon, S., Iglesias, N., Li, Z., and Lingner, J. (2008). The Rat1p
5’ to 3’ exonuclease degrades telomeric repeat-containing RNA and promotes
telomere elongation in Saccharomyces cerevisiae. Mol Cell 32, 465-477.
Luo, Y., Li, T., Yu, F., Kramer, T., and Cristea, I.M. (2009). Resolving the Composition
of Protein Complexes using a MALDI LTQ Orbitrap. Journal of the American Society
for Mass Spectrometry In press.
256

Luse, D.S., Haynes, J.R., VanLeeuwen, D., Schon, E.A., Cleary, M.L., Shapiro,
S.G., Lingrel, J.B., and Roeder, R.G. (1981). Transcription of the beta-like globin
genes and pseudogenes of the goat in a cell-free system. Nucleic Acids Res 9,
4339-4354.
Lusser, A., and Kadonaga, J.T. (2003). Chromatin remodeling by ATP-dependent
molecular machines. Bioessays 25, 1192-1200.
Magnaghi, P., Roberts, C., Lorain, S., Lipinski, M., and Scambler, P.J. (1998).
HIRA, a mammalian homologue of Saccharomyces cerevisiae transcriptional corepressors, interacts with Pax3. Nat Genet 20, 74-77.
Makarov, V.L., Lejnine, S., Bedoyan, J., and Langmore, J.P. (1993). Nucleosomal
organization of telomere-specific chromatin in rat. Cell 73, 775-787.
Malik, H.S., and Henikoff, S. (2003). Phylogenomics of the nucleosome. Nat Struct
Biol 10, 882-891.
Malik, S., and Roeder, R.G. (2005). Dynamic regulation of pol II transcription by
the mammalian Mediator complex. Trends Biochem Sci 30, 256-263.
Marion, R.M., Strati, K., Li, H., Tejera, A., Schoeftner, S., Ortega, S., Serrano, M.,
and Blasco, M.A. (2009). Telomeres acquire embryonic stem cell characteristics in
induced pluripotent stem cells. Cell Stem Cell 4, 141-154.
Marson, A., Levine, S.S., Cole, M.F., Frampton, G.M., Brambrink, T., Johnstone, S.,
Guenther, M.G., Johnston, W.K., Wernig, M., Newman, J., et al. (2008). Connecting
microRNA genes to the core transcriptional regulatory circuitry of embryonic stem
cells. Cell 134, 521-533.
Martens, J.H., O’Sullivan, R.J., Braunschweig, U., Opravil, S., Radolf, M., Steinlein,
P., and Jenuwein, T. (2005). The profile of repeat-associated histone lysine
methylation states in the mouse epigenome. EMBO J 24, 800-812.
Marzluff, W.F., Gongidi, P., Woods, K.R., Jin, J., and Maltais, L.J. (2002). The
human and mouse replication-dependent histone genes. Genomics 80, 487-498.
Matsui, T., Segall, J., Weil, P.A., and Roeder, R.G. (1980). Multiple factors required
for accurate initiation of transcription by purified RNA polymerase II. J Biol Chem
255, 11992-11996.
Matthews, A.G., Kuo, A.J., Ramon-Maiques, S., Han, S., Champagne, K.S., Ivanov,
D., Gallardo, M., Carney, D., Cheung, P., Ciccone, D.N., et al. (2007). RAG2 PHD
finger couples histone H3 lysine 4 trimethylation with V(D)J recombination. Nature
450, 1106-1110.

257

McDowell, T.L., Gibbons, R.J., Sutherland, H., O’Rourke, D.M., Bickmore,
W.A., Pombo, A., Turley, H., Gatter, K., Picketts, D.J., Buckle, V.J., et al. (1999).
Localization of a putative transcriptional regulator (ATRX) at pericentromeric
heterochromatin and the short arms of acrocentric chromosomes. Proc Natl Acad
Sci U S A 96, 13983-13988.
McKittrick, E., Gafken, P.R., Ahmad, K., and Henikoff, S. (2004). Histone H3.3
is enriched in covalent modifications associated with active chromatin. Proc Natl
Acad Sci U S A 101, 1525-1530.
McStay, B., and Grummt, I. (2008). The epigenetics of rRNA genes: from molecular
to chromosome biology. Annu Rev Cell Dev Biol 24, 131-157.
Meissner, A., Eminli, S., and Jaenisch, R. (2009). Derivation and manipulation of
murine embryonic stem cells. Methods Mol Biol 482, 3-19.
Meissner, A., Mikkelsen, T.S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., Zhang,
X., Bernstein, B.E., Nusbaum, C., Jaffe, D.B., et al. (2008). Genome-scale DNA
methylation maps of pluripotent and differentiated cells. Nature 454, 766-770.
Meisterernst, M., Roy, A.L., Lieu, H.M., and Roeder, R.G. (1991). Activation of
class II gene transcription by regulatory factors is potentiated by a novel activity.
Cell 66, 981-993.
Mendenhall, E.M., and Bernstein, B.E. (2008). Chromatin state maps: new
technologies, new insights. Curr Opin Genet Dev 18, 109-115.
Meneghini, M.D., Wu, M., and Madhani, H.D. (2003). Conserved histone variant
H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin.
Cell 112, 725-736.
Meshorer, E., Yellajoshula, D., George, E., Scambler, P.J., Brown, D.T., and Misteli,
T. (2006). Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic
stem cells. Dev Cell 10, 105-116.
Metzler-Guillemain, C., Luciani, J., Depetris, D., Guichaoua, M.R., and Mattei,
M.G. (2003). HP1beta and HP1gamma, but not HP1alpha, decorate the entire XY
body during human male meiosis. Chromosome Res 11, 73-81.
Meyne, J., Ratliff, R.L., and Moyzis, R.K. (1989). Conservation of the human
telomere sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci U S A 86,
7049-7053.
Michaelson, J.S., Bader, D., Kuo, F., Kozak, C., and Leder, P. (1999). Loss of
Daxx, a promiscuously interacting protein, results in extensive apoptosis in early
mouse development. Genes Dev 13, 1918-1923.
258

Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P.,
Bernstein, B.E., Jaenisch, R., Lander, E.S., and Meissner, A. (2008). Dissecting
direct reprogramming through integrative genomic analysis. Nature 454, 49-55.
Mikkelsen, T.S., Ku, M., Jaffe, D.B., Issac, B., Lieberman, E., Giannoukos, G.,
Alvarez, P., Brockman, W., Kim, T.K., Koche, R.P., et al. (2007). Genome-wide
maps of chromatin state in pluripotent and lineage-committed cells. Nature 448,
553-560.
Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.L., Rupniewski, I.,
Beausejour, C.M., Waite, A.J., Wang, N.S., Kim, K.A., et al. (2007). An improved
zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol
25, 778-785.
Minden, J.S., Dowd, S.R., Meyer, H.E., and Stuhler, K. (2009). Difference gel
electrophoresis. Electrophoresis 30 Suppl 1, S156-161.
Minucci, S., and Pelicci, P.G. (2006). Histone deacetylase inhibitors and the promise
of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38-51.
Mito, Y., Henikoff, J.G., and Henikoff, S. (2005). Genome-scale profiling of histone
H3.3 replacement patterns. Nat Genet 37, 1090-1097.
Mito, Y., Henikoff, J.G., and Henikoff, S. (2007). Histone replacement marks the
boundaries of cis-regulatory domains. Science 315, 1408-1411.
Mizuta, H., and Kuroda, Y. (2004). Cloning and functional characterization of a rat
Daxx that functions as a corepressor for the androgen receptor. Cell Biol Int 28,
609-614.
Monod, J., and Jacob, F. (1961). Teleonomic mechanisms in cellular metabolism,
growth, and differentiation. Cold Spring Harb Symp Quant Biol 26, 389-401.
Montgomery, N.D., Yee, D., Chen, A., Kalantry, S., Chamberlain, S.J., Otte, A.P.,
and Magnuson, T. (2005). The murine polycomb group protein Eed is required for
global histone H3 lysine-27 methylation. Curr Biol 15, 942-947.
Moore, M., Klug, A., and Choo, Y. (2001). Improved DNA binding specificity from
polyzinc finger peptides by using strings of two-finger units. Proc Natl Acad Sci U
S A 98, 1437-1441.
Morgan, H.D., Santos, F., Green, K., Dean, W., and Reik, W. (2005). Epigenetic
reprogramming in mammals. Hum Mol Genet 14 Spec No 1, R47-58.
Moriniere, J., Rousseaux, S., Steuerwald, U., Soler-Lopez, M., Curtet, S., Vitte,
A.L., Govin, J., Gaucher, J., Sadoul, K., Hart, D.J., et al. (2009). Cooperative
259

binding of two acetylation marks on a histone tail by a single bromodomain. Nature
461, 664-668.
Murata, T., Kurokawa, R., Krones, A., Tatsumi, K., Ishii, M., Taki, T., Masuno, M.,
Ohashi, H., Yanagisawa, M., Rosenfeld, M.G., et al. (2001). Defect of histone
acetyltransferase activity of the nuclear transcriptional coactivator CBP in
Rubinstein-Taybi syndrome. Hum Mol Genet 10, 1071-1076.
Muromoto, R., Nakao, K., Watanabe, T., Sato, N., Sekine, Y., Sugiyama, K., Oritani,
K., Shimoda, K., and Matsuda, T. (2006). Physical and functional interactions
between Daxx and STAT3. Oncogene 25, 2131-2136.
Nakayama, T., Nishioka, K., Dong, Y.X., Shimojima, T., and Hirose, S. (2007).
Drosophila GAGA factor directs histone H3.3 replacement that prevents the
heterochromatin spreading. Genes Dev 21, 552-561.
Natsume, R., Eitoku, M., Akai, Y., Sano, N., Horikoshi, M., and Senda, T. (2007).
Structure and function of the histone chaperone CIA/ASF1 complexed with histones
H3 and H4. Nature 446, 338-341.
Ng, H.H., and Bird, A. (1999). DNA methylation and chromatin modification. Curr
Opin Genet Dev 9, 158-163.
Ng, R.K., and Gurdon, J.B. (2005). Epigenetic memory of active gene transcription
is inherited through somatic cell nuclear transfer. Proc Natl Acad Sci U S A 102,
1957-1962.
Ng, R.K., and Gurdon, J.B. (2008). Epigenetic memory of an active gene state
depends on histone H3.3 incorporation into chromatin in the absence of transcription.
Nat Cell Biol 10, 102-109.
Niwa, H. (2007). How is pluripotency determined and maintained? Development
134, 635-646.
Niwa, H., Miyazaki, J., and Smith, A.G. (2000). Quantitative expression of Oct-3/4
defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24,
372-376.
Nottke, A., Colaiacovo, M.P., and Shi, Y. (2009). Developmental roles of the histone
lysine demethylases. Development 136, 879-889.
Nourani, A., Robert, F., and Winston, F. (2006). Evidence that Spt2/Sin1, an HMGlike factor, plays roles in transcription elongation, chromatin structure, and genome
stability in Saccharomyces cerevisiae. Mol Cell Biol 26, 1496-1509.
O’Carroll, D., Erhardt, S., Pagani, M., Barton, S.C., Surani, M.A., and Jenuwein, T.
260

(2001). The polycomb-group gene Ezh2 is required for early mouse development.
Mol Cell Biol 21, 4330-4336.
O’Neill, L.P., and Turner, B.M. (2003). Immunoprecipitation of native chromatin:
NChIP. Methods 31, 76-82.
Odom, D.T., Dowell, R.D., Jacobsen, E.S., Nekludova, L., Rolfe, P.A., Danford, T.W.,
Gifford, D.K., Fraenkel, E., Bell, G.I., and Young, R.A. (2006). Core transcriptional
regulatory circuitry in human hepatocytes. Mol Syst Biol 2, 2006 0017.
Ohinata, Y., Payer, B., O’Carroll, D., Ancelin, K., Ono, Y., Sano, M., Barton, S.C.,
Obukhanych, T., Nussenzweig, M., Tarakhovsky, A., et al. (2005). Blimp1 is a critical
determinant of the germ cell lineage in mice. Nature 436, 207-213.
Olins, A.L., and Olins, D.E. (1974). Spheroid chromatin units (v bodies). Science
183, 330-332.
Olins, D.E., and Olins, A.L. (2003). Chromatin history: our view from the bridge.
Nat Rev Mol Cell Biol 4, 809-814.
Ooi, S.K., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H.,
Tempst, P., Lin, S.P., Allis, C.D., et al. (2007). DNMT3L connects unmethylated
lysine 4 of histone H3 to de novo methylation of DNA. Nature 448, 714-717.
Ooi, S.L., Priess, J.R., and Henikoff, S. (2006). Histone H3.3 variant dynamics in
the germline of Caenorhabditis elegans. PLoS Genet 2, e97.
Orsi, G.A., Couble, P., and Loppin, B. (2009). Epigenetic and replacement roles
of histone variant H3.3 in reproduction and development. Int J Dev Biol 53, 231243.
Ottaviani, A., Gilson, E., and Magdinier, F. (2008). Telomeric position effect: from
the yeast paradigm to human pathologies? Biochimie 90, 93-107.
Oudet, P., Gross-Bellard, M., and Chambon, P. (1975). Electron microscopic and
biochemical evidence that chromatin structure is a repeating unit. Cell 4, 281300.
Palm, W., and de Lange, T. (2008). How shelterin protects mammalian telomeres.
Annu Rev Genet 42, 301-334.
Perez-Burgos, L., Peters, A.H., Opravil, S., Kauer, M., Mechtler, K., and Jenuwein,
T. (2004). Generation and characterization of methyl-lysine histone antibodies.
Methods Enzymol 376, 234-254.
Phillips, D.M. (1963). The presence of acetyl groups of histones. Biochem J 87,
261

258-263.
Picketts, D.J., Higgs, D.R., Bachoo, S., Blake, D.J., Quarrell, O.W., and Gibbons,
R.J. (1996). ATRX encodes a novel member of the SNF2 family of proteins:
mutations point to a common mechanism underlying the ATR-X syndrome. Hum
Mol Genet 5, 1899-1907.
Pina, B., and Suau, P. (1987). Changes in histones H2A and H3 variant composition
in differentiating and mature rat brain cortical neurons. Dev Biol 123, 51-58.
Pisano, S., Marchioni, E., Galati, A., Mechelli, R., Savino, M., and Cacchione,
S. (2007). Telomeric nucleosomes are intrinsically mobile. J Mol Biol 369, 11531162.
Plumb, M., Stein, J., and Stein, G. (1983). Influence of DNA synthesis inhibition on
the coordinate expression of core human histone genes during S phase. Nucleic
Acids Res 11, 7927-7945.
Pogo, B.G., Allfrey, V.G., and Mirsky, A.E. (1966). RNA synthesis and histone
acetylation during the course of gene activation in lymphocytes. Proc Natl Acad
Sci U S A 55, 805-812.
Pokholok, D.K., Harbison, C.T., Levine, S., Cole, M., Hannett, N.M., Lee, T.I., Bell,
G.W., Walker, K., Rolfe, P.A., Herbolsheimer, E., et al. (2005). Genome-wide map
of nucleosome acetylation and methylation in yeast. Cell 122, 517-527.
Polo, S.E., and Almouzni, G. (2006). Chromatin assembly: a basic recipe with
various flavours. Curr Opin Genet Dev 16, 104-111.
Polo, S.E., Roche, D., and Almouzni, G. (2006). New histone incorporation marks
sites of UV repair in human cells. Cell 127, 481-493.
Prochasson, P., Florens, L., Swanson, S.K., Washburn, M.P., and Workman, J.L.
(2005). The HIR corepressor complex binds to nucleosomes generating a distinct
protein/DNA complex resistant to remodeling by SWI/SNF. Genes Dev 19, 25342539.
Pusarla, R.H., and Bhargava, P. (2005). Histones in functional diversification. Core
histone variants. FEBS J 272, 5149-5168.
Puto, L.A., and Reed, J.C. (2008). Daxx represses RelB target promoters via DNA
methyltransferase recruitment and DNA hypermethylation. Genes Dev 22, 9981010.
Quail, M.A., Kozarewa, I., Smith, F., Scally, A., Stephens, P.J., Durbin, R., Swerdlow,
H., and Turner, D.J. (2008). A large genome center’s improvements to the Illumina
262

sequencing system. Nat Methods 5, 1005-1010.
Raisner, R.M., Hartley, P.D., Meneghini, M.D., Bao, M.Z., Liu, C.L., Schreiber, S.L.,
Rando, O.J., and Madhani, H.D. (2005). Histone variant H2A.Z marks the 5’ ends
of both active and inactive genes in euchromatin. Cell 123, 233-248.
Ramirez-Carrozzi, V.R., Braas, D., Bhatt, D.M., Cheng, C.S., Hong, C., Doty, K.R.,
Black, J.C., Hoffmann, A., Carey, M., and Smale, S.T. (2009). A unifying model for
the selective regulation of inducible transcription by CpG islands and nucleosome
remodeling. Cell 138, 114-128.
Rando, O.J., and Chang, H.Y. (2009). Genome-Wide Views of Chromatin Structure.
Annual review of biochemistry.
Ray-Gallet, D., Quivy, J.P., Scamps, C., Martini, E.M., Lipinski, M., and Almouzni,
G. (2002). HIRA is critical for a nucleosome assembly pathway independent of
DNA synthesis. Mol Cell 9, 1091-1100.
Rea, S., Eisenhaber, F., O’Carroll, D., Strahl, B.D., Sun, Z.W., Schmid, M., Opravil,
S., Mechtler, K., Ponting, C.P., Allis, C.D., et al. (2000). Regulation of chromatin
structure by site-specific histone H3 methyltransferases. Nature 406, 593-599.
Recht, J., Tsubota, T., Tanny, J.C., Diaz, R.L., Berger, J.M., Zhang, X., Garcia, B.A.,
Shabanowitz, J., Burlingame, A.L., Hunt, D.F., et al. (2006). Histone chaperone
Asf1 is required for histone H3 lysine 56 acetylation, a modification associated with
S phase in mitosis and meiosis. Proc Natl Acad Sci U S A 103, 6988-6993.
Ren, B., Robert, F., Wyrick, J.J., Aparicio, O., Jennings, E.G., Simon, I., Zeitlinger,
J., Schreiber, J., Hannett, N., Kanin, E., et al. (2000). Genome-wide location and
function of DNA binding proteins. Science 290, 2306-2309.
Ringrose, L., and Paro, R. (2004). Epigenetic regulation of cellular memory by the
Polycomb and Trithorax group proteins. Annual review of genetics 38, 413-443.
Rinn, J.L., Kertesz, M., Wang, J.K., Squazzo, S.L., Xu, X., Brugmann, S.A.,
Goodnough, L.H., Helms, J.A., Farnham, P.J., Segal, E., et al. (2007). Functional
demarcation of active and silent chromatin domains in human HOX loci by
noncoding RNAs. Cell 129, 1311-1323.
Roberts, C., Sutherland, H.F., Farmer, H., Kimber, W., Halford, S., Carey,
A., Brickman, J.M., Wynshaw-Boris, A., and Scambler, P.J. (2002). Targeted
mutagenesis of the Hira gene results in gastrulation defects and patterning
abnormalities of mesoendodermal derivatives prior to early embryonic lethality.
Mol Cell Biol 22, 2318-2328.
Robertson, A.G., Bilenky, M., Tam, A., Zhao, Y., Zeng, T., Thiessen, N., Cezard, T.,
263

Fejes, A.P., Wederell, E.D., Cullum, R., et al. (2008). Genome-wide relationship
between histone H3 lysine 4 mono- and tri-methylation and transcription factor
binding. Genome Res 18, 1906-1917.
Roeder, R.G. (2003). Lasker Basic Medical Research Award. The eukaryotic
transcriptional machinery: complexities and mechanisms unforeseen. Nat Med 9,
1239-1244.
Roeder, R.G., and Rutter, W.J. (1969). Multiple forms of DNA-dependent RNA
polymerase in eukaryotic organisms. Nature 224, 234-237.
Roeder, R.G., and Rutter, W.J. (1970). Specific nucleolar and nucleoplasmic RNA
polymerases. Proc Natl Acad Sci U S A 65, 675-682.
Rogakou, E.P., Pilch, D.R., Orr, A.H., Ivanova, V.S., and Bonner, W.M. (1998).
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.
J Biol Chem 273, 5858-5868.
Rogers, R.S., Inselman, A., Handel, M.A., and Matunis, M.J. (2004). SUMO modified
proteins localize to the XY body of pachytene spermatocytes. Chromosoma 113,
233-243.
Rosenfeld, N., Aharonov, R., Meiri, E., Rosenwald, S., Spector, Y., Zepeniuk, M.,
Benjamin, H., Shabes, N., Tabak, S., Levy, A., et al. (2008). MicroRNAs accurately
identify cancer tissue origin. Nat Biotechnol 26, 462-469.
Ross, M.H., Pawlina, W., and Barnash, T.A. (2009). Atlas of descriptive histology
(Sunderland, Mass., Sinauer Associates).
Rossant, J. (2009). Reprogramming to pluripotency: from frogs to stem cells. Cell
138, 1047-1050.
Ruthenburg, A.J., Allis, C.D., and Wysocka, J. (2007a). Methylation of lysine 4 on
histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 25,
15-30.
Ruthenburg, A.J., Li, H., Patel, D.J., and Allis, C.D. (2007b). Multivalent engagement
of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 8,
983-994.
Ruthenburg, A.J., Wang, W., Graybosch, D.M., Li, H., Allis, C.D., Patel, D.J., and
Verdine, G.L. (2006). Histone H3 recognition and presentation by the WDR5
module of the MLL1 complex. Nat Struct Mol Biol 13, 704-712.
Saga, Y. (2008). Mouse germ cell development during embryogenesis. Curr Opin
Genet Dev 18, 337-341.
264

Sakai, A., Schwartz, B.E., Goldstein, S., and Ahmad, K. (2009). Transcriptional and
Developmental Functions of the H3.3 Histone Variant in Drosophila. Curr Biol.
Salomoni, P., and Khelifi, A.F. (2006). Daxx: death or survival protein? Trends Cell
Biol 16, 97-104.
Sanematsu, F., Takami, Y., Barman, H.K., Fukagawa, T., Ono, T., Shibahara, K.,
and Nakayama, T. (2006). Asf1 is required for viability and chromatin assembly
during DNA replication in vertebrate cells. J Biol Chem 281, 13817-13827.
Santenard, A., and Torres-Padilla, M.E. (2009). Epigenetic reprogramming in
mammalian reproduction: Contribution from histone variants. Epigenetics 4.
Santos-Rosa, H., Schneider, R., Bannister, A.J., Sherriff, J., Bernstein, B.E., Emre,
N.C., Schreiber, S.L., Mellor, J., and Kouzarides, T. (2002). Active genes are trimethylated at K4 of histone H3. Nature 419, 407-411.
Saxonov, S., Berg, P., and Brutlag, D.L. (2006). A genome-wide analysis of CpG
dinucleotides in the human genome distinguishes two distinct classes of promoters.
Proc Natl Acad Sci U S A 103, 1412-1417.
Scaturro, M., Cestelli, A., Castiglia, D., Nastasi, T., and Di Liegro, I. (1995).
Posttranscriptional regulation of H1 zero and H3.3B histone genes in differentiating
rat cortical neurons. Neurochem Res 20, 969-976.
Schneiderman, J.I., Sakai, A., Goldstein, S., and Ahmad, K. (2009). The XNP
remodeler targets dynamic chromatin in Drosophila. Proc Natl Acad Sci U S A 106,
14472-14477.
Schoeftner, S., and Blasco, M.A. (2008). Developmentally regulated transcription
of mammalian telomeres by DNA-dependent RNA polymerase II. Nat Cell Biol 10,
228-236.
Schoeftner, S., and Blasco, M.A. (2009). A ‘higher order’ of telomere regulation:
telomere heterochromatin and telomeric RNAs. EMBO J.
Schones, D.E., Cui, K., Cuddapah, S., Roh, T.Y., Barski, A., Wang, Z., Wei, G.,
and Zhao, K. (2008). Dynamic regulation of nucleosome positioning in the human
genome. Cell 132, 887-898.
Schotta, G., Ebert, A., Dorn, R., and Reuter, G. (2003). Position-effect variegation
and the genetic dissection of chromatin regulation in Drosophila. Semin Cell Dev
Biol 14, 67-75.
Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B., and Cavalli, G.
(2007). Genome regulation by polycomb and trithorax proteins. Cell 128, 735265

745.
Schwartz, B.E., and Ahmad, K. (2005). Transcriptional activation triggers deposition
and removal of the histone variant H3.3. Genes Dev 19, 804-814.
Schwartz, B.E., and Ahmad, K. (2006). 2. Chromatin assembly with H3 histones:
full throttle down multiple pathways. Curr Top Dev Biol 74, 31-55.
Sealy, L., and Chalkley, R. (1978). DNA associated with hyperacetylated histone is
preferentially digested by DNase I. Nucleic Acids Res 5, 1863-1876.
Seandel, M., James, D., Shmelkov, S.V., Falciatori, I., Kim, J., Chavala, S., Scherr,
D.S., Zhang, F., Torres, R., Gale, N.W., et al. (2007). Generation of functional
multipotent adult stem cells from GPR125+ germline progenitors. Nature 449, 346350.
Segal, E., Fondufe-Mittendorf, Y., Chen, L., Thastrom, A., Field, Y., Moore, I.K.,
Wang, J.P., and Widom, J. (2006). A genomic code for nucleosome positioning.
Nature 442, 772-778.
Segal, E., and Widom, J. (2009). What controls nucleosome positions? Trends
Genet 25, 335-343.
Segall, J., Matsui, T., and Roeder, R.G. (1980). Multiple factors are required for the
accurate transcription of purified genes by RNA polymerase III. J Biol Chem 255,
11986-11991.
Sfeir, A., Kosiyatrakul, S.T., Hockemeyer, D., MacRae, S.L., Karlseder, J.,
Schildkraut, C.L., and de Lange, T. (2009). Mammalian telomeres resemble fragile
sites and require TRF1 for efficient replication. Cell 138, 90-103.
Shahbazian, M.D., and Grunstein, M. (2007). Functions of site-specific histone
acetylation and deacetylation. Annual review of biochemistry 76, 75-100.
Shen, X., Liu, Y., Hsu, Y.J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.C., and Orkin,
S.H. (2008). EZH1 mediates methylation on histone H3 lysine 27 and complements
EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 32,
491-502.
Shi, X., Hong, T., Walter, K.L., Ewalt, M., Michishita, E., Hung, T., Carney, D., Pena,
P., Lan, F., Kaadige, M.R., et al. (2006). ING2 PHD domain links histone H3 lysine
4 methylation to active gene repression. Nature 442, 96-99.
Shibahara, K., and Stillman, B. (1999). Replication-dependent marking of DNA by
PCNA facilitates CAF-1-coupled inheritance of chromatin. Cell 96, 575-585.
Shilatifard, A. (2008). Molecular implementation and physiological roles for histone
266

H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 20, 341-348.
Shukla, V.K., Doyon, Y., Miller, J.C., DeKelver, R.C., Moehle, E.A., Worden, S.E.,
Mitchell, J.C., Arnold, N.L., Gopalan, S., Meng, X., et al. (2009). Precise genome
modification in the crop species Zea mays using zinc-finger nucleases. Nature
459, 437-441.
Siegel, T.N., Hekstra, D.R., Kemp, L.E., Figueiredo, L.M., Lowell, J.E., Fenyo, D.,
Wang, X., Dewell, S., and Cross, G.A. (2009). Four histone variants mark the
boundaries of polycistronic transcription units in Trypanosoma brucei. Genes
Dev.
Sikorski, T.W., and Buratowski, S. (2009). The basal initiation machinery: beyond
the general transcription factors. Curr Opin Cell Biol 21, 344-351.
Sims, R.J., 3rd, Chen, C.F., Santos-Rosa, H., Kouzarides, T., Patel, S.S., and
Reinberg, D. (2005). Human but not yeast CHD1 binds directly and selectively
to histone H3 methylated at lysine 4 via its tandem chromodomains. J Biol Chem
280, 41789-41792.
Sims, R.J., 3rd, and Reinberg, D. (2009). Stem cells: Escaping fates with open
states. Nature 460, 802-803.
Sklar, V.E., Schwartz, L.B., and Roeder, R.G. (1975). Distinct molecular structures
of nuclear class I, II, and III DNA-dependent RNA polymerases. Proc Natl Acad Sci
U S A 72, 348-352.
Smith, C.L., and Peterson, C.L. (2005). ATP-dependent chromatin remodeling.
Curr Top Dev Biol 65, 115-148.
Smith, S., and Stillman, B. (1989). Purification and characterization of CAF-I, a
human cell factor required for chromatin assembly during DNA replication in vitro.
Cell 58, 15-25.
Sobel, R.E., Cook, R.G., and Allis, C.D. (1994). Non-random acetylation of histone
H4 by a cytoplasmic histone acetyltransferase as determined by novel methodology.
J Biol Chem 269, 18576-18582.
Sobel, R.E., Cook, R.G., Perry, C.A., Annunziato, A.T., and Allis, C.D. (1995).
Conservation of deposition-related acetylation sites in newly synthesized histones
H3 and H4. Proc Natl Acad Sci U S A 92, 1237-1241.
Spector, M.S., Raff, A., DeSilva, H., Lee, K., and Osley, M.A. (1997). Hir1p and
Hir2p function as transcriptional corepressors to regulate histone gene transcription
in the Saccharomyces cerevisiae cell cycle. Mol Cell Biol 17, 545-552.

267

Stock, J.K., Giadrossi, S., Casanova, M., Brookes, E., Vidal, M., Koseki, H.,
Brockdorff, N., Fisher, A.G., and Pombo, A. (2007). Ring1-mediated ubiquitination
of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells.
Nat Cell Biol 9, 1428-1435.
Straathof, K.C., Pule, M.A., Yotnda, P., Dotti, G., Vanin, E.F., Brenner, M.K., Heslop,
H.E., Spencer, D.M., and Rooney, C.M. (2005). An inducible caspase 9 safety
switch for T-cell therapy. Blood 105, 4247-4254.
Strahl, B.D., and Allis, C.D. (2000). The language of covalent histone modifications.
Nature 403, 41-45.
Struhl, K. (1998). Histone acetylation and transcriptional regulatory mechanisms.
Genes Dev 12, 599-606.
Sutcliffe, E.L., Parish, I.A., He, Y.Q., Juelich, T., Tierney, M.L., Rangasamy, D.,
Milburn, P.J., Parish, C.R., Tremethick, D.J., and Rao, S. (2009). Dynamic histone
variant exchange accompanies gene induction in T cells. Mol Cell Biol 29, 19721986.
Tagami, H., Ray-Gallet, D., Almouzni, G., and Nakatani, Y. (2004). Histone H3.1
and H3.3 complexes mediate nucleosome assembly pathways dependent or
independent of DNA synthesis. Cell 116, 51-61.
Tahiliani, M., Mei, P., Fang, R., Leonor, T., Rutenberg, M., Shimizu, F., Li, J., Rao,
A., and Shi, Y. (2007). The histone H3K4 demethylase SMCX links REST target
genes to X-linked mental retardation. Nature 447, 601-605.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663676.
Talbert, P.B., and Henikoff, S. (2009). Chromatin-based transcriptional punctuation.
Genes Dev 23, 1037-1041.
Tamura, T., Smith, M., Kanno, T., Dasenbrock, H., Nishiyama, A., and Ozato, K.
(2009). Inducible deposition of the histone variant H3.3 in interferon-stimulated
genes. J Biol Chem.
Tanaka, M., Hennebold, J.D., Macfarlane, J., and Adashi, E.Y. (2001). A mammalian
oocyte-specific linker histone gene H1oo: homology with the genes for the oocytespecific cleavage stage histone (cs-H1) of sea urchin and the B4/H1M histone of
the frog. Development 128, 655-664.
Tanaka, T.S. (2009). Transcriptional heterogeneity in mouse embryonic stem cells.
Reprod Fertil Dev 21, 67-75.
268

Tang, J., Wu, S., Liu, H., Stratt, R., Barak, O.G., Shiekhattar, R., Picketts, D.J.,
and Yang, X. (2004). A novel transcription regulatory complex containing death
domain-associated protein and the ATR-X syndrome protein. J Biol Chem 279,
20369-20377.
Tang, Y., Poustovoitov, M.V., Zhao, K., Garfinkel, M., Canutescu, A., Dunbrack,
R., Adams, P.D., and Marmorstein, R. (2006). Structure of a human ASF1a-HIRA
complex and insights into specificity of histone chaperone complex assembly. Nat
Struct Mol Biol 13, 921-929.
Taunton, J., Hassig, C.A., and Schreiber, S.L. (1996). A mammalian histone
deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272,
408-411.
te Riele, H., Maandag, E.R., and Berns, A. (1992). Highly efficient gene targeting
in embryonic stem cells through homologous recombination with isogenic DNA
constructs. Proc Natl Acad Sci U S A 89, 5128-5132.
Teng, G., and Papavasiliou, F.N. (2007). Immunoglobulin somatic hypermutation.
Annu Rev Genet 41, 107-120.
Terranova, R., Agherbi, H., Boned, A., Meresse, S., and Djabali, M. (2006). Histone
and DNA methylation defects at Hox genes in mice expressing a SET domaintruncated form of Mll. Proc Natl Acad Sci U S A 103, 6629-6634.
Thatcher, T.H., MacGaffey, J., Bowen, J., Horowitz, S., Shapiro, D.L., and Gorovsky,
M.A. (1994). Independent evolutionary origin of histone H3.3-like variants of
animals and Tetrahymena. Nucleic Acids Res 22, 180-186.
Tommerup, H., Dousmanis, A., and de Lange, T. (1994). Unusual chromatin in
human telomeres. Mol Cell Biol 14, 5777-5785.
Torres-Padilla, M.E., Bannister, A.J., Hurd, P.J., Kouzarides, T., and ZernickaGoetz, M. (2006). Dynamic distribution of the replacement histone variant H3.3 in
the mouse oocyte and preimplantation embryos. Int J Dev Biol 50, 455-461.
Tumbar, T., Guasch, G., Greco, V., Blanpain, C., Lowry, W.E., Rendl, M., and Fuchs,
E. (2004). Defining the epithelial stem cell niche in skin. Science 303, 359-363.
Tupler, R., Perini, G., and Green, M.R. (2001). Expressing the human genome.
Nature 409, 832-833.
Turner, B.M. (2000). Histone acetylation and an epigenetic code. Bioessays 22,
836-845.
Urnov, F.D., Miller, J.C., Lee, Y.L., Beausejour, C.M., Rock, J.M., Augustus, S.,
269

Jamieson, A.C., Porteus, M.H., Gregory, P.D., and Holmes, M.C. (2005). Highly
efficient endogenous human gene correction using designed zinc-finger nucleases.
Nature 435, 646-651.
van der Heijden, G.W., Derijck, A.A., Posfai, E., Giele, M., Pelczar, P., Ramos, L.,
Wansink, D.G., van der Vlag, J., Peters, A.H., and de Boer, P. (2007). Chromosomewide nucleosome replacement and H3.3 incorporation during mammalian meiotic
sex chromosome inactivation. Nat Genet 39, 251-258.
van der Heijden, G.W., Dieker, J.W., Derijck, A.A., Muller, S., Berden, J.H., Braat,
D.D., van der Vlag, J., and de Boer, P. (2005). Asymmetry in histone H3 variants
and lysine methylation between paternal and maternal chromatin of the early
mouse zygote. Mech Dev 122, 1008-1022.
Vaquerizas, J.M., Kummerfeld, S.K., Teichmann, S.A., and Luscombe, N.M. (2009).
A census of human transcription factors: function, expression and evolution. Nat
Rev Genet 10, 252-263.
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith,
H.O., Yandell, M., Evans, C.A., Holt, R.A., et al. (2001). The sequence of the human
genome. Science 291, 1304-1351.
Venters, B.J., and Pugh, B.F. (2009). How eukaryotic genes are transcribed. Crit
Rev Biochem Mol Biol 44, 117-141.
Vermeulen, M., Mulder, K.W., Denissov, S., Pijnappel, W.W., van Schaik, F.M.,
Varier, R.A., Baltissen, M.P., Stunnenberg, H.G., Mann, M., and Timmers, H.T.
(2007). Selective anchoring of TFIID to nucleosomes by trimethylation of histone
H3 lysine 4. Cell 131, 58-69.
Verreault, A., Kaufman, P.D., Kobayashi, R., and Stillman, B. (1996). Nucleosome
assembly by a complex of CAF-1 and acetylated histones H3/H4. Cell 87, 95104.
Verreault, A., Kaufman, P.D., Kobayashi, R., and Stillman, B. (1998). Nucleosomal
DNA regulates the core-histone-binding subunit of the human Hat1 acetyltransferase.
Curr Biol 8, 96-108.
Vickaryous, M.K., and Hall, B.K. (2006). Human cell type diversity, evolution,
development, and classification with special reference to cells derived from the
neural crest. Biol Rev Camb Philos Soc 81, 425-455.
Vidali, G., Boffa, L.C., Bradbury, E.M., and Allfrey, V.G. (1978). Butyrate suppression
of histone deacetylation leads to accumulation of multiacetylated forms of histones
H3 and H4 and increased DNase I sensitivity of the associated DNA sequences.
Proc Natl Acad Sci U S A 75, 2239-2243.
270

Visel, A., Blow, M.J., Li, Z., Zhang, T., Akiyama, J.A., Holt, A., Plajzer-Frick, I.,
Shoukry, M., Wright, C., Chen, F., et al. (2009). ChIP-seq accurately predicts
tissue-specific activity of enhancers. Nature 457, 854-858.
Waddington, C.H. (1942). The epigenotype. Endeavour 1, 18–20.
Waddington, C.H. (1957). The strategy of the genes; a discussion of some aspects
of theoretical biology (London,, Allen & Unwin).
Wang, A., Kurdistani, S.K., and Grunstein, M. (2002). Requirement of Hos2 histone
deacetylase for gene activity in yeast. Science 298, 1412-1414.
Wang, Z., Gerstein, M., and Snyder, M. (2009a). RNA-Seq: a revolutionary tool for
transcriptomics. Nat Rev Genet 10, 57-63.
Wang, Z., Zang, C., Cui, K., Schones, D.E., Barski, A., Peng, W., and Zhao, K.
(2009b). Genome-wide mapping of HATs and HDACs reveals distinct functions in
active and inactive genes. Cell 138, 1019-1031.
Wang, Z., Zang, C., Rosenfeld, J.A., Schones, D.E., Barski, A., Cuddapah, S.,
Cui, K., Roh, T.Y., Peng, W., Zhang, M.Q., et al. (2008). Combinatorial patterns of
histone acetylations and methylations in the human genome. Nat Genet 40, 897903.
Waterborg, J.H., and Robertson, A.J. (1996). Common features of analogous
replacement histone H3 genes in animals and plants. J Mol Evol 43, 194-206.
Watson, J.D. (2003). Celebrating the genetic jubilee: a conversation with James D.
Watson. Interviewed by John Rennie. Scientific American 288, 66-69.
Weake, V.M., and Workman, J.L. (2008). Histone ubiquitination: triggering gene
activity. Mol Cell 29, 653-663.
Weaver, J.R., Susiarjo, M., and Bartolomei, M.S. (2009). Imprinting and epigenetic
changes in the early embryo. Mamm Genome.
Wederell, E.D., Bilenky, M., Cullum, R., Thiessen, N., Dagpinar, M., Delaney, A.,
Varhol, R., Zhao, Y., Zeng, T., Bernier, B., et al. (2008). Global analysis of in vivo
Foxa2-binding sites in mouse adult liver using massively parallel sequencing.
Nucleic Acids Res 36, 4549-4564.
Weinmann, R., Raskas, H.J., and Roeder, R.G. (1974). Role of DNA-dependent
RNA polymerases II and III in transcription of the adenovirus genome late in
productive infection. Proc Natl Acad Sci U S A 71, 3426-3439.
Weinmann, R., and Roeder, R.G. (1974). Role of DNA-dependent RNA polymerase
271

3 in the transcription of the tRNA and 5S RNA genes. Proc Natl Acad Sci U S A 71,
1790-1794.
Weintraub, H., and Groudine, M. (1976). Chromosomal subunits in active genes
have an altered conformation. Science 193, 848-856.
Weintraub, H., Tapscott, S.J., Davis, R.L., Thayer, M.J., Adam, M.A., Lassar, A.B.,
and Miller, A.D. (1989). Activation of muscle-specific genes in pigment, nerve, fat,
liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci U
S A 86, 5434-5438.
Wells, D., Hoffman, D., and Kedes, L. (1987). Unusual structure, evolutionary
conservation of non-coding sequences and numerous pseudogenes characterize
the human H3.3 histone multigene family. Nucleic Acids Res 15, 2871-2889.
Wethkamp, N., and Klempnauer, K.H. (2009). Daxx Is a Transcriptional Repressor
of CCAAT/Enhancer-binding Protein {beta}. J Biol Chem 284, 28783-28794.
Whitcomb, S.J., Basu, A., Allis, C.D., and Bernstein, E. (2007). Polycomb Group
proteins: an evolutionary perspective. Trends Genet 23, 494-502.
Williams, S.K., Truong, D., and Tyler, J.K. (2008). Acetylation in the globular core
of histone H3 on lysine-56 promotes chromatin disassembly during transcriptional
activation. Proc Natl Acad Sci U S A 105, 9000-9005.
Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., and Campbell, K.H. (1997). Viable
offspring derived from fetal and adult mammalian cells. Nature 385, 810-813.
Wilusz, J.E., Sunwoo, H., and Spector, D.L. (2009). Long noncoding RNAs:
functional surprises from the RNA world. Genes Dev 23, 1494-1504.
Wirbelauer, C., Bell, O., and Schubeler, D. (2005). Variant histone H3.3 is deposited
at sites of nucleosomal displacement throughout transcribed genes while active
histone modifications show a promoter-proximal bias. Genes Dev 19, 1761-1766.
Wolffe, A. (1992). Chromatin Structure and Function (San Diego, Academic
Press).
Wong, L.H., Ren, H., Williams, E., McGhie, J., Ahn, S., Sim, M., Tam, A., Earle,
E., Anderson, M.A., Mann, J., et al. (2009). Histone H3.3 incorporation provides
a unique and functionally essential telomeric chromatin in embryonic stem cells.
Genome Res 19, 404-414.
Wu, R.S., Tsai, S., and Bonner, W.M. (1982). Patterns of histone variant synthesis
can distinguish G0 from G1 cells. Cell 31, 367-374.

272

Wunsch, A.M., and Lough, J. (1987). Modulation of histone H3 variant synthesis
during the myoblast-myotube transition of chicken myogenesis. Dev Biol 119, 9499.
Wysocka, J., Swigut, T., Milne, T.A., Dou, Y., Zhang, X., Burlingame, A.L., Roeder,
R.G., Brivanlou, A.H., and Allis, C.D. (2005). WDR5 associates with histone H3
methylated at K4 and is essential for H3 K4 methylation and vertebrate development.
Cell 121, 859-872.
Wysocka, J., Swigut, T., Xiao, H., Milne, T.A., Kwon, S.Y., Landry, J., Kauer, M.,
Tackett, A.J., Chait, B.T., Badenhorst, P., et al. (2006). A PHD finger of NURF
couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442,
86-90.
Xie, W., Song, C., Young, N.L., Sperling, A.S., Xu, F., Sridharan, R., Conway, A.E.,
Garcia, B.A., Plath, K., Clark, A.T., et al. (2009). Histone h3 lysine 56 acetylation is
linked to the core transcriptional network in human embryonic stem cells. Mol Cell
33, 417-427.
Xue, Y., Gibbons, R., Yan, Z., Yang, D., McDowell, T.L., Sechi, S., Qin, J., Zhou, S.,
Higgs, D., and Wang, W. (2003). The ATRX syndrome protein forms a chromatinremodeling complex with Daxx and localizes in promyelocytic leukemia nuclear
bodies. Proc Natl Acad Sci U S A 100, 10635-10640.
Yamanaka, S. (2009). A fresh look at iPS cells. Cell 137, 13-17.
Yan, W., Ma, L., Burns, K.H., and Matzuk, M.M. (2003). HILS1 is a spermatidspecific linker histone H1-like protein implicated in chromatin remodeling during
mammalian spermiogenesis. Proc Natl Acad Sci U S A 100, 10546-10551.
Yang, P.K., and Kuroda, M.I. (2007). Noncoding RNAs and intranuclear positioning
in monoallelic gene expression. Cell 128, 777-786.
Yang, X., Smith, S.L., Tian, X.C., Lewin, H.A., Renard, J.P., and Wakayama,
T. (2007). Nuclear reprogramming of cloned embryos and its implications for
therapeutic cloning. Nat Genet 39, 295-302.
Ye, X., Zerlanko, B., Zhang, R., Somaiah, N., Lipinski, M., Salomoni, P., and Adams,
P.D. (2007). Definition of pRB- and p53-dependent and -independent steps in
HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci.
Mol Cell Biol 27, 2452-2465.
Yehezkel, S., Segev, Y., Viegas-Pequignot, E., Skorecki, K., and Selig, S. (2008).
Hypomethylation of subtelomeric regions in ICF syndrome is associated with
abnormally short telomeres and enhanced transcription from telomeric regions.
Hum Mol Genet 17, 2776-2789.
273

Yuan, G.C., Liu, Y.J., Dion, M.F., Slack, M.D., Wu, L.F., Altschuler, S.J., and Rando,
O.J. (2005). Genome-scale identification of nucleosome positions in S. cerevisiae.
Science 309, 626-630.
Yuan, J., Pu, M., Zhang, Z., and Lou, Z. (2009). Histone H3-K56 acetylation is
important for genomic stability in mammals. Cell Cycle 8, 1747-1753.
Zaratiegui, M., Irvine, D.V., and Martienssen, R.A. (2007). Noncoding RNAs and
gene silencing. Cell 128, 763-776.
Zhang, R., Chen, W., and Adams, P.D. (2007). Molecular dissection of formation of
senescence-associated heterochromatin foci. Mol Cell Biol 27, 2343-2358.
Zhang, R., Poustovoitov, M.V., Ye, X., Santos, H.A., Chen, W., Daganzo, S.M.,
Erzberger, J.P., Serebriiskii, I.G., Canutescu, A.A., Dunbrack, R.L., et al. (2005).
Formation of MacroH2A-containing senescence-associated heterochromatin foci
and senescence driven by ASF1a and HIRA. Dev Cell 8, 19-30.
Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E.,
Nussbaum, C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based analysis
of ChIP-Seq (MACS). Genome Biol 9, R137.
Zhao, R., Bodnar, M.S., and Spector, D.L. (2009). Nuclear neighborhoods and
gene expression. Curr Opin Genet Dev 19, 172-179.
Zheng, D., Zhao, K., and Mehler, M.F. (2009). Profiling RE1/REST-mediated
histone modifications in the human genome. Genome Biol 10, R9.
Zofall, M., Fischer, T., Zhang, K., Zhou, M., Cui, B., Veenstra, T.D., and Grewal,
S.I. (2009). Histone H2A.Z cooperates with RNAi and heterochromatin factors to
suppress antisense RNAs. Nature 461, 419-422.

274

